{
    "filename": "pdf.pdf",
    "content_type": "application/pdf",
    "file_size": 9955322,
    "metadata": {
        "identifiers": {
            "doi": "10.3390/molecules25040942",
            "url": "https://www.mdpi.com/1420-3049/25/4/942/pdf"
        },
        "date": 2020,
        "title": "Synthetic Compounds with 2-Amino-1,3,4-Thiadiazole Moiety Against Viral Infections",
        "author": "Georgeta Serban",
        "affiliations": [
            "Pharmaceutical Chemistry Department, Faculty of Medicine and Pharmacy, University of Oradea, 29 Nicolae Jiga, 410028 Oradea, Romania; getaserban_2000@yahoo.com; Tel.: +4-0756-276-377"
        ],
        "journal": "Molecules",
        "volume": "25",
        "abstract": "Viral infections have resulted in millions of victims in human history. Although great efforts have been made to find effective medication, there are still no drugs that truly cure viral infections. There are currently approximately 90 drugs approved for the treatment of human viral infections. As resistance toward available antiviral drugs has become a global threat to health, there is an intrinsic need to identify new scaffolds that are useful in discovering innovative, less toxic and highly active antiviral agents. 1,3,4-Thiadiazole derivatives have been extensively studied due to their pharmacological profile, physicochemical and pharmacokinetic properties. This review provides an overview of the various synthetic compounds containing the 2-amino-1,3,4-thiadiazole moiety that has been evaluated for antiviral activity against several viral strains and could be considered possible prototypes for the development of new antiviral drugs.",
        "keywords": [
            "2-amino-1,3,4-thiadiazole",
            "viral infections",
            "antiviral agents",
            "drug resistance",
            "inhibitory concentration",
            "mechanism of action"
        ],
        "references": "@book{beale2011a,\n  author = {Beale, Jr, J.M.},\n  title = {Antiviral agents. In Wilson and Gisvold\u2019s Textbook of Organic Medicinal and Pharmaceutical Chemistry},\n  edition = {12th ed},\n  editor = {},\n  date = {2011},\n  pages = {330\u2013336},\n  publisher = {Baltimore, MD, USA},\n  language = {},\n  address = {Wilkins}\n}\n@article{rohwer2013a,\n  author = {Rohwer, F. and Barrot, K.},\n  title = {Viral information},\n  journal = {Biol. Philos},\n  date = {2013},\n  volume = {28},\n  pages = \"283\u2013297.\" # \"pp. 1274\u20131302.\",\n  medium = {CrossRef},\n  edition = {7th ed},\n  editor = {Lemke, T.L. and Williams, D.A. and Roche, V.F. and Zito, S.W.},\n  publisher = {Lippincott Williams and Wilkins, Wolters Kluwer},\n  unmatched-author = {3. Woster, P. M.},\n  source = {Antiviral agents and protease inhibitors. In Foye\u2019s Principles of Medicinal Chemistry},\n  unmatched-pages = {pp. 1274\u20131302.},\n  language = {},\n  address = {Baltimore, MD, USA}\n}\n@article{berzofsky2004a,\n  author = {Berzofsky, J.A. and Ahlers, J.D. and Janik, J. and Morris, J. and Oh, S.K. and Terabe, M. and Belyakov, I.M.},\n  title = {Progress on new vaccine strategies against chronic viral infections},\n  journal = {J. Clin. Invest},\n  date = {2004-05-05},\n  volume = {114},\n  pages = {450\u2013462},\n  publisher = {Weekly epidemiological record},\n  url = {http://www.who.int/wer},\n  source = {World Health Organization. Human papillomavirus vaccines: WHO position paper},\n  unmatched-accessed = {(accessed on 11 January 2020).},\n  language = {},\n  type = {CrossRef] [PubMed},\n  urldate = {Available online:}\n}\n@article{el-essawy2008a,\n  author = {El-Essawy, F.A. and El-Sayed, W.A. and El-Kafrawy, S.A. and Morshedy, A.S. and Abdel-Rahman, A.H.},\n  title = {Anti-Hepatitis B virus activity of new 1,2,4-triazol-2-yl- and1,3,4-oxadiazol-2-yl-2-pyridinone derivatives},\n  journal = {Z. Naturforsch},\n  date = {2008},\n  volume = {63},\n  pages = \"667\u2013674.\" # \"1802\u20131817.\",\n  medium = {CrossRef},\n  unmatched-author = {Tonelli, M.; Cichero, E.},\n  source = {Fight against H1N1 Influenza A virus: recent insights towards the development of druggable compounds},\n  unmatched-journal = {Curr. Med. Chem.},\n  unmatched-volume = {23,},\n  unmatched-pages = {1802\u20131817.},\n  language = {},\n  urldate = {[PubMed] 8.}\n}\n@article{diaba2015a,\n  author = {Diaba, F. and Montiel, J.A. and Serban, G. and Bonjoch, J.},\n  title = {Synthesis of normorphans through an efficient intramolecular carbamoylation of ketones},\n  journal = {Org. Lett},\n  date = {2015},\n  volume = {17},\n  pages = {3860\u20133863},\n  language = {}\n}\n@article{serban2011a,\n  author = {Serban, G. and Abe, H. and Takeuchi, Y.},\n  title = {Synthetic studies of substituted pyridine aldehydes as intermediates for the synthesis of toddaquinoline, its derivatives and other natural products},\n  journal = {Heterocycles},\n  date = {2011},\n  volume = {83},\n  medium = {CrossRef},\n  unmatched-volume = {10.},\n  language = {}\n}\n@article{serban2008a,\n  author = {Serban, G. and Abe, H. and Takeuchi, Y. and Harayama, T.},\n  title = {A new approach to the benzopyridoxepine core by metal mediated intramolecular biaryl ether formation},\n  journal = {Heterocycles},\n  date = {2008},\n  volume = {75},\n  pages = {2949\u20132958},\n  language = {}\n}\n@article{serban2007a,\n  author = {Serban, G. and Shigeta, Y. and Nishioka, H. and Abe, H. and Takeuchi, Y. and Harayama, T.},\n  title = {Studies toward the synthesis of toddaquinoline by intramolecular cyclization},\n  journal = {Heterocycles},\n  date = {2007},\n  volume = {71},\n  pages = {1623\u20131630},\n  language = {}\n}\n@article{gupta2015a,\n  author = {Gupta, R.},\n  title = {Biological significance of nitrogen containing heterocyclic compounds\u2014a mini review},\n  journal = {IJCA},\n  date = {2015},\n  volume = {8},\n  pages = {18\u201323},\n  language = {}\n}\n@book{joule2016a,\n  author = {Joule, J.A.},\n  title = {Natural products containing nitrogen heterocycles\u2014some highlights 1990\u20132015. In Advances in Heterocyclic Chemistry: Heterocyclic Chemistry in the 21st Century\u2014A Tribute to Alan Katritzky},\n  edition = {1st ed},\n  editor = {Scriven, E.F.V. and Ramsden, C.A.},\n  publisher = {Academic Press Elsevier},\n  date = {2016},\n  volume = {119},\n  pages = {81\u2013106},\n  language = {},\n  address = {Cambridge, UK}\n}\n@article{takashima2019a,\n  author = {Takashima, K. and Hayakawa, D. and Gouda, H. and Toyooka, N.},\n  title = {Formal syntheses of (-)-Lepadiformines},\n  edtior = {A},\n  journal = {Chem},\n  date = {2019},\n  volume = {84},\n  pages = \"5222\u20135229.\" # \"10257\u201310274.\",\n  medium = {CrossRef},\n  source = {Analysis of the structural diversity, substitution patterns, and frequency of nitrogen heterocycles among U. S. FDA approved pharmaceuticals},\n  unmatched-author = {C and (-)-Fasicularin. J. Org. 15. Vitaku, E.; Smith, D. T.; Njardarson, J. T.},\n  unmatched-journal = {J. Med. Chem.},\n  unmatched-volume = {57,},\n  unmatched-pages = {10257\u201310274.},\n  language = {}\n}\n@book{shukla2017a,\n  author = {Shukla, P.K. and Verma, A. and Mishra, P.},\n  title = {Significance of nitrogen heterocyclic nuclei in the search of pharmacological active compounds. In New Perspective in Agricultural and Human Health},\n  editor = {Shukla, R.P. and Mishra, R.S. and Tripathi, A.D. and Yadav, A.K. and Tiwari, M. and Mishra, R.R.},\n  publisher = {Bharti Publication},\n  date = {2017},\n  pages = {100\u2013126},\n  language = {},\n  address = {New Delhi, India}\n}\n@article{rajput2017a,\n  author = {Rajput, A.P. and Kankhare, A.R.},\n  title = {Synthetic utility of azaheterocycles: A short review},\n  journal = {Int. J. Pharm. Sci. Invent},\n  date = {2017},\n  volume = {6},\n  pages = {19\u201325},\n  language = {}\n}\n@article{de2016a,\n  author = {De Clercq, E. and Li, G.},\n  title = {Approved antiviral drugs over the past 50 years},\n  journal = {Clin. Microbiol. Rev},\n  date = {2016},\n  volume = {29},\n  pages = \"695\u2013747.\" # \"1009\u20131026.\",\n  medium = {CrossRef},\n  unmatched-author = {19. Razonable, R. R.},\n  source = {Antiviral drugs for viruses other than human immunodeficiency virus},\n  unmatched-journal = {Mayo Clin. Proc.},\n  unmatched-volume = {86,},\n  unmatched-pages = {1009\u20131026.},\n  unmatched-medium = {[CrossRef]},\n  unmatched-accessed = {[PubMed] 20.},\n  language = {},\n  urldate = {[PubMed]}\n}\n@article{serban2018a,\n  author = {Serban, G. and Stanasel, O. and Serban, E. and Bota, S.},\n  title = {2-Amino-1,3,4-thiadiazole as a potential scaffold for promising antimicrobial agents. Drug Des},\n  journal = {Devel. Ther},\n  date = {2018},\n  volume = {12},\n  pages = {1545\u20131566},\n  language = {}\n}\n@article{schenone2006a,\n  author = {Schenone, S. and Brullo, C. and Bruno, O. and Bondavalli, F. and Ranise, A. and Filippelli, W. and Rinaldi, B. and Capuano, A. and Falcone, G.},\n  title = {New 1,3,4-thiadiazole derivatives endowed with analgesic and anti-inflammatory activities},\n  journal = {Bioorg Med Chem},\n  date = {2006},\n  volume = {14},\n  pages = {1698\u20131705},\n  medium = {CrossRef},\n  language = {}\n}\n@article{labanauskas2001a,\n  author = {Labanauskas, L. and Kalcas, V. and Udrenaite, E. and Gaidelis, P. and Brukstus, A. and Dauksas, A.},\n  title = {Synthesis of 3-(3,4-dimethoxyphenyl)-1H-1,2,4-triazole-5-thiol and 2-amino-5-(3,4-dimethoxyphenyl)-1,3,4-thiadiazole derivatives exhibiting anti-inflammatory activity},\n  journal = {Pharmazie},\n  date = {2001},\n  volume = {56},\n  pages = {617\u2013619},\n  language = {}\n}\n@article{clerici2001a,\n  author = {Clerici, F. and Pocar, D. and Guido, M. and Loche, A. and Perlini, V. and Brufani, M.},\n  title = {Synthesis of 2-amino-5-sulfanyl1,3,4-thiadiazole derivatives and evaluation of their antidepressant and anxiolytic activity},\n  journal = {J Med Chem},\n  date = {2001},\n  volume = {44},\n  pages = {931\u2013936},\n  medium = {CrossRef},\n  language = {}\n}\n@article{basso2019a,\n  author = {Basso, A. and Liu, M. and Dai, C. and Gray, K. and Nale, L. and Tevar, S. and Lee, S. and Liang, L. and Ponery, A. and Yaremko, B.},\n  title = {SCH 2047069, a novel oral kinesin spindle protein inhibitor, shows single-agent antitumor activity and enhances the efficacy of chemotherapeutics},\n  journal = {Mol. Cancer Ther},\n  date = {2019},\n  volume = {9},\n  pages = {2993\u20133002},\n  medium = {CrossRef},\n  more-authors = {true},\n  language = {}\n}\n@article{dawood2017a,\n  author = {Dawood, K.M. and Farghaly, T.A.},\n  title = {Thiadiazole inhibitors: A patent review. Expert Opin},\n  journal = {Ther. Pat},\n  date = {2017},\n  volume = {27},\n  pages = {477\u2013505},\n  medium = {CrossRef},\n  language = {}\n}\n@article{haider2015a,\n  author = {Haider, S. and Alam, M.S. and Hamid, H.},\n  title = {1,3,4-Thiadiazoles: a potent multi targeted pharmacological scaffold},\n  journal = {Eur. J. Med. Chem},\n  date = {2015},\n  volume = {92},\n  pages = {156\u2013177},\n  medium = {CrossRef-PubMed},\n  language = {}\n}\n@article{serban2019a,\n  author = {Serban, G.},\n  title = {Future prospects in the treatment of parasitic diseases: 2-amino-1,3,4-thiadiazoles in leishmaniasis},\n  journal = {Molecules},\n  date = {2019},\n  volume = {24},\n  medium = {CrossRef-PubMed},\n  language = {}\n}\n@article{li2013a,\n  author = {Li, Y. and Geng, J. and Liu, Y. and Yu, S. and Zhao, G.},\n  title = {Thiadiazole\u2014A promising structure in Medicinal Chemistry},\n  journal = {ChemMedChem},\n  date = {2013},\n  volume = {8},\n  pages = {27\u201341},\n  medium = {CrossRef-PubMed},\n  language = {}\n}\n@article{senff-ribeiro2004a,\n  author = {Senff-Ribeiro, A. and Echevarria, A. and Silva, E.F. and Franco, C.R.C. and Veiga, S.S. and Oliveira, M.B.M.},\n  title = {Cytotoxic effect of a new 1,3,4-thiadiazolium mesoionic compound (MI-D) on cell lines of human mellanoma},\n  journal = {Br. J. Cancer},\n  date = {2004},\n  volume = {91},\n  pages = {297\u2013304},\n  medium = {CrossRef-PubMed},\n  language = {}\n}\n@article{wermuth2011a,\n  author = {Wermuth, C.G.},\n  title = {Are pyridazines privileged structures?},\n  journal = {Med. Chem. Commun},\n  date = {2011},\n  volume = {2},\n  pages = \"935\u2013941.\" # \"831\u2013840.\",\n  medium = {CrossRef},\n  note = {PubMed] 32},\n  unmatched-author = {31. Biziere, K.; Worms, P.; Kan, J. P.; Mandel, P.; Garattini, S.; Roncucci, R.},\n  source = {Minaprine, a new drug with antidepressant properties},\n  unmatched-journal = {Drugs Exp. Clin. Res.},\n  unmatched-volume = {1985, 11,},\n  unmatched-pages = {831\u2013840.},\n  language = {}\n}\n@article{ueno1997a,\n  author = {Ueno, S. and Bracamontes, J. and Zorumski, C. and Weiss, D.S. and Steinbach, J.H.},\n  title = {Bicuculline and gabazine are allosteric inhibitors of channel opening of the GABA A receptor},\n  journal = {J. Neurosci},\n  date = {1997},\n  volume = {17},\n  pages = {625\u2013634},\n  medium = {CrossRef},\n  language = {},\n  urldate = {[PubMed] 33.}\n}\n@article{holla2002a,\n  author = {Holla, B.S. and Poorjary, K.N. and Rao, B.S. and Shivananda, M.K.},\n  title = {New bis-aminomercaptotriazoles and bis-triazolothiadiazoles as possible anticancer agents},\n  journal = {Eur. J. Med. Chem},\n  date = {2002},\n  volume = {37},\n  pages = {511\u2013517},\n  note = {CrossRef] 34},\n  language = {}\n}\n@article{yousif2013a,\n  author = {Yousif, E. and Majeed, A. and Al-Sammarrae, K. and Salih, N. and Salimon, J. and Abdullah, B.},\n  title = {Metal complexes of Schiff base: preparation, characterization and antibacterial activity},\n  journal = {Arabian J. Chem},\n  date = {2013},\n  language = {}\n}\n@article{juszczak2008a,\n  author = {Juszczak, M. and Matysiak, J. and Brzana, W. and Niewiadomy, A. and Rzeski, W.},\n  title = {Evaluation of antiproliferative activity of 2-(monohalogenophenylamino)-5-(2,4-dihydroxyphenyl)-1,3,4-thiadiazoles. Arzneim. Forsch},\n  journal = {Drug Res},\n  date = {2008},\n  volume = {58},\n  pages = {353\u2013357},\n  note = {CrossRef] 36},\n  language = {}\n}\n@article{matysiak2006a,\n  author = {Matysiak, J.},\n  title = {Evaluation of antiproliferative effect in vitro of some 2-amino-5-(2,4-dihydroxyphenyl)-1,3,4thiadiazole derivatives},\n  journal = {Chem. Pharm. Bull},\n  date = {2006},\n  volume = {54},\n  pages = {988\u2013991},\n  medium = {CrossRef},\n  language = {},\n  urldate = {[PubMed] 37.}\n}\n@article{yoosefian2015a,\n  author = {Yoosefian, M. and Chermahini, Z.J. and Raissi, H. and Mola, A. and Sadeghi, M.},\n  title = {A theoretical study on the structure of 2-amino-1,3,4-thiadiazole and its 5-substituted derivatives in the gas phase, water, THF and DMSO solutions},\n  journal = {J. Mol. Liq},\n  date = {2015},\n  volume = {203},\n  pages = {137\u2013142},\n  note = {CrossRef] 38},\n  language = {}\n}\n@article{serban-a,\n  author = {Serban, G.},\n  title = {2-Amino-1,3,4-thiadiazoles as prospective agents in trypanosomiasis and other parasitoses},\n  journal = {Acta Pharm},\n  volume = {2020},\n  pages = {259\u2013290},\n  medium = {CrossRef},\n  number = {70},\n  language = {},\n  urldate = {[PubMed] 39.}\n}\n@article{serban2015a,\n  author = {Serban, G.},\n  title = {5-Arylamino-1,3,4-thiadiazol-2-yl acetic acid esters as intermediates for the synthesis of new bisheterocyclic compounds},\n  journal = {Farmacia},\n  date = {2015},\n  volume = {63},\n  pages = {146\u2013149},\n  language = {}\n}\n@article{serban2005a,\n  author = {Serban, G. and Coman, M. and Curea, E.},\n  title = {Synthesis of some heterocyclic nitro\u2013coumarins by Knoevenagel condensation},\n  journal = {Farmacia},\n  date = {2005},\n  volume = {53},\n  pages = {78\u201384},\n  language = {}\n}\n@article{serban2005b,\n  author = {Serban, G. and Matinca, D. and Bradea, O. and Gherman, L. and Coman, M. and Curea, E.},\n  title = {The study of the biological activity of some heterocyclic coumarins},\n  journal = {Farmacia},\n  date = {2005},\n  volume = {53},\n  pages = {91\u201399},\n  language = {}\n}\n@article{serban2002a,\n  author = {Serban, G. and Suciu, A. and Coman, M. and Curea, E.},\n  title = {Synthesis and physical-chemical study of some 3-(5-arylamino-1,3,4-thiadiazol-2-yl)cou\u2013marins},\n  journal = {Farmacia},\n  date = {2002},\n  volume = {50},\n  pages = {50\u201354},\n  language = {}\n}\n@incollection{horvath2014a,\n  author = {Horvath, T. and Serban, G. and Cuc, S.},\n  title = {Synthesis of new 2-phenylamino-5-[(\u03b1-acylamino)-p-X-stiryl] -1,3,4-thiadiazole compounds},\n  source = {Farmacia},\n  date = {2014},\n  volume = {62},\n  pages = {422\u2013427},\n  language = {}\n}\n@article{serban2001a,\n  author = {Serban, G. and Coman, M. and Curea, E. and Proinov, L.},\n  title = {Synthesis and description of some heterocyclic coumarins},\n  journal = {Farmacia},\n  date = {2001},\n  volume = {49},\n  pages = {45\u201352},\n  language = {}\n}\n@book{unknown-a,\n  title = {Global AIDS Update 2016. Joint United Nations Programme on},\n  publisher = {HIV/AIDS, Geneva, Switzerland},\n  url = {https://www.unaids.org/sites/default/files/media_asset/global-AIDS-update-2016en.pdf},\n  unmatched-accessed = {(accessed on 17 July 2018).},\n  language = {},\n  urldate = {Available online:}\n}\n@article{sharma2013a,\n  author = {Sharma, P.C. and Sinhmar, A. and Sharma, A. and Rajak, H. and Pathak, D.P.},\n  title = {Medicinal significance of benzothiazole scaffold: An insight view},\n  journal = {J. Enzyme Inhib. Med. Chem},\n  date = {2013},\n  volume = {28},\n  pages = {240\u2013266},\n  medium = {CrossRef},\n  language = {}\n}\n@article{xiaohe2010a,\n  author = {Xiaohe, Z. and Yu, Q. and Hong, Y. and Xiuqing, S. and Rugang, Z.},\n  title = {Synthesis, biological evaluation and molecular modeling studies of N-aryl-2-arylthioacetamides as non-nucleoside HIV-1 reverse transcriptase inhibitors},\n  journal = {Chem. Biol. Drug Des},\n  date = {2010},\n  volume = {76},\n  pages = {330\u2013339},\n  medium = {CrossRef-PubMed},\n  language = {}\n}\n@book{harms2007a,\n  author = {Harms, A.},\n  title = {Non-nucleoside reverse transcriptase inhibitors. In The art of drug synthesis},\n  editor = {Johnson, D.S. and Li, J.J.},\n  publisher = {Wiley Interscience, John Wiley and Sons, Inc},\n  date = {2007},\n  pages = {84},\n  language = {},\n  address = {Hoboken: New Jersey, NJ, USA}\n}\n@article{tatar2015a,\n  author = {Tatar, E. and Kucukguzel, S.G. and Karakus, S. and De Clercq, E. and Andrei, G. and Snoeck, R. and Pannecouque, C. and OktemOkullu, S. and Unubol, N. and Kocagoz, T.},\n  title = {Synthesis and biological evaluation of some new 1,3,4-thiadiazole and 1,2,4-triazole derivatives from L-methionine as antituberculosis and antiviral agents},\n  journal = {Marmara Pharm. J},\n  date = {2015},\n  volume = {19},\n  pages = {88\u2013102},\n  medium = {CrossRef},\n  more-authors = {true},\n  language = {}\n}\n@book{wit2008a,\n  author = {Wit, F.W.N.M. and Lange, J.M.A. and Volberding, P.A.},\n  title = {New HIV Drug Development. In Global HIV/AIDS Medicine},\n  editor = {Volberding, P.A. and Sande, M.A. and Greene, W.C. and Lange, J.M.A.},\n  publisher = {Elsevier},\n  date = {2008},\n  pages = {123\u2013134},\n  language = {},\n  address = {Philadelphia, PA, USA}\n}\n@article{schiller2009a,\n  author = {Schiller, D.S. and Youssef-Bessler, M.},\n  title = {Etravirine: A second-generation nonnucleoside reverse transcriptase inhibitor (NNRTI) active against NNRTI-resistant strains of HIV},\n  journal = {Clin. Ther},\n  date = {2009},\n  volume = {31},\n  pages = {692\u2013704},\n  medium = {CrossRef-PubMed},\n  language = {}\n}\n@article{miller2011a,\n  author = {Miller, C.D. and Crain, J. and Tran, B. and Patel, N.},\n  title = {Rilpivirine: A new addition to the anti-HIV-1 armamentarium},\n  journal = {Drugs Today},\n  date = {2011},\n  volume = {47},\n  pages = {5\u201315},\n  medium = {CrossRef-PubMed},\n  language = {}\n}\n@misc{unknown-b,\n  title = {Doravirine combination pill looks good for initial HIV treatment},\n  url = {https://www.aidsmap.com/news/jul-2017/doravirine-combination-pill-looks-good-initial-hiv-treatment},\n  unmatched-accessed = {(accessed on 5 June 2018).},\n  language = {},\n  urldate = {Available online:}\n}\n@inproceedings{gatell2016a,\n  author = {Gatell, J.M. and Raffi, F. and Plettenberg, A. and Smith, D. and Portilla, J. and Hoffmann, C. and Arasteh, K. and Thompson, M. and Xu, X. and Teppler, H.},\n  title = {Doravirine 100 mg QD vs Efavirenz + TDF/FTC in ART-Naive HIV+ Patients: Week 48 Results},\n  booktitle = {Proceedings of the Conference on Retroviruses and Opportunistic Infections},\n  date = {2016-02-22},\n  source = {abstract number 470},\n  language = {},\n  address = {Boston, MA, USA}\n}\n@misc{unknown-c,\n  title = {FDA Accepts New Drug Applications for Merck\u2019s Doravirine, the Company\u2019s Investigational Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI), for Treatment of HIV-1 Infection},\n  url = {http://investors.merck.com/news/press-release-details/2018/FDA-Accepts-New-Drug-Applications-forMercks-Doravirine-the-Companys-Investigational-Non-Nucleoside-Reverse-Transcriptase-InhibitorNNRTI-for-Treatment-of-HIV-1-Infection/default.aspx},\n  unmatched-accessed = {(accessed on 5 June 2018).},\n  language = {},\n  urldate = {Available online:}\n}\n@misc{unknown-d,\n  title = {FDA approves Merck\u2019s Pifeltro},\n  url = {https://www.drugs.com/newdrugs/fdaapproves-merck-s-pifeltro-doravirine-hiv-1-appropriate-patients-4815.html},\n  unmatched-accessed = {(accessed on 6 November 2019).20 September 2019. Available online: (accessed on 6 November 2019).},\n  unmatched-url = {https://investors.merck.com/news/press-release-details/2019/Mercks-PIFELTROdoravirine-and-DELSTRIGO-doravirinelamivudinetenofovir-disoproxil-fumarate-Receive-US-FDAApproval-for-Use-in-Appropriate-Adults-Living-with-HIV-1-Who-Are-Virologically-Suppressed/default.aspx},\n  language = {},\n  urldate = {(doravirine). Available online:}\n}\n@CrossRef{margolis2014a,\n  author = {Margolis, D.A. and Eron, J.J. and DeJesus, E. and White, S. and Wannamaker, P. and Stancil, B. and Johnson, M.},\n  title = {Unexpected finding of delayed-onset seizures in HIV-positive, treatment-experienced subjects in the Phase IIb evaluation of fosdevirine (GSK2248761). Antivir},\n  source = {Ther.},\n  date = {2014},\n  volume = {19},\n  pages = {69\u201378},\n  medium = {CrossRef},\n  language = {}\n}\n@article{vernazza2013a,\n  author = {Vernazza, P. and Wang, C. and Pozniak, A. and Weil, E. and Pulik, P. and Cooper, D.A. and Kaplan, R. and Lazzarin, A. and Valdez, H. and Goodrich, J.},\n  title = {Efficacy and safety of lersivirine (UK-453,061) versus efavirenz in antiretroviral treatment-naive HIV-1 infected patients: week 48 primary analysis results from an ongoing, multicenter, randomized, double-blind, Phase IIb trial},\n  journal = {J. Acquir. Immune Defic. Syndr},\n  date = {2013},\n  volume = {62},\n  pages = {171\u2013179},\n  medium = {CrossRef},\n  more-authors = {true},\n  language = {}\n}\n@article{platten2013a,\n  author = {Platten, M. and Fatkenheuer, G.},\n  title = {Lersavirine\u2014a new drug for HIV infection therapy},\n  journal = {Expert. Opin. Investig. Drugs},\n  date = {2013},\n  volume = {22},\n  pages = {1687\u20131694},\n  medium = {CrossRef},\n  language = {}\n}\n@article{sacks2017a,\n  author = {Sacks, D. and Ledwaba, J. and Morris, L. and Hunt, G.M.},\n  title = {Rapid detection of common HIV-1 drug resistance mutations by use of high-resolution melting analysis and unlabeled probes},\n  journal = {J. Clin. Microbiol},\n  date = {2017},\n  volume = {55},\n  pages = {122\u2013133},\n  medium = {CrossRef},\n  language = {}\n}\n@article{yahi1999a,\n  author = {Yahi, N. and Tamalet, C. and Tourres, C. and Tivoli, N. and Ariasi, F. and Volot, F. and Gastaut, J.A. and Gallais, H. and Moreau, J. and Fantini, J.},\n  title = {Mutation patterns of the reverse transcriptase and protease genes in Human Immunodeficiency Virus type 1-infected patients undergoing combination therapy: survey of 787 sequences},\n  journal = {J. Clin. Microbiol},\n  date = {1999},\n  volume = {37},\n  pages = {4099\u20134106},\n  medium = {CrossRef},\n  language = {}\n}\n@article{hu2014a,\n  author = {Hu, Y. and Li, C.Y. and Wang, X.M. and Yang, Y.H. and Zhu, H.L.},\n  title = {1,3,4-Thiadiazole: synthesis, reactions and applications in medicinal, agricultural, and materials chemistry},\n  journal = {Chem. Rev},\n  date = {2014},\n  volume = {114},\n  pages = {5572\u20135610},\n  medium = {CrossRef},\n  language = {}\n}\n@article{szulczyk2017a,\n  author = {Szulczyk, D. and Tomaszewski, P. and Jozwiak, M. and Koziol, A.E. and Lis, T. and Collu, D. and Iuliano, F. and Struga, M.},\n  title = {Synthesis and biological activities of ethyl 2-(2-pyridylacetate) derivatives containing thiourea, 1,2,4-triazole, thiadiazole and oxadiazole moieties},\n  journal = {Molecules},\n  date = {2017},\n  volume = {22},\n  pages = {409},\n  medium = {CrossRef-PubMed},\n  language = {}\n}\n@article{akhtar2007a,\n  author = {Akhtar, T. and Hameed, S. and Al-Masoudi, N.A. and Khan, K.M.},\n  title = {Synthesis and anti-HIV activity of new chiral 1,2,4-triazoles and 1,3,4-thiadiazoles},\n  journal = {Heteroatom Chem},\n  date = {2007},\n  volume = {18},\n  pages = {316\u2013322},\n  medium = {CrossRef},\n  language = {}\n}\n@article{hamad2010a,\n  author = {Hamad, N.S. and Al-Haidery, N.H. and Al-Masoudi, I.A. and Sabri, M. and Sabri, L. and Al-Masoudi, N.A.},\n  title = {Amino acid derivatives, part 4: synthesis and anti-HIV activity of new naphthalene derivatives},\n  journal = {Arch. Pharm. Chem. Life Sci},\n  date = {2010},\n  volume = {343},\n  pages = {397\u2013403},\n  medium = {CrossRef-PubMed},\n  language = {}\n}\n@article{wang2006a,\n  author = {Wang, Z. and Wu, B. and Kuhen, K.L. and Bursulaya, B. and Nguyen, T.N. and Nguyen, D.G. and He, Y.},\n  title = {Synthesis and biological evaluations of sulfanyltriazoles as novel HIV-1 non-nucleoside reverse transcriptase inhibitors},\n  journal = {Bioorg. Med. Chem. Lett},\n  date = {2006},\n  volume = {16},\n  pages = {4174\u20134177},\n  medium = {CrossRef-PubMed},\n  language = {}\n}\n@article{muraglia2006a,\n  author = {Muraglia, E. and Kinzel, O.D. and Laufer, R. and Miller, M.D. and Moyer, G. and Munshi, V. and Orvieto, F. and Palumbi, M.C. and Pescatore, G. and Rowley, M.},\n  title = {Tetrazole thioacetanilides: potent non-nucleoside inhibitors of WT HIV reverse transcriptase and its K103N mutant},\n  journal = {Bioorg. Med. Chem. Lett},\n  date = {2006},\n  volume = {16},\n  pages = {2748\u20132752},\n  medium = {CrossRef-PubMed},\n  more-authors = {true},\n  language = {}\n}\n@article{zhan2008a,\n  author = {Zhan, P. and Liu, X. and Cao, Y. and Wang, Y. and Pannecouque, C. and De Clercq, E.},\n  title = {1,2,3-Thiadiazole thioacetanilides as a novel class of potent HIV-1 non-nucleoside reverse transcriptase inhibitors},\n  journal = {Bioorg. Med. Chem. Lett},\n  date = {2008},\n  volume = {18},\n  pages = {5368\u20135371},\n  medium = {CrossRef-PubMed},\n  language = {}\n}\n@article{zhang2007a,\n  author = {Zhang, Z. and Xu, W. and Koh, Y.H. and Shim, J.H. and Girardet, J.L. and Yeh, L.T. and Hamatake, R.K. and Hong, Z.},\n  title = {A novel non-nucleoside analogue that inhibits human immunodeficiency virus type 1 isolates resistant to current non-nucleoside reverse transcriptase inhibitors},\n  journal = {Antimicrob. Agents Chemother},\n  date = {2007},\n  volume = {51},\n  pages = {429\u2013437},\n  medium = {CrossRef},\n  language = {}\n}\n@article{huang2011a,\n  author = {Huang, Y. and Zhao, L. and Jia, B. and Wu, L. and Li, Y. and Curthoys, N. and Zheng, J.C.},\n  title = {Glutaminase dysregulation in HIV-1-infected human microglia mediates neurotoxicity: relevant to HIV-1 associated neurocognitive disorders},\n  journal = {J. Neurosci},\n  date = {2011},\n  volume = {31},\n  pages = {15195\u201315204},\n  medium = {CrossRef},\n  language = {}\n}\n@article{zhao2004a,\n  author = {Zhao, J. and Lopez, A.L. and Erichsen, D. and Herek, S. and Cotter, R.L. and Curthoys, N.P. and Zheng, J.},\n  title = {Mitochondrial glutaminase enhances extracellular glutamate production in HIV-1-infected macrophages: Linkage to HIV-1 associated dementia},\n  journal = {J. Neurochem},\n  date = {2004},\n  volume = {88},\n  pages = {169\u2013180},\n  medium = {CrossRef},\n  language = {}\n}\n@CrossRef{stumvoll1999a,\n  author = {Stumvoll, M. and Perriello, G. and Meyer, C. and Gerich, J.},\n  title = {Role of glutamine in human carbohydrate metabolism in kidney and other tissues. Kidney Int},\n  date = {1999},\n  volume = {55},\n  pages = {778\u2013792},\n  medium = {CrossRef},\n  language = {}\n}\n@article{smith1990a,\n  author = {Smith, R.J.},\n  title = {Glutamine metabolism and its physiological importance},\n  journal = {J. Parenter. Enteral. Nutr},\n  date = {1990},\n  volume = {14},\n  pages = {40\u201344},\n  medium = {CrossRef-PubMed},\n  language = {}\n}\n@article{bromley2015a,\n  author = {Bromley, S.D. and Bennett, M.K. and Gross, M.I. and Li, J. and Chen, L. and Goyal, B. and Laidig, G. and Stanton, T.F. and Sjogren, E.B.},\n  title = {Treatment of viral infections with inhibitors of glutaminase},\n  journal = {PCT Int. Appl},\n  publisher = {PCT/US2014/061746; WO 2015/061432 A1},\n  date = {2015},\n  language = {}\n}\n@article{newsholme2003a,\n  author = {Newsholme, P. and Lima, M.M.R. and Procopio, J. and Pithon-Curi, T.C. and Doi, S.Q. and Bazotte, R.B. and Curi, R.},\n  title = {Glutamine and glutamate as vital metabolites},\n  journal = {Braz. J. Med. Biol. Res},\n  date = {2003},\n  volume = {36},\n  pages = {153\u2013162},\n  medium = {CrossRef-PubMed},\n  language = {}\n}\n@article{behar2001a,\n  author = {Behar, K.L. and Rothman, D.L.},\n  title = {In vivo NMR studies of glutamate-GABA-glutamine cycling in rodent and human cortex: the central role of glutamine},\n  journal = {J. Nutr},\n  date = {2001},\n  volume = {131},\n  pages = {2498\u20132504},\n  medium = {CrossRef-PubMed},\n  language = {}\n}\n@article{erdmann2007a,\n  author = {Erdmann, N. and Zhao, J. and Lopez, A.L. and Herek, S. and Curthoys, N. and Hexum, T.D. and Tsukamoto, T. and Ferraris, D. and Zheng, J.},\n  title = {Glutamate production by HIV-1 infected human macrophage is blocked by the inhibition of glutaminase},\n  journal = {J. Neurochem},\n  date = {2007},\n  volume = {102},\n  pages = {539\u2013549},\n  medium = {CrossRef},\n  language = {}\n}\n@article{babayo2014a,\n  author = {Babayo, A. and Thairu, Y. and Nasir, I.A. and Baba, M.M.},\n  title = {Serological evidence and sociodemographic risk factors of recent cytomegalovirus infection in pregnant women attending a tertiary hospital in Maiduguri, Nigeria},\n  journal = {J. Med. Microbiol. Infec. Dis},\n  date = {2014},\n  volume = {2},\n  pages = {49\u201355},\n  language = {}\n}\n@article{forbes1989a,\n  author = {Forbes, B.A.},\n  title = {Acquisition of cytomegalovirus infection: An update},\n  journal = {Clin. Microbiol. Rev},\n  date = {1989},\n  volume = {2},\n  pages = {204\u2013216},\n  medium = {CrossRef},\n  language = {}\n}\n@book{spruance2003a,\n  author = {Spruance, S.L.},\n  title = {Viral infections. In The Merck Manual of Medical Information: Second Home Edition},\n  editor = {Beers, M.HMerck Research Laboratories and Merck and Co},\n  date = {2003},\n  pages = {1164},\n  publisher = {Whitehouse Station, NJ, USA},\n  language = {},\n  address = {Inc.}\n}\n@techreport{unknown-e,\n  title = {and Congenital CMV Infection},\n  url = {https://www.cdc.gov/cmv/overview.html},\n  unmatched-accessed = {(accessed on 11 July 2018).},\n  language = {},\n  urldate = {Available online:},\n  institution = {Centers for Disease Control and Prevention. Cytomegalovirus (CMV}\n}\n@article{tan2014a,\n  author = {Tan, B.H.},\n  title = {Cytomegalovirus treatment. Curr},\n  source = {Ganciclovir: An update of its use in the prevention of cytomegalovirus infection and disease in transplant recipients},\n  date = {2014},\n  volume = {6},\n  pages = \"256\u2013270.\" # \"1153\u20131183.\",\n  medium = {CrossRef},\n  journal = {Drugs},\n  note = {CrossRef] 85},\n  unmatched-author = {84. McGavin, J. K.; Goa, K. L.},\n  unmatched-volume = {61,},\n  unmatched-pages = {1153\u20131183.},\n  language = {}\n}\n@article{unknown2013a,\n  title = {A case of severe ganciclovir-induced encephalopathy},\n  journal = {Case Rep. Neurol},\n  date = {2013},\n  volume = {5},\n  pages = {183\u2013186},\n  note = {CrossRef] 86},\n  language = {}\n}\n@book{organization2018a,\n  author = {Organization, World Health},\n  title = {Battle against Respiratory},\n  publisher = {Viruses (BRaVe) initiative. Available online},\n  url = {http://www.who.int/influenza/patient_care/clinical/brave/en/},\n  event = {on 14},\n  date = {2018-06},\n  language = {}\n}\n@book{organization-a,\n  author = {Organization, World Health},\n  title = {Research needs for the battle against respiratory viruses (BRAve)},\n  publisher = {Background document 2013. Available online},\n  url = {http://www.who.int/influenza/patient_care/clinical/BRaVe_Research_},\n  language = {},\n  urldate = {Agenda_2013.pdf (on 14 June 2018).}\n}\n@article{bellos2010a,\n  author = {Bellos, A. and Mulholland, K. and O\u2019Brien, K.L. and Qazi, S.A. and Gayer, M. and Checchil, F.},\n  title = {The burden of acute respiratory infections in crisis-affected populations: A systematic review},\n  journal = {Confl. Health},\n  date = {2010},\n  volume = {4},\n  pages = \"1\u201312.\" # \"283\u2013291.\",\n  medium = {CrossRef},\n  unmatched-author = {90. Straliotto, S. M.; Siqueira, M. M.; Muller, R. L.; Fischer, G. B.; Cunha, M. L. T.; Nestor, S. M.},\n  source = {Viral etiology of acute respiratory infections among children in Porto Alegre},\n  unmatched-journal = {RS, Brazil. Rev. Soc. Bras. Med. Tro.},\n  unmatched-volume = {35,},\n  unmatched-pages = {283\u2013291.},\n  unmatched-medium = {[CrossRef]},\n  language = {},\n  urldate = {[PubMed] 91.}\n}\n@article{da2015a,\n  author = {Da Silva, R.C. and da Silva Mendes, G. and Rojas, M.A. and Amorim, A.R. and Couceiro, J.N. and Lupi, O. and Elabras, J. and Pires, G. and Valle, S. and Santos, N.},\n  title = {Frequency of viral etiology in symptomatic adult upper respiratory tract infections},\n  journal = {Braz. J. Infect. Dis},\n  date = {2015},\n  volume = {19},\n  pages = {30\u201335},\n  publisher = {CrossRef] [PubMed] 92},\n  language = {}\n}\n@article{fendrick2003a,\n  author = {Fendrick, A.M. and Monto, A.S. and Nightengale, B. and Sarnes, M.},\n  title = {The economic burden of non-influenza-related viral respiratory tract infections in the United States},\n  journal = {Arch. Intern. Med},\n  date = {2003},\n  volume = {163},\n  pages = {487\u2013494},\n  medium = {CrossRef},\n  language = {},\n  urldate = {[PubMed] 93.}\n}\n@book{johnson2007a,\n  author = {Johnson, D.S. and Li, J.J.},\n  title = {Neuraminidase inhibitors for influenza: oseltamivir phosphate (Tamiflu) and zanamivir (Relenza). In The art of drug synthesis},\n  editor = {Johnson, D.S. and Li, J.J.},\n  publisher = {Wiley Interscience, John Wiley and Sons, Inc},\n  date = {2007},\n  pages = {95\u201396},\n  language = {},\n  address = {Hoboken: New Jersey, NJ, USA}\n}\n@article{al-muharrmi2010a,\n  author = {Al-Muharrmi, Z.},\n  title = {Understanding the Influenza A H1N1 2009 pandemic},\n  journal = {SQU Med. J},\n  date = {2010},\n  volume = {10},\n  pages = {187\u2013195},\n  language = {}\n}\n@article{tonelli2017a,\n  author = {Tonelli, M. and Naesens, L. and Gazzarrini, S. and Santucci, M. and Cichero, E. and Tasso, B. and Moroni, A. and Costi, M.P. and Loddo, R.},\n  title = {Host dihydrofolate reductase (DHFR)-directed cycloguanil analogues endowed with activity against influenza virus and respiratory syncytial virus},\n  journal = {Eur. J. Med. Chem},\n  date = {2017},\n  volume = {135},\n  pages = \"467\u2013478.\" # \"229\u2013243.\",\n  medium = {CrossRef},\n  note = {CrossRef] 97. World},\n  event = {Health Organization. Fact sheets on sustainable development goals: health target, Viral hepatitis, World Health Organization 2017},\n  url = {www.euro.who.int/sdgs.},\n  unmatched-author = {96. Francesconi, V.; Giovannini, L.; Santucci, M.; Cichero, E.; Costi, M. P.; Naesens, L.; Giordanetto, F.; Tonelli, M.},\n  source = {Synthesis, biological evaluation and molecular modeling of novel azaspiro dihydrotriazines as influenza virus inhibitors targeting the host factor dihydrofolate reductase (DHFR). Eur},\n  unmatched-journal = {J. Med. Chem.},\n  unmatched-volume = {155,},\n  unmatched-pages = {229\u2013243.},\n  unmatched-url = {http://www.euro.who.int/__data/assets/pdf_file/0003/348222/Fact-sheet-SDG-viral-hepatitis-FINALen.pdf?ua=1},\n  unmatched-accessed = {(accessed on 23 January 2020).},\n  language = {},\n  address = {Copenhagen, Denmark},\n  urldate = {Available online:}\n}\n@book{organization2019a,\n  author = {Organization, World Health},\n  title = {Hepatitis B in the WHO European Region, Fact sheet \u2013 July 2019},\n  publisher = {World Health Organization},\n  date = {2019},\n  url = {http://www.euro.who.int/__data/assets/pdf_file/0007/377251/Fact-Sheet-Hepatitis-B_2019-ENG.pdf},\n  unmatched-accessed = {(accessed on 23 January 2020).},\n  language = {},\n  urldate = {Available online:}\n}\n@misc{b-a,\n  author = {B, F.D.A.Hepatitis and treatments, C.},\n  url = {https://www.fda.gov/patients/hepatitis-b-c/hepatitis-band-c-treatments},\n  unmatched-accessed = {(accessed on 23 January 2020).},\n  urldate = {Available online:}\n}\n@article{kurkela2008a,\n  author = {Kurkela, S. and Ratti, O. and Huhtamo, E. and Uzcategui, N. and Nuorti, J.P. and Laakkonen, J. and Manni, T. and Helle, P. and Vaheri, A. and Vapalahti, O.},\n  title = {Sindbis virus infection in resident birds, migratory birds, and humans, Finland},\n  journal = {Emerg. Infect. Dis},\n  date = {2008},\n  volume = {14},\n  pages = {41\u201347},\n  medium = {CrossRef},\n  language = {}\n}\n@article{kucukguzel2007a,\n  author = {Kucukguzel, S.G. and Kucukguzel, I. and Tatar, E. and Rollas, S. and Sahin, F. and Gulluce, M. and De Clercq, E. and Kabasakal, L.},\n  title = {Synthesis of some novel heterocyclic compounds derived from diflunisal hydrazide as potential anti-infective and anti-inflammatory agents},\n  journal = {Eur. J. Med. Chem},\n  date = {2007},\n  volume = {42},\n  pages = {893\u2013901},\n  medium = {CrossRef},\n  language = {}\n}\n@article{bonina1982a,\n  author = {Bonina, L. and Orzalesi, G. and Merendino, R. and Arena, A. and Mastroeni, P.},\n  title = {Structure-activity relationships of new antiviral compounds},\n  journal = {Antimicrob. Agents Chemother},\n  date = {1982},\n  volume = {22},\n  pages = {1067\u20131069},\n  medium = {CrossRef},\n  language = {}\n}\n@incollection{streissle1985a,\n  author = {Streissle, G. and Paesseus, A. and Oediger, H.},\n  title = {New antiviral compounds},\n  booktitle = {Advances in Virus Research},\n  editor = {Maramorosch, K. and Murphy, F.A. and Shatkin, A.J.},\n  publisher = {Academic Press., Elsevier},\n  date = {1985},\n  volume = {30},\n  pages = {115},\n  language = {},\n  address = {London, UK}\n}\n@article{cui2010a,\n  author = {Cui, T. and Chum, M.P. and Lam, Y. and Gao, Y.},\n  title = {Compounds for use as anti-viral agents},\n  journal = {Singapore Pat. Appl. SG},\n  volume = {162629},\n  pages = {1},\n  date = {2010},\n  language = {}\n}\n@article{yadav2001a,\n  author = {Yadav, L.D.S. and Singh, S.},\n  title = {Synthesis of antiviral acyclic C-nucleosides incorporating thiazolo-1,3,4-oxa(thia)diazole or thiazolo-1,2,4-triazole structure as a nucleobase},\n  journal = {Indian J. Chem},\n  date = {2001},\n  volume = {40},\n  pages = {440\u2013442},\n  medium = {CrossRef},\n  language = {}\n}\n",
        "links": [
            "http://www.mdpi.com/journal/molecules"
        ],
        "emails": [
            "getaserban_2000@yahoo.com"
        ],
        "pages": "942",
        "references_ris": "TY  - BOOK\nAU  - Beale, Jr, J.M.\nTI  - Antiviral agents. In Wilson and Gisvold\u2019s Textbook of Organic Medicinal and Pharmaceutical Chemistry\nET  - 12th ed\nPY  - 2011\nDA  - 2011\nSP  - 330\nEP  - 336\nPB  - Baltimore, MD, USA\nLA  - \nCY  - Wilkins\nER  - \n\nTY  - JOUR\nAU  - Rohwer, F.\nAU  - Barrot, K.\nTI  - Viral information\nT2  - Biol. Philos\nPY  - 2013\nDA  - 2013\nVL  - 28\nSP  - \"283\nEP  - 297.\" # \"pp. 1274\nC1  - CrossRef\nET  - 7th ed\nA2  - Lemke, T.L.\nA2  - Williams, D.A.\nA2  - Roche, V.F.\nA2  - Zito, S.W.\nPB  - Lippincott Williams and Wilkins, Wolters Kluwer\nC1  - 3. Woster, P. M.\nT2  - Antiviral agents and protease inhibitors. In Foye\u2019s Principles of Medicinal Chemistry\nC1  - pp. 1274\u20131302.\nLA  - \nCY  - Baltimore, MD, USA\nER  - \n\nTY  - GEN\nAU  - Berzofsky, J.A.\nAU  - Ahlers, J.D.\nAU  - Janik, J.\nAU  - Morris, J.\nAU  - Oh, S.K.\nAU  - Terabe, M.\nAU  - Belyakov, I.M.\nTI  - Progress on new vaccine strategies against chronic viral infections\nT2  - J. Clin. Invest\nPY  - 2004\nDA  - 2004/05/05\nVL  - 114\nSP  - 450\nEP  - 462\nPB  - Weekly epidemiological record\nUR  - http://www.who.int/wer\nT2  - World Health Organization. Human papillomavirus vaccines: WHO position paper\nC1  - (accessed on 11 January 2020).\nLA  - \nC1  - Available online:\nER  - \n\nTY  - JOUR\nAU  - El-Essawy, F.A.\nAU  - El-Sayed, W.A.\nAU  - El-Kafrawy, S.A.\nAU  - Morshedy, A.S.\nAU  - Abdel-Rahman, A.H.\nTI  - Anti-Hepatitis B virus activity of new 1,2,4-triazol-2-yl- and1,3,4-oxadiazol-2-yl-2-pyridinone derivatives\nT2  - Z. Naturforsch\nPY  - 2008\nDA  - 2008\nVL  - 63\nSP  - \"667\nEP  - 674.\" # \"1802\nC1  - CrossRef\nC1  - Tonelli, M.; Cichero, E.\nT2  - Fight against H1N1 Influenza A virus: recent insights towards the development of druggable compounds\nC1  - Curr. Med. Chem.\nC1  - 23,\nC1  - 1802\u20131817.\nLA  - \nC1  - [PubMed] 8.\nER  - \n\nTY  - JOUR\nAU  - Diaba, F.\nAU  - Montiel, J.A.\nAU  - Serban, G.\nAU  - Bonjoch, J.\nTI  - Synthesis of normorphans through an efficient intramolecular carbamoylation of ketones\nT2  - Org. Lett\nPY  - 2015\nDA  - 2015\nVL  - 17\nSP  - 3860\nEP  - 3863\nLA  - \nER  - \n\nTY  - JOUR\nAU  - Serban, G.\nAU  - Abe, H.\nAU  - Takeuchi, Y.\nTI  - Synthetic studies of substituted pyridine aldehydes as intermediates for the synthesis of toddaquinoline, its derivatives and other natural products\nT2  - Heterocycles\nPY  - 2011\nDA  - 2011\nVL  - 83\nC1  - CrossRef\nC1  - 10.\nLA  - \nER  - \n\nTY  - JOUR\nAU  - Serban, G.\nAU  - Abe, H.\nAU  - Takeuchi, Y.\nAU  - Harayama, T.\nTI  - A new approach to the benzopyridoxepine core by metal mediated intramolecular biaryl ether formation\nT2  - Heterocycles\nPY  - 2008\nDA  - 2008\nVL  - 75\nSP  - 2949\nEP  - 2958\nLA  - \nER  - \n\nTY  - JOUR\nAU  - Serban, G.\nAU  - Shigeta, Y.\nAU  - Nishioka, H.\nAU  - Abe, H.\nAU  - Takeuchi, Y.\nAU  - Harayama, T.\nTI  - Studies toward the synthesis of toddaquinoline by intramolecular cyclization\nT2  - Heterocycles\nPY  - 2007\nDA  - 2007\nVL  - 71\nSP  - 1623\nEP  - 1630\nLA  - \nER  - \n\nTY  - JOUR\nAU  - Gupta, R.\nTI  - Biological significance of nitrogen containing heterocyclic compounds\u2014a mini review\nT2  - IJCA\nPY  - 2015\nDA  - 2015\nVL  - 8\nSP  - 18\nEP  - 23\nLA  - \nER  - \n\nTY  - BOOK\nAU  - Joule, J.A.\nTI  - Natural products containing nitrogen heterocycles\u2014some highlights 1990\u20132015. In Advances in Heterocyclic Chemistry: Heterocyclic Chemistry in the 21st Century\u2014A Tribute to Alan Katritzky\nET  - 1st ed\nA2  - Scriven, E.F.V.\nA2  - Ramsden, C.A.\nPB  - Academic Press Elsevier\nPY  - 2016\nDA  - 2016\nVL  - 119\nSP  - 81\nEP  - 106\nLA  - \nCY  - Cambridge, UK\nER  - \n\nTY  - JOUR\nAU  - Takashima, K.\nAU  - Hayakawa, D.\nAU  - Gouda, H.\nAU  - Toyooka, N.\nTI  - Formal syntheses of (-)-Lepadiformines\nC1  - A\nT2  - Chem\nPY  - 2019\nDA  - 2019\nVL  - 84\nSP  - \"5222\nEP  - 5229.\" # \"10257\nC1  - CrossRef\nT2  - Analysis of the structural diversity, substitution patterns, and frequency of nitrogen heterocycles among U. S. FDA approved pharmaceuticals\nC1  - C and (-)-Fasicularin. J. Org. 15. Vitaku, E.; Smith, D. T.; Njardarson, J. T.\nC1  - J. Med. Chem.\nC1  - 57,\nC1  - 10257\u201310274.\nLA  - \nER  - \n\nTY  - BOOK\nAU  - Shukla, P.K.\nAU  - Verma, A.\nAU  - Mishra, P.\nTI  - Significance of nitrogen heterocyclic nuclei in the search of pharmacological active compounds. In New Perspective in Agricultural and Human Health\nA2  - Shukla, R.P.\nA2  - Mishra, R.S.\nA2  - Tripathi, A.D.\nA2  - Yadav, A.K.\nA2  - Tiwari, M.\nA2  - Mishra, R.R.\nPB  - Bharti Publication\nPY  - 2017\nDA  - 2017\nSP  - 100\nEP  - 126\nLA  - \nCY  - New Delhi, India\nER  - \n\nTY  - JOUR\nAU  - Rajput, A.P.\nAU  - Kankhare, A.R.\nTI  - Synthetic utility of azaheterocycles: A short review\nT2  - Int. J. Pharm. Sci. Invent\nPY  - 2017\nDA  - 2017\nVL  - 6\nSP  - 19\nEP  - 25\nLA  - \nER  - \n\nTY  - JOUR\nAU  - De Clercq, E.\nAU  - Li, G.\nTI  - Approved antiviral drugs over the past 50 years\nT2  - Clin. Microbiol. Rev\nPY  - 2016\nDA  - 2016\nVL  - 29\nSP  - \"695\nEP  - 747.\" # \"1009\nC1  - CrossRef\nC1  - 19. Razonable, R. R.\nT2  - Antiviral drugs for viruses other than human immunodeficiency virus\nC1  - Mayo Clin. Proc.\nC1  - 86,\nC1  - 1009\u20131026.\nC1  - [CrossRef]\nC1  - [PubMed] 20.\nLA  - \nC1  - [PubMed]\nER  - \n\nTY  - JOUR\nAU  - Serban, G.\nAU  - Stanasel, O.\nAU  - Serban, E.\nAU  - Bota, S.\nTI  - 2-Amino-1,3,4-thiadiazole as a potential scaffold for promising antimicrobial agents. Drug Des\nT2  - Devel. Ther\nPY  - 2018\nDA  - 2018\nVL  - 12\nSP  - 1545\nEP  - 1566\nLA  - \nER  - \n\nTY  - JOUR\nAU  - Schenone, S.\nAU  - Brullo, C.\nAU  - Bruno, O.\nAU  - Bondavalli, F.\nAU  - Ranise, A.\nAU  - Filippelli, W.\nAU  - Rinaldi, B.\nAU  - Capuano, A.\nAU  - Falcone, G.\nTI  - New 1,3,4-thiadiazole derivatives endowed with analgesic and anti-inflammatory activities\nT2  - Bioorg Med Chem\nPY  - 2006\nDA  - 2006\nVL  - 14\nSP  - 1698\nEP  - 1705\nC1  - CrossRef\nLA  - \nER  - \n\nTY  - JOUR\nAU  - Labanauskas, L.\nAU  - Kalcas, V.\nAU  - Udrenaite, E.\nAU  - Gaidelis, P.\nAU  - Brukstus, A.\nAU  - Dauksas, A.\nTI  - Synthesis of 3-(3,4-dimethoxyphenyl)-1H-1,2,4-triazole-5-thiol and 2-amino-5-(3,4-dimethoxyphenyl)-1,3,4-thiadiazole derivatives exhibiting anti-inflammatory activity\nT2  - Pharmazie\nPY  - 2001\nDA  - 2001\nVL  - 56\nSP  - 617\nEP  - 619\nLA  - \nER  - \n\nTY  - JOUR\nAU  - Clerici, F.\nAU  - Pocar, D.\nAU  - Guido, M.\nAU  - Loche, A.\nAU  - Perlini, V.\nAU  - Brufani, M.\nTI  - Synthesis of 2-amino-5-sulfanyl1,3,4-thiadiazole derivatives and evaluation of their antidepressant and anxiolytic activity\nT2  - J Med Chem\nPY  - 2001\nDA  - 2001\nVL  - 44\nSP  - 931\nEP  - 936\nC1  - CrossRef\nLA  - \nER  - \n\nTY  - JOUR\nAU  - Basso, A.\nAU  - Liu, M.\nAU  - Dai, C.\nAU  - Gray, K.\nAU  - Nale, L.\nAU  - Tevar, S.\nAU  - Lee, S.\nAU  - Liang, L.\nAU  - Ponery, A.\nAU  - Yaremko, B.\nTI  - SCH 2047069, a novel oral kinesin spindle protein inhibitor, shows single-agent antitumor activity and enhances the efficacy of chemotherapeutics\nT2  - Mol. Cancer Ther\nPY  - 2019\nDA  - 2019\nVL  - 9\nSP  - 2993\nEP  - 3002\nC1  - CrossRef\nC1  - true\nLA  - \nER  - \n\nTY  - JOUR\nAU  - Dawood, K.M.\nAU  - Farghaly, T.A.\nTI  - Thiadiazole inhibitors: A patent review. Expert Opin\nT2  - Ther. Pat\nPY  - 2017\nDA  - 2017\nVL  - 27\nSP  - 477\nEP  - 505\nC1  - CrossRef\nLA  - \nER  - \n\nTY  - JOUR\nAU  - Haider, S.\nAU  - Alam, M.S.\nAU  - Hamid, H.\nTI  - 1,3,4-Thiadiazoles: a potent multi targeted pharmacological scaffold\nT2  - Eur. J. Med. Chem\nPY  - 2015\nDA  - 2015\nVL  - 92\nSP  - 156\nEP  - 177\nC1  - CrossRef-PubMed\nLA  - \nER  - \n\nTY  - JOUR\nAU  - Serban, G.\nTI  - Future prospects in the treatment of parasitic diseases: 2-amino-1,3,4-thiadiazoles in leishmaniasis\nT2  - Molecules\nPY  - 2019\nDA  - 2019\nVL  - 24\nC1  - CrossRef-PubMed\nLA  - \nER  - \n\nTY  - JOUR\nAU  - Li, Y.\nAU  - Geng, J.\nAU  - Liu, Y.\nAU  - Yu, S.\nAU  - Zhao, G.\nTI  - Thiadiazole\u2014A promising structure in Medicinal Chemistry\nT2  - ChemMedChem\nPY  - 2013\nDA  - 2013\nVL  - 8\nSP  - 27\nEP  - 41\nC1  - CrossRef-PubMed\nLA  - \nER  - \n\nTY  - JOUR\nAU  - Senff-Ribeiro, A.\nAU  - Echevarria, A.\nAU  - Silva, E.F.\nAU  - Franco, C.R.C.\nAU  - Veiga, S.S.\nAU  - Oliveira, M.B.M.\nTI  - Cytotoxic effect of a new 1,3,4-thiadiazolium mesoionic compound (MI-D) on cell lines of human mellanoma\nT2  - Br. J. Cancer\nPY  - 2004\nDA  - 2004\nVL  - 91\nSP  - 297\nEP  - 304\nC1  - CrossRef-PubMed\nLA  - \nER  - \n\nTY  - JOUR\nAU  - Wermuth, C.G.\nTI  - Are pyridazines privileged structures?\nT2  - Med. Chem. Commun\nPY  - 2011\nDA  - 2011\nVL  - 2\nSP  - \"935\nEP  - 941.\" # \"831\nC1  - CrossRef\nN1  - PubMed] 32\nC1  - 31. Biziere, K.; Worms, P.; Kan, J. P.; Mandel, P.; Garattini, S.; Roncucci, R.\nT2  - Minaprine, a new drug with antidepressant properties\nC1  - Drugs Exp. Clin. Res.\nC1  - 1985, 11,\nC1  - 831\u2013840.\nLA  - \nER  - \n\nTY  - JOUR\nAU  - Ueno, S.\nAU  - Bracamontes, J.\nAU  - Zorumski, C.\nAU  - Weiss, D.S.\nAU  - Steinbach, J.H.\nTI  - Bicuculline and gabazine are allosteric inhibitors of channel opening of the GABA A receptor\nT2  - J. Neurosci\nPY  - 1997\nDA  - 1997\nVL  - 17\nSP  - 625\nEP  - 634\nC1  - CrossRef\nLA  - \nC1  - [PubMed] 33.\nER  - \n\nTY  - JOUR\nAU  - Holla, B.S.\nAU  - Poorjary, K.N.\nAU  - Rao, B.S.\nAU  - Shivananda, M.K.\nTI  - New bis-aminomercaptotriazoles and bis-triazolothiadiazoles as possible anticancer agents\nT2  - Eur. J. Med. Chem\nPY  - 2002\nDA  - 2002\nVL  - 37\nSP  - 511\nEP  - 517\nN1  - CrossRef] 34\nLA  - \nER  - \n\nTY  - JOUR\nAU  - Yousif, E.\nAU  - Majeed, A.\nAU  - Al-Sammarrae, K.\nAU  - Salih, N.\nAU  - Salimon, J.\nAU  - Abdullah, B.\nTI  - Metal complexes of Schiff base: preparation, characterization and antibacterial activity\nT2  - Arabian J. Chem\nPY  - 2013\nDA  - 2013\nLA  - \nER  - \n\nTY  - JOUR\nAU  - Juszczak, M.\nAU  - Matysiak, J.\nAU  - Brzana, W.\nAU  - Niewiadomy, A.\nAU  - Rzeski, W.\nTI  - Evaluation of antiproliferative activity of 2-(monohalogenophenylamino)-5-(2,4-dihydroxyphenyl)-1,3,4-thiadiazoles. Arzneim. Forsch\nT2  - Drug Res\nPY  - 2008\nDA  - 2008\nVL  - 58\nSP  - 353\nEP  - 357\nN1  - CrossRef] 36\nLA  - \nER  - \n\nTY  - JOUR\nAU  - Matysiak, J.\nTI  - Evaluation of antiproliferative effect in vitro of some 2-amino-5-(2,4-dihydroxyphenyl)-1,3,4thiadiazole derivatives\nT2  - Chem. Pharm. Bull\nPY  - 2006\nDA  - 2006\nVL  - 54\nSP  - 988\nEP  - 991\nC1  - CrossRef\nLA  - \nC1  - [PubMed] 37.\nER  - \n\nTY  - JOUR\nAU  - Yoosefian, M.\nAU  - Chermahini, Z.J.\nAU  - Raissi, H.\nAU  - Mola, A.\nAU  - Sadeghi, M.\nTI  - A theoretical study on the structure of 2-amino-1,3,4-thiadiazole and its 5-substituted derivatives in the gas phase, water, THF and DMSO solutions\nT2  - J. Mol. Liq\nPY  - 2015\nDA  - 2015\nVL  - 203\nSP  - 137\nEP  - 142\nN1  - CrossRef] 38\nLA  - \nER  - \n\nTY  - JOUR\nAU  - Serban, G.\nTI  - 2-Amino-1,3,4-thiadiazoles as prospective agents in trypanosomiasis and other parasitoses\nT2  - Acta Pharm\nVL  - 2020\nSP  - 259\nEP  - 290\nC1  - CrossRef\nIS  - 70\nLA  - \nC1  - [PubMed] 39.\nER  - \n\nTY  - JOUR\nAU  - Serban, G.\nTI  - 5-Arylamino-1,3,4-thiadiazol-2-yl acetic acid esters as intermediates for the synthesis of new bisheterocyclic compounds\nT2  - Farmacia\nPY  - 2015\nDA  - 2015\nVL  - 63\nSP  - 146\nEP  - 149\nLA  - \nER  - \n\nTY  - JOUR\nAU  - Serban, G.\nAU  - Coman, M.\nAU  - Curea, E.\nTI  - Synthesis of some heterocyclic nitro\u2013coumarins by Knoevenagel condensation\nT2  - Farmacia\nPY  - 2005\nDA  - 2005\nVL  - 53\nSP  - 78\nEP  - 84\nLA  - \nER  - \n\nTY  - JOUR\nAU  - Serban, G.\nAU  - Matinca, D.\nAU  - Bradea, O.\nAU  - Gherman, L.\nAU  - Coman, M.\nAU  - Curea, E.\nTI  - The study of the biological activity of some heterocyclic coumarins\nT2  - Farmacia\nPY  - 2005\nDA  - 2005\nVL  - 53\nSP  - 91\nEP  - 99\nLA  - \nER  - \n\nTY  - JOUR\nAU  - Serban, G.\nAU  - Suciu, A.\nAU  - Coman, M.\nAU  - Curea, E.\nTI  - Synthesis and physical-chemical study of some 3-(5-arylamino-1,3,4-thiadiazol-2-yl)cou\u2013marins\nT2  - Farmacia\nPY  - 2002\nDA  - 2002\nVL  - 50\nSP  - 50\nEP  - 54\nLA  - \nER  - \n\nTY  - CHAP\nAU  - Horvath, T.\nAU  - Serban, G.\nAU  - Cuc, S.\nTI  - Synthesis of new 2-phenylamino-5-[(\u03b1-acylamino)-p-X-stiryl] -1,3,4-thiadiazole compounds\nT2  - Farmacia\nPY  - 2014\nDA  - 2014\nVL  - 62\nSP  - 422\nEP  - 427\nLA  - \nER  - \n\nTY  - JOUR\nAU  - Serban, G.\nAU  - Coman, M.\nAU  - Curea, E.\nAU  - Proinov, L.\nTI  - Synthesis and description of some heterocyclic coumarins\nT2  - Farmacia\nPY  - 2001\nDA  - 2001\nVL  - 49\nSP  - 45\nEP  - 52\nLA  - \nER  - \n\nTY  - BOOK\nTI  - Global AIDS Update 2016. Joint United Nations Programme on\nPB  - HIV/AIDS, Geneva, Switzerland\nUR  - https://www.unaids.org/sites/default/files/media_asset/global-AIDS-update-2016en.pdf\nC1  - (accessed on 17 July 2018).\nLA  - \nC1  - Available online:\nER  - \n\nTY  - JOUR\nAU  - Sharma, P.C.\nAU  - Sinhmar, A.\nAU  - Sharma, A.\nAU  - Rajak, H.\nAU  - Pathak, D.P.\nTI  - Medicinal significance of benzothiazole scaffold: An insight view\nT2  - J. Enzyme Inhib. Med. Chem\nPY  - 2013\nDA  - 2013\nVL  - 28\nSP  - 240\nEP  - 266\nC1  - CrossRef\nLA  - \nER  - \n\nTY  - JOUR\nAU  - Xiaohe, Z.\nAU  - Yu, Q.\nAU  - Hong, Y.\nAU  - Xiuqing, S.\nAU  - Rugang, Z.\nTI  - Synthesis, biological evaluation and molecular modeling studies of N-aryl-2-arylthioacetamides as non-nucleoside HIV-1 reverse transcriptase inhibitors\nT2  - Chem. Biol. Drug Des\nPY  - 2010\nDA  - 2010\nVL  - 76\nSP  - 330\nEP  - 339\nC1  - CrossRef-PubMed\nLA  - \nER  - \n\nTY  - BOOK\nAU  - Harms, A.\nTI  - Non-nucleoside reverse transcriptase inhibitors. In The art of drug synthesis\nA2  - Johnson, D.S.\nA2  - Li, J.J.\nPB  - Wiley Interscience, John Wiley and Sons, Inc\nPY  - 2007\nDA  - 2007\nSP  - 84\nLA  - \nCY  - Hoboken: New Jersey, NJ, USA\nER  - \n\nTY  - JOUR\nAU  - Tatar, E.\nAU  - Kucukguzel, S.G.\nAU  - Karakus, S.\nAU  - De Clercq, E.\nAU  - Andrei, G.\nAU  - Snoeck, R.\nAU  - Pannecouque, C.\nAU  - OktemOkullu, S.\nAU  - Unubol, N.\nAU  - Kocagoz, T.\nTI  - Synthesis and biological evaluation of some new 1,3,4-thiadiazole and 1,2,4-triazole derivatives from L-methionine as antituberculosis and antiviral agents\nT2  - Marmara Pharm. J\nPY  - 2015\nDA  - 2015\nVL  - 19\nSP  - 88\nEP  - 102\nC1  - CrossRef\nC1  - true\nLA  - \nER  - \n\nTY  - BOOK\nAU  - Wit, F.W.N.M.\nAU  - Lange, J.M.A.\nAU  - Volberding, P.A.\nTI  - New HIV Drug Development. In Global HIV/AIDS Medicine\nA2  - Volberding, P.A.\nA2  - Sande, M.A.\nA2  - Greene, W.C.\nA2  - Lange, J.M.A.\nPB  - Elsevier\nPY  - 2008\nDA  - 2008\nSP  - 123\nEP  - 134\nLA  - \nCY  - Philadelphia, PA, USA\nER  - \n\nTY  - JOUR\nAU  - Schiller, D.S.\nAU  - Youssef-Bessler, M.\nTI  - Etravirine: A second-generation nonnucleoside reverse transcriptase inhibitor (NNRTI) active against NNRTI-resistant strains of HIV\nT2  - Clin. Ther\nPY  - 2009\nDA  - 2009\nVL  - 31\nSP  - 692\nEP  - 704\nC1  - CrossRef-PubMed\nLA  - \nER  - \n\nTY  - JOUR\nAU  - Miller, C.D.\nAU  - Crain, J.\nAU  - Tran, B.\nAU  - Patel, N.\nTI  - Rilpivirine: A new addition to the anti-HIV-1 armamentarium\nT2  - Drugs Today\nPY  - 2011\nDA  - 2011\nVL  - 47\nSP  - 5\nEP  - 15\nC1  - CrossRef-PubMed\nLA  - \nER  - \n\nTY  - GEN\nTI  - Doravirine combination pill looks good for initial HIV treatment\nUR  - https://www.aidsmap.com/news/jul-2017/doravirine-combination-pill-looks-good-initial-hiv-treatment\nC1  - (accessed on 5 June 2018).\nLA  - \nC1  - Available online:\nER  - \n\nTY  - CONF\nAU  - Gatell, J.M.\nAU  - Raffi, F.\nAU  - Plettenberg, A.\nAU  - Smith, D.\nAU  - Portilla, J.\nAU  - Hoffmann, C.\nAU  - Arasteh, K.\nAU  - Thompson, M.\nAU  - Xu, X.\nAU  - Teppler, H.\nTI  - Doravirine 100 mg QD vs Efavirenz + TDF/FTC in ART-Naive HIV+ Patients: Week 48 Results\nT2  - Proceedings of the Conference on Retroviruses and Opportunistic Infections\nPY  - 2016\nDA  - 2016/02/22\nT2  - abstract number 470\nLA  - \nCY  - Boston, MA, USA\nER  - \n\nTY  - GEN\nTI  - FDA Accepts New Drug Applications for Merck\u2019s Doravirine, the Company\u2019s Investigational Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI), for Treatment of HIV-1 Infection\nUR  - http://investors.merck.com/news/press-release-details/2018/FDA-Accepts-New-Drug-Applications-forMercks-Doravirine-the-Companys-Investigational-Non-Nucleoside-Reverse-Transcriptase-InhibitorNNRTI-for-Treatment-of-HIV-1-Infection/default.aspx\nC1  - (accessed on 5 June 2018).\nLA  - \nC1  - Available online:\nER  - \n\nTY  - GEN\nTI  - FDA approves Merck\u2019s Pifeltro\nUR  - https://www.drugs.com/newdrugs/fdaapproves-merck-s-pifeltro-doravirine-hiv-1-appropriate-patients-4815.html\nC1  - (accessed on 6 November 2019).20 September 2019. Available online: (accessed on 6 November 2019).\nC1  - https://investors.merck.com/news/press-release-details/2019/Mercks-PIFELTROdoravirine-and-DELSTRIGO-doravirinelamivudinetenofovir-disoproxil-fumarate-Receive-US-FDAApproval-for-Use-in-Appropriate-Adults-Living-with-HIV-1-Who-Are-Virologically-Suppressed/default.aspx\nLA  - \nC1  - (doravirine). Available online:\nER  - \n\nTY  - GEN\nAU  - Margolis, D.A.\nAU  - Eron, J.J.\nAU  - DeJesus, E.\nAU  - White, S.\nAU  - Wannamaker, P.\nAU  - Stancil, B.\nAU  - Johnson, M.\nTI  - Unexpected finding of delayed-onset seizures in HIV-positive, treatment-experienced subjects in the Phase IIb evaluation of fosdevirine (GSK2248761). Antivir\nT2  - Ther.\nPY  - 2014\nDA  - 2014\nVL  - 19\nSP  - 69\nEP  - 78\nC1  - CrossRef\nLA  - \nER  - \n\nTY  - JOUR\nAU  - Vernazza, P.\nAU  - Wang, C.\nAU  - Pozniak, A.\nAU  - Weil, E.\nAU  - Pulik, P.\nAU  - Cooper, D.A.\nAU  - Kaplan, R.\nAU  - Lazzarin, A.\nAU  - Valdez, H.\nAU  - Goodrich, J.\nTI  - Efficacy and safety of lersivirine (UK-453,061) versus efavirenz in antiretroviral treatment-naive HIV-1 infected patients: week 48 primary analysis results from an ongoing, multicenter, randomized, double-blind, Phase IIb trial\nT2  - J. Acquir. Immune Defic. Syndr\nPY  - 2013\nDA  - 2013\nVL  - 62\nSP  - 171\nEP  - 179\nC1  - CrossRef\nC1  - true\nLA  - \nER  - \n\nTY  - JOUR\nAU  - Platten, M.\nAU  - Fatkenheuer, G.\nTI  - Lersavirine\u2014a new drug for HIV infection therapy\nT2  - Expert. Opin. Investig. Drugs\nPY  - 2013\nDA  - 2013\nVL  - 22\nSP  - 1687\nEP  - 1694\nC1  - CrossRef\nLA  - \nER  - \n\nTY  - JOUR\nAU  - Sacks, D.\nAU  - Ledwaba, J.\nAU  - Morris, L.\nAU  - Hunt, G.M.\nTI  - Rapid detection of common HIV-1 drug resistance mutations by use of high-resolution melting analysis and unlabeled probes\nT2  - J. Clin. Microbiol\nPY  - 2017\nDA  - 2017\nVL  - 55\nSP  - 122\nEP  - 133\nC1  - CrossRef\nLA  - \nER  - \n\nTY  - JOUR\nAU  - Yahi, N.\nAU  - Tamalet, C.\nAU  - Tourres, C.\nAU  - Tivoli, N.\nAU  - Ariasi, F.\nAU  - Volot, F.\nAU  - Gastaut, J.A.\nAU  - Gallais, H.\nAU  - Moreau, J.\nAU  - Fantini, J.\nTI  - Mutation patterns of the reverse transcriptase and protease genes in Human Immunodeficiency Virus type 1-infected patients undergoing combination therapy: survey of 787 sequences\nT2  - J. Clin. Microbiol\nPY  - 1999\nDA  - 1999\nVL  - 37\nSP  - 4099\nEP  - 4106\nC1  - CrossRef\nLA  - \nER  - \n\nTY  - JOUR\nAU  - Hu, Y.\nAU  - Li, C.Y.\nAU  - Wang, X.M.\nAU  - Yang, Y.H.\nAU  - Zhu, H.L.\nTI  - 1,3,4-Thiadiazole: synthesis, reactions and applications in medicinal, agricultural, and materials chemistry\nT2  - Chem. Rev\nPY  - 2014\nDA  - 2014\nVL  - 114\nSP  - 5572\nEP  - 5610\nC1  - CrossRef\nLA  - \nER  - \n\nTY  - JOUR\nAU  - Szulczyk, D.\nAU  - Tomaszewski, P.\nAU  - Jozwiak, M.\nAU  - Koziol, A.E.\nAU  - Lis, T.\nAU  - Collu, D.\nAU  - Iuliano, F.\nAU  - Struga, M.\nTI  - Synthesis and biological activities of ethyl 2-(2-pyridylacetate) derivatives containing thiourea, 1,2,4-triazole, thiadiazole and oxadiazole moieties\nT2  - Molecules\nPY  - 2017\nDA  - 2017\nVL  - 22\nSP  - 409\nC1  - CrossRef-PubMed\nLA  - \nER  - \n\nTY  - JOUR\nAU  - Akhtar, T.\nAU  - Hameed, S.\nAU  - Al-Masoudi, N.A.\nAU  - Khan, K.M.\nTI  - Synthesis and anti-HIV activity of new chiral 1,2,4-triazoles and 1,3,4-thiadiazoles\nT2  - Heteroatom Chem\nPY  - 2007\nDA  - 2007\nVL  - 18\nSP  - 316\nEP  - 322\nC1  - CrossRef\nLA  - \nER  - \n\nTY  - JOUR\nAU  - Hamad, N.S.\nAU  - Al-Haidery, N.H.\nAU  - Al-Masoudi, I.A.\nAU  - Sabri, M.\nAU  - Sabri, L.\nAU  - Al-Masoudi, N.A.\nTI  - Amino acid derivatives, part 4: synthesis and anti-HIV activity of new naphthalene derivatives\nT2  - Arch. Pharm. Chem. Life Sci\nPY  - 2010\nDA  - 2010\nVL  - 343\nSP  - 397\nEP  - 403\nC1  - CrossRef-PubMed\nLA  - \nER  - \n\nTY  - JOUR\nAU  - Wang, Z.\nAU  - Wu, B.\nAU  - Kuhen, K.L.\nAU  - Bursulaya, B.\nAU  - Nguyen, T.N.\nAU  - Nguyen, D.G.\nAU  - He, Y.\nTI  - Synthesis and biological evaluations of sulfanyltriazoles as novel HIV-1 non-nucleoside reverse transcriptase inhibitors\nT2  - Bioorg. Med. Chem. Lett\nPY  - 2006\nDA  - 2006\nVL  - 16\nSP  - 4174\nEP  - 4177\nC1  - CrossRef-PubMed\nLA  - \nER  - \n\nTY  - JOUR\nAU  - Muraglia, E.\nAU  - Kinzel, O.D.\nAU  - Laufer, R.\nAU  - Miller, M.D.\nAU  - Moyer, G.\nAU  - Munshi, V.\nAU  - Orvieto, F.\nAU  - Palumbi, M.C.\nAU  - Pescatore, G.\nAU  - Rowley, M.\nTI  - Tetrazole thioacetanilides: potent non-nucleoside inhibitors of WT HIV reverse transcriptase and its K103N mutant\nT2  - Bioorg. Med. Chem. Lett\nPY  - 2006\nDA  - 2006\nVL  - 16\nSP  - 2748\nEP  - 2752\nC1  - CrossRef-PubMed\nC1  - true\nLA  - \nER  - \n\nTY  - JOUR\nAU  - Zhan, P.\nAU  - Liu, X.\nAU  - Cao, Y.\nAU  - Wang, Y.\nAU  - Pannecouque, C.\nAU  - De Clercq, E.\nTI  - 1,2,3-Thiadiazole thioacetanilides as a novel class of potent HIV-1 non-nucleoside reverse transcriptase inhibitors\nT2  - Bioorg. Med. Chem. Lett\nPY  - 2008\nDA  - 2008\nVL  - 18\nSP  - 5368\nEP  - 5371\nC1  - CrossRef-PubMed\nLA  - \nER  - \n\nTY  - JOUR\nAU  - Zhang, Z.\nAU  - Xu, W.\nAU  - Koh, Y.H.\nAU  - Shim, J.H.\nAU  - Girardet, J.L.\nAU  - Yeh, L.T.\nAU  - Hamatake, R.K.\nAU  - Hong, Z.\nTI  - A novel non-nucleoside analogue that inhibits human immunodeficiency virus type 1 isolates resistant to current non-nucleoside reverse transcriptase inhibitors\nT2  - Antimicrob. Agents Chemother\nPY  - 2007\nDA  - 2007\nVL  - 51\nSP  - 429\nEP  - 437\nC1  - CrossRef\nLA  - \nER  - \n\nTY  - JOUR\nAU  - Huang, Y.\nAU  - Zhao, L.\nAU  - Jia, B.\nAU  - Wu, L.\nAU  - Li, Y.\nAU  - Curthoys, N.\nAU  - Zheng, J.C.\nTI  - Glutaminase dysregulation in HIV-1-infected human microglia mediates neurotoxicity: relevant to HIV-1 associated neurocognitive disorders\nT2  - J. Neurosci\nPY  - 2011\nDA  - 2011\nVL  - 31\nSP  - 15195\nEP  - 15204\nC1  - CrossRef\nLA  - \nER  - \n\nTY  - JOUR\nAU  - Zhao, J.\nAU  - Lopez, A.L.\nAU  - Erichsen, D.\nAU  - Herek, S.\nAU  - Cotter, R.L.\nAU  - Curthoys, N.P.\nAU  - Zheng, J.\nTI  - Mitochondrial glutaminase enhances extracellular glutamate production in HIV-1-infected macrophages: Linkage to HIV-1 associated dementia\nT2  - J. Neurochem\nPY  - 2004\nDA  - 2004\nVL  - 88\nSP  - 169\nEP  - 180\nC1  - CrossRef\nLA  - \nER  - \n\nTY  - GEN\nAU  - Stumvoll, M.\nAU  - Perriello, G.\nAU  - Meyer, C.\nAU  - Gerich, J.\nTI  - Role of glutamine in human carbohydrate metabolism in kidney and other tissues. Kidney Int\nPY  - 1999\nDA  - 1999\nVL  - 55\nSP  - 778\nEP  - 792\nC1  - CrossRef\nLA  - \nER  - \n\nTY  - JOUR\nAU  - Smith, R.J.\nTI  - Glutamine metabolism and its physiological importance\nT2  - J. Parenter. Enteral. Nutr\nPY  - 1990\nDA  - 1990\nVL  - 14\nSP  - 40\nEP  - 44\nC1  - CrossRef-PubMed\nLA  - \nER  - \n\nTY  - JOUR\nAU  - Bromley, S.D.\nAU  - Bennett, M.K.\nAU  - Gross, M.I.\nAU  - Li, J.\nAU  - Chen, L.\nAU  - Goyal, B.\nAU  - Laidig, G.\nAU  - Stanton, T.F.\nAU  - Sjogren, E.B.\nTI  - Treatment of viral infections with inhibitors of glutaminase\nT2  - PCT Int. Appl\nPB  - PCT/US2014/061746; WO 2015/061432 A1\nPY  - 2015\nDA  - 2015\nLA  - \nER  - \n\nTY  - JOUR\nAU  - Newsholme, P.\nAU  - Lima, M.M.R.\nAU  - Procopio, J.\nAU  - Pithon-Curi, T.C.\nAU  - Doi, S.Q.\nAU  - Bazotte, R.B.\nAU  - Curi, R.\nTI  - Glutamine and glutamate as vital metabolites\nT2  - Braz. J. Med. Biol. Res\nPY  - 2003\nDA  - 2003\nVL  - 36\nSP  - 153\nEP  - 162\nC1  - CrossRef-PubMed\nLA  - \nER  - \n\nTY  - JOUR\nAU  - Behar, K.L.\nAU  - Rothman, D.L.\nTI  - In vivo NMR studies of glutamate-GABA-glutamine cycling in rodent and human cortex: the central role of glutamine\nT2  - J. Nutr\nPY  - 2001\nDA  - 2001\nVL  - 131\nSP  - 2498\nEP  - 2504\nC1  - CrossRef-PubMed\nLA  - \nER  - \n\nTY  - JOUR\nAU  - Erdmann, N.\nAU  - Zhao, J.\nAU  - Lopez, A.L.\nAU  - Herek, S.\nAU  - Curthoys, N.\nAU  - Hexum, T.D.\nAU  - Tsukamoto, T.\nAU  - Ferraris, D.\nAU  - Zheng, J.\nTI  - Glutamate production by HIV-1 infected human macrophage is blocked by the inhibition of glutaminase\nT2  - J. Neurochem\nPY  - 2007\nDA  - 2007\nVL  - 102\nSP  - 539\nEP  - 549\nC1  - CrossRef\nLA  - \nER  - \n\nTY  - JOUR\nAU  - Babayo, A.\nAU  - Thairu, Y.\nAU  - Nasir, I.A.\nAU  - Baba, M.M.\nTI  - Serological evidence and sociodemographic risk factors of recent cytomegalovirus infection in pregnant women attending a tertiary hospital in Maiduguri, Nigeria\nT2  - J. Med. Microbiol. Infec. Dis\nPY  - 2014\nDA  - 2014\nVL  - 2\nSP  - 49\nEP  - 55\nLA  - \nER  - \n\nTY  - JOUR\nAU  - Forbes, B.A.\nTI  - Acquisition of cytomegalovirus infection: An update\nT2  - Clin. Microbiol. Rev\nPY  - 1989\nDA  - 1989\nVL  - 2\nSP  - 204\nEP  - 216\nC1  - CrossRef\nLA  - \nER  - \n\nTY  - BOOK\nAU  - Spruance, S.L.\nTI  - Viral infections. In The Merck Manual of Medical Information: Second Home Edition\nA2  - Beers, M.HMerck Research Laboratories\nA2  - Merck\nA2  - Co\nPY  - 2003\nDA  - 2003\nSP  - 1164\nPB  - Whitehouse Station, NJ, USA\nLA  - \nCY  - Inc.\nER  - \n\nTY  - RPRT\nTI  - and Congenital CMV Infection\nUR  - https://www.cdc.gov/cmv/overview.html\nC1  - (accessed on 11 July 2018).\nLA  - \nC1  - Available online:\nC1  - Centers for Disease Control and Prevention. Cytomegalovirus (CMV\nER  - \n\nTY  - JOUR\nAU  - Tan, B.H.\nTI  - Cytomegalovirus treatment. Curr\nT2  - Ganciclovir: An update of its use in the prevention of cytomegalovirus infection and disease in transplant recipients\nPY  - 2014\nDA  - 2014\nVL  - 6\nSP  - \"256\nEP  - 270.\" # \"1153\nC1  - CrossRef\nT2  - Drugs\nN1  - CrossRef] 85\nC1  - 84. McGavin, J. K.; Goa, K. L.\nC1  - 61,\nC1  - 1153\u20131183.\nLA  - \nER  - \n\nTY  - JOUR\nTI  - A case of severe ganciclovir-induced encephalopathy\nT2  - Case Rep. Neurol\nPY  - 2013\nDA  - 2013\nVL  - 5\nSP  - 183\nEP  - 186\nN1  - CrossRef] 86\nLA  - \nER  - \n\nTY  - BOOK\nAU  - Organization, World Health\nTI  - Battle against Respiratory\nPB  - Viruses (BRaVe) initiative. Available online\nUR  - http://www.who.int/influenza/patient_care/clinical/brave/en/\nC1  - on 14\nPY  - 2018\nDA  - 2018/06\nLA  - \nER  - \n\nTY  - BOOK\nAU  - Organization, World Health\nTI  - Research needs for the battle against respiratory viruses (BRAve)\nPB  - Background document 2013. Available online\nUR  - http://www.who.int/influenza/patient_care/clinical/BRaVe_Research_\nLA  - \nC1  - Agenda_2013.pdf (on 14 June 2018).\nER  - \n\nTY  - JOUR\nAU  - Bellos, A.\nAU  - Mulholland, K.\nAU  - O\u2019Brien, K.L.\nAU  - Qazi, S.A.\nAU  - Gayer, M.\nAU  - Checchil, F.\nTI  - The burden of acute respiratory infections in crisis-affected populations: A systematic review\nT2  - Confl. Health\nPY  - 2010\nDA  - 2010\nVL  - 4\nSP  - \"1\nEP  - 12.\" # \"283\nC1  - CrossRef\nC1  - 90. Straliotto, S. M.; Siqueira, M. M.; Muller, R. L.; Fischer, G. B.; Cunha, M. L. T.; Nestor, S. M.\nT2  - Viral etiology of acute respiratory infections among children in Porto Alegre\nC1  - RS, Brazil. Rev. Soc. Bras. Med. Tro.\nC1  - 35,\nC1  - 283\u2013291.\nC1  - [CrossRef]\nLA  - \nC1  - [PubMed] 91.\nER  - \n\nTY  - JOUR\nAU  - Da Silva, R.C.\nAU  - da Silva Mendes, G.\nAU  - Rojas, M.A.\nAU  - Amorim, A.R.\nAU  - Couceiro, J.N.\nAU  - Lupi, O.\nAU  - Elabras, J.\nAU  - Pires, G.\nAU  - Valle, S.\nAU  - Santos, N.\nTI  - Frequency of viral etiology in symptomatic adult upper respiratory tract infections\nT2  - Braz. J. Infect. Dis\nPY  - 2015\nDA  - 2015\nVL  - 19\nSP  - 30\nEP  - 35\nPB  - CrossRef] [PubMed] 92\nLA  - \nER  - \n\nTY  - JOUR\nAU  - Fendrick, A.M.\nAU  - Monto, A.S.\nAU  - Nightengale, B.\nAU  - Sarnes, M.\nTI  - The economic burden of non-influenza-related viral respiratory tract infections in the United States\nT2  - Arch. Intern. Med\nPY  - 2003\nDA  - 2003\nVL  - 163\nSP  - 487\nEP  - 494\nC1  - CrossRef\nLA  - \nC1  - [PubMed] 93.\nER  - \n\nTY  - BOOK\nAU  - Johnson, D.S.\nAU  - Li, J.J.\nTI  - Neuraminidase inhibitors for influenza: oseltamivir phosphate (Tamiflu) and zanamivir (Relenza). In The art of drug synthesis\nA2  - Johnson, D.S.\nA2  - Li, J.J.\nPB  - Wiley Interscience, John Wiley and Sons, Inc\nPY  - 2007\nDA  - 2007\nSP  - 95\nEP  - 96\nLA  - \nCY  - Hoboken: New Jersey, NJ, USA\nER  - \n\nTY  - JOUR\nAU  - Al-Muharrmi, Z.\nTI  - Understanding the Influenza A H1N1 2009 pandemic\nT2  - SQU Med. J\nPY  - 2010\nDA  - 2010\nVL  - 10\nSP  - 187\nEP  - 195\nLA  - \nER  - \n\nTY  - JOUR\nAU  - Tonelli, M.\nAU  - Naesens, L.\nAU  - Gazzarrini, S.\nAU  - Santucci, M.\nAU  - Cichero, E.\nAU  - Tasso, B.\nAU  - Moroni, A.\nAU  - Costi, M.P.\nAU  - Loddo, R.\nTI  - Host dihydrofolate reductase (DHFR)-directed cycloguanil analogues endowed with activity against influenza virus and respiratory syncytial virus\nT2  - Eur. J. Med. Chem\nPY  - 2017\nDA  - 2017\nVL  - 135\nSP  - \"467\nEP  - 478.\" # \"229\nC1  - CrossRef\nN1  - CrossRef] 97. World\nC1  - Health Organization. Fact sheets on sustainable development goals: health target, Viral hepatitis, World Health Organization 2017\nUR  - www.euro.who.int/sdgs.\nC1  - 96. Francesconi, V.; Giovannini, L.; Santucci, M.; Cichero, E.; Costi, M. P.; Naesens, L.; Giordanetto, F.; Tonelli, M.\nT2  - Synthesis, biological evaluation and molecular modeling of novel azaspiro dihydrotriazines as influenza virus inhibitors targeting the host factor dihydrofolate reductase (DHFR). Eur\nC1  - J. Med. Chem.\nC1  - 155,\nC1  - 229\u2013243.\nC1  - http://www.euro.who.int/__data/assets/pdf_file/0003/348222/Fact-sheet-SDG-viral-hepatitis-FINALen.pdf?ua=1\nC1  - (accessed on 23 January 2020).\nLA  - \nCY  - Copenhagen, Denmark\nC1  - Available online:\nER  - \n\nTY  - BOOK\nAU  - Organization, World Health\nTI  - Hepatitis B in the WHO European Region, Fact sheet \u2013 July 2019\nPB  - World Health Organization\nPY  - 2019\nDA  - 2019\nUR  - http://www.euro.who.int/__data/assets/pdf_file/0007/377251/Fact-Sheet-Hepatitis-B_2019-ENG.pdf\nC1  - (accessed on 23 January 2020).\nLA  - \nC1  - Available online:\nER  - \n\nTY  - GEN\nAU  - B, F.D.A.Hepatitis\nAU  - treatments, C.\nUR  - https://www.fda.gov/patients/hepatitis-b-c/hepatitis-band-c-treatments\nC1  - (accessed on 23 January 2020).\nC1  - Available online:\nER  - \n\nTY  - JOUR\nAU  - Kurkela, S.\nAU  - Ratti, O.\nAU  - Huhtamo, E.\nAU  - Uzcategui, N.\nAU  - Nuorti, J.P.\nAU  - Laakkonen, J.\nAU  - Manni, T.\nAU  - Helle, P.\nAU  - Vaheri, A.\nAU  - Vapalahti, O.\nTI  - Sindbis virus infection in resident birds, migratory birds, and humans, Finland\nT2  - Emerg. Infect. Dis\nPY  - 2008\nDA  - 2008\nVL  - 14\nSP  - 41\nEP  - 47\nC1  - CrossRef\nLA  - \nER  - \n\nTY  - JOUR\nAU  - Kucukguzel, S.G.\nAU  - Kucukguzel, I.\nAU  - Tatar, E.\nAU  - Rollas, S.\nAU  - Sahin, F.\nAU  - Gulluce, M.\nAU  - De Clercq, E.\nAU  - Kabasakal, L.\nTI  - Synthesis of some novel heterocyclic compounds derived from diflunisal hydrazide as potential anti-infective and anti-inflammatory agents\nT2  - Eur. J. Med. Chem\nPY  - 2007\nDA  - 2007\nVL  - 42\nSP  - 893\nEP  - 901\nC1  - CrossRef\nLA  - \nER  - \n\nTY  - JOUR\nAU  - Bonina, L.\nAU  - Orzalesi, G.\nAU  - Merendino, R.\nAU  - Arena, A.\nAU  - Mastroeni, P.\nTI  - Structure-activity relationships of new antiviral compounds\nT2  - Antimicrob. Agents Chemother\nPY  - 1982\nDA  - 1982\nVL  - 22\nSP  - 1067\nEP  - 1069\nC1  - CrossRef\nLA  - \nER  - \n\nTY  - CHAP\nAU  - Streissle, G.\nAU  - Paesseus, A.\nAU  - Oediger, H.\nTI  - New antiviral compounds\nT2  - Advances in Virus Research\nA2  - Maramorosch, K.\nA2  - Murphy, F.A.\nA2  - Shatkin, A.J.\nPB  - Academic Press., Elsevier\nPY  - 1985\nDA  - 1985\nVL  - 30\nSP  - 115\nLA  - \nCY  - London, UK\nER  - \n\nTY  - JOUR\nAU  - Cui, T.\nAU  - Chum, M.P.\nAU  - Lam, Y.\nAU  - Gao, Y.\nTI  - Compounds for use as anti-viral agents\nT2  - Singapore Pat. Appl. SG\nVL  - 162629\nSP  - 1\nPY  - 2010\nDA  - 2010\nLA  - \nER  - \n\nTY  - JOUR\nAU  - Yadav, L.D.S.\nAU  - Singh, S.\nTI  - Synthesis of antiviral acyclic C-nucleosides incorporating thiazolo-1,3,4-oxa(thia)diazole or thiazolo-1,2,4-triazole structure as a nucleobase\nT2  - Indian J. Chem\nPY  - 2001\nDA  - 2001\nVL  - 40\nSP  - 440\nEP  - 442\nC1  - CrossRef\nLA  - \nER  - \n\n",
        "author_conclusions": [],
        "table_captions": [
            {
                "id": "1",
                "caption": "Structural detailXs aXnd IC50 valRues of RcompoIuCnd50s(7\u03bc\u20131M0 ()adIaCp5t0ed(\u03bcfrMom) [47])"
            },
            {
                "id": "5",
                "caption": "Antiviral evaluation and in vitro cytotoxicity of compounds 45\u201348 (adapted from [49])"
            },
            {
                "id": "6",
                "caption": "Antiviral evaluation and ivnivtritor(ocTHAycKytSCtoo-VtKVtoo-xxO)1iiccSiittyyoof fcocmompSovipunoinrdudubnss4di5ss\u20134485\u2013(a4d8ap(CatvedodiaxrfpursotasemcdBk[f44ir9eo])m. 14[4o9f P]2)2u. nvtioruTsoro"
            },
            {
                "id": "7",
                "caption": "Antiviral evaluation and in vitro cytotoxicity of compounds 56\u201359 (adapted from [102]). Antiviral evaluation and in vitro"
            }
        ],
        "figure_captions": [
            {
                "id": "1",
                "caption": "Influence of substituents of 1,3,4-thiadiazole derivatives 1\u20135 on anti-HIV activity"
            },
            {
                "id": "2",
                "caption": "The influence of substituents of 1,3,4-thiadiazole derivatives 7\u201310 on anti-HIV activity"
            },
            {
                "id": "6",
                "caption": "The influence of substituents of 1,3,45-4thiadiazole derivat5iv5es 50\u201355 on viral inhibition"
            },
            {
                "id": "8",
                "caption": "The influence of substituents of 1,3,4-thiadiazole derivatives 56\u201359 on antiviral activity"
            },
            {
                "id": "9",
                "caption": "TThhee ggeenneerraall ffoorrmmula of derivatives 60"
            }
        ],
        "tables_url": "https://scholarcy.nyc3.digitaloceanspaces.com/tables/docker-test/55716faf2ba843d5940856ee02fd808a.xlsx",
        "figure_urls": [
            "https://scholarcy.nyc3.digitaloceanspaces.com/images/docker-test/55716faf2ba843d5940856ee02fd808a/img-000.png",
            "https://scholarcy.nyc3.digitaloceanspaces.com/images/docker-test/55716faf2ba843d5940856ee02fd808a/img-001.png",
            "https://scholarcy.nyc3.digitaloceanspaces.com/images/docker-test/55716faf2ba843d5940856ee02fd808a/img-002.png",
            "https://scholarcy.nyc3.digitaloceanspaces.com/images/docker-test/55716faf2ba843d5940856ee02fd808a/img-003.png",
            "https://scholarcy.nyc3.digitaloceanspaces.com/images/docker-test/55716faf2ba843d5940856ee02fd808a/img-004.png"
        ]
    },
    "sections": {
        "conclusions": [
            "TThhee researrchh focusedd on 1,3,4-thiaddiiaazzoollee ddeerriivvaattiivveess iinnddiiccaatteess aa bbrrooaadd speeccttrruumm of phaarrmTmhaaeccoollrooeggsieiccaaarllcahaccttifivovicittuiieesssedaassssoooncciiaat1tee,d3d,4ww-tihitthihagdgoioaoozddolpephhyydsseiicrcioovccahhteievmmeisiccaalilnaadnnidcdaptpehhsaarrmamaabccorookkaiindneettisicpc pepcrrtoorpupemerrttiieeossf.. Tphhiasrmaarrtaticcicolelleopgrpiecrseaeslneatnscttasivliaitteirleiastteuarrsaestourecrvieaiterewedvoiwef w2it-haomgf ion2oo-da-1mp,3ihn,4yo-st-ih1c,io3ac,d4hi-aetzhmoiailcedadilaezaronivldeatpidvheearsrivtmhaaatitcvohekasvinetehbtaiectenphreaovpaeleurbateiteesnd. eTfovhraislaunaatrtietvidicrlael fapocrrteisveiantyntstaigvaairilanitlsetrasaetucvtreievraitrlyevviireaawlgsatoirnafsin2t -sa. msIneivnaeodr-da1l,i3ti,o4vn-tihrtoaialtdhieaszt2ro-aaliemnsdin.eor-iIv1n,a3t,i4v-aetdhsdiatihdtiaioatnzhoalevtoemobietehetney, 2ea-vnaatmilvuiianrtaoel-da1c,3ti,4vfo-itrhyiiasdaanilastziovodilreapl emnodaiceetntiyvt ,oitnyatnhteiavgniaraaitnul sretacotfisvtehivteyesruaiblsstaivtlusiroeanltds,easptnerdnaidsntesrnu. tctuIonrne\u2013atahcdteidviinttiyaotsnutruedtioeosf hatthhveee s2su-habomswtiinntuote-h1ne,t3sm,,4oa-tnshtdieaffisdtircauizecontulterseu\u2013mbasocttiieitvtuyiet,yntasstnuftodivriiearsnalthiavavicreatilsvhaitcoytwivniistythaienlsmoeaocdshteceplfeafniscsdi.eeBnntatsseuodbnsotnitthuteheenntlsiattefuorraretaunroetfivditarhtaael, asthuctebivs2ti-itatyumeiinnntose-,a1ac,3hn,d4c-ltsahtsrisau.dcBtiuaazrsoee\u2013ldeacsotcinavffittohyledstlmiutedaryiaebtsuehrcaeovdnesasitdhae,orwtehdne at2hp-eaomsmsiionbsolte-1ep,f3hfi,a4cri-emthnaitacsdoupiabhzsootirlteugesrncoatusffpfooltrdhaamtnctaiavynirbbaeel cainoctcniosvriidptyeorrieandteedaacpinhotsocslitabhslese.sptBrhauascretmduraeocnofptkhhnoeorlewitgenrraocotuumprepthodauatntacda,sntthobee2ni-hnaacmonricnpeooa-rn1a,tt3iev,d4i-rtaihnlitaaocdttiihavezitoyslteraunscdctaucffrooenltdorfibmkunatyoeswbtneo ccthoomensspiedoaeurrcnehddasantdopodesensvhibeallnoecppemhaeannrmttivoaifcronalpewhaocmtrieveigdtyricoiaunnpedsthacsaotannctraianbltubetreensiantciovoerthpteoortsaheteaerdtcrheinatatmondethndet eosvtfrevuliocrptaumlrienenfoetfctokifonnonswe.wn mcoemdpicoinuensdasstaoneanlthearnncaetivaenttiovitrhael tarcetaitvmiteynat nodf vcioranltrinibfuectetisontos. the search and development of new mFuenddiicning:esThaissarenseaaltrechrnraetcieviveetdontoheexttreerantaml feunntdoinfgv.iral infections."
        ],
        "disclosures": [
            "The author declares no conflicts of interest."
        ],
        "introduction": [
            "Viruses are the smallest among all self-replicating organisms and yet they are the etiological agents of many difficult to treat diseases in human populations [1]. There are broad types of human infections caused by viruses, such as respiratory infections (common cold, Influenza), digestive infections (viral gastroenteritis), central nervous system infections (viral meningitis, viral encephalitis), skin or mucosal infections (herpes, measles, mumps, smallpox and rubella), hepatic infections (hepatitis A, B, C, E), blood infections (acquired immunodeficiency syndrome) and hemorrhagic fever (yellow fever, Ebola hemorrhagic fever). Viruses are the most abundant and diverse biological entities on Earth and this is the reason for the high incidence of viral infections [2]. In addition, some viruses are etiological agents in the development of human tumors, particularly cervical cancer and hepatic cancer [3].",
            "The main method and most cost-effective strategy for preventing viral infections is through vaccination, which is meant to prevent outbreaks by increasing immunity [4]. Vaccines for the prevention of several common acute viral infections, such as polio, rubella, measles, mumps, Influenza, yellow fever, encephalitis, rabies, smallpox and hepatitis B were developed during the 20th century and are available on a large scale [1,4]. Efforts to develop safe and effective vaccines against viruses that cause chronic infections, such as human immunodeficiency virus or hepatitis C virus did not give the expected results [1,4,5]."
        ]
    },
    "structured_content": {
        "1. Human Viral Infections": [
            "Viruses are the smallest among all self-replicating organisms and yet they are the etiological agents of many difficult to treat diseases in human populations [1]. There are broad types of human infections caused by viruses, such as respiratory infections (common cold, Influenza), digestive infections (viral gastroenteritis), central nervous system infections (viral meningitis, viral encephalitis), skin or mucosal infections (herpes, measles, mumps, smallpox and rubella), hepatic infections (hepatitis A, B, C, E), blood infections (acquired immunodeficiency syndrome) and hemorrhagic fever (yellow fever, Ebola hemorrhagic fever). Viruses are the most abundant and diverse biological entities on Earth and this is the reason for the high incidence of viral infections [2]. In addition, some viruses are etiological agents in the development of human tumors, particularly cervical cancer and hepatic cancer [3].",
            "The main method and most cost-effective strategy for preventing viral infections is through vaccination, which is meant to prevent outbreaks by increasing immunity [4]. Vaccines for the prevention of several common acute viral infections, such as polio, rubella, measles, mumps, Influenza, yellow fever, encephalitis, rabies, smallpox and hepatitis B were developed during the 20th century and are available on a large scale [1,4]. Efforts to develop safe and effective vaccines against viruses that cause chronic infections, such as human immunodeficiency virus or hepatitis C virus did not give the expected results [1,4,5].",
            "For many viral infections, only symptomatic treatment is indicated, while it is expected the immune system to fight off the virus. However, there are high-virulence viruses that cause serious viral infections where antiviral treatment is essential for patient survival. Although great efforts have been made to find effective medication, there are still no drugs that truly cure viral infections. Moreover, Molecules 2020, 25, 942; doi:10.3390/molecules25040942 www.mdpi.com/journal/molecules",
            "Molecules 2020, 25, 942 due to the ability of viruses to undergo rapid mutations, the mechanisms involved in developing resistance to antiviral drugs are activated in most cases [1,3]. As resistance toward antiviral drugs is becoming a global health threat, there is an intrinsic need to identify new scaffolds that are useful in discovering innovative, less toxic and highly active antiviral agents [3,6,7].",
            "2. Nitrogen-Containing Heterocycles and Thiadiazole Ring in Biology and Medicinal Chemistry",
            "Nitrogen-containing heterocycles are widely distributed in nature and are essential in vegetal and animal metabolism. They are found in nucleic acids, vitamins, antibiotics, alkaloids, etc. [8\u201314]. In addition, nitrogen-containing heterocycles are important targets for medicinal chemistry, as they are found in more than half of the commercially available drugs and can also act as versatile intermediates in the synthesis of complex products that exhibit outstanding biological activities [15]. Most of the nitrogen-containing heterocyclic compounds exhibit better biological activity than non-nitrogen compounds [12,16,17]. Currently, there are approximately 90 drugs approved for use in the treatment of nine human viral infections caused by human immunodeficiency virus (HIV), hepatitis B virus (HBV), hepatitis C virus (HCV), herpes simplex virus (HSV), Influenza virus, human cytomegalovirus (HCMV), varicella-zoster virus (VZV), respiratory syncytial virus (RSV) and human papillomavirus [18]. Most of these drugs (e.g., acyclovir, cidofovir, idoxuridine, nevirapine, pleconaril, ribavirin, etc.) are nitrogen heterocycle molecules [3,19].",
            "Five-membered aromatic systems with three heteroatoms at symmetrical positions, such as the 1,3,4-thiadiazole ring, have been extensively studied due to their pharmacological profile and physicochemical and pharmacokinetic properties. 1,3,4-Thiadiazole derivatives are known as compounds having significant and diverse biological activities such as antibacterial, antifungal, antitubercular [20], analgesic and anti-inflammatory [21,22], antidepressant and anxiolytic [23], kinesin inhibitors [24], etc. The 1,3,4-thiadiazole ring is also found in several medicines such as acetazolamide, methazolamide, cefazolin, cefazedone, sulfamethizole or megazol [20,25\u201327]. The 1,3,4-thiadiazole nucleus provides the compounds with high lipophilicity and the ability to form mesoionic systems associated with discrete regions of positive and negative charges. These distinct features allow mesoionic compounds to efficiently cross cellular membranes, leading to good oral absorption, bioavailability and strong unique interactions with biological molecules (e.g., DNA, proteins, etc.) thus increasing the potential of 1,3,4-thiadiazole derivatives to exhibit biological activities [20,27\u201329]. The thiadiazole ring is a bioisostere of the pyrimidine and pyridazine rings. The pyrimidine nucleus is commonly found in naturally occurring compounds of biochemical importance, as well as in drugs (e.g., pyrimidine nucleosides and nucleotides, nucleic acids, antiviral drugs), while the pyridazine nucleus is a component of some pharmacologically active compounds [20,30\u201332]. The thiadiazole ring also acts as a bioisostere of the thiazole ring, and therefore thiadiazole derivatives can act in the same way as third- and fourth-generation antibacterial cephalosporins. This is an additional feature that highlights the high potential of this ring system in medicinal chemistry [20,28]. Many researchers suppose there is a connection between the biological potential of 1,3,4-thiadiazoles and the strongly aromatic character of the 1,3,4-thiadiazole ring, as well as the presence of the toxophoric =N-C-Slinkage group. Furthermore, the high in vivo stability and low toxicity for higher organisms are also attributed to the 1,3,4-thiadiazole ring [20,33,34]. In addition, the amine derivatives of 1,3,4-thiadiazole are also studied. 2-Amino-1,3,4-thiadiazole moiety and its derivatives are known for their antitumor, antitrypanosomal and uricogenic properties [20,25,27,35\u201338]. 2-Amino-1,3,4-thiadiazole derivatives are currently being synthesized in many laboratories, and in previous papers, we described several 2-amino-1,3,4-thiadiazoles that exhibit antibacterial, antifungal, antitubercular [20,39\u201344], and antiparasitic activities [27,38]. The purpose of this paper is to present some small molecules possessing the 2-amino-1,3,4-thiadiazole moiety that have shown antiviral activity.",
            "3. The Activity of 2-Amino-1,3,4-Thiadiazole Derivatives Against Human Viral Pathogens",
            "About 37 million people infected with human immunodeficiency virus (HIV) (Retroviridae family) were reported in 2016 [45], with the highest incidence of infection in sub-Saharan Africa. In the Third World, HIV infection coupled with tropical diseases, malaria and tuberculosis causes a high level of mortality. Due to sexual transmission, acquired immunodeficiency syndrome (AIDS) affects many young workers and therefore the disease has not only a social impact, but also a significant economic impact in these regions [3].",
            "In the past two and half decades, different organic compounds have been developed as drug candidates for the treatment of AIDS targeting one or more stages of the virus life cycle such as absorption, fusion, entry, un-coating, reverse transcription, integration, transcription and maturation [46]. HIV-1 reverse transcriptase (RT) is an essential enzyme that converts single-stranded RNA from the viral genome into double-stranded DNA before its integration into host DNA [47]. Since RT is a key enzyme in the life cycle of HIV-1, some HIV-1 RT inhibitors with nucleoside or non-nucleoside structures are currently used in AIDS treatment [48]. Nucleoside reverse transcriptase inhibitors (NRTIs) such as zidovudine, didanosine, zalcitabine, stavudine, lamivudine, abacavir, tenofovir or emtricitabine interact competitively with the catalytic site of the RT, while the non-nucleoside reverse transcriptase inhibitors (NNRTIs)\u2014nevirapine, delavirdine, efavirenz, etc.\u2014follow an allosteric interaction with a site adjacent to the NRTI binding site, the non-nucleoside inhibitor binding site (NNBS) [47]. Due to their high selectivity and low cytotoxicity, NNRTIs have gained an increasingly important role in HIV infection therapy [49]. Five drugs in the class of NNRTIs have been approved for the treatment of HIV infection: nevirapine, delavirdine and efavirenz as the first generation drugs and etravirine (Intelence tablets, Janssen Therapeutics Company, 2008) and rilpivirine (Edurant tablets, Janssen Therapeutics Company, 2011) as the next-generation NNRTIs [46,50\u201352]. Doravirine (MK-1439A) is a new NNRTI developed by Merck Company that completed two 48-week studies in 2017 [53]. Doravirine demonstrated antiretroviral activity and immunological effects similar to efavirenz with significantly fewer central nervous system adverse events [54]. In January 2018, US Food and Drug Administration (FDA) accepted for review two new drug applications (NDAs) for doravirine, as a once-daily tablet in combination with other antiretroviral agents and as a once-daily fixed-dose combination single tablet of doravirine with lamivudine and tenofovir disoproxil fumarate [55]. On 30 August 2018, FDA approved both applications of doravirine for AIDS treatment as Pifeltro tablets (doravirine 100 mg) and Delstrigo tablets (doravirine 100 mg, lamivudine 300 mg and tenofovir disoproxil fumarate 300 mg) [56,57]. Several NNRTIs (e.g., fosdevirine, lersivirine) underwent clinical development programs but were discontinued due to unfavorable pharmacokinetic, efficacy and/or safety factors [58\u201360].",
            "Approximately 17 million patients have access to antiretroviral therapy capable of controlling viremia and reducing mortality [61]. However, long-term treatment with antiretroviral agents can lead to drug resistance due to rapid mutations in the viral genome resulting in RT mutations and HIV chemotherapy failure [62]. These concerns have attracted a particular focus on research into new antiretroviral drugs that address the limitations of currently available agents for the treatment of HIV infection [46,59].",
            "As a bioisostere of pyrimidine, a nucleoside component of nucleic acids, the thiadiazole ring can impart antiviral activity [28]. Studies concerning the antiviral activity of 1,3,4-thiadiazole derivatives often gave compounds with moderate or lower in vitro anti-HIV-1 and anti-HIV-2 activity than the reference drugs [63,64]. A relevant example is the chiral 2-substituted 5-(4-chlorophenylamino)-1,3,4-thiadiazoles 1\u20135 synthesized by Akhtar et al by acidic cyclodehydration of the corresponding thiosemicarbazides [65].",
            "Molecules 2020, 25, 942 Molecules 2020, 25, 942 Molecules 2020, 25, 942 Molecules 2020, 25, 942",
            "1wvl0aacsrhT\u03bcEoltcahcT\u03bcEoltcahcT\u03bcEoltcoohaooehoh4o.gnaoooofgagChffgaaChChg0giwwlnew.wnlemeatmndmnlaeal10lu/101u/u/5fh55gffcmimcm0iicc40-0434-s-nesprss\u00b1nneprprsehsEtmeIemm.IeI,..a,,seaiaeLn0esn>oL0sLn0s\u03bcn>no>onanCvno.nl1tnnllcatttccaa)utl)eu)ugtetei\u00b1fhv\u00b1\u00b1r5T.o.gfvrxvo.og.gtrxr1xHc211HHnHcca/0nn-ya4iaTamaehTiTmim1imee2tim112t2tttdmttddtm7m\u03bcniI>ttiirIIh.iuI.hh.i..r.rivViviv25opVV2.os2V55nppLossoocgaooooooe4saeeaiaii1neod-foxontw,/-)f-\u03bcfn\u2013ntwtw\u03bc\u03bclllH2bm2\u03bcyH2Hd2.bb\u03bcy\u03bcyuciuue1tggg4em.tie4e4Tetitoiehgxng5g2Iin(tnhILIii(ta(th/hf7(//sf7f7nssVhmsnhnVVa/hshs5mf//dmsmffadcdSat.\u03bcaattm..tmemttdete4fdtde44tlrtIer\u03bcrtptreoercrgriLicciLi\u2013Lrea\u2013\u2013i1eaeanLe11nvna\u2264LeneLebrntnorgrrtten/1xi11xxiiiseimisshffieeifhhenhdfhfuh/vnn2hvcvs2n2tuoss1udumooddRSsaRiSRSeayaiaioauahn5eHh5eh5eLiHHbrlbbrtrlulRIgucuR(IRnbIggnntmdctotLRooiS=a3i=i=3s3tcrc\u2264csasccc\u2264c\u2264iOcca\u03bcateaOcO\u03bcct\u03bctwCi.wCswCIetOoooeooop1ooieeevsCieiweCgCCwow1CCg11HnggsDn=nsDnDmrNdssnnmrmerdodeeeDastrHu/HHHy/Hs/H(eyyss(e(cedhcdctomd)uhytmtm)i)SCtNSpSalttrp(pchaae(,)rr(n(hhe(,e(,ewtoanOaCIae,OOCIcCIeoeocncCLsoneonELwLseeRaEwEwHcwHHcctdv=tt==nHHeuwttHoHHHuut.toiHot5cC.w.iHitHtCTvCrvvihvrrvihvhOvI0cieiCOnIbOIt3)CCnba1Hnb33))av3aaviVvHhI353iViHViHC/5ie5i)edCeCiiii))atbdC0asatvtEtddtC0ClC0ti2ttCltCli2i2aianrIraa-ieytHb-ie-ieyyotiHbtHbloo,iCESVo[2en>SoySoi(2l25>>yyei(i1(t55t11i6wnii013cwwnn013013r.atnyCl.at.nadtn-5ltl/o//5hhiu)ahheiai12uy)u)sE0eae1a(1HNtsEsEO((HNtHNeOO;t5tee;L;b]4LLhtede4)4n(41.ysdedenu(4n(4ysys0C.vNCCvivNNo.EEt)Emoi)3)oioeidodds;Ranec;RL;>Rfnefneo5ccOffo\u03bcCo55w.\u03bcC\u03bcCNwwOiNnNo0OOorC0oo3i0CirCorgCoCfCgmngo)fc1f)n1)1gc,5tggr1,5,5rrm.m.Rm.oH0R3RhHw\u00b1mgHH0a0(33HmHme/h4//)hhoON))dOOvEcNNddvSmvcc.mlSmSeTm..2dTT2p22322pup3c3huuoh\u03bc0havoeoCCSharvaveCetCmCSSCCttvIIkIoLomoph.ecLmLlrmhhescfe\u00b1calrglrHNs\u00b1sauO\u00b1adNHNHHN8OOHN5auHNH-HuHuuiokmuiuiokkemmolee/l0liv[vmvela[[0ua2aem00u(aunr\u03bc2e2-enr(a(ad-6n-nr)uru66RarCSniRRaiaC.CSsSniniii..gssefggee5dg8ndcdi5id5ad8n8ncedncdvtNHLttNHeNHCvfiHsCCaHsHs]aiaa/]a]iainTfseeTfTfdceaefv\u03bc.fmfv\u03bcv.a\u03bc.iec5lHiiae3e55lHlHo33rritoo-nrriNil-n-nNNfeta)cengee)cg)cngilngiuiTlilr3oirL2r33m5s22vsysvmtmsstvysvsySttdv/SSa//e-eitrheett(mhh(mca(ma(m((mcamcao1lieNcf115sNoNcdc255sodod22MynootoootooctHtsynHHyy)hd)Li))ipad)Ldi)Lipapawmmsiyrwmwmv;Mvtv;v;sMMsttnTontIinnhIiIiohhtoohecffeNHVeeffffNHeNHVVp-poeewopHpdidoodtTiooitoootCsTT4csCosCsdcCdodcncCCot-aoh-a-arcorcrcm-ewIa--o1s5Haa1s1s15H5Hxcrxxl4yrroVl4yl4ymhdtcEhhcExtcEetiiii(iiph(e((ticas(ti(tio-sc(soocoCc(cl(iCCocoCeFCCoeFeFd1soyplisnosocoiemiiEememwsswnwtiHtnntitHitH5tint55(nuanld((g(yllrgglyy0rrtC00eslMbsslMslMp3oeparp33yeeaansu>susu>>tc)tyi)5)5ttdwioddiioorCdco(srCoCaTcocorbnroo0TTbnbnca1MuC11eoouCuC(5eeooffnelHyn-nollHHyy--iF25o22eon0noe>ne4nlnrnnn44Illo1IIn11T2.,2if2..wIf%f5)wIwI5dc65))dc6d)tc6gaCla)t)tCCIaacr-IItd0he0h0hee1cBccB4IceBvouwee)vvwweHe\u03bcH5H%n\u03bc\u03bc5I5%ien%nt,2ieies))rni))rmrrisBiiss,,3l,rgitnep3l3.lrgitrgitve)ltat6)r)llatat)ecrrraeerarafs/,a(rhis/es/,,(i(hshascsaaeeacnmce1eg3nanmntm3na3nmnccnncctt\u03bcgysttttlggvss)n)zmhdt)zm)zmitiaddiiliaiaapLaappaLoLivgiaaoovsievdwtwfoffvmrmm(evon(fev(elovio/nnffiiEleEEEyntEaoemEtgctaoaoEiidcecededeyenyyetteClgCtCClggttCClalaChhtey5leide555llLidmidzmmahwyavdva5wwyyv,v555r05r5r00050000Eim00iiaeeeraae%e0(on%%o%onintmatitivmtmevvEtCl>tttl>lh>ttohdhCdsdye>gossyheyesahhmaaCi5etieiteteu,eadeC(l,c,1gl(l1Eg10g((EEEu1cErEuu5crorHoircCclH2HrrCeCh225hhCaon0w2tCCaaoeCeoeoeCCeemd.0r..etCttt4IC.Cmtsts4I4Is5sam5m5v4e5idVe5e5VVv0out00oouup0t500tl55llarvh\u03bcp0vvaef\u03bc\u03bc0\u03bce0w-oefplefpww-o-ollioaHlt1at1tnla1ivaaoaagvvruggoror0eutunE0e0eiliidlldedauI/aatd./u/euutatdd.lu.lunaaellC0mVh0m0mthlohololonnennnuhedeu0uo0o0oiit5-wwiiittwwsddLnsnsdoLdLdnn3ne1eo0so3r3eeff...",
            "gggrrrCoCCoouuuHHHppp(((sssCCCbbbHHHeee3n3n3n)))eee222fffi(ii((ccc111iii)))aaalolloorfrrffoooCCCrrrHHHaaann2n22CtCCttiiivvHvHHiiir2rr22aaSaSSlllCCCaaaHHHcccttt333iiivvv(((i5ii55ttt)y)y)y bbbuuutttyyylll gggrrrooouuupppsss (((222,,, 333))) CCCHHH(((OOOHHH)))CCCHHH333 (((444)));;; dSddSSeueeuucccbbbrrrssseeetttaiaaiittstssuuueeetttdddiiioooaaannnnnnwtwwttiiivvviiittitiihhrhrraaabbbllluuuaaallclcckkktttyiyyiivvvgiggiitttrrryyyooouuupppsss",
            "1\u20135 1\u20135 on on anti-HIV anti-HIV aaccttiivviittyy...",
            "--w(o0acda-\u03bc1[asv-sa-\u03bc1acd[asv-sa-\u03bc1acd[asvsa21S216216ce21o6s.c)cegceofoiec)gc)gigi,,eeg9geI.,,7rrr.,,7.,7erc53rrmrrcecerem5m3ete53r53r/t6uer//vu\u2013ueevo<v\u2013t\u2013i-,ohottmnihi-,mnmne-,-,4SvaSdSeae47asvevp4d747msespepddm\u03bcmeStAetSAt-SAntma-n1tntm-0m--Li-0a-0asoLLssistoroiiigorrtipootttba)emp]taahemepmnp]t]tcunhnvuuuihhuu[in.i.m[/i[nini.i.msd(mhavsd(sd(rdh6vidmdhdh6v6vcddiHnciciSoHnHenSaoeSoeesreea6atSe6e6teetueeeeeteeuuwtdttniefwduwdtdtnunffLnuud]Idh]Ish]tIuhnn6ouuoocncV.c1s6V.Vr.m1is1s6s6mm1yrreiieeeydryafedredrmuc(,ae-amecamc,,ee,-ol3--Hdb33iadlzdllbb3iaoal\u2013rldizo1izo\u2013c\u2013a11bnaaabbe,araee,o,ereooo,rreeai4tooai4ai4nIna4snsdeastasesseuaeesdestfaladdtVct-flc-lc-lesctss-steu-ctctststetetitotur--otttrrroeotittrele2ityimyirr-lhlyyyit2yi2hhiiott-iiiteoioih--srranic1ssanranvn-rrvnHvnmtu-H-Himtmtifia\u2013ffoaeyiiioooaaiwaiyyoowaiwagiaiggnsatfrtnnzafftHttdHfIHttlzzdifpIfIeloldidpihpeotonhhyd)Vyytoci)V)VttiioroddImiatrIedIdieImatirmaeatreteIteIaamilcIaahIaIa-lhVlh--iVidVtiaidtdctIiiccIIiiy1cr-ziv11ffchffurzrzechcffhffBeeuuBtBzntoHt-oeuf--eufeurfatorriatioaoieitcitm1iicc1o)1e(memo)lo)dty((hmclolyoyhthcclttollrsIaIooysasarruletapuuneNestataiynINnsNeVsytyetmttheemtmthpfihItnrrttnnrirarnrlidirleldndnB-aeeNaioaabeN)Noiaoiacaee)b)adebbta1dadpdaftppaaafleftatalelei)anhririnnfnllfnfnrlrdlRnaedrdRncRneaamrcrhcoieamt2mieieohs2a(2ioohshsdindderinriinideercrsTiitmc.hTcvTe.hn.hvoveammieIeaea9tIioeIe99ttttooeettvtIIaioatIIIzInaiaaitdradttzezi2ddi2eid2psIiddepsIpsIoeenisiaatmnnnsostmtdmffoBoB,Brdd,,iiiitrir\u03bciiii2ttt\u03bci\u03bcttltvotttsnfenlNvlveonrfne)fNNnoror)i)eeoeieeeoioei.eii(ighi((uvfggcdeuuc9dedeccdrSccccrSrSaa-taa--/ysite//acas2rseIeyaacayacarehreAeaeaemv(AnAphmmnnh(hIi((tscitficttMtfrctfcoccirrMeonoIMMiun6\u03bcndiauu6u6ddialiRuautnyRRttry6yBllLobL(LooibbgovgigrigvseOvmrrOcOTSmlsm)lslTscn)c))TtTwnnetawtw-eebeaani--hsh/i(iahh(A(aaT2rm22mrrrmnmHaTaTnnhHHaatrazrruoioiseoiooiisois-eeii--ai)iirnntRtininnntnt))tttnonatntannfawanmnIfnLfh(wanwaciIIhihiiuuueVerE-ed)wnVVrg-r-yhztygyOzztgtgOOHadydHHedydydtdaheea(tahtahCseMa-ssMMaa--shsseHhdhlfd(sdalilnl2(.s(esilil22dteIetI.bI.5soeetEtbbdeeHN6eEeEsuHN6eHN6esVsnhVVThhh0ThTahIisasyERiraisassyaEyERRaCaMCCnVdtnnibyity--iydyt--stv-yddissyvyoinTvvoor42TTHr542r42n.HiH5y5-e-deehddav.hh0avTve.a.e0a0aeeae2Hae---ataatltra(Niairnrcsaav(Nia(iN-naiwncnvcouvv2ooHrtnsorrtcntnssoso4ccvIe2mveve2m2mriNcarrN-ctNcaaeehVtNttpeeNtNptpt-ometttr(t-oa-oheeRrmrrmphlhRRrlallch(SalalahahN(S(Saahoa-uhauahulmoRlNlRRNeNomiO2msmiOdiOovossdidoNofoioiNiNenfosoenenffsslantTnnnTTuoreaauouloi0uaraDrbueuiDhDbb(iehihpeseneoIdoeoerpdIIds.gbdrprpngbgbigRRtigiig0RRtstii)h)hfc)tfcfcbceahhbcbbceNHeaahhahh,tgNHuNH0,,rgaganaOaaOnnOtOoiesoos0ssisct0isa0ar3tnterrhlcbpcgeeltlpept,teehtem,,ah.eeh.emmtaaD.e..eD.soiDsDttoosso0iwago00hiw\u03bcwdonohhsndiad[iesnsan[att[rvtatrr0vvnlp60)0ce)pp6p)o6)accplgepeadaytlleytytl,e3ek63e3eeseR-idk6kl6sid.ridlelss/apneeapap-enr--noeetm]naonoye]]aaeecHocdOccHHb\u03bcec[eco-b\u03bcbx\u03bcddooxxun-ctnnf-ct-tct6tfft2ttntsdteeL2.ttteegr2i.2.ttteiegriagIriDtticiIIh6s-hephvssveieevovrV-viveioeoV-V-r/rlcyN//uvNN]uvuavyna3itynynnaemea)3iinmienmem33iimmtvhltvinvgtt-tiligtlgottic-l-ltltlfo----tyattoayaya(yivaooyay(iaLiaradag(a(LtyLgsgyyd4xcddanccc4ax4ainotn,rtxix,,ttrtireeevb,titybhbttmetdiySihw,hme,meyoaybyww5myoyoababivsyi5iiv5vtssyenyv)yInenlvvvneen)e-lhultnn)n)uutte---ie-ielii-i--idet--ie\u2248ettddinitidN2-ynwntedttsd2-2-satttsiNNttiattitdhnddhhinnsfh,y-sfosfiihyhy--yoonlmllm1i-acmmiuisiauaSco-cu-uubSuSooeeEe(eetetEEttt3(o(uarooararaIb(hwahacIbIidbuhwbhwec(c(ddieyeC3yCy5Ccvmcibcmn5mn5liinnsllatys\u2248saatt\u2248nt\u22483eilnn-eieilliih5-t-isiEd5ht5ohtdttsddddttts(snr3po0nl(ni(hpo0po0ihihht1hhype1t1otaeeypCyptNt)NiNsvasvisvhuaaai3iusiulata3,t3illiltltsshwbllihhbbieoihr5aeotueoehrhnarat3tedNtncine3e3dNtdNtahei0echeitheieaeiclclaiaeill3itealtel33atateogueneeotoduusdntnitdedeicRimiicRicR3li3v3alliooinlaeanecololneneyccoveeeyeyoovva)aTaa))TzTaaatlnznnztathstntnta,ssltgt,,ilglsgeiiisonsiiaonoInoalaoaotIyaIattvtnivvtioosutctsioioososysssmyytobmolmtmttmolmoltiatioiy-fifsy-fyio-fiofefwthwfwfittvih[hf2fvv(2m2el(m(mytiteivy0syieite6ti0i0SoaSSd-ihniaadt-rd-iitnhnheattttee.aa6ryio..rryhyIhavvgI9Ihhhahvav9oo9eeotrreoeoareoorerraa]lnyylle6<eeeyeysss6<6ere<eeeee.ffss))ssrrl))f)fll",
            "A new class of HIV-1 NNRTIs, N-aryl-2-arylthioacetamides, has been identified in the last years [67\u201370]. Studies on the crystalline structure of the RT-NNRTI complex suggested that NNRTIs hMaovleecualesco20m20m, 2o5,n94m2 ode of action and interact with a hydrophobic pocket. N-aryl-2-arylthioacetam5 iodf e2s2 aaddoopptteedd aa bbuutttteerrflflyy--lliikkee ccoonnffoorrmmaattiioonn iinn wwhhiicchh tthhee aarryylltthhiioo mmooiieettyy aanndd tthhee pphheennyyll rriinngg mmiimmiicc tthhee bbuutttteerrflflyywwininggs.s.SASARRstustduiedsiesshoswhoewd ethdatththaet athryeltahrioylmthoioietmy ostireotyngsltyroinnflgulyenicnefdlutehnecaendtitvhirealaancttiivviirtayl, laecatdivinitgy,toledadiffinergetnot dreisffuelrtesndterpeesnudltisndgeopnenthdeinsgteorinc/tehleecsttreornicic/epleroctpreorntiicesporof ptheertgiersouopf sth[e47g]r.oBuapssed[4o7n]. tdaBhceaeerssiteveadamfitiionvMdndeoelsiencdtu7hgel\u2013eesrs1si2,v0e0X2aa0itf,saii2vn5on,edh9es4iwe2n7ge\u2013Nst1,N0alXaR.siTasnIoysehnw[e4th7Nee]t.sNizaRel.TdIss2y[-n4(t57h-]ae. msizinedo-12,-3(,54--atmhiiandoi-a1z,o3,l4-2-t-hyilathdiioa)z-oNl--2(a-yryltlh5)iooaf)c2-e2Nta-(maridyle) adopted a butterfly-like conformation in which the arylthio moiety and the phenyl ring mimic the butterfly wings. SAR studies showedNthNat the arylthHio moiety strongly influenced the antiviral activity, leading Based on these tfoinddiifnfegrse,ntXriaesoHuhl2etNs edtepaleS.nsdyinngtShoensiztheOde sNteric/eXlectronic properties of the groups [47]. 2-(5X-amino-R1,3,4-thiadiazol-2-ylthio)-N-(aryl) acetamide derivatives 7\u201310 as new NNRTIs [47]."
        ],
        "H N anti-HIV-1 actOivityX": [
            "X compRared to standard drug zidovudine (halfA-mltahxoimugahl itnhheiybietoxrhyibcitoendcelnetsrsataionnti-HICI5V0 -1= a0c.0t1iv6ity\u03bcMco),mtphaerseedcotompstoaunnddasrdshdorwugedzisdigonviufidciannet (ahnatlif--HmIaVx-i1maacltivinithyibaittmoriycrocomnocleanrtcroatnicoenntIrCa5ti0on=s7-0(1I.0C01506w\u03bcitMhi)n, tthheesreancgoemopfo7u.5n0d\u2013s20s.8h3ow\u03bcMed) (sTigabnliefic1a).nItt ahnatsi-bHeIeVn-1obaAcslettirhvvoieutydghatththmaetyicthreoexmh2ib-oailtmaedrincloeosn-s1c,ea3nn,4tti-r-tHahtIiiVao-dn1isaa(zcIotCilve5i0tymwcoiotimhetipynarmtehdaeyrtoabnesgtaaendogafor7od.d5d0gr\u2013ur2go0u.z8pi3dof\u03bcovMruda)in(eTtia-HblIeV1-)1.",
            "Iatchtiavsitbye(hbeanylfo-pmbrosaexvirimvdaeinldgitnhhpairbtoittmohreiysi2cn-oagnmcaeinnnttoirva-ti1iro,a3nl,4aI-Cgth5e0 ina=tds0.i.a0Mz1o6olre\u03bceMomv)o,eirteh,tetysheme ceaolymecbptoeruoanndgicsoopshdroogwpreeodrutipseigsfnooirfficatanhnteti-NH-IaVr-y1l agcrtoivuiptyianbnyftliu-pHerInoVcv-e1iddaicntaigvnittpiyvraoirtmamliscprinoomgteoanlancrytic.voniTrcahelnetariganteitonrnotsd.(uIMCc5t0oiworneitohvoinfetrh,eeltehrcaetnrgeoelneoc-fwt7r.oi5tn0h\u2013idc2r0pa.8wr3o\u03bcipnMegr)t(igTerasoboulefp1ts)h,. IetsuNc-haryasl goufcplrornruomostouruprippflbeinarsuirtentogfhaieiflletcraduruostousooiurtvtemrbeoopiintendtfyeecterithnenpibhtfdefohyhlolyuruebeuapleosnntnronerrNoytrsicnoivfveluvl-miuedppddbidorhhieesanratttreeonlghhiinnmttvpayuipyyvtaeolrtliltttoterhhieramodvyseinlnnuleicp2spgbyio-7honap.sn.(tgemthedTSinntapieheAnuycnhnreoylteRieyi-.vninvd1lnaTsyi,te3rtsttlharr,rui4elioivr-vndiaidtennihagignsuefgitetlaisc8nruvd(to(tdseideasdaoun.eenuz7ngrrMcodci.iegvtlovoiSed9aeofarAt)snmetie,toviRtleovevehoeidnseefceesrsthtte,yr8uhaloate8dhmnannacetintct-aeraiwedetyorshnldneeibsed9tt-ceahuwr)ts,rondgaiot9tvteergnh)ignair,viedrocihwsaciroaerapt/ldinaenewrncdollhaggieepnacradcteoggctnhtriutrrvtacaigoopivneeitruntstdioftyitopivhuoycrispfearm,pcasatnsso,nhlrottuotemsieiarcvpu-rNceHhpciietr-cihIaravaatV/trrhiesliatye-leya1slfledsancuctottoorftiorhvttinhihentiieeeycr",
            "Npo-psihtieonnycsol.msIupnabrsaetdditdtuoiettinhoetnsu,inntshfluebusentintaucttueedrdepthhoeefnatynhl etdierNreitv-raaotrivyvielra7r.linSaAgcRtiivnstifutlyudiemensocseuredggtethhsatendatthnhaetitivrtihpreaoslsteiptrioicot/nelnse.ctyIrnoanasicdcdaintiobne, tohbesneravtuepdrerofopoferrtthdieeesrNiov-faatrtihyvelerNi1n-0pghwiennifltyhul easnupcbesydtritiutmheneidtasynlitnirfvilnuireganlwcpedhoitcethhnecwyanaatssirtcehatrenovmbireoaolsbtascaetcirvtviivteyedmcfooormredpetohriuavnnadttihv(eeFiri1g0uwreit2h) a[4p7y].rimpidoysiltiroinnsg. Iwn haidcdhitwioans, thhee nmatousrteaocftitvhee cNo-marpylourinngd i(nFfilgueunrceed2)t[h4e7]a.ntiviral potency as can be observed for derivative 10 with a pyrimidyl ring which was the most active compound (Figure 2)",
            "[47]. TTaabbllee11..SSttrruuccttuurraallddeettaaiillssaannddIICC5500 vvaalluueess ooff ccoommppoouunnddss 77\u2013\u20131100 ((aaddaapptteedd ffrroomm [[4477]]))..",
            "33,52,52-,-(,54(5HCC-,-3F6FFF,-522233(-))O,(252C-CFFH23112)3116402)...642198..03319\u00b1\u00b1\u00b103 001\u00b1\u00b1...12800744..284411764.5..19003\u00b1\u00b1\u00b1100.0..28644",
            "RR susbusbtistutittiuontiownithwiFthatoFmsat(o8m, 9s) (8, 9) enehnahnacnesceanstiavnirtaivl aircatilvaitcytivity",
            "Figure 2F.HigT2uNhree2iH.nNT2flhSNueNeinnNfclSueSNeonfceSsuoOfbssuHNtOibtsuHNtNXietunN=eNtnsNNtos hfoef1Rt1,eR3,3r,4o,4-c-ttyhhciilaaiddciiarazinzogoislnetlisrtienedtrnrontedcerdgrornuetiehvdgcraeatuitinsvthociesvaentsianetoonisasvfntc7iaevC\u2013tonsii1rHvfta07ii3lvt\u2013oCOyain1crHg0taair3vlnooOiauttniycp-gHta(ir1vnIoV0itut)iyap-Hct(i1IvV0it)ya.ctivity.",
            "MolecuMleso2le02c0u,l2a5r, 9m42odeling studies for the pyrimidyl derivative 10 showed the formation of two pot6enotfia22l iaercstbadptrropdsaptrropdsaenhhetuiesyhnnyiecyrrforcorrnorontstipiaiuilpnoididiunoestacaeduttcgiaedgvelgmtnuelrkbcmtdknidsnilihtainmihoncTtMTcttoriclMThccirti[tuiimnriesaeitnefaaate6ahfaashsesohai,sirtcgsozttcgniatho4ffztweiateimiliaeinioihtniaoholonelz]oloezolzoohles.egnaecscgnleensosolennlicnecieeactiseuddniddnldlamuioi\u03c0rlsmuisiseiinvliltiniincraetignnraealgo\u2013[ctelenteabihuiaibrishu4airsaruid\u03c0nwtrasdnMrohiMyorii7lyyrismnlemlnihgbeaasgnboaiana]iettsdbTsntdmyi.aTiaitmfisrroifsoitoanitnanig-dntnroo-5oelottcelnne4oton4oeaetahoeadrenr-synrrsrordodcoc(mnddyicccntrfaaycaatacpnfuaeofegueayedeenmdclrrmrpasybspliarlslbeldltleNezilastilmaatsirolmnonolstoansothaai5rciai5rcchHdNtuhsltnudgsltgrnui-abereuit-eehenirhh(leynthi(liyItnsBcolontcpluvitnpeVotesyostsyursountnSauwtysagiut-syse,atisd,-aidtlfu2cdlautcrra1ttacr\u03c0royoaci\u03c0rr[t-tzrreriltdtsteildir6iiofyhurdfoioh\u2013uwdhdi\u2013vdooviow4diiglwtev\u03c0cgiRee\u03c0ccinesmicfhsfnif]tanotetsityetsahyT.vautryesu-itycfniv-ifniechsnac.2ehonsrn2nrrofruftcltloli-Iotaollia-hieotahlbahemiosbyvneosdzyeomazlrmgslrligyoriroliawsreibclawtsbpanrmaacanlmnacecnttctctiet)iiodoNicigeihoateNicdethd-atndsovneooetr1rnout.frdnefpesiastoNnisisftNnr,ofordtthHnodt3itohotonyyhyntnhipnBipiyn,dBliynoin,l-o4onHtadiHtaoydsrSlysiStMtlfdaiv-fwanv)oin)rh1nortIrw-ccI[wi-oc[ohotioVn01tioeVn4n,eT1tht4mhttmhlglhiiif,s7vhiift,gv7--vta3-vaet3veehefb14a]fhi1ea]Rhiid,Roigi,dn.ohidne.4etrn4ttrctccrTiat,rwTynyyt-ewygyo-aogaoheoehtgit.szdl.zflahntrlflahaeraeuiloeaoeIraoornIrvzinssszdisndnelenamcafeealftitetitne-bsltdznedeislsddtinte2raHreprcareipiryceioaiooceirr-ntidceotiasdootasvoarneivtvIrtnvtMthetmnzdtormnVzrdvmornardeuaeuc-eooogogooidegtidd-dtadTpdtpdnitilvt1snilevbaieirnv-ieihv-oTioon-iinol2nb-uin2onofineeorr(eeurrnug-ntog-stfaianeainecahandcta,atncat,ls.1Rlie.1mrhehmthhmdeethstdH0MtrHao0MTaohairanyhflpybioibmi.ciimconeynodnte1nTsvdyr1eTstaDetwheoiw0heropin0-a-mrnue-veIvlaea4moaa4tozIyliezlseigsiinzekaiInwzetawevvtiredvpiBrcyicdgcndeyicdgsdninnoeeeneeetime),etia,geateersorunleerrsdledetirlo,trtirlo,trcinhpg1scernhihseurihgdingtanviavf1iseetpsehtennieiona-riibha-trbh\u2013natvnsnvdelbsddgfvbgayte1aiyteteeheeeieoHcsieaetoHimds6mvnvrnihaftrftfMtrbrofoMerioeIhiieIwohteioeicitVeoactifcnVnsifnnshirtihsiTorisctTknoeReoozo-mReoug-mheuienT1rianT1radnTanliTealbyam1gobattam1gttisig.ss.(atcu1ss(drfantu1rpspDiaispDiyosia\u2013ossto\u2013idtcttordtorystayMnsh1iurteno1ureneseenemaeteazar6asrte6pvsnetepvrsyirshoyiiTpaipcmfunednomfenolllen-eiluoiaiuoetlyfaiut4yfugstisaiwtdiflewnfledn-Iaidi-IssratstlzItcoalIdiliaittdtwieiitttIwnieiInoneehnhhrknnhnhhBrkoerBerdddlngygoeeeeeesgoreefeeeel)r) efavirenz as a standard drug [64].",
            "ohohotattahhhlloeeoergrgrEEEececxcxxnoonocccmomoeemeappapppplltttkkoooffyfyuuouoollnnrrnrggddddddrrsssoeeoerwruwurwiiipvpvvaaaasassasstttaeaieieivvtvvtvveeeCeCeenn1n133111l1lalaooownwnwwwwddhhheee//iiroiorcrccrh(rh(h(EEECCsCssCCh4h4h55o5o0o0oo0wwwfvvfvapaeaepeldldlhdhuuueeeleellonnososs1wywyw1>>>ll-17ar7ar7a6i0ci0c0cnnttt\u03bcig\u03bci\u03bcgivvvMMMilliiteetty)y))dydppp(((ttEErrEroooooCCCavavv555iii00d0dnnnvvevgeggaccaattrltrllhhuheuueaaaaeaeetstsstsseesssooouuuoofffbbbrr444sssl7l77tttooiiitts\u03bc\u03bcst\u03bcuuussMMMtttooiiiooo))f)f,,n,nnaatttchhcwwhwtteeeiiiiivvtttaaahhihiccttcyytthhthiiivvaava((FFlliilioottotiiyyyggggguueeoeoonnrnrfffeesssttthh3o3hooee))rrer.. AhAalltlthohogoueunggohhaplpkyyyrrildidginrinoeeudpdeserriavitvaCatit3viveaesnsdddi/doidrnnCoto4teoxefhxpihbhiibteinst eyslleelrceitncivtgievleaendatnit-otHi-aHIVdI-Ve1c-ar1ecaatiscvetiitvoyir,ttylho, estshfaeocfftaatchcttaitvthicatoytmc(oFpmioguupnrodeun31)d1. sA1h1lothwshoeoudwgsheodmpyesroaimdniteniveairndatelirvaiivcrtaaitvliivatyecstmivdaiitdyyenmnoctaoyeuxrehanigbceoitfuusreratlgheecetrifvrueersteahanertrci-hrHeosInVeat-h1rciashcstotirvnuicttythu,irsteh.setSrfuuabccsttuetqrheua.et Sncutobcmhspeeqmouuiecnandlt m1c1hoedsmhifioiccwaaletidomnsosodbmiyfeicsauatnbiotsitnvistiuratbilyoancsstuiovbnisttyaitruomtmiaoayntisecnrocinonugasrrawogmeithaftudircitffhreeirnregnrsetsgweraoirtuhchpdsoimnffaetryheilnsetasdtgrrtuoocutcuporsme.pmSoauuybnsdleesqawudeitnthot iccmhoempmrpoiovcaueldndmascotwidviiitfthiycai[mt6i4op]nr.osvbeyd ascutbivsittiytu[t6io4]n.s on aromatic rings with different groups may lead to compounds with improved aCctHiv3ity [64].",
            "Cl 11 Cl substitution with methyl beneficial for activity halogen or halogenoalkyl groups at C3",
            "F Cl 16 Cl dheacloregaesneotrhehaalcotgiveintyo,alEkCyl50gvroaulupessa>t C730 \u03bcM decrease the activity, EC50 values > 70 \u03bcM introduction of halogen at C3 and/or C4 ilnotsrsodoufcatciotinviotyf ,hEalCo5g0evnaalut eCs3>a1n0d0/o\u03bcrMC4 loss of activity, EC50 values >100 \u03bcM",
            "Figur1e43. The influence1o5f substituents of116,3,4-thiadiazole derivatives 11\u201316 on anti-HIV activity.",
            "FFiigguurree 33.. TThhee iinnfflluueennccee ooff ssuubbssttiittuueennttss ooff 11,,33,,44--tthhiiaaddiiaazzoollee ddeerriivvaattiivveess 1111\u2013\u20131166 oonn aannttii--HHIIVV aaccttiivviittyy..",
            "The invasion of the central nervous system (CNS) by the HIV-1 virus frequently causes brain inflaTmThhmeeaiitnnivovnaassiiaoonnndooffpttrhhoeegrcceeesnnsttirvraaell nnneeerruvvrooouulossgssiycyassltteedmmis((eCCaNNseSSs,)) bbwyyhttihhchee HHarIIeVV--c11ovvmiirrmuusosnffrlreyeqqurueeefnnetrtllryyedccaautuosseeasssbbrHraaIiinVn iiannsflfslaoammciammteaadttiioonnneaunarnodcdporgpongriortegivsrseeisvdseiivsnoeerudnreeorulsorgo(HilcoaAgliNdcaiDsle)ad[s7ies1se],a.wsHehsAi,cNhwDahrieaccfhfoemactrmse 7oc%nol\u2013my1rm5e%foenrorleyfdArtIeoDfaeSrsrHpeadItVietaonstssaosacinaHdteIVdis nacsehsuaorrcoaiccaotteegrdnizinteidevuebrdyoicsnooegrudnrieotrinsvae(lHddAiysNosfrDudn)ecr[7tsi1o(]Hn. HAinANclNDudD) i[na7gff1]es.cyHtnsAa7p%Nti\u2013Dc15da%affmeocaftgsAe7I,D%nS\u2013eu1p5rao%tnieaonlftdsAeaIgnDedSniespraacthtiiaeornnatcsatneadrnidzceeidlsl bcdhyraonrpaeocuutretorn[iz7ae2ld]d. CbyyseflunlsneiucntrviooonnlavilenddcyliusnfduHinnAgctNisoyDnnaipnpacttlihucoddgianemngeassgyisen,aanrpeetiumcrdoacnarmaolpadgheeag,genenseeuarrnaotdnioamnl idacrneogdgelcnieael,rlawdtirhooincphoaunardte[c7te2hl]el. Cdmreaollipsnoitunatvrgo[7el2vts]e.doCfienHllHIsViAn-1vNionDlvfepecdatitoihnnoHgineAntNheseDisbrpaaraietnhm.oWgacehrneoenpsihisnafagerecestemadnawdcrimothpihcHraoIgVgel-si1aa,,nmwdahcmircoihcprahoragegliteahs,ewamnhdaicimnh itacarrreoggtehltisea ominfacHirneIVatsa-e1rgitenhtfseecotpfiroHondIViun-c1tthiionenfbercaatniiondn. Wrinelhetheanesebinrofaefincst.eeWdvehwreainlthisnHofleIuVcbt-el1ed, mwneaituchrrooHptoIhVxai-gc1e, fsmaacantcodrrosmp, hiscaurgoceghsliaaansidngcmlrueitacasrmeogtahltieea, piinnrcodrdueuaciscnetigotnnheeaunrpdornoraedlluedacatsimeonoagf easne[v7d1e]rr.aellesaoslue bolef nseeuvreoratol xsicolfuabctleorsn,esuurcohtoaxsicglfuatcatmorast,e,suincdhucaisngglnuetuamroantael, dinadmuacGginelug[t7an1me]u.irnoenaisl dthaemamgoes[t71a]b.undant amino acid in the human body and is involved in more metaGGbloluulittcaammpiirnnoeeciesisstsheteshemthomasntoastbaunanybduoanntdhtaeanrmt aianmmoiinancooidaaicnciiddth. eiGnhluuthmtaeamnhiubnomedaiysnapnbdroodidsyuincavendodlvfiersdomiinnvmgollouvreteadmmiaentteambaoonlridce pmarmeotcmaebososneliisac tbhpyaronthcaeensesyneoszythtmhearenagmlauintnayomaoincthiedes.ryGnaltmuhteiantmaosiena[ce7id3is,.7p4Gr]o.ludTtuhacemecidnoenfrvoiemsrspigorlnoudtoaufmcgealdutetafarmnodminaemgtolmugtoalnumitaaamtbeyatatenhdies acmatamlyozneiad bbyy tthhee emnzityomcheognldurtiaaml einnezysmynet,hgeltuatsaem[7in3,a7s4e].[7T2h,7e5c]o. nTvheersgilountaomf ignleu/tgalmutianme atotegcluytcalemiantethise chautamlyaznedbobdyythpelamysitoscehvoenradlriiaml epnozrtyamnte,mgleutatabmoliincasfuen[7ct2i,o7n5s].. TThheugs,lugtalumtainmei/ngeluatanmdagteluctyacmleatine tahree human body plays several important metabolic functions. Thus, glutamine and glutamate are",
            "Menozleycumlese20g2l0u, t2a5m, 94in2 e synthetase [73,74]. The conversion of glutamine to glutamate is catalyz7edof b2y2 the mitochondrial enzyme, glutaminase [72,75]. The glutamine/glutamate cycle in the human body pprlaeycus rsseovresratol itmhepobritoasnytnmtheetsaisboolficpfruontecitniosn, sn.euTrhoutsra, ngslumtaitmteirns,e nauncdlegoltuidtaems,anteucalreeicpareccidusrsaonrds tooththeer ibmiopsoyrnttahnetsibsioolfopgriocatelimnso, lneecuurleost.raTnhsemgitltuetrasm, ninuec/lgeolutitdaemsa, tneuccylecilceaicsidthseansudbostthraetreimfopr othrteansyt nbtiohleosgisicoafl umroelaecinultehse. Tlihveerg,lguetanmesiinseo/gf laumtammoanteiacyincltehies kthidenseuybsstarnatde ffoorr htheepasytinctahnesdisreonf aulrgealuicnotnheeolgiveenre,sgise.nTeshies golfuatmamminoen/igaluintatmheatkeiedxncehyasnagnedrefgourlhateepsatthice aancdid-rbeansael bgalulacnocneeoingeknidesniesy. sT, hacetsglaustaamn ionxei/dgaltuivtaemfuateel feoxrchthanegientreesgtuinlaetsesanthde caeclilds-boafstehbeailmanmceuinneksidysnteeyms, aanctds apsroanviodxeisdathtievetrfauneslpfoorrtthoef innittersotgineens abnetdwceeellns oorfgthanesim[7m4\u2013u7n6e].sTyhseteemxiastnedncperoovf iadgeslutthaemtrinaen/sgplourttamofanteitrcoygcelenibneCtwNeSenwoasrgcaonnsfi[r7m4\u2013e7d6i]n. Tthheeleaxsitsyteenacres [o7f6a,7g7l]u. taPmhoinspe/hgaltuet-aamctaivteatceydclemiintoCchNoSnwdraisalcognlufitrammeidnainsethies lathsteypearersd[o7m6,i7n7a]n. tPheonszpyhmaete-tahcattivuatseeds gmluittoacmhoinnedriinal gthluetabmrainina.seGisluthtaempirneedoims ipnraensteenntzyinmethtehaet xutsreascegllluutlaamr ifnleuiidn tohfe bthraeinb. rGailnutaamt ihniegihs pcorensceennttirnattihoenesxatnradcepllruolvairdfleusidanofatbhuenbdraanint astuhbisgthractoenfcoerngtrlauttiaomnsinaansdep[r7o2v,7id5]e.sTahnearbeufonrde,anitt hsuabssbtreaetne hfoyrpgoltuhteasmizinedaseth[7a2t,7m5]i.toTchheornefdorriea,litghlaustabmeeinnahsyepoatchtievsaiztieodnthiast mreistpoochnosinbdleriaflogrlutthaemihniagshe alcetvivelastioonf gisluretasmpoantesibinle ftohre thberahinigsholfevHelIsVo-1f gilnufteacmteadtepinatitehnetsbra[7in2]s. oWf HhiIlVe-1gliuntfaecmteadtepmatieednitaste[s72d].ifWferheinlet pglhuytsaimolaotgeimc epdrioacteesssdeisff, eerelenvtapthedysieoxlotrgaiccepllruolcaerssceosn, ecleenvtaratetdioenxstroafcegllluultaarmcoantececnatrnatiinondsucoef gnluetuarmonaatel dcaanmiangdeu(cee.gn.e, udreomneanl tdiaa,mbargaien(ea.tgro.,pdheym) e[7n1ti,a7,2b].rain atrophy) [71,72].",
            "SSoommee gglluuttaammiinnaassee iinnhhiibbiittoorrss ((ee..gg..,, 66--ddiiaazzoo--55--ooxxoo--LL--nnoorrlleeuucciinnee,, eettcc..)) wweerreessttuuddieieddiinn vviittrroo ffoorr tthheeiirr aabbiilliittyy ttoo pprreevveenntt tthhee ggeenneerraattiioonn ooff gglluuttaammaattee bbyy HHIIVV--11 iinnffeecctteedd mmaaccrroopphhaaggeess.. TThhee rreessuullttss ssuuppppoorrtt tthhee hhyyppootthheessiiss tthhaatt gglluuttaammiinnaassee mmeeddiiaatteess gglluuttaammaattee ggeenneerraattiioonn iinn HHIIVV--iinnffeecctteedd hhuummaann mmaaccrroopphhaaggeess.. WWhheenngglulutatammininaasesewwaass iinnhhiibbiitteedd bbyy vvaarriioouuss iinnhhiibbiittoorrss,, HHIIVV--iinndduucceedd gglluuttaammaattee pprroodduuccttiioonn ddeeccrreeaasseedd aanndd tthhee nneeuurroonnaall ddaammaaggee wwaass ddiimmiinniisshheedd [[7711,,7722,,7788]].. FFuurrtthheerrmmoorree,, ffoorr ssoommee gglluuttaammiinnaassee iinnhhiibbiittoorrss,, aa nnoonn--ccoommppeettiittiivvee mmeecchhaanniissmm ooff iinnhhiibbiittiioonn hhaass bbeeeenn ddeessccrriibbeedd [[7788]].. TThheessee ffiinnddiinnggss ssuuppppoorrtt gglluuttaammiinnaassee aass aa ppootteennttiiaall ccoommppoonneenntt ooff tthhee HHAANNDD pprroocceessss aanndd ccaann pprroovviiddee aa nneeww tthheerraappeeuuttiicc tatargrgeet tfofrotrhethtreeattrmeaetnmt oenf nt eoufronceougrnoictiovgenditiisvoerdderissoarsdsoercsiataesdsowciitahteHdIVwiinthfecHtioIVn [i7n1f,e7c2t,i7o8n]. [I7n1c,7o2n,n7e8c].tioInn wcoitnhntehcetisoenrewsuiltths, tahleasregerensuumltbs,eraolfagrlguetanmuimnabseerinohfibgiltuotrasmhainvainseg ainbhiisb-tihtoiarsdihazaovlieng(17a) banisd-thaipadyiraidzoazleine(1-t7h)iaadnidazoalep(1y8ri)dsakzeilneeto-tnhi(aFdigiauzroele4),(r1e8s)pesckteivleetloyn, w(eFriegusyrenth4)e,sirzeesdpaecstaivmeleyt,howderoef stryenatthinegsizoerdpraesvaenmteinthgomduolftitpreleatvinirgaloirnpfercetvioennsti,ningcmluudlitnipgleinvfiercatlioinnfsewctiiothnsre, tinrocvluirduisnegsi[n7f5e]c.tions with retroviruses [75].",
            "R1, R2 = H, alkyl, alkoxy, hydroxy R = alkyl, hydroxyalkyl, aminoalkyl, acylaminoalkyl, alkenyl, alkoxy, aryl, arylalkyl, aryloxyalkyl, heteroaryl, heteroarylalkyl, heteroaryloxy, heteroaryloxyalkyl, etc. R' = H, alkyl, alkoxy, aminoalkyl, alkylaminoalkyl, heterocyclylalkyl, arylalkyl or heterocyclylalkoxy",
            "FFiigguurree 44.. TThhee ggeenneerraall ffoorrmmuullaa ooff gglluuttaammiinnaassee iinnhhiibbiittoorrss 1177 aanndd 1188..",
            "Multiple experiments were performed in order to study the biological profile of the compounds. SomeMoufltthipelesynetxhpeesriizmedendtesrivwaetriveespaerrefoprrmoeddrugins, worhdicehr utnodesrtupdhyysitohleogbiciocloongdiciatilonpsro(ifnilveivoof), tahree ccoomnvpeortuenddisn.toSothmeethoefrtahpeesuytnictahlelysiazcetdivdeepraivreantitvceosmapreoupnrodd. rSutugds,iewshhiacvheuanlsdoebrepehnycsoionldougcitcecdotnodoibtitoanins pc(diohnenraidvrvmiuavctaoitvce),eedusatrtaoiencoadcblootpnanrvieenepropatrehrdmaatroiimonrnetaoscpeshtuhuateiritcmatahballecpererafuepotpreicauuartalsilectyiaoialnnlcyschesuapucmttiatiavabnbelelpepeaafxtorciereinpnutitsesecncotionsm.mhpInpuormuainsdaiddnn.igtpSioaattnnui,yedntihoetfess tcahhouaemtvhsepyorrnaislstshianoesgssbuiazemneednye othfatthethseydntehreivsaizteivdeds emriavyatbiveeussaenddaolonneeoorrminorceopmhbairnmaaticoenutwiciathllyknacocwepntaabnlteiveixracilpdieruntgss..InStaudddieitsioonn, the authors assume that the derivatives may be used alone or in combination with known antiviral drugs. Studies on kidney-type glutaminase inhibition showed good results for many derivatives such as compound 19 with an IC50 value of 0.24 \u03bcM and its deuterium derivative 20 with an IC50 value of 0.54 \u03bcM [75].",
            "kidney-type glutaminase inhibition showed good results for many derivatives such as compound 19 with aMnoleIcCul5e0s 2v02a0l,u2e5, o94f20.24 \u03bcM and its deuterium derivative 20 with an IC50 value of 0.54 \u03bcM8 o[f7252].",
            "HumHanumcyatnomcyetgoma1l9oegvairlouvsir(uHsC(MHCVM, HVe,rHpeesrvpiersivdiareidfaaemfaimlyi)lyis) aisuabiuqbuiqituoiu2to0sudsedoexoyxryibriobnounuclceliecicacaicdidvirus tthraant simn3vvth.fie2ierars.ucttsHitscicsouaathprnlmrate.yartonHaitpnnhCClsfeeyemMtcvootiismsVfrsupaeissogle,planoslar.pouegHvlcaeeihrCdsouMsafs[s7af(V9rHlulo,rsC8amip0ngMr]eeei.V,snaHs)[dfa7esCl9ci,vftM8rea0od,V]m.cpeHiinrenCvoffieMepcccoltVtevieoadtinnghpifrnceeoacaoutnlpigoslbehneectcrdhaeairtcnrioqeobuucnegtsirh,acecsoddpqniuerttrehiarmccretotdacuwontghndihtrthoabhucrbteogoawrhsdiztihytomhonflribitluzokaoidl.dnVyastnaeftrlldhutaiaivcndtaedslcrtaircrayl the vitrruasn,sHsmuuicsmhsiaoanns cutyhrtiornomeu,eggshaloiovvragir,auncser(tvHraiCcnosMpvVlaag,niHtnaeatrilopsnese,vcirfrreiodtimaoenfmsa,mostiphlyee)rrmistoanucdhbiiblqdrueiaotosrut tsmradinleksom.xVyisresirbiotoincnauvlcitlareaicbnlasomcoiddission throuvtgriahrunossfrtughsaitonnint,rfeiascntsaslppsloeaonpptolaestsoiiofbnalel,l f[ar7go9e,m8s0[]7m.9,Bo8lt0oh]o.edHr CttoeMsctVshiilnnddfeiocctraitotenratcnhaasntmb6ie0s%asci\u2013oq9nu0i%rveidaotfbhltrohooeudgahdtrhuaolntrispzfooupnstuiaollanat,inoidns also possibvelxeerpt[ei7cr9aiel,8nt0crae].ndBsHmloCiosMsdioVtne.isntHsfeCicnMtdioVincasatptersetohamdaste6ftr0iom%me\u20139idn0uf%ericnotegfdthpeeioarpdlilufeeltth[p8r1oo]pu. guAhllatdhtiiooruencgethxcmopneotrsaitectnofwcetihdtheHsbeCoidnMyfeVfcltuinoidnfessction at somtahreaettaicmsayremrydputthoreminvagitrituch,sec,eisrrutlacihfineap[s8au1ti]re.innAte,gltsrhaooluiuvpags,hscuemcrhvoisactsoovbfaagbthiineesasltehsiaenctfraeercteitoionnnfse,scstaperedermbaesfayonmrdepbbtiroretmahsattnmidci,lcckhe.irlVdtaerrientnicpoaarl tient grouptarsdaunsulstmschiwssaiitsohnbwatebhairkeoesuntgehhdatiomargmreauninnetfresacyntssetpdelmabnsetdafotuiroeent,boifdrrtioshmeaasnmedsoocthrhemirldetdroeicnacthoiiorlndasdo(uer.lgtt.sr,awHnIsiVtmh-iisnwsfieeocantkedevnipaeadtbileionmotsdm, une sdcyeelsvltseelomteaaoitorshfxdrrpaesepgtaunhabeasdplstnerselTfesueiyuverhhtewmsstrneeuoioarctoipnntmeoernfhtsdieodi,rdpamlwmselHnliitnasvsa-eaCnleebieatiantnlsaikoMolcsrsesedl,peeaoeVncycsstsdeeeipiirdptrfnonmthouoitafriesargemmiinsmntcsnaitutmbrspieslrneo)loaeueedqencvtcnniaiuos[eecagen7yimrnatr9asstdttes,tmylii8ogeemoscm0mvmreten]oeenel.esemullsdsadoBup(tenspieoilpsdcmod.fdpsagsoeuteulrfcd.hvoe,ecatdeserrHhnttusreeohieatraIsobuhVisdttinnemslembi-lgsni[raaine7eteenbtnra9nhfasdeis,eesetc8baeiecsitc2to[srstima7t]vdeho.tlt9dieayehraf]nteat.mfeptttoahH[dare8rraoeetd1Ctiafiqf]iieM.cnu6ltnHaoA0fhirettVn%Ceilsecotg,Mth\u2013pmineos9todseiV0erumarg(d%bgsbeeaieioh.lcngfnenaoaof.mnl,eftrtdocdHterotrtaehsbierIcovntVeaeiarnetsmon-tmalpihfondaabletpafaruihenenensnelctrtdstteil[ieema7napcrd9thcetioemrn]tcipp.ainlfivdauHvueptatrcelniiCitaetneeneientMnoondiosstnuotsVeniyssrsf,v)steceramanl supprogerasgnsacinoicntlroa[v7ni9rsp,8ola2rn].ot rraelcliypiaednmts)inciasntedreedvelvoaplgsaenvceirceloivllinres[s8e3s].thAaltthreoquugihre tmoleedraicbaillittryeaotfmgenant c[7ic9l]o.vHirCManVd",
            "Tivshaaelgbfialenrscttoi-cllrioenvmeiradirinsulgaastcecrneeptctoianmbslmeev, eehnreadmlecadetlofloslorogtfihcteahletroherautmnmeauennrobtlooodfgyHicfaColrMsaiVdleoinnegffeftecictmitosencaaannrdecoinacnctrubarev. erNneeaoucuttisrvogaptaeenndciaicf,lovir or oratthhlleryopmaedrbsmoocniyntdioseptveeernleoiadpsavniamdlgmaanunenmceiicsalyoasvrteeirmth[8seu3mp].paAirnelsttshoixooinuc g[e7hf9fe,t8co2tls]e.trhaabtilliimtyitotfhgeraanpcyicwloitvhirthaenseddvraulggsa.nSceirculmovir is accepctraebalteTin,hiheneemfilreasvtt-oelilnsoegmicdaaryluoginsrcnrreeacuosremolmdougerniicndageldsgiadfonerceictffhloeevcittrsrectahatenmraeopncytc,uorwf. hNHicCehuMtrrVeoqpuineirnfeeiscat,imothnornoaitmroerbiinongctryaotvofeprneonuaisal and anemgfiuaannaccrtiiceolonthvie[r8m4o]r.aioEnrnatcloelyxpihcaadleomffpeianctihtssytetrhiesadtthvlieamlgniatenutchrioceltrooavxpiircy [we8f3fie]t.chtAtholtfehsogeuagdnhcriuctlgoolsve.irraSbeairlniutdymvocafrlgegaaantniccniiciclnlooevvilirer v[a8en5lds]. may increavFsaoelsgcdaaunrnrciienctlgoisvgaiarlnsiocsiacalvcoceveriyprteatfhbfeelecr,taiphveeym,awnatthio-ilHcohgCirMceaqVl uodirrreunsge,muaronondloictgoiidcroainflogsvioidrfeirseeanffbaelrcotfsaudnc-acsntpioeocnctrc[uu8mr4.].aNnEetnuivctireropaplhewanliiotahp, athy iadsnruttihg-HestcfFg[phu8rocCoane3rnastooaeM]eccud.tmutaniNisVnrtorabeneiooncondedvattcetioerv[y[hiu8lx8istlit64oeig2gyac]]vp-,..hlaeaseaAemlognElnsffeainliadaevanimcncrvoeaecgstaelp-nite1ydrdohoyH,on3affia,ueCfln4nonogfmc-MfepevtarehpmabenicVritahetacih.israirvdiyesBcooeiaolaatfrodaiotzes4hnbuvox7ttrrilihtd2ierioch-nerHisaedutagymdyCnegnn-rgsaMdttsiehhaivpcnunVeaaaversctttucoaiiodizsvlcttlxrireogleemuioudxscaavgmiineccwi,thrfocsafiiaiemgnetttcnfhchrhdflpettoeesiaolcacrvveniuatttdvhiimtpnrreioaoayvdlfetf[l,ioson8rlwviagwfw5tmila]nri[he.ntia8etirhiccsc3pettihF]hghacit.voleeroobriorssotevrattycoeqdoipardauxayradiigniacrcw-naeinesttisipidtyanvtenhsmiitcttsvhtHtyoharaHauCnlteaglCmsiMlgsateiMoomanVadricViinnarintpcutssgilhovtgvotalrseHivyoerv.riamfarCeSylteremMwb[reer8uenaeffiV5etmsna]hen.el.tcBtoivthe",
            "Ngaososovadyelaac2tt-ivaaimtcyoinnacgoea-n1int,r3sat,t4Hi-otCnhMioafVd2.ia5Bzo\u03bcotMhled. drTuehgreisvdcaaetugivrseeeesaowhfiigethnhzlayenvmeteilvoiinfrhanilebpaithciotrionvtoirtxayincgaitegydatihfnrasottmliHm2Ci0t%sMtrVteoaht1ma0v0e%net.been paten[At8e3md].o[n8g6]t.heAmlaorsgt eacntiuvme cboemrpoofu4n7d2s,sfyonutrhdeesriizveadtivceosmexphoiubinteddsaw1e0r0e%teinshteibditiinonarnatHe,C29MdVerpivoaltyivmeserase assayshaotwaNedocvoenalnc2e-niantmhraiibntiiotoi-on1n,3o,4rf-att2he5iaod\u03bcfiMa9z.0o.lT1e%hde\u2013e9rd9iv.e9ag%triveeaesnodwfi1teh6nzadnyetmriviveiraatiilnvhaecsitbivisthiitooywnaegrdaainnagsntedHinChfrMiobmiVtioh2na0v%reatbeteoeon1f 00%. Amonp8g0a.t3teh%net\u2013e8md9.[o98s%6t]..aTAchtilrvaeregcsetornmuucmptuobruearnl osdefsr4,i7efso2 usstyranndtdhereoisvuizatetadimvceoosnmegpxtohuiebnmidtseodswt aearc1et0itv0ees%t1e,di3n,4ihn-itbahnitaiHdoinCazMroalVteepd, oe2lr9yivmdaeetirrviavessae:tives showa1es,d3s-adyaionaxtoia-n1hc,3oi-bndicitheionytndrraotri-ao2tn-ebeonofzf2o5f9u0\u03bcr.aM1n%.-5T\u2013-9hca9er.b9do%exgarmeaeniddoef 1ed6nezryidvmearteiivvienashtiivsbueitcsihonsahrsoanw2g1e\u2013edd30,faron9m-oicn2tah0d%ibecitteoinoa1nm00ir%dae.te of 80.3%Ad\u2013em8r9iov.n9agt%ivt.heeTs hmsuroceshet aasstcrt3iuv1c\u2013et3uc8oramanlpdsoe2ur-neiedthsso,sxftoyau-n1rd-dnoearpuihvt taahtmiavmeosindegexhtdhieberiitvmeadotiasvte1s0a0cs%uticvihneah1si,b33i9,t4i\u2013o-4nt2hr(iaTatdaeb,ia2le9zsod2le,er3idvaeanrtdiivv4ea)s.tives: 1dM,e3or-isdvtids81Mt1aaohho,0,cet33xe.otoirf-3-ivoiwsdvd%vstte-iiiaahe1otso\u2013omytd,ex8xif3vso9[oe-t8eud.-a-hd916s1tncee%ii,],m3shh3r.du-.i-iydevdnecTad,ihrhiahhshitritvrayhbyoieav3sdeid-ett1e23riirmovo\u2013sso-1tbne-3\u2013-ro22sb3e8us--8nerbtbbcaaltezeeaaoutnnlnnoecornzztddfanigouoovlg2ffrfes2uu-taete-roroc9rnetaaoih0tn-enttm.ho5hs1-h-x5-o5e%psecy--xtco1ca\u2013-ayaa11u,9rn3rr--b,9n-dbn3b1.dod9oa-o-ioxdsn%xpxouaaaiahxbotmmmpoteahxa-lhinii1omaodddtd,nm-3eheoe1g-iand,1dd3mmdgt6ieeo-hedortiydhdridtiivdheieeheevartriryysimotaivivdd-tvsao2aieieertv-sstiorsrbitveivi-eeavesa2esnsscuas-,ztsbstcigosuviuhseoofvehccunoehhoiar1zdstaws,ao3nacssfe,as2-s4uud35cn1-9-ratc\u20132cha\u2013fbh3a1afi4ne0noar\u20132,b-lda3dc5o(sii0o9T-nax-,cnzahaof3acoobmi9c9lrbrlltu-\u2013beeaiiotdds4doidaceoe22exntedn,caasrte(3iiedm-tTvnrrHhaeaaiaaianectCbtmdtsieedvl.Menieted4AhosasV)seeft:.me2r\u2013iide4se).. At thMe ossatmoef tthiemdee,ritvhaetivmesosbtelaocntgivteo cthoem1p,3o-duinoxdos-1b,3e-ldoinhgydtroo-t2h-bisenszeorfiuersa,ns-o5-ciatrcbaonxabmeidNceoNsnecrliuesd. eAdt that tahcetiv1it1a,t3hy,cOO3-etd-i[OvOd8siiiao6tomy]xOxO.o[oe8--611ti],,m3.3-2-ed1d,i-hHiH3thhyO0NONyeddrmor-oNSNoS2-s-2tbNN-eabncNHNHeztinovRRzfeuorcfaounmr-a5pRRn-oc-auNHNH5rn-bcdoaNNsxrSSabmNNeolixod3anNHeNH1mg-3OOmti8odoetihemtiysosiieesrtiyeas,isgsooaoidgt ocasocndafbfseocladcffoHn3Hof9cOoNONll-dru4CCOO2dN22faHHeondS5S5rNti-taHhnaNHNHCttiM-RtRHhVeCMV",
            "MolMMMMecMMoMouoollllleeooeeoeMcMcMcMlclMlsueeuueuccocl2oolololueueluelel0lleseseslsleelc2ceceecc22uu22ssu0suu00l00ll,22lel2e2e22e2es20s0s000ss0025222,,2,,22000,022022002,,9,25525520222420,,0,,,0055259,9,929,,,,244254422999522,52255444,9,,,22294999244442222",
            "TcoambTcTcTcTcoloooaaTcpTcaaeTcmmmmboobobboaaaM2mmTcTcllmTcpblbpluTcTcpbpeeoo.eeoaooaMoolaolnoplapoampmlbmeebmeemub2u2bSu2bu2dooocolp.l.lunlp.n.teplnu2lun2espup2eeorleecSdSod..eSoSdnd.nouuno2u2sTcttu2sttsu2lSSdsdsu2.uo2Srd1rnc2erra..nutstun.20.m2tsusunt\u2013Sn2d2sbrrr2uS2d1cS1dct31S1cudSucsd2l2u0p20rtt\u2013t\u2013etrst\u2013t0\u2013tst,11ucscu2rs21ucrouu3rar3233u0t\u2013t\u201321uct\u20132uur2(ur2025Rrul0urR,0u0RRt3\u201331aac3a.1c,ana1c1u2crr3d0rt(0\u2013RRld(9Rt0l\u2013R((l5tl\u2013Std\u2013aauraaau0R4aau3u,3eaat3d(3(ldlsd(2ddldrddr9r0Raa(0rtRlra0pR0Raeuaea42aadedaaeadaddad(dl2tt(dt1lcp(tt(plilpeapeaaaeeaaaaalt\u2013eadtttdtdusittpddptidtipd3idepaaellaeelalereas0tRsateedstisdaiaatdidaifteeltlpeeltpltpapr(nslsaassddaaadadfaaftofftititrndrnideirnrlndealaeaealmolfffosfosodddesdsdarrdnnrnrnmmhmtmooopodaddaadfaaf[hmfhfummhtIhrnmIirnI8IrnrnIe[l[ounh[u[noumnhunIodhson86dh8dII8d8dI[munmm[[mh6hmu[nmun]86hhhun66a888afm)hh]6h]mImi]h]irhnhIhim6.a6iihIa)I6)naa[]))b[ounbbiu[nbb[.ad.un]n]8un).n.]8iinnb8ia8am).)amin)ihmibb6himib6cm.h.h6tn6n.itnthttc]cIiy]cctiii]ii]aiici[i)aioyun)aiyabto)ty)yob8tot.obyccbn.ocn.i.inntmnioth6ttnyyintyoinoonooiiooo]tmtittctat(tcm)nmniccmnmibmoo(i%oi(.y(n(yoyoy%o%oemm%%imetete(e(ent(ttn)gonncog%%gogo%igge)e))ye)m)aomaamam(aagg(g(t(l))nl%ll)%oll%%eaooaoeaooeoemgllvgvvl(vggv)voo)o)%)aiaieiiaairivvvrrrlrrlgullou)iuoiuuiuooarrsrvsvsvssulvusuoi(iiissr(Hsr(v((r(rHuHuHHHuui((C(rssHHsCHsCuCCCM(s(MCCM((CMMHMHHVH(MMMVHVCV)VCVCC)VV)CpMV))MRMM)oMp))p)RppRRRVpVlVVooyoppopRVRoR))lml))llooyoy)lyyppylRlpRlmpemRRRmmyypyRormooommoameleleellylsyreyryrryeeeeamamaarmmmrrrssassiaaaeeeeneeeesesssrrhrrereeaeiiaaiiaaIinnnnsbssnissiiihehneehnhineenhtIiIiIIhiihihhbiibniiobnbininnnnIIiibinIniiiniibbbhhhnbtnhthhnthtihhiiIiiiIiiiitIioihoIvhiitotihoIbItnitinibbbnbiinbbbbniiannnoinniioohiooihtiilihiibbthiibntihnnhuttntintiiovttivviviiboiiibioeiiiioion(abatotobaatvvosonbbivnv%iniinliltllnitnaauoinovnauoiuaiiuoittvl)lotvtalevonvneilfneuiue(uii(a(u(lnoasosana%sos%oue%e%ell((9enl(lnusesnun(os%ou%uo(%os)%)s))eo%fefefef(oo(o(f(ss)o)%os)%s)%ff%f)92ffoo2oo))o))fffff 22",
            "Other compounds also showed good inhibitory activity. These derivatives contain a five- to six-mOemthbererceodmspaotuurnadtesdahlseotesrhoocwyceldic gmoooidetiyn, hsiubcihtorays iamctiidvaitzyo.liTdhinesyel,dteetrrivahatyidverosfcuornytla, ipnipaerfiivdein- ytol, msixo-rmpheomlibneyrle, dthsioamtuorraptehdolhineytel roorc5y-ctlioc1m0-omieetmy,bseurecdh aarsomimaitdicaozroluidnsinaytul,ratetetrdahheytderroocfuyrcylilc, mpiopieertyidsiuncyhl, amsofurpryhlo,lpinyyrlr,oltyhli,opmyorirdpyhlo, lbinenylzootrhi5a-ztooly1l,0e-mtc.em(eb.ge.r,edderaivroamtivaetisc4o3r,44u)n[s8a6t]u.rated heterocyclic moiety such as furyl, pyrrolyl, pyridyl, benzothiazolyl, etc. (e.g., derivatives 43,44) [86].",
            "WWhile tthhe ssyynntthheesized ddeerivatives have shown iinnhhibitory activity against HCMV polymerase, ttheir antiviral activiittyy ccaannnnoottbbeelilmimitieteddtotoaaspspeceicfificcmmecehcahnainsimsmofoafcatciotino.nT.hTehsesceomcopmopuonudnsdmsamy abye baectiavcetiavgeaaingsatincystocmyteogmaleogvairlouvsibruysHbCyMHVCpMoVlympoelryamseeirnahsiebitniohniboitriobny oorthbeyr motehcehranmisemchsaonfisamctsioonf. aInctiaodnd. iItnioand, diutiroing, dthuerinexgptehreimexepnetsri,mmeanntys, omfatnhyesoefctohmespeocuonmdpsoaulsnodshaolswoesdhoawcteivditayctaigvaitiynsatgoatihnestr ohtehreprehs evripruesevsi,rsuuscehs,assuvcharaicsevllaar-izcoeslltae-rzvoisrtuers v(VirZuVs )(,VEZpVs)t,eiEnp\u2013sBtaeirnr\u2013vBiraurrs v(EirBuVs)(,EhBeVrp),ehsesripmepslseixmvpirleuxs v(HiruSVs ()H, aSnVd), ahnudmhaunmhaenrpheesrvpiersuvsirtuyspteyp8e (8H(HVH-V8-)8. )P. hPahramrmacaecuetuictiaclalccoommppoossitiitoionnss ccoonnttaaiinniinngg ssuucchh ccoommppoouunnddssoor rthtehier ipr hpahrmaramceaucteiucatilclyalalycceapcctaebplteabsaleltssaulstesfuulsaesfualntaisviaranltaivgiernaltsahgaevnetsalshoavbe eanlsotudbeieedn. Sstudieds .hSatvuedbieesenhacovnedbuecetnedcofonrdtuhceteaddmfoirnitshteraatidomn ionfispthraatrimonacoefuptihcalrmpraecpeaurtaictaiolnpsrbepyaprartieonntserbayl, tpoapriecnatle, roarla, ltorpirceaclt,aol raoluoter, rdeecptaelnrdoiuntge,odnetpheenpduinrpgoosne othf ethpeuirrpuosesetooftrtehaetiirnutesrentaol otreeaxttienrtnearlnvailroalr ienxfteecrtnioanl svi[r8a6l].infections [86].",
            "AAccuuttee rreessppiirraattoorryy iinnffeeccttiioonnss aarree aa mmaajjoorr gglloobbaall hheeaalltthh pprroobblleemm rreessppoonnssiibbllee ffoorr aabboouutt 33..99 mmiilllliioonn ddeeaatthhsswwoorlrdldwwidide eeaecahcyheayre[a8r7,8[887].,8T8h].esTehiensfeectiinofnesctairoenosf athree toofp fithvee ctoaupsefsivoef mcaourstaelsityofwmoroldrtwaliidtey awnodrltdhwe ildeeadainndg tchaeusleeaodfinmgocrataulsiteyoafmmoonrgtaclihtyildarmenonugndcehrildfirveenyuenadrseroffiavgeeyienarms aonfyagdeevinelompainngy cdoeuvnetloripeisng[8c7o,8u9n].trAiecsu[8te7,8re9s]p. Aircautoteryreisnpfiercattioornysinafreectmioonsst aorfetemnocsat uosfteedn cbayusveirdubsyesv. iOruvseers.2O0v0evr i2r0a0l sveirroatlyspeersotayrpeeasssaorceiaatessdowciaitthedhuwmitahn hreusmpiarnatoreryspdiriasetoarsyesd[9is0e]aisnecslu[d90in] ginInclfluudeinngzaIAnflaunednzInaflAuenanzad BInvfliuruens,zareBspvirirautosr, yressypnircayttoiaryl vsiyrnucsy(tRiaSlVv)i,rupsar(aRiSnVflu),epnazraaivnifrluusen(PzaIVv)i,rhuus m(PaInV)a,dheunmovainruasd(eHnoAvdirVu)s, h(HumAadnVc),ohrounmavanirucsor(oHnCaovVir)u, shu(HmCaonVrh),inhouvmirauns r(hHinRoVv),irhuusm(HanRmV)e,thapunmeaunmmoveitraupsn(eHuMmPoVvi)raunsd(HhuMmPaVn) baoncdavhiruums a(Hn BbooVc)a.vIinruasdd(HitiBoonV, t)w. oInhuamddaintiponol,ytowmoavhiruumseasn(HpPolyyVo)m, KavIPiryuVseasnd(HWPyUVP)y,VK, hIPayvVe baenend dWetUecPtyeVd ,inhapvaetiebnetesnwditehtercetsepdiraintopryatiinefnetcstiwonitsh[9r1e]s.pTirhaetsoeriynfiencfteicotniosnasffe[9c1t ]a.llTahgeesegrionufepcst,ibountsnaefaferlcyt aallll saegveergereopuipsos,debsuot cncuearrilny cahlilldsreevneruendeeprisfiovdeesyeoacrcs,utrheinelcdheirlldyraenduinmdmerunfiovceomyeparrosm, itsheedeinlddeirvliyduaanlds (iem.gm.,uHnIoVc-oinmfpecrtoemdipseadtieintdsi)v[i8d7u,8a9ls].(eIn.ga.,dHulItVs,-ivnifreacltreedsppiartaiteonrtys)in[8fe7c,8ti9o]n. sInaraedtuhletsc,avuisrealorfe3s0p%ir\u2013a5to0r%y oinffpencteiuonmsoanrieathcaesceasu, 8se0%of o3f0%as\u2013th50m%a ocfopmnpeluicmatoinoinascaanseds2, 800%%\u20136o0f%asothf mcharoconmicpolbicsatrtiuocntsivaenpdu2l0m%o\u2013n6a0r%y doifsecahseroenxiaccerobbasttirouncsti[v8e7]. pCuolnmsoeqnuareyntlyd,icsoeamsme oenxvaicrearlbraetsipoinrasto[r8y7i]n. feCcotinosnesqcuaeunstelya,grceoamtermeocnonovmiriacl breusrpdiernattohraynimnfaencytioonthsecraculisneicaagl creoantdeirtieocnosnionmteircmbsuordf menedthicaanl mexapneynsoetshaenrdclpinroicdaul cctoivnidtyitliosnssesin[8t7e,r9m2]s. Tohf emWedoircldalHexepaletnhsOesrgaanndizpartioodnuhcatisvsituyplpoosrsteesd[t8h7e,9m2]o. nTihtoeriWngorolfdaHcuetaeltrhesOpirrgaatonriyzadtiosenasheasswsuoprlpdowritdede stihnecem1o9n7i7to[r9i1n]g. of acute respiratory diseases worldwide since 1977 [91].",
            "TThe IInnflfluueennzzaa vviirruuss bbeelloonnggss ttoo tthhee OOrrtthhoommyyxxoovviirriiddaaee ffaammiilly aanndd ccaauusseess rreessppiirraattoorryy iinnffeeccttiions iinn aabout 220% ooff tthhee gglloobbaall ppooppuullaation eevvery yyeeaar.. The 1918 flflu pandemic was caused by Inflfluenza A ssubtype H1N1 and kkiillled 5500 mmiilllliioonn ppeeoopplle aarroouunndd tthhee wwoorrlldd [[9933]].. The Asian Inflfluenza caused by IInflfluenza A ssuubtype H2N2 occurred in 11957 aand tthhe HHoonng KKoonng IInnflfluuenza ccaused by IInnflfluenza A ssuubbttyyppeeHH33NN22totookkplpalcaecieni1n961896a8ndanmdadmeafdaer ffeawr efrewviecrtimvisctihmans thean19t1h8eS1p9a1n8isShpflaun.isAhbfolu.t 7A0bpoeuotp7le0 dpieeodpilne Adiseida iinn2A00si4a\u20132in00250d04u\u2013e2t0o0t5hdeuHe5tNo1thsteraHin5Nof1asvtiraaninflouf[9a3v]i.anThfelu2[09039].flTuhpea2n0d0e9mfilcu(spwanindeemfluic) w(sawsitnhee fsleuc)onwdaspatnhdeesmeciconindvoplavnindgema sictraininvoolfvIinnflguaensztaraAinvoirfuIsn. fIltuwenazsaclAassvifiireuds.asItInwflausenclzaassAifiHed1Na1s 2In00fl9uaenzdathAe gHe1nNet1ic2m00a9tearniadl otrhiegigneanteedticfrommattehrriaele odriiffgeirneantet dspfercoimes:thureme adni,ffaevrieannt asnpdecsiwesi:nheu[7m,9a4n],. avian and swine [7,94]. The chemotherapy or prophylaxis of Influenza infections comprises agents blocking the Influenza A virus M2 proton-selective ion channel (amantadine, rimantadine) and neuraminidase inhibitors (zanamivir, oseltamivir, laninamivir, peramivir) [1,93]. Both classes can",
            "The chemotherapy or prophylaxis of Influenza infections comprises agents blocking the Influenza",
            "A virus M2 proton-selective ion channel (amantadine, rimantadine) and neuraminidase inhibitors (zanamivir, oseltamivir, laninamivir, peramivir) [1,93]. Both classes can induce virus resistance and therefore there is an urgent need to develop new antiviral agents with novel mechanisms of action.",
            "An alitnedruncaetivvierucsornecseisptatnhcaesarnedcethnetrlyefoerme ethrgereedisanadn uitrgisenbtanseededotno tdheeveidloepanoefwdeasnitgivniirnalgangeewntsmwoitlhecules targentionvgelhmosetcchealnlifsamcstoorfsatchtiaotna. rAenhaijlatecrkneadtivbeyctohnecevpirtuhsasdruercienngtliytsemreeprlgiceadtiaonnd. iHt ios sbta-staedrgoentinthge aidnetaivirals are anofadlteesrignnaitnivgensetwratmeoglyecfuolresadtadrgrestisnignghohsotscteslltrfuactourrsesthiantvaorlevehdijaicnketdhebvyirtuhes lviifreucsydculer.inTghiits type of inhreipbliitcoartisonc.ouHlodste-txahrgibeittinag saingtnivifiircaalsntalrye garneaatleterrnbaatrirvieerstfroartesgeylefcotrinagdddrreussgi-nrgeshisotsatnsttrvuicrtuusreess and, in adidnivtioolvne,ddiinsptlhaeyvbirruosaldif-espcyecclter.uTmhisantytpiveioraf linahcitbivitiotryswcohueldn einxhteibraitcatisniggnwifiicthanatlcyegllruealaterrtbaargrreietrcfoomr mon to sevseelreacltivnigrudsreusg.-rTehsiesthanotstvfiarucstoesr-adnirde,citnedadadnittiivonir,adl itshpelaryapbyroiasdr-escpeencttrlyumstuadntiievdir.aTl hacistivisitiyncwrheeansingly recogitnnhteiezrraeapdcytainissgarewrceietlnhetvlayansctteulaldupilepadrr.otTaahcrhgisettiosciconomcmrmebaosanitnvgtoliyrasrelevrceeorsgainsl itzvaeinrdcueasesasan. dTrehpleervohavnoistdtaepfsapcbrtroooara-cdhdi-rtseopctceeocdmtrbaunamttivvaiirrnaatlliviral agentrses[i9s5ta,9n6ce].and provides broad-spectrum antiviral agents [95,96].",
            "ManMy asntyudsiteusdieasrearceucrurernretnlytlybebieningg ddeevveellooppeedd totofifinnddnenwewInfIlnuflenuzeanzinahiibnihtoirbsi.toTrast.arTaettaarl. et al synthseysnitzheedsiz2e-pdh2e-pnhyelnaymlainmoin-1o,-31,,43-,4th-tihaidadiaiazzooleleddeerrivattiivveess4455\u2013\u20134488[4[94]9. ].",
            "The Tanhetivanirtaivliaracltiavcittivyitaygaaginaisntsst osmomeerreessppiirraattoorryyvviriruusessessuscuhchasaIsnfIlnuflenuzeanAzaHA1NH11, NIn1fl,uIennflzua eAnza A H3N2Hth,3eINnrfle2s,uuIenltnfslzuaaerenBzs,auPmBar,maPiaanrriflazuiendefnliunzeanT-za3ab,-lR3e,S5RV. S,NVRo,eaRocvetoiivrvuiitrsyu-1sw-a1anasdnodbFseFelerilnvineeedCCaotortrohonenaahvviigirrhuuessstwwcaaossnicinnevnveterssattitgiigoanatettdeedsatnaeddnd the resulotsr aartesusbutmoxmicacroinzceedntirnatTioanblaeg5a.inNstoInafclutievniztya BwaansdoRbsSeVrv[4e9d]. at the highest concentration tested or at subtoxic concentration against Influenza B and RSV [49].",
            "E(C\u03bc5M0 ) C(C\u03bc5M0 ) E(C\u03bc5M0 ) C(C\u03bc5M0 ) E(C\u03bc50M) M(C\u03bcCM) E(C\u03bc5M0 ) M(\u03bcCMC ) E(\u03bcCM50 ) C(\u03bcCM50 )",
            "(\u03bcM42) (\u03bc>M1)00 (\u03bc3M1).4 (\u03bc>M1)00 (\u03bcM> 2) 0 (\u03bc\u2265M2)0 (\u03bc>M2)0 (\u03bc\u2265M2)0 (>\u03bcM10)0 (>\u03bcM10)0",
            "MCC: minimum cytotoxic concentration.",
            "The iTnhveitro antiviralinassay showedviNtr-o{3-(methylthiaon)-t1iv-[i5ra-(lphenylaminaos)s-1a,y3,4-thiadiazols-h2o-ywl]epdropyl}",
            "benzaNm-{3id-(em4e5thayslthaino)I-n1-fl[5u-e(pnhzeanyAlaHm3inNo2)-1v,i3r,u4-sthsiuadbitayzpoel-2in-yhl]ipbriotopry.l}WbeinthzaamnidEeC4550 avsalauneInofflu3e1n.4za\u03bcAM, the derivHat3Niv2ev4ir5uswsausbttyhpeeminohsibt iptoort.eWntitahmanonEgC5t0hvealtueestoefd31c.o4m\u03bcpMo,uthneddsearnivdatmiveod45erwataes athcetimveosctopmotpeanrted to standaamrdondgruthge otessetletdamcoivmipr,obuuntdas apnrdommiosdinegrastecaaffctoivlde fcoormfpuatruerde tdoesvtaenlodpamrdednrtusg. Doseerlitvamatiivvier,sb4u7taand 48 exhibpirtoemd iascintigvistcyafafgoladinfsotrPfaurtauirnefldueevnezloap-3maenndts.RDeoervivirautisv-e1sa4n7d apnrdob4a8bleyxhthibeittehdioaucrtievaitmy oaigeatiynsftavors antivPiraarlaiancftliuveintyzao-3natnhdesReesotvriariunss-1(Faingduprero5b)a[b4l9y].the thiourea moiety favors antiviral activity on these strains (Figure 5) [49].",
            "S N amideamgriodeupgr(o4u5p)(45) beneficbieanleafigcaiainl satgaIninfsltuIennfzluaeAnzaHA3NH23N2 amaminieneggrorouupp((4466)) lolsosssofofaacctitviviittyy bbeenneefficiciaialtahlatnaihgaodnaiguodiRanrueiseRnratoesePvgatoirarPovgruauirasriopr-nua1uf(sil4p-nu71ef(,ln4u4z7e8a,n)-34z8a)-3",
            "FigureFi5g.ureTh5e. Tinhfle uinefnluceenocef souf bssutbistutiteunetnstsofof1,13,3,4,4--tthhiiaaddiiaazzoollee ddeerirvivataivtievses454\u201354\u201384o8noanntai-nretis-priersaptoirryatory Fviirguusreevsi\u2019r5au.csteTisvh\u2019 ieatcyit.nivfiltuye. nce of substituents of 1,3,4-thiadiazole derivatives 45\u201348 on anti-respiratory viruses\u2019 activity.",
            "3.4. HVeipraatliVthisierVaplairhtuietspiesastiistisailsivaelrivienrflianmflammamtiaotinonrersepspoonnssiibbllee ffoorr aabboouutt11717,10,00000dedaethasthesveervyeyreyaryeinarthine the",
            "EuropVEeiuraarnol pRheeeagpniaoRtniet.gisPioainst.ieaPnalttisivemnertasiymnhfalayavmheamavneataainocunatceruetfesoprfomornmasisabaslearefrcoeecrneantbtinoinfuefetcct1tiio7o1nn,,,0ww00iitthhderreealltaahttisivveeelvylyerraryappiydiedoanorsniesntetthoer wEodauruiscafuhrfayeoarsrlopcleodiHhonyennrifraiCffmtcoefantVecnrfwirtcaoRlieiohdconarnerrmn,ystgofHwmsoniiw.soDriiToicmantusVhfyhs.sf.souiePtomorTrrafoamenatlohftlenyisa.enaetstrrTrmnnmleaephedtniaefiseilasdsdorvdmrmse,speeiiwioffaltasmeofrnysieietivrrchaoheehaefincimnanrnvoomvtdaeohnvenisaeiemmtddcaiprnpainiipadfnneiftnahifoageifectpefcrhcietqeuplstereuinotaepoverintntnaiceirttfstkcihiuoimotilasimursyvsnmpevmedpasvarianiiracap(nrcudHtnusrtgsosoAcaoehgqeonnsVsruermee,ai((hshccHHHlpskuteuihAllvBAmnymeeVVtt[Vaaea9l,,innil,n7nHvyHd]fHh,e.eCBhrciecBnoVaeWVdtfmVlai,,ateolhhmH,HcptnhitlHC[al,iDe9eogtwVC[7Vene9H]l,Vi.y7wtwaHA]h,W,n.iiiDVtHntdrhhWhVefiDeoHtllHhchearaVtEetiniBHilHoVveddVanAeEe)n,HHlvwVVwHydeEAilitCorVoiHthVanrhpV)pfEHmHewdioVoBdceiErirfftV)ntVihoHetHo,wnrnDeEsitneViVhstt ionffteecntioloefnacdiisrsruhtoossuciashllrayonndmicililvdine,rfwecciattinhocnmerso[as9nt7dp].epTorhpoelgreerreeascrseoivvaeebroliiunvtger1q5duamicmkilllaiyognaenwpdeiocthpolmethpleilveditneeglvyew,liointphfemcchetirnootnnoiwcf iHctihBrrVHhoBsVis, HanCdVliiovnreferHctcDiaoVncaoenfrtde[na9b7lo]e.uatdT1sh4teomrecilhlairoronenwaicbitoihnufHteCc1tV5iominnsfielalcintoidonnppirneoogthpreelesEsuliivrvoeipnleigavnewrRidtehgaimocnharg[o9en7w]i.ciStHahfeBthVaendidneeffevfceetcliotoipvnemaenndt oabf ocuirtrvh1a4occsmiinseilsalifnodnr thwlievitpehrreHvceaCnntVcioenirnof[fe9cH7t]Bi.oVTnihnienferecthtioaenrEehuaarvboeopbueetaenn15aRvemagiliiaolblniloen[s9i7np]ce.eotSphaelfee19la9ivn0isdn. TgehffewesceittihvvaeccchvinraoecsncaiicnlseoHs BfoVr itnhfeecptripeorvnoevanindtiedopnarboootfeucHtioB1n4VfmrionimflleiHcotnDioVwn iihnthfaevcHteiCobnVe. eUinnnfaeovcrattuiiolnanabtelienlys,tihtnheceeEHutChrVoe pv1ea9ac9nc0insR.eehTgahisoennsoe[t9vy7ae]tc. bcSienaefenesdaaenvlsdeoloeppffreeodcvtiidvee pvaroccteinc[te9i7so,f9no8fr]r.toMhmeanpHyrDepvVaetniientnifotesnctioniofenHc.tBeUdVnwfinoifrthetucHtnioaBntVehlayar,vetheaedbuHeeltCns Vabvovraaniclacbbienlfeoersheiantshcentohhteepya1et9tit9bi0seseB.nTvdhaeeccsvieenlveoapbceeccdianm[e9se7a,9ls8o].",
            "pMraonvyidapveaaptiilreaonbtlteesciitnnioftenhceftre1od9m9w0sHi.thIDnHVthBienVsfeeaccratesioeasnd,.udUlrtusngfbotorrretnuatnbmaeetfenoltryei,stththheeehHoenpClyaVtoivtpiasticoBcnivn[a9ec8hc].ianSseenvbeoertcayal mentuebcaleeveoansiilddaeebvaleenldionptehde 1[anda99vcoe7t9arni,0ii9v-vlsn8iaa.tntte]ubyeet.vIoilclnnevean(Mloenepe-tif.noarhsnogceusnveu.wvti,ciysrdhilrbeeire)eet)doophca.cos1aarideaDr9tdsepine9eeueiarrt0snneniei,s-vdttvut.Hdsioae-siIrrHrteBniu,tiinvhvV[Cggt3afeehrVe,t(9staicecerv9zotse.a]eegsoweacsatdp.tts,nciimrtvwaadowheisdfetviceytineahihtsarnfhtr,,no(otiedeaivtsnHv.inlrgii-bitrutcHBr.hi,,aa-giVeesHnlBbvnftdoVoBeraitrncrcVeeru,etalcei(gplyoatee(srmnaved.oegfds.ivpiegor.pwui,,n.rtr,aill,ticoatastahsihmngvdsdrriHbeoe[iartfv9n,fhozBoo8siuroeVcvvon]pd.ioifhrrarioSn,beenn,svepledeebyivafe,nruoHtne,totirvertetCpeieealcisblVrtacl,b,itivaonaahvtcivcesnuareucvi,lncread[ih,lrs9plbie,asen8eromlp]etleacseo.av,imuidvStdtitriiureerirpte)evnvdeiaasnaauioestnrntrmvdfBleeaoydii,relnvi,vcnnnnietoatreso,unu)cloinbtsccsfotriol-ieeoavrennslluo[babelum3edsunicd,avibi9vtldnjeiue9ooi-eeroc]rrdH,,asaaiCimnnndeVddee, tcehnroofnooivcbisirtn)afceolecrtiinoanmnstai-nwHyiCtchoVuHnatBrcViteisvaaintnydd Hf(ienC.dgVi.n, gcbanonecwbe,pelrecesuvsrierrxe,pnegtnlrysaizvcoeopnarntertovivliilrre,adledolbrruaegsvsveiisrn,aclnueedrceeipdssa.istDyviu[r9e,7]ts.ooftohsebcuovsitrs, toeflaapnrtievviirra)1la,2dr-reDuiignhsyudfsoreor-[c43h,,69r-o9d]nimaicnethdheycplh-a2rt-oiotnixsioc,-a1in-c[cf(ee5c-s(tspiothonenstrywelaaimttmhinHeon)Bt-1Vi,s3a,a4n-mdthaiHajodCriaVozobclas-t2na-ycblee)mcinuetrhmryealn]nptylyyrcicodouinnnettr-r3oi-leclsaedanodr efivnednincrgubornenediwt.r,iDlleeus4es9etoxwpatehsnepscirvoepestaasrneodtfivfairrnoatmlivditrrhuaelgdscorirsurgaessnpfeoocnredscisnhigtryopn[h9ice7h]h.yeltphaiotisteims, iacacrcbeaszsidtoe tbryeactymcelinzattiiosna imn ajor obsta1cs,l2ue-lfDiunirhimcyadcnridyo-[c46o],6.uT-ndhtiermideesetrahivnyadlt-i2vfi-eno4dx9ionw-g1a-sn[(tee5ws-t(e,pdlhefesosnryeaxlnaptmievniirnsaiolv)ae-c1tai,v3ni,tt4iyv-taihrgaiaalidndsiratuzthgoesl-hi2se-pyaaln)tmieticseetBshsvyiitlry]ups[y9(7rHi]dB. iVn)e-3-",
            "carbo1nu,2si-tiDrnigliehHy4ed9prGow-24a.2,s6.2-p.d1r5iempceealtrlhelydinl-ef2,r-oaomxhout-mh1-ae[n(c5ho-(erpprehasteopnboylanlsadtmoinmignaopc)e-h1lel,3hli,yn4el-tthhthiioatdsepiamrzoiodclua-c2reb-syalzH)imBdVeethvbiyyrla]clpypycarlriitdzicailnteieso-.n3-cina rsbuolfnuirtCirciylaetocti4od9x[ic6wi]t.yaTswhpearsdeeaprlasiroveadtteivsftereod4m9bwythatsehetecsocterelrldesvfpoiaorbnaildnititynivgmireaptlhhaoecdhtiyv(lMitthyTioTasgeaamsisniascyta)tr.hbPearzheiledimpeaintbiatyrisycByscvcrlieirzeunasitni(ogHnBVin) suCuChusisyygliittfnnhoouggttrioosivvniHnHucxxaahdbilliaeecuuciiscpbcpiieettaitiiGGydytottuoeof22w[fder3w.6.n2y23a0]ht.a..3s.2i2a1o.sTg.3a\u03bc.cn1h1hltM\u03bc5as5iteivoMhln)sccdie.hoett)eeey1ilFlablrs,lrnt3iitaoeltvle,digo4imsndan-rtaatteyeeihbis,tdnv,ieyhaaasealcedetttbs4chhihieHvyat9euuiizvtBrwmomcytieVtehlsayeaaalueslngnriwlnviattncsehdiiih,engatseeehl,sbtixplpettaiadSlanaHvicnIttdtaifoyBooaonItbVfbbChmrl1libeaa5aw1lesesi0ns1tetitt1hyttvocothioowcamvmomdnaliourmancaa(elemMupcIltcChdeoaoaeTrl5oiefcll0eelTdtd0vtdililv.aieai3tntnli(shsoutMes\u03bceaytetaothMtTtyagohehpTge)f,aas.tya0tlthtrPoai.aei3npnprdwsresrd\u03bcsrimtonloaaMictedmyrdayh-d,uk)2utei.leo-ndcocohetraPaewnousersrpexygpecHrHilayolmcsiaBttmcimBmoitarVtyVtyeiiioissnevi(xvnvnabuBCiigrceiidrCrnyviaitsanagyi5lcrl0esauip(gpcfnC(vsfaorIaodCaCeor(rlilHtedd55tcui00incacBelitlenVeeosdgs)f.. i3n3d3i.3ca\u03bcitneMdp)rohamingdohtianinsghealienbctiitt-oiHvriBytVyaicantcidtviveixittyySaI[6go]a.fi1n1s1t1HcBoVmpwairtehdatno tIhCe50svtaanludearodf d0.r3ug\u03bcMlam, liovwudciynteot(oICxi5c0itvyal(uCeCo5f0 svv0tahun.aa1ebllt\u03bcuuis1-MeetH,i3to)Bu,o.4fVfe-F3nt3r0hato3.ci1oma.t3\u03bcindvM\u03bcititahtMhy)zee.o)s[1lFe6ae,]rn3r.ore,di4msn-autghls,ttiehsaal,endesicditeatictzvharoienetlsyesuberilenittNnswdc,Cgoeo,ixntaOmcSnlcIuodaoidneNtfeht1idbee1ses1tCeh1tHcSotaNowc3gtoneopNmctylhNHmupreidaordriemeiedntdiaeettk-sho2ea-ttooathgneppeerstyothmrameinadridyismnaibenrae-dgk2ae-dsocragnauopeffgorodolmladmmsauiyiinsbvinsbuptgedritoisunamceeanogf(fttoIoiConoldd5ng0 in promoting anti-HBV activity [6].",
            "Sindbis fever, a less common human viral disease, is caused by a mosquito-borne virus called (Si53SiSEdinnF0n.iii5nuenif\u2013nfnhe.rdder5dcilMuocbv5abStbStpmiinaiiiwoisisnoestsdnnacvindev,devn(sivrsblFSrebiseliuiriswiairnisnunthnssu5eelsfeha(s0afshdeToevut\u2013nvuu(oeev(e5TmdgeTnsmde5aor,boVraavg,afwg,eSnoinaanareawvsrediuvsnldirlaeihesrheaeRrendirsaiesdasesudttevsfaevipasnavceesceesomotioibraferbmafmaaitedna)leemlye,mmdemdfanS)noi.ociolRoilrytDnnryunieu)aev)tep.hspno.hihssotunDtopuyDiiAramrlvimetyteta)efisee,asrrgdapadipatnSacnhiliioitafitnenveaenv,ueiscwwAiotrtottrhtanihiaunhsvdllleleisleAiyemdyvttdyrwfdieawiiasrasritaielsfeeaicidfgaetdaadaelreswaesw,ivaeibegniA,nd,ulrdelsiiduiiiutomsitsmsissgstoCscteirctirrentairshtaiaevbaueboui[dpuedlns1ufishretaa0gSetaigdii1oidecl[oean]1noavnob.ndb0gligydb0yroraoru]iafars.faCspepv1emShahmSh,siis3iiirnoinncou[,csds41aadsasuq-0lbq,lbTuc[1asiuai1shh]yirsir0.tietmoea0avoava-d]si-psbi.srbirtunoasu1oosurzos,urms3n,ocrn,c,ethla4eshhesty-vyaievTdacmismrishreinrunpnriupnaisftoEsvtodeoorucacrmcitmattatrhahiilozaolvelaeloeptnreetridnliecsdsnec",
            "wSwereedteenstaedndfoRr uasnstiiav)i,raSloauctthivAityfraicgaaN,inANsut sstervHNaelirRaalavnidruCsehsin[1a0[11]0. 0].",
            "The derivatives 50 R(m=eCtChH6y3Hl)(45Ca0Hn);d3(Cp5H)12(5C(3aH)l;=lyCCl6)HH2s4h(O5oC1w)H;e3Cd(p6Ha) n5(5t(i45v)2i;r)Cal6Ha1c1ti(v5i5ty) against herpes simplex virusT-h1eTdKe-rKivOatSivaensd50h(emrpeethsyCsli6)mHap4nCdleHx531(vp(i)arlu(l5ys3-l1));sTChK6oHw-K4eOOdCSaHnA3t(iCpv)Vir(a,5l4Sa)i;nctCdiv6bHiitsy11va(ig5rau5i)sn,sCt hoexrspaecskiseimvpirluesx vBi4ruasn-1d",
            "TPKu-nKtToOhTSeoadrnoedrvihivreaurtpsiveaestssai5mc0opn(lcmeexenvtthriaryutli)so-na1noTdfK15-6K1\u03bcO(gaS/lmlAyClL).VsT,hhSoienwhdeibgdihsaevnsittriuavnsi,rtaiCvloiraxacsltaiacvckittiyevivatyigrauwisnaBst4ehxahneridbpiPetseudnstiaomgTapoilnersoxt vSiirnudsb-a1itsTavKcior-uKnscOebSnytardantediroihnveaortfpiv1ee6s 5\u03bcs0igm/ampt Llae.xcTovhniercuhensig-t1hraeTtsiKtoan-KnotOifvS9ir.Aa6lC\u03bcaVgct/,imvSiiLtny.dIwbt iassseveemixrhusisbt,hitCaetdoxtahsgaeacsikniizseet vSoifrnudthsbeiBsa4vmairinundso bPgyuronduteopriTvsoaurtboivsvteiit5ruu0esanatttaiancfoclonunceecnnecntertdartaittohionenoafonf9t.i16v6i\u03bcr\u03bcaggl/m/amcLLt.i.vItTitshyee.emhWisghhtihleeastdtaehnreitvisvaiiztrieavloeafsct5thi0eviatymndwina5os1gerwxohiutihpbistseumdbasaltlgitaauilenknsytl iSgnirnfloduubepniscesvdhirotuhwseebadynatdinvetirirviavilraatlcivtaievcti5itv0y.itaWyt, ahcioclemondpceoerunivntardatistviwoesnit5ho0fba9un.l6dk\u03bcy51ga/wrmoimLth.asIttmicsa(e5lel2ma, ls5k3ythlaagntrdotuh5ep4)ssoiszhreocwyocfeltdohaaelnkatymilv(ir5na5ol) aggcrrtooiuvuipptyss, uwcobemsrteiptnuoouetnctdasipnwaflbiutlhenbocufelvdkiyrtahalerionamhniatbitivtciro(a5nl2(,aF5ci3tgivuainrtedy6.5)W4[)1ho0ir1le]c.ydceloriavlaktyilv(e5s5)50graonudps5w1 ewreitnhotsmcaaplal ballekoyfl vgirroaul pinshsihboitwioend(Fanigtuivriera6l) groups were not capable oa[1fct0vi1vir]i.atyl ,inchomibiptioounnC(dFHsi3gwuinirtcehre6ba)su[el1sk0ay1n]ta.ivroirmal aatcitciv(i5ty2(,5503)",
            "CH3 inCcrHea2sCeHs a=nCtiHvi2ralbeancteifviictiyal(5fo0r) antiviral activity (51)",
            "CH2CH=CH2 beneficial for antiviral activity (51) exchange with bulky groups exchange with bulky groupCsH3"
        ],
        "53 CH3 loss of activity": [],
        "52 OCH3 53 loss of activity": [
            "2-PFihgeunrye l6a.mTThihneeoiin-n1ffll,u3e,4n-ctehioafdsuiabzsotilteuednetrsiovfa1t,i3v,e4s-th4i5a\u2013d4ia8zowleedreeraivlsaotivsecsre50e\u2013n5e5donagvairinalsitnhiebriptieosn.simplex HSV-1 and HSV-2, herpes simplex virus-1 TK-KOS ACV, Sindbis virus, Coxsackie virus B4 and Punt22o--PPThhoeernnoyyvllaairmmuiisnn(ooT--1a1,b,33l,,e44--6tth)hii[aa4dd9i]ia.azzWoolhleeilddeeearrimivvaiadttieivve4es5s 44a55n\u2013\u2013d4488amwwieenrree 4aa6llssoodissdccrrneeoeetnneedxdhaaibggiaatiinnassntttihhveeirrappleeasscsstiimmvipptylleeaxxt HHsuSSbVVt--o11xaiacnndcdoHnHScSeVnV-2t-r,2ah,teihorepnresp,seissnimsviipmtrlepoxlteevxsirtvsuisrs-uh1soT-w1Ke-TdKKOa-nKStOAivSCirVaAl,CSaVicnt,divSbiiitnsydvfbiorirus stv,hiCirouousxr,seaCacokdxieesravicvikrauiteisvBvei4srua4ns7dBaPn4udann4td8o, TPhouirgnohtolvigiTrhuotsrino(gTvawibrulhesa6t()oT[ta4hb9el]re. s6Wt)uhd[4iil9ees].ahWmavihdeielree4pa5moarnitdededa4tmh5aiantnedde4r6aivmdaiitdniveneo4st6beedxaihdriinbngiot tahneexti-hvNiibrHaitl-CaancStt-iiNvviiHtrya-lagatrcostuuivpbitthoyaxvaicte csduoenbmctoeoxnnitcsrtarctaoiotnencdse,naintnrtavivtiitiorronalste,ascitntsivvsihtyorow. Dteeedsrtaisvnasthtiivoviwreae4ld8aceatxnivhtiitvbyitrfeaodlraathccttiioivvuiitrtyyeafaodgrearitnihvsiaottudivrifeefaser4de7enartinvsdtarta4iiv8n,esshoi4gf7hHlaiSgnVhdtai4nn8gd, whbiohgtahhtliodgtehhrteiivrnagsttiuwvdehisae4st 7ohtaahnvederr4set8pusodhritoeeswdhetadhvaaetcrdteievprioitvyrataetigdvaetihsnasbtedSairenirndivgbaittshivevei-rsNubHse,a-CCroiSnx-gNsatHchke-ige-NrvoHiurup-CshSBa-4vNeaHnd-degmPruoonnustpotrhTaatoevrdeo advneitrmiuvosirn(aFsltiragacuttreivedi7tay)n.[t4Di9ve]ir.riavlaaticvtiev4it8ye. xDheirbiivteadtivaect4iv8iteyxhagibaiitnesdt adcifftievrietyntasgtaraininsts doiffHfeSreVnat nstdrabiontshodfeHriSvVatiavneds 4b7otahndde4r8ivsahtoivweesd4a7catinvdity48agshaionwsteSdinadctbiivsitvyiraugsa, iCnosxt sSainckdibeivsivruirsuBs4, CanodxsPauckniteovTiorruosvBi4ruasn(dFiPguunreto7)T[o4r9o]. virus (Figure 7) [49].",
            "MoleculesT2a02b0l,e265,. 9A4n2 tiviral evaluation and in vitro cytotoxicity of compounds 45\u201348 (adapted from [49]). 14 of 22",
            "EC(5\u2265\u03bcH0 M2S0V)M-1CC(>\u03bcM20E)C5H0 S(\u2265\u03bcVM2M-20C) C (\u03bcM(T)AKC-KV(O)\u03bcMS ) >E2C05A0 CVM\u2265) C2C0",
            "E(EC>\u03bcSS5CviM2V0inni50ird0dr)uubbsMsiissCM(\u2265\u03bcCCM20C)ECCCvVoi5o(xr0iE>\u03bcxursusCasM2asccB50kMB0k)4i4ieCe CM(\u2265\u03bcCM2PE0CPuC)unv5nV0tiortiou(rTE>\u03bcusTMoCsMo2rr50Coo0)C",
            "> 100 (\u03bcEMC>5)0100(M\u03bcMCC>) 10(E0\u03bcCM50) > 1M(0\u03bc0CMC) >(E1\u03bcC0M050) M>(\u03bc1CM0C)0 (E\u03bc>CM510)00 M(\u03bcCM>C)100E(\u03bcCM50>) 10M(0\u03bcCMC)> 1E(0\u03bcC0M50 ) >M(1\u03bcC0MC0 ) > 100",
            "47 45 > 100 (>\u03bc2M>01) 00(\u2265\u03bc2M0>) 10(>0\u03bcM20)> 1(\u22650\u03bc0M20) >(1>\u03bc0M200) (>\u03bc\u22651M200)0 (\u03bc>>M202)0 (\u03bc\u2265M210)00(\u03bc>M20)> 2(0\u03bc\u2265M20) 1(0\u03bc0>M20) >(\u03bc\u22652M02)0",
            ">00-.2.990 - >>122-055000 - >00-.2.4M40 CC->>:1m220-550i00nim>>>u-22m-255000cyto>>1t20o2--505x00ic co>>n>-2-c452e05n0tra>t2i-20o->5n02.50>>-2-45>0 25>02-02-50> 25>1-041-2",
            "MCC: minimSCumH3cytotoxic concentration.",
            "4==843--CCRNF=3,43--CCl F3,4-Cl thiotuhrieoaugrreoaupgroup bebneenfiecfiaicl iaaglaiangsat iHnSsVt H, SSinVd,biSsivnidrubsi,s virus, CoCxosaxcskaicekvieruvs,irPuusn,toPTuonrtoovTirourso virus",
            "F77i..gTTuhhreee7ii.nnTfflhluueeeinnnfcclueeeoonffcessuuofbbsssuttbiittsuutieetunnettnsstoos ffof111,,33,3,,4,44---ttthhhiiiaaadddiaiiaazzzooolelleededdrieevrraiitvvivaaettisivv4ee5ss\u2013444855o\u2013\u2013n4488anootinnviaarannlttaiivvctiiirrvaaitllyaa. ccttiivviittyy..",
            "2-Amin2o-A-5m-(in2o-s-5u-(l2p-hsualmphoaymlopyhlpehneynly)-l)1-,13,3,4,4--tthhiiaaddiiaazzoolele5656redreudceudcethde trhepelirceaptiolincaotfiosnomoef DsoNmAe DNA virus2e-sAvsmiurucihsneosa-s5u-ac(dh2e-asnsuoalvdpeihrnauomsviAoruydsl1pA7hdea1n7nyadnl)hd-1eh,r3epr,4pe-estshssiiimamdpilaleezxxoHlHeSSV5V-61-1arneaddnRudNcReAdNvAtirhuevseirrsuespsuelcihscasatusiocPhnoliaoosvfiPrsuooslmi1o,evirDuNs A1, EvcirhuosveisruEscsuhc2ohvainarusdsaC2doeaxnnsdoavcCkiorixuessavcAikruides1v7Bir4aunsadtBc4hoaentrcpceoennstcresanitmtiroapntlisoenxrsaHnragSniVgni-gn1gfarfonrmodmR220N0tAoto1v10i0r00u\u03bc\u03bcsges/mmsLuLc[[1h1002a2,s1,01P30o]3.l]iI.onIvnirvuistr1o, eExcpheorvimirvueitsnrot2seawxnpederreiCmpoeenxrtsfsaocwrkmeireeedvpieurrsufoisnrmgBe4sdaamutspcinolgensscoaemfn1tpr0lae6stihoufnm1s0ra6 anhnuagmninaengupafnlrooeiumdplHo2i0Ed ptHo-2E1pc0-e20llc\u03bcselgtlhs/mathtLawt [ew1r0ee2rei,1n0fe3c].teIdn wrEvisneiciigdtfhtrenhuoocicvtf1eiiei0cnrdxau(isrgipnTeinnsgwfcaevfteno2brelciiiryiltrctfdvemheiatceidi7rlarode)1enir.wnuod0aetRltsnigupysetiashungcliirwiantnfc1enhersad0iedgtcatturistiEtinneciovcpowgifnhneipuetrgocehresaatvrierevltcoiufremiuaoucrrnlsaoesrelcil.mpcmut2ohsrDlnnveeaipicppenidtclraslreieeiistoictprnumvienaoetsaltcsrrnyiioteoantifchlnivteglaanai.lecotltah.tsDnt5wiiaaDob6eamenoeirrc,twrfcieepotivovh5dacnlnaae0eosccttamsaiiee\u03bchvtvunnpoiegatetglthrf/e5rcahmo5t6a1oterl6ity0lsoLnwiy6noacw.aaisenTnhscsoanhtuuhfhsitoimvmerbi5fghaei0etbhatie5itaglen\u03bcdohy0ghsganataaal/t\u03bctymcioincntangofiLeavs/hmcu2.mtceoi0pptTbanaiLohllcv\u03bcigolute.eaeginivnoiTd/bntdiamnrerhsaga5stHeLtwta6liaoEisilm(bannnlTtpseshravao-satyiirb2fbrtieaala2niectclc0ilisnloteos7,\u03bclnorthv)slrgdn.siaii/wbgreimRtnatihndahtesLlesii,gaofiasatgntcrraawdanwiiinentnalrssgyest, trheecomrdecehvdiaranaglisamtirnuoscttfuEaracclthipoornvo,tiertiuhness ap2urvetvihreoinortsninsagsttshhuaemtaswesetemhraebtlcycooommf vppilroeuutsenplydar5tiin6chlemisba[i1yt0e2ad]c.tatona tchoenvceirnatlrsattriuocntuorfa2l0pr\u03bcogt/eminLs p(Treavbelent7i)n.gRteDhgeeariravdsasitnievmgestbhloyef mocofemvciphroauunsnipdsma5r6toicfwlaeecsret[i1op0nr2e,p]t.hareeda.uMtheothrsylasdseurimvaetivthe a5t7coanmdpaolluynl dde5r6ivmatiavye a5c8t on the viralDsterrrueivcdtauutcirevadeltsphoerforectepoilmincsaptpoiournenvodfeRn5N6tiAnwgveitrrheuespearses(psPeaomrlieobdvl.iyrMuosef1tvhainyrdul dsCeoprxaisvrataciktciilveeesvi5[r17u0sa2Bn]4.d) aatllcyolncdeenrtirvaatitoinvseo5f850reduced 1trh0eed0ur\u03bcecDgpee/dlmaTrincihtvLahdeatse,1ieto0iwrrv0neeehps\u03bcsouilglilfe/ctomsaRfestLNuit,cohgwoAngymhelosvipltfdeitroReheuuretNhsiniveyAmdasl ptdv(io5ePvir6rreotiuavlnwsai5ocet9ieevsvroeiw(erfP5uat9ophsslewri1eocsapiovsdaamiencrroucdNepmhsdlaCepN.1itnloeeMatxflneoyselrdyataihcinCnnkytaaoiilcvecxttidisrivvavaeeilcerraakuicvgaisteaaigvitBavniitv4siiyntr)eu(asFalts5litg7Bvaucil4rorlaa)ennlva8csdi)tetrr[can1aaol0itnlnr2lssa]yct.t(elriTanoaditnbnrelsasretio7vi(o)fTa.nat5isb0vloeeafn755d8)0. TaTnhhedesse1e0rr0eess\u03bcuugllt/tsmsssLuu,ggwggehessitltetthheeethiimymlppdooerrrttiaavnnaccteievooeff5tth9heewssaiidsdeeccochmhSaapiinnlefNHtfoeorlRryaaninnttiaivvcitiriravalelaaaccgttiaivviinittysyt((aFFliliggvuuirrreael88)s)t[r[11a00i2n2]s]..(Table 7).",
            "4 C\u00d7o1n0cn88: concen2tr\u00d7ati1o0n66; MNC: ma3xi\u00d7m1u0m99noncytotox2ic\u00d7co1n0c9e9ntration. 3 \u00d7 1088",
            "Concn: concentration; MNC: maximum noncytotoxic concentration.",
            "loss of activity against DNA viruses beneficial for activity against RNA viruses free amine group (56) increases antiviral activity",
            "Cui et al synthesized several pyrrolyl-1,3,4-thiadiazoles with general formula 60 (Figure 9). The cCoumipeot ualn.dsys nshthoewsiezdedansteivveirraall apcytirvroitlyyla-g1a,3i,n4s-tthsioamdieavzoirluessews iotfhtgheenFelraavlivfoirrimdaue lfaam60il(yFisguucrhea9s).WTehset cNoimlepvoiurunsdasnsdhodwenegduaenvtiirvuirsa[l25a,c1t0iv4i]t.y against some viruses of the Flaviviridae family such as West Nile virus and dengue virus [25,104].",
            "TThhee uussee ooff nnoonn--nnuucclleeoossiiddee ddeerriivvaattiivveess aass aannttiivviirraall cchheemmootthheerraappeeuuttiicc aaggeennttss hhaass ssttiimmuullaatteedd eexxtteennssiivvee rreesseeaarrcchhiinnttooththeesysynnththeseissisofocfocmompopuonudnsdosfotfhtishicslacslsa.sHs.oHwoevweerv, mer,anmyaannytiavnirtaivlidrarul gdsruagres narueclneuocsildeoesiadnealaongaslotghsatthaactt abcyt bsyupsupprepsrseinssgintghethseysnythnethsiessiosfovf ivrairlaDl DNNAAoor rRRNNAAwwhhiicchh lleeaaddss ttoo iinnhhiibbiittiioonn ooff vviirruuss rreepplliiccaattiioonn oorr cceellll ddiivviissiioonn.. RReesseeaarrcchh hhaass bbeeeenn ccaarrrriieedd oouutt ttoo ffiinndd nneeww nnuucclleeoossiiddee antiviral agents in which the natural nucleobases have been replaced by heterocyclic rings, as can be seen in derivatives 61\u201364 [105].",
            "aMnotlievcuilreas l20a2g0e, n25t,s9i4n2 which the natural nucleobases have been replaced by heterocyclic rings, as c1a6nofb2e2 saenetniviinradl eargievnattsiviensw61h\u2013ic6h4 t[h10e5n].atural nucleobases have been replaced by heterocyclic rings, as can be seen in derivatives 61\u201364 [105].",
            "oacf6adaoacf6adaalsdct6fooehoommomml4l4hmbob4eeettrarrm\u2014em\u2014rtnhrtohraaaaabvaaiiiarrwtrroorctvtvppeviie7r7aaaahagThTonTnuuaaaosoann6onn6enreemhhiitghtgrlt%du%uttitttnnii)wieieciihiiihevvn.pvnnccdgcccdgugeeooooocacgTeoddeaeaalnnstlllostlloossturohroonsoonhshnaueoenniirrrrrn66etteevssvbstww.r.d.timtii33thdhevarvalrelsvTueeococootTsutaTirieppi[ahaaidariorolalrw1wrtvhbvh6eae)an)nvveahmmiit0..1esseeselneleedeedley5aTttTtssdpspdgsdsaiiiba]laahcthcaa.6o6oncocuigbbcgigiwawteeblb44uudtdtdfhtrieeeootiiiitionsnasevaevaanlleyvvoobb6iutiuussssdrdriitttwdiid2eettoiiDbybytrpsfsfyynonaayssafoohsrosrr-nrtgtg(latatdrr6ax6uuiioowTwiiwntntcit1vtet1yaadfdfaeetntuuhoggaraighglhasbsiinfioeneessaeaerdvsrdeeeloonangabdcnideniacaeeccffeeettueddtDrDtraru8ummvvvvniivyoaoaiti,ovllv-va-yamiitttalntnte6ex6Frxrnerlaluaullratat2u2uyaysiettutttthhirrglwlgwctihiltahnla6eeavyvyoiohuoiihrhtteoeg1nnotoleobelebe[[onraae\u2013n11ffsadseaduuudxtvdgvgee6c0c0srrrytptic1icri4roo:5yo5yydy6n6niiotot0in]nn]nlglliti1ln1lgg(u.u)1.ooonccrrcr\u2013.\u2013a0ppngnogvevievioo66tcTnana0ninriuritmo44tcctt10ghogo((ttrprrnsooTTm0rmruoeuopoidtndapnatt0aagwprpoooseetttiti0apbboanaiidtrdrutteogolgullgmhohio((peernccfinantcancandllooeoohpdoiocisisoao8a8xyxnannnnesam::mmt,tt,tyynlsst6sntmvi1111rsrtsFt.Ftpgdp2tioo00i00iggliair\u2014hgogovyvTg0vl0g0l0arry1tununi0000iuoiuohll08irrrtinytinbnuiurraeafpaf0p2hhnppdedeieifllplplm%pecpecfbpppuaueam1sm1sseo6m6mcpnnwwets0t0tvvcs22rtrrr.e.ntmt))otiieia\u2014ae\u2014aell.T.ofTrrcaynayiruririaa.anehnhTnTnneneet88lllciiresesshshddbnon22tiGouissne%eifi%ibfbfvlpnpolnplllle11Ceieiutueolasfgsfaagna00sssoeheetebtccrrnrhtht0te0uucgecnwaonhaoatrdtrtrnttaddisssncnclalaepiepiceoyyiiioioeeyyntlstsnatdttppprlrrnnuiiuieylbobizoezmzomdmmmmnl,ldaiiriiilltteooongnniio.co.ssotoaaurvbllahtagggffrirywoywonGGmiasvnneeevggeeteaeeCdCCeCdCbibiawirictnntrvraaccmhehvhhehyioeeaceaceevddeeeee,epmattlrlrnnounnonueaedeiiraa6eavavboosbooossrlrapl4lstppcppicepieeesnlsfl6htvov\u2014yytotooofeofeoit3iiuouaucaddd,di,rdrrvtvtci7tvhutvhiiliialniiodittiuuiuutu6ttenaeahvghvlhdiiyemmymmom%ddnnnndeheeeessr,, TTTaaabbbllleee 888... SSStttrrruuuccctttuuurrraaalll dddeeetttaaaiiilllsss aaannnddd aaannntttiiivvviiirrraaalll aaaccctttiiivvviiitttyyy ooofff cccooommmpppooouuunnndddsss 666111\u2013\u2013\u2013666444 (((aaadddaaapppttteeeddd fffrrrooommm [[[111000555]]])))...",
            "VV1iirr0aa0ll0ViinnpirffpaeemlccIttniioofennctcciooo1nnn00ttCrrpooolpln(t(mr%%ol)) (%) 1000619p0p00mppm 1002p61p0m0 ppm",
            "Din-cxryealosbesutayclti(v6i2ty, 64) increases activity (61, 62) CH3O group s(t6r1en, g6h2t)eCnHth3eOacgtrivoiutpy strenghten the activity",
            "CH3 group (63, 64) moCdeHra3tegaronutipvi(r6a3l ,a6c4ti)vity moderate antiviral activity",
            "FFFiiiggguuurrreee 111000... IIInnnfffllluuueeennnccceeeooofffsssuuubbbssstttiiitttuuueeennntttsssooofff111,,,333,,,444---ttthhhiiiaaadddiiiaaazzzooollleee dddeeerrriiivvvaaatttiiivvveeesss 666111\u2013\u2013\u2013666444 ooonnn aaannntttiiivvviiirrraaalll aaaccctttiiivvviiitttyyy..."
        ],
        "4. Conclusions": [
            "TThhee researrchh focusedd on 1,3,4-thiaddiiaazzoollee ddeerriivvaattiivveess iinnddiiccaatteess aa bbrrooaadd speeccttrruumm of phaarrmTmhaaeccoollrooeggsieiccaaarllcahaccttifivovicittuiieesssedaassssoooncciiaat1tee,d3d,4ww-tihitthihagdgoioaoozddolpephhyydsseiicrcioovccahhteievmmeisiccaalilnaadnnidcdaptpehhsaarrmamaabccorookkaiindneettisicpc pepcrrtoorpupemerrttiieeossf.. Tphhiasrmaarrtaticcicolelleopgrpiecrseaeslneatnscttasivliaitteirleiastteuarrsaestourecrvieaiterewedvoiwef w2it-haomgf ion2oo-da-1mp,3ihn,4yo-st-ih1c,io3ac,d4hi-aetzhmoiailcedadilaezaronivldeatpidvheearsrivtmhaaatitcvohekasvinetehbtaiectenphreaovpaeleurbateiteesnd. eTfovhraislaunaatrtietvidicrlael fapocrrteisveiantyntstaigvaairilanitlsetrasaetucvtreievraitrlyevviireaawlgsatoirnafsin2t -sa. msIneivnaeodr-da1l,i3ti,o4vn-tihrtoaialtdhieaszt2ro-aaliemnsdin.eor-iIv1n,a3t,i4v-aetdhsdiatihdtiaioatnzhoalevtoemobietehetney, 2ea-vnaatmilvuiianrtaoel-da1c,3ti,4vfo-itrhyiiasdaanilastziovodilreapl emnodaiceetntiyvt ,oitnyatnhteiavgniaraaitnul sretacotfisvtehivteyesruaiblsstaivtlusiroeanltds,easptnerdnaidsntesrnu. tctuIonrne\u2013atahcdteidviinttiyaotsnutruedtioeosf hatthhveee s2su-habomswtiinntuote-h1ne,t3sm,,4oa-tnshtdieaffisdtircauizecontulterseu\u2013mbasocttiieitvtuyiet,yntasstnuftodivriiearsnalthiavavicreatilsvhaitcoytwivniistythaienlsmoeaocdshteceplfeafniscsdi.eeBnntatsseuodbnsotnitthuteheenntlsiattefuorraretaunroetfivditarhtaael, asthuctebivs2ti-itatyumeiinnntose-,a1ac,3hn,d4c-ltsahtsrisau.dcBtiuaazrsoee\u2013ldeacsotcinavffittohyledstlmiutedaryiaebtsuehrcaeovdnesasitdhae,orwtehdne at2hp-eaomsmsiionbsolte-1ep,f3hfi,a4cri-emthnaitacsdoupiabhzsootirlteugesrncoatusffpfooltrdhaamtnctaiavynirbbaeel cainoctcniosvriidptyeorrieandteedaacpinhotsocslitabhslese.sptBrhauascretmduraeocnofptkhhnoeorlewitgenrraocotuumprepthodauatntacda,sntthobee2ni-hnaacmonricnpeooa-rn1a,tt3iev,d4i-rtaihnlitaaocdttiihavezitoyslteraunscdctaucffrooenltdorfibmkunatyoeswbtneo ccthoomensspiedoaeurrcnehddasantdopodesensvhibeallnoecppemhaeannrmttivoaifcronalpewhaocmtrieveigdtyricoiaunnpedsthacsaotannctraianbltubetreensiantciovoerthpteoortsaheteaerdtcrheinatatmondethndet eosvtfrevuliocrptaumlrienenfoetfctokifonnonswe.wn mcoemdpicoinuensdasstaoneanlthearnncaetivaenttiovitrhael tarcetaitvmiteynat nodf vcioranltrinibfuectetisontos. the search and development of new mFuenddiicning:esThaissarenseaaltrechrnraetcieviveetdontoheexttreerantaml feunntdoinfgv.iral infections.",
            "Conflicts of Interest: The author declares no conflicts of interest."
        ],
        "References": [
            "1. Beale, J.M., Jr. Antiviral agents. In Wilson and Gisvold\u2019s Textbook of Organic Medicinal and Pharmaceutical Chemistry, 12th ed.; Beale, J.M., Jr., Block, J.H., Eds.; Lippincott Williams and Wilkins: Baltimore, MD, USA, 2011; pp. 330\u2013336.",
            "2. Rohwer, F.; Barrot, K. Viral information. Biol. Philos. 2013, 28, 283\u2013297. [CrossRef] 3. Woster, P.M. Antiviral agents and protease inhibitors. In Foye\u2019s Principles of Medicinal Chemistry, 7th ed.; Lemke, T.L., Williams, D.A., Roche, V.F., Zito, S.W., Eds.; Lippincott Williams and Wilkins, Wolters Kluwer: Baltimore, MD, USA, 2013; pp. 1274\u20131302. 4. Berzofsky, J.A.; Ahlers, J.D.; Janik, J.; Morris, J.; Oh, S.K.; Terabe, M.; Belyakov, I.M. Progress on new vaccine strategies against chronic viral infections. J. Clin. Invest. 2004, 114, 450\u2013462. [CrossRef] [PubMed] 5. World Health Organization. Human papillomavirus vaccines: WHO position paper, May 2017, Weekly epidemiological record. Available online: http://www.who.int/wer (accessed on 11 January 2020). 6. El-Essawy, F.A.; El-Sayed, W.A.; El-Kafrawy, S.A.; Morshedy, A.S.; Abdel-Rahman, A.H. Anti-Hepatitis B virus activity of new 1,2,4-triazol-2-yl- and1,3,4-oxadiazol-2-yl-2-pyridinone derivatives. Z. Naturforsch. 2008, 63c, 667\u2013674. [CrossRef] [PubMed] 7. Tonelli, M.; Cichero, E. Fight against H1N1 Influenza A virus: recent insights towards the development of druggable compounds. Curr. Med. Chem. 2016, 23, 1802\u20131817. [CrossRef] [PubMed] 8. Diaba, F.; Montiel, J.A.; Serban, G.; Bonjoch, J. Synthesis of normorphans through an efficient intramolecular carbamoylation of ketones. Org. Lett. 2015, 17, 3860\u20133863. [CrossRef] 9. Serban, G.; Abe, H.; Takeuchi, Y. Synthetic studies of substituted pyridine aldehydes as intermediates for the synthesis of toddaquinoline, its derivatives and other natural products. Heterocycles 2011, 83, 1989\u20132000. [CrossRef] 10. Serban, G.; Abe, H.; Takeuchi, Y.; Harayama, T. A new approach to the benzopyridoxepine core by metal mediated intramolecular biaryl ether formation. Heterocycles 2008, 75, 2949\u20132958. [CrossRef] 11. Serban, G.; Shigeta, Y.; Nishioka, H.; Abe, H.; Takeuchi, Y.; Harayama, T. Studies toward the synthesis of toddaquinoline by intramolecular cyclization. Heterocycles 2007, 71, 1623\u20131630. [CrossRef] 12. Gupta, R. Biological significance of nitrogen containing heterocyclic compounds\u2014a mini review. IJCA 2015, 8, 18\u201323. 13. Joule, J.A. Natural products containing nitrogen heterocycles\u2014some highlights 1990\u20132015. In Advances in Heterocyclic Chemistry: Heterocyclic Chemistry in the 21st Century\u2014A Tribute to Alan Katritzky, 1st ed.; Scriven, E.F.V., Ramsden, C.A., Eds.; Academic Press Elsevier: Cambridge, UK, 2016; Volume 119, pp. 81\u2013106. 14. Takashima, K.; Hayakawa, D.; Gouda, H.; Toyooka, N. Formal syntheses of (-)-Lepadiformines A, C and (-)-Fasicularin. J. Org. Chem. 2019, 84, 5222\u20135229. [CrossRef] 15. Vitaku, E.; Smith, D.T.; Njardarson, J.T. Analysis of the structural diversity, substitution patterns, and frequency of nitrogen heterocycles among U.S FDA approved pharmaceuticals. J. Med. Chem. 2014, 57, 10257\u201310274. [CrossRef] [PubMed] 16. Shukla, P.K.; Verma, A.; Mishra, P. Significance of nitrogen heterocyclic nuclei in the search of pharmacological active compounds. In New Perspective in Agricultural and Human Health; Shukla, R.P., Mishra, R.S., Tripathi, A.D., Yadav, A.K., Tiwari, M., Mishra, R.R., Eds.; Bharti Publication: New Delhi, India, 2017; pp. 100\u2013126. 17. Rajput, A.P.; Kankhare, A.R. Synthetic utility of azaheterocycles: A short review. Int. J. Pharm. Sci. Invent. 2017, 6, 19\u201325. 18. De Clercq, E.; Li, G. Approved antiviral drugs over the past 50 years. Clin. Microbiol. Rev. 2016, 29, 695\u2013747. [CrossRef] [PubMed] 19. Razonable, R.R. Antiviral drugs for viruses other than human immunodeficiency virus. Mayo Clin. Proc. 2011, 86, 1009\u20131026. [CrossRef] [PubMed] 20. Serban, G.; Stanasel, O.; Serban, E.; Bota, S. 2-Amino-1,3,4-thiadiazole as a potential scaffold for promising antimicrobial agents. Drug Des. Devel. Ther. 2018, 12, 1545\u20131566. [CrossRef] 21. Schenone, S.; Brullo, C.; Bruno, O.; Bondavalli, F.; Ranise, A.; Filippelli, W.; Rinaldi, B.; Capuano, A.; Falcone, G. New 1,3,4-thiadiazole derivatives endowed with analgesic and anti-inflammatory activities. Bioorg Med Chem. 2006, 14, 1698\u20131705. [CrossRef]",
            "22. Labanauskas, L.; Kalcas, V.; Udrenaite, E.; Gaidelis, P.; Brukstus, A.; Dauksas, A. Synthesis of 3-(3,4-dimethoxyphenyl)-1H-1,2,4-triazole-5-thiol and 2-amino-5-(3,4-dimethoxyphenyl)-1,3,4-thiadiazole derivatives exhibiting anti-inflammatory activity. Pharmazie 2001, 56, 617\u2013619.",
            "23. Clerici, F.; Pocar, D.; Guido, M.; Loche, A.; Perlini, V.; Brufani, M. Synthesis of 2-amino-5-sulfanyl1,3,4-thiadiazole derivatives and evaluation of their antidepressant and anxiolytic activity. J Med Chem. 2001, 44, 931\u2013936. [CrossRef]",
            "24. Basso, A.; Liu, M.; Dai, C.; Gray, K.; Nale, L.; Tevar, S.; Lee, S.; Liang, L.; Ponery, A.; Yaremko, B.; et al SCH 2047069, a novel oral kinesin spindle protein inhibitor, shows single-agent antitumor activity and enhances the efficacy of chemotherapeutics. Mol. Cancer Ther. 2019, 9, 2993\u20133002. [CrossRef]",
            "25. Dawood, K.M.; Farghaly, T.A. Thiadiazole inhibitors: A patent review. Expert Opin. Ther. Pat. 2017, 27, 477\u2013505. [CrossRef]",
            "26. Haider, S.; Alam, M.S.; Hamid, H. 1,3,4-Thiadiazoles: a potent multi targeted pharmacological scaffold. Eur. J. Med. Chem. 2015, 92, 156\u2013177. [CrossRef] [PubMed]",
            "27. Serban, G. Future prospects in the treatment of parasitic diseases: 2-amino-1,3,4-thiadiazoles in leishmaniasis. Molecules 2019, 24, 1557. [CrossRef] [PubMed]",
            "28. Li, Y.; Geng, J.; Liu, Y.; Yu, S.; Zhao, G. Thiadiazole\u2014A promising structure in Medicinal Chemistry. ChemMedChem 2013, 8, 27\u201341. [CrossRef] [PubMed]",
            "29. Senff-Ribeiro, A.; Echevarria, A.; Silva, E.F.; Franco, C.R.C.; Veiga, S.S.; Oliveira, M.B.M. Cytotoxic effect of a new 1,3,4-thiadiazolium mesoionic compound (MI-D) on cell lines of human mellanoma. Br. J. Cancer 2004, 91, 297\u2013304. [CrossRef] [PubMed]",
            "30. Wermuth, C.G. Are pyridazines privileged structures? Med.Chem.Commun. 2011, 2, 935\u2013941. [CrossRef] 31. Biziere, K.; Worms, P.; Kan, J.P.; Mandel, P.; Garattini, S.; Roncucci, R. Minaprine, a new drug with antidepressant properties. Drugs Exp. Clin. Res. 1985, 11, 831\u2013840. [PubMed] 32. Ueno, S.; Bracamontes, J.; Zorumski, C.; Weiss, D.S.; Steinbach, J.H. Bicuculline and gabazine are allosteric inhibitors of channel opening of the GABA A receptor. J. Neurosci. 1997, 17, 625\u2013634. [CrossRef] [PubMed] 33. Holla, B.S.; Poorjary, K.N.; Rao, B.S.; Shivananda, M.K. New bis-aminomercaptotriazoles and bis-triazolothiadiazoles as possible anticancer agents. Eur. J. Med. Chem. 2002, 37, 511\u2013517. [CrossRef] 34. Yousif, E.; Majeed, A.; Al-Sammarrae, K.; Salih, N.; Salimon, J.; Abdullah, B. Metal complexes of Schiff base: preparation, characterization and antibacterial activity. Arabian J. Chem. 2013, 5. [CrossRef] 35. Juszczak, M.; Matysiak, J.; Brzana, W.; Niewiadomy, A.; Rzeski, W. Evaluation of antiproliferative activity of 2-(monohalogenophenylamino)-5-(2,4-dihydroxyphenyl)-1,3,4-thiadiazoles. Arzneim. Forsch. Drug Res. 2008, 58, 353\u2013357. [CrossRef] 36. Matysiak, J. Evaluation of antiproliferative effect in vitro of some 2-amino-5-(2,4-dihydroxyphenyl)-1,3,4thiadiazole derivatives. Chem. Pharm. Bull. 2006, 54, 988\u2013991. [CrossRef] [PubMed] 37. Yoosefian, M.; Chermahini, Z.J.; Raissi, H.; Mola, A.; Sadeghi, M. A theoretical study on the structure of 2-amino-1,3,4-thiadiazole and its 5-substituted derivatives in the gas phase, water, THF and DMSO solutions. J. Mol. Liq. 2015, 203, 137\u2013142. [CrossRef] 38. Serban, G. 2-Amino-1,3,4-thiadiazoles as prospective agents in trypanosomiasis and other parasitoses. Acta Pharm. 2020, 70, 259\u2013290. [CrossRef] [PubMed] 39. Serban, G. 5-Arylamino-1,3,4-thiadiazol-2-yl acetic acid esters as intermediates for the synthesis of new bisheterocyclic compounds. Farmacia 2015, 63, 146\u2013149. 40. Serban, G.; Coman, M.; Curea, E. Synthesis of some heterocyclic nitro\u2013coumarins by Knoevenagel condensation. Farmacia 2005, 53, 78\u201384. 41. Serban, G.; Matinca, D.; Bradea, O.; Gherman, L.; Coman, M.; Curea, E. The study of the biological activity of some heterocyclic coumarins. Farmacia 2005, 53, 91\u201399. 42. Serban, G.; Suciu, A.; Coman, M.; Curea, E. Synthesis and physical-chemical study of some 3-(5-arylamino-1,3,4-thiadiazol-2-yl)cou\u2013marins. Farmacia 2002, 50, 50\u201354. 43. Horvath, T.; Serban, G.; Cuc, S. Synthesis of new 2-phenylamino-5-[(\u03b1-acylamino)-p-X-stiryl] -1,3,4-thiadiazole compounds. Farmacia 2014, 62, 422\u2013427. 44. Serban, G.; Coman, M.; Curea, E.; Proinov, L. Synthesis and description of some heterocyclic coumarins. Farmacia 2001, 49, 45\u201352.",
            "45. Global AIDS Update 2016. Joint United Nations Programme on HIV/AIDS, Geneva, Switzerland. Available online: https://www.unaids.org/sites/default/files/media_asset/global-AIDS-update-2016en.pdf (accessed on 17 July 2018).",
            "46. Sharma, P.C.; Sinhmar, A.; Sharma, A.; Rajak, H.; Pathak, D.P. Medicinal significance of benzothiazole scaffold: An insight view. J. Enzyme Inhib. Med. Chem. 2013, 28, 240\u2013266. [CrossRef]",
            "47. Xiaohe, Z.; Yu, Q.; Hong, Y.; Xiuqing, S.; Rugang, Z. Synthesis, biological evaluation and molecular modeling studies of N-aryl-2-arylthioacetamides as non-nucleoside HIV-1 reverse transcriptase inhibitors. Chem. Biol. Drug Des. 2010, 76, 330\u2013339. [CrossRef] [PubMed]",
            "48. Harms, A. Non-nucleoside reverse transcriptase inhibitors. In The art of drug synthesis; Johnson, D.S., Li, J.J., Eds.; Wiley Interscience, John Wiley and Sons, Inc., Hoboken: New Jersey, NJ, USA, 2007; p. 84.",
            "49. Tatar, E.; Kucukguzel, S.G.; Karakus, S.; De Clercq, E.; Andrei, G.; Snoeck, R.; Pannecouque, C.; OktemOkullu, S.; Unubol, N.; Kocagoz, T.; et al Synthesis and biological evaluation of some new 1,3,4-thiadiazole and 1,2,4-triazole derivatives from L-methionine as antituberculosis and antiviral agents. Marmara Pharm. J. 2015, 19, 88\u2013102. [CrossRef]",
            "50. Wit, F.W.N.M.; Lange, J.M.A.; Volberding, P.A. New HIV Drug Development. In Global HIV/AIDS Medicine; Volberding, P.A., Sande, M.A., Greene, W.C., Lange, J.M.A., Eds.; Elsevier: Philadelphia, PA, USA, 2008; pp. 123\u2013134.",
            "51. Schiller, D.S.; Youssef-Bessler, M. Etravirine: A second-generation nonnucleoside reverse transcriptase inhibitor (NNRTI) active against NNRTI-resistant strains of HIV. Clin. Ther. 2009, 31, 692\u2013704. [CrossRef] [PubMed]",
            "52. Miller, C.D.; Crain, J.; Tran, B.; Patel, N. Rilpivirine: A new addition to the anti-HIV-1 armamentarium. Drugs Today 2011, 47, 5\u201315. [CrossRef] [PubMed]",
            "53. Doravirine combination pill looks good for initial HIV treatment. Available online: https: //www.aidsmap.com/news/jul-2017/doravirine-combination-pill-looks-good-initial-hiv-treatment;http: //www.aidsmap.com/Doravirine-combination-pill-looks-good-for-initial-HIV-treatment/pagee3160520 (accessed on 5 June 2018).",
            "54. Gatell, J.M.; Raffi, F.; Plettenberg, A.; Smith, D.; Portilla, J.; Hoffmann, C.; Arasteh, K.; Thompson, M.; Xu, X.; Teppler, H. Doravirine 100 mg QD vs Efavirenz + TDF/FTC in ART-Naive HIV+ Patients: Week 48 Results. In Proceedings of the Conference on Retroviruses and Opportunistic Infections, Boston, MA, USA, 22\u201325 February 2016. abstract number 470.",
            "55. FDA Accepts New Drug Applications for Merck\u2019s Doravirine, the Company\u2019s Investigational Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI), for Treatment of HIV-1 Infection. Available online: http://investors.merck.com/news/press-release-details/2018/FDA-Accepts-New-Drug-Applications-forMercks-Doravirine-the-Companys-Investigational-Non-Nucleoside-Reverse-Transcriptase-InhibitorNNRTI-for-Treatment-of-HIV-1-Infection/default.aspx (accessed on 5 June 2018).",
            "56. FDA approves Merck\u2019s Pifeltro (doravirine). Available online: https://www.drugs.com/newdrugs/fdaapproves-merck-s-pifeltro-doravirine-hiv-1-appropriate-patients-4815.html (accessed on 6 November 2019).",
            "57. Merck\u2019s Pifeltro (doravirine) and Delstrigo (doravirine/lamivudine/tenofovir disoproxil fumarate) receive FDA approval for use in appropriate adults living with HIV-1 who are virologically suppressed. 20 September 2019. Available online: https://investors.merck.com/news/press-release-details/2019/Mercks-PIFELTROdoravirine-and-DELSTRIGO-doravirinelamivudinetenofovir-disoproxil-fumarate-Receive-US-FDAApproval-for-Use-in-Appropriate-Adults-Living-with-HIV-1-Who-Are-Virologically-Suppressed/default. aspx (accessed on 6 November 2019).",
            "58. Margolis, D.A.; Eron, J.J.; DeJesus, E.; White, S.; Wannamaker, P.; Stancil, B.; Johnson, M. Unexpected finding of delayed-onset seizures in HIV-positive, treatment-experienced subjects in the Phase IIb evaluation of fosdevirine (GSK2248761). Antivir. Ther. 2014, 19, 69\u201378. [CrossRef]",
            "59. Vernazza, P.; Wang, C.; Pozniak, A.; Weil, E.; Pulik, P.; Cooper, D.A.; Kaplan, R.; Lazzarin, A.; Valdez, H.; Goodrich, J.; et al Efficacy and safety of lersivirine (UK-453,061) versus efavirenz in antiretroviral treatment-naive HIV-1 infected patients: week 48 primary analysis results from an ongoing, multicenter, randomized, double-blind, Phase IIb trial. J. Acquir. Immune Defic. Syndr. 2013, 62, 171\u2013179. [CrossRef]",
            "60. Platten, M.; Fatkenheuer, G. Lersavirine\u2014a new drug for HIV infection therapy. Expert. Opin. Investig. Drugs 2013, 22, 1687\u20131694. [CrossRef]",
            "61. Sacks, D.; Ledwaba, J.; Morris, L.; Hunt, G.M. Rapid detection of common HIV-1 drug resistance mutations by use of high-resolution melting analysis and unlabeled probes. J. Clin. Microbiol. 2017, 55, 122\u2013133. [CrossRef]",
            "62. Yahi, N.; Tamalet, C.; Tourres, C.; Tivoli, N.; Ariasi, F.; Volot, F.; Gastaut, J.A.; Gallais, H.; Moreau, J.; Fantini, J. Mutation patterns of the reverse transcriptase and protease genes in Human Immunodeficiency Virus type 1-infected patients undergoing combination therapy: survey of 787 sequences. J. Clin. Microbiol. 1999, 37, 4099\u20134106. [CrossRef]",
            "63. Hu, Y.; Li, C.Y.; Wang, X.M.; Yang, Y.H.; Zhu, H.L. 1,3,4-Thiadiazole: synthesis, reactions and applications in medicinal, agricultural, and materials chemistry. Chem. Rev. 2014, 114, 5572\u20135610. [CrossRef]",
            "64. Szulczyk, D.; Tomaszewski, P.; Jozwiak, M.; Koziol, A.E.; Lis, T.; Collu, D.; Iuliano, F.; Struga, M. Synthesis and biological activities of ethyl 2-(2-pyridylacetate) derivatives containing thiourea, 1,2,4-triazole, thiadiazole and oxadiazole moieties. Molecules 2017, 22, 409. [CrossRef] [PubMed]",
            "65. Akhtar, T.; Hameed, S.; Al-Masoudi, N.A.; Khan, K.M. Synthesis and anti-HIV activity of new chiral 1,2,4-triazoles and 1,3,4-thiadiazoles. Heteroatom Chem. 2007, 18, 316\u2013322. [CrossRef]",
            "66. Hamad, N.S.; Al-Haidery, N.H.; Al-Masoudi, I.A.; Sabri, M.; Sabri, L.; Al-Masoudi, N.A. Amino acid derivatives, part 4: synthesis and anti-HIV activity of new naphthalene derivatives. Arch. Pharm. Chem. Life Sci. 2010, 343, 397\u2013403. [CrossRef] [PubMed]",
            "67. Wang, Z.; Wu, B.; Kuhen, K.L.; Bursulaya, B.; Nguyen, T.N.; Nguyen, D.G.; He, Y. Synthesis and biological evaluations of sulfanyltriazoles as novel HIV-1 non-nucleoside reverse transcriptase inhibitors. Bioorg. Med. Chem. Lett. 2006, 16, 4174\u20134177. [CrossRef] [PubMed]",
            "68. Muraglia, E.; Kinzel, O.D.; Laufer, R.; Miller, M.D.; Moyer, G.; Munshi, V.; Orvieto, F.; Palumbi, M.C.; Pescatore, G.; Rowley, M.; et al Tetrazole thioacetanilides: potent non-nucleoside inhibitors of WT HIV reverse transcriptase and its K103N mutant. Bioorg. Med. Chem. Lett. 2006, 16, 2748\u20132752. [CrossRef] [PubMed]",
            "69. Zhan, P.; Liu, X.; Cao, Y.; Wang, Y.; Pannecouque, C.; De Clercq, E. 1,2,3-Thiadiazole thioacetanilides as a novel class of potent HIV-1 non-nucleoside reverse transcriptase inhibitors. Bioorg. Med. Chem. Lett. 2008, 18, 5368\u20135371. [CrossRef] [PubMed]",
            "70. Zhang, Z.; Xu, W.; Koh, Y.H.; Shim, J.H.; Girardet, J.L.; Yeh, L.T.; Hamatake, R.K.; Hong, Z. A novel non-nucleoside analogue that inhibits human immunodeficiency virus type 1 isolates resistant to current non-nucleoside reverse transcriptase inhibitors. Antimicrob. Agents Chemother. 2007, 51, 429\u2013437. [CrossRef]",
            "71. Huang, Y.; Zhao, L.; Jia, B.; Wu, L.; Li, Y.; Curthoys, N.; Zheng, J.C. Glutaminase dysregulation in HIV-1-infected human microglia mediates neurotoxicity: relevant to HIV-1 associated neurocognitive disorders. J. Neurosci. 2011, 31, 15195\u201315204. [CrossRef]",
            "72. Zhao, J.; Lopez, A.L.; Erichsen, D.; Herek, S.; Cotter, R.L.; Curthoys, N.P.; Zheng, J. Mitochondrial glutaminase enhances extracellular glutamate production in HIV-1-infected macrophages: Linkage to HIV-1 associated dementia. J. Neurochem. 2004, 88, 169\u2013180. [CrossRef]",
            "73. Stumvoll, M.; Perriello, G.; Meyer, C.; Gerich, J. Role of glutamine in human carbohydrate metabolism in kidney and other tissues. Kidney Int. 1999, 55, 778\u2013792. [CrossRef]",
            "74. Smith, R.J. Glutamine metabolism and its physiological importance. J. Parenter. Enteral. Nutr. 1990, 14, 40S\u201344S. [CrossRef] [PubMed]",
            "75. Bromley, S.D.; Bennett, M.K.; Gross, M.I.; Li, J.; Chen, L.; Goyal, B.; Laidig, G.; Stanton, T.F.; Sjogren, E.B. Treatment of viral infections with inhibitors of glutaminase. PCT Int. Appl. PCT/US2014/061746; WO 2015/061432 A1. 2015.",
            "76. Newsholme, P.; Lima, M.M.R.; Procopio, J.; Pithon-Curi, T.C.; Doi, S.Q.; Bazotte, R.B.; Curi, R. Glutamine and glutamate as vital metabolites. Braz. J. Med. Biol. Res. 2003, 36, 153\u2013162. [CrossRef] [PubMed]",
            "77. Behar, K.L.; Rothman, D.L. In vivo NMR studies of glutamate-GABA-glutamine cycling in rodent and human cortex: the central role of glutamine. J. Nutr. 2001, 131, 2498\u20132504. [CrossRef] [PubMed]",
            "78. Erdmann, N.; Zhao, J.; Lopez, A.L.; Herek, S.; Curthoys, N.; Hexum, T.D.; Tsukamoto, T.; Ferraris, D.; Zheng, J. Glutamate production by HIV-1 infected human macrophage is blocked by the inhibition of glutaminase. J. Neurochem. 2007, 102, 539\u2013549. [CrossRef]",
            "79. Babayo, A.; Thairu, Y.; Nasir, I.A.; Baba, M.M. Serological evidence and sociodemographic risk factors of recent cytomegalovirus infection in pregnant women attending a tertiary hospital in Maiduguri, Nigeria. J. Med. Microbiol. Infec. Dis. 2014, 2, 49\u201355.",
            "80. Forbes, B.A. Acquisition of cytomegalovirus infection: An update. Clin. Microbiol. Rev. 1989, 2, 204\u2013216. [CrossRef]",
            "81. Spruance, S.L. Viral infections. In The Merck Manual of Medical Information: Second Home Edition; Beers, M.H., Ed.; Merck Research Laboratories, Merck and Co., Inc.: Whitehouse Station, NJ, USA, 2003; p. 1164.",
            "82. Centers for Disease Control and Prevention. Cytomegalovirus (CMV) and Congenital CMV Infection. Available online: https://www.cdc.gov/cmv/overview.html (accessed on 11 July 2018).",
            "83. Tan, B.H. Cytomegalovirus treatment. Curr. Treat. Options Infect. Dis. 2014, 6, 256\u2013270. [CrossRef] 84. McGavin, J.K.; Goa, K.L. Ganciclovir: An update of its use in the prevention of cytomegalovirus infection and disease in transplant recipients. Drugs 2001, 61, 1153\u20131183. [CrossRef] 85. Sakamoto, H.; Hirano, M.; Nose, K.; Ueno, S.; Oki, T.; Sugimoto, K.; Nishioka, T.; Kusunoki, S.; Nakamura, Y.",
            "A case of severe ganciclovir-induced encephalopathy. Case Rep. Neurol. 2013, 5, 183\u2013186. [CrossRef] 86. Thaisrivongs, S.; Turner, S.R. 1,3,4-Thiadiazoles useful for the treatment of CMV infections. US Patent",
            "6,150,385, 2000. 87. World Health Organization. Battle against Respiratory Viruses (BRaVe) initiative. Available online: http://www.who.int/influenza/patient_care/clinical/brave/en/ (accessed on 14 June 2018). 88. World Health Organization. Research needs for the battle against respiratory viruses (BRAve). Background document 2013. Available online: http://www.who.int/influenza/patient_care/clinical/BRaVe_Research_ Agenda_2013.pdf (accessed on 14 June 2018). 89. Bellos, A.; Mulholland, K.; O\u2019Brien, K.L.; Qazi, S.A.; Gayer, M.; Checchil, F. The burden of acute respiratory infections in crisis-affected populations: A systematic review. Confl. Health 2010, 4, 1\u201312. [CrossRef] 90. Straliotto, S.M.; Siqueira, M.M.; Muller, R.L.; Fischer, G.B.; Cunha, M.L.T.; Nestor, S.M. Viral etiology of acute respiratory infections among children in Porto Alegre, RS, Brazil. Rev. Soc. Bras. Med. Tro. 2002, 35, 283\u2013291. [CrossRef] [PubMed] 91. Da Silva, R.C.; da Silva Mendes, G.; Rojas, M.A.; Amorim, A.R.; Couceiro, J.N.; Lupi, O.; Elabras, J.; Pires, G.; Valle, S.; Santos, N. Frequency of viral etiology in symptomatic adult upper respiratory tract infections. Braz. J. Infect. Dis. 2015, 19, 30\u201335. [CrossRef] [PubMed] 92. Fendrick, A.M.; Monto, A.S.; Nightengale, B.; Sarnes, M. The economic burden of non-influenza-related viral respiratory tract infections in the United States. Arch. Intern. Med. 2003, 163, 487\u2013494. [CrossRef] [PubMed] 93. Johnson, D.S.; Li, J.J. Neuraminidase inhibitors for influenza: oseltamivir phosphate (Tamiflu) and zanamivir (Relenza). In The art of drug synthesis; Johnson, D.S., Li, J.J., Eds.; Wiley Interscience, John Wiley and Sons, Inc., Hoboken: New Jersey, NJ, USA, 2007; pp. 95\u201396. 94. Al-Muharrmi, Z. Understanding the Influenza A H1N1 2009 pandemic. SQU Med. J. 2010, 10, 187\u2013195. 95. Tonelli, M.; Naesens, L.; Gazzarrini, S.; Santucci, M.; Cichero, E.; Tasso, B.; Moroni, A.; Costi, M.P.; Loddo, R. Host dihydrofolate reductase (DHFR)-directed cycloguanil analogues endowed with activity against influenza virus and respiratory syncytial virus. Eur. J. Med. Chem. 2017, 135, 467\u2013478. [CrossRef] 96. Francesconi, V.; Giovannini, L.; Santucci, M.; Cichero, E.; Costi, M.P.; Naesens, L.; Giordanetto, F.; Tonelli, M. Synthesis, biological evaluation and molecular modeling of novel azaspiro dihydrotriazines as influenza virus inhibitors targeting the host factor dihydrofolate reductase (DHFR). Eur. J. Med. Chem. 2018, 155, 229\u2013243. [CrossRef] 97. World Health Organization. Fact sheets on sustainable development goals: health target, Viral hepatitis, World Health Organization 2017, Copenhagen, Denmark, www.euro.who.int/sdgs. Available online: http://www.euro.who.int/__data/assets/pdf_file/0003/348222/Fact-sheet-SDG-viral-hepatitis-FINALen.pdf?ua=1 (accessed on 23 January 2020). 98. World Health Organization. Hepatitis B in the WHO European Region, Fact sheet \u2013 July 2019, World Health Organization 2019. Available online: http://www.euro.who.int/__data/assets/pdf_file/0007/377251/ Fact-Sheet-Hepatitis-B_2019-ENG.pdf?ua=1 (accessed on 23 January 2020). 99. FDA. Hepatitis B and C treatments. Available online: https://www.fda.gov/patients/hepatitis-b-c/hepatitis-band-c-treatments (accessed on 23 January 2020). 100. Kurkela, S.; Ratti, O.; Huhtamo, E.; Uzcategui, N.; Nuorti, J.P.; Laakkonen, J.; Manni, T.; Helle, P.; Vaheri, A.; Vapalahti, O. Sindbis virus infection in resident birds, migratory birds, and humans, Finland. Emerg. Infect. Dis. 2008, 14, 41\u201347. [CrossRef]",
            "101. Kucukguzel, S.G.; Kucukguzel, I.; Tatar, E.; Rollas, S.; Sahin, F.; Gulluce, M.; De Clercq, E.; Kabasakal, L. Synthesis of some novel heterocyclic compounds derived from diflunisal hydrazide as potential anti-infective and anti-inflammatory agents. Eur. J. Med. Chem. 2007, 42, 893\u2013901. [CrossRef]",
            "102. Bonina, L.; Orzalesi, G.; Merendino, R.; Arena, A.; Mastroeni, P. Structure-activity relationships of new antiviral compounds. Antimicrob. Agents Chemother. 1982, 22, 1067\u20131069. [CrossRef]",
            "103. Streissle, G.; Paesseus, A.; Oediger, H. New antiviral compounds. In Advances in Virus Research; Maramorosch, K., Murphy, F.A., Shatkin, A.J., Eds.; Academic Press., Elsevier: London, UK, 1985; Volume 30, p. 115.",
            "104. Cui, T.; Chum, M.P.; Lam, Y.; Gao, Y. Compounds for use as anti-viral agents. Singapore Pat. Appl. SG 162629 A1 20100729. 2010.",
            "105. Yadav, L.D.S.; Singh, S. Synthesis of antiviral acyclic C-nucleosides incorporating thiazolo-1,3,4-oxa(thia)diazole or thiazolo-1,2,4-triazole structure as a nucleobase. Indian J. Chem. 2001, 40B, 440\u2013442. [CrossRef]"
        ]
    },
    "participants": [
        {
            "participant": "people",
            "number": 37000000,
            "context": "Human Immunodeficiency Virus (HIV). <mark class=\"stats\">About 37 million people infected with human immunodeficiency virus (HIV) (Retroviridae family) were reported in 2016 [45], with the highest incidence of infection in sub-Saharan Africa</mark>. In the Third World, HIV infection coupled with tropical diseases, malaria and tuberculosis causes a high level of mortality"
        },
        {
            "participant": "patients",
            "number": 17000000,
            "context": "Several NNRTIs (e.g., fosdevirine, lersivirine) underwent clinical development programs but were discontinued due to unfavorable pharmacokinetic, efficacy and/or safety factors [58\u201360]. <mark class=\"stats\">Approximately 17 million patients have access to antiretroviral therapy capable of controlling viremia and reducing mortality [61]</mark>. However, long-term treatment with antiretroviral agents can lead to drug resistance due to rapid mutations in the viral genome resulting in RT mutations and HIV chemotherapy failure [62]"
        }
    ],
    "statistics": [],
    "keywords": [
        "mechanism of action",
        "NNRTI",
        "2-amino-1,3,4-thiadiazole",
        "herpes simplex virus",
        "synthesis",
        "natural product",
        "central nervous system",
        "antiviral drug",
        "thiadiazole moiety",
        "inhibitory concentration",
        "thiadiazole derivative",
        "viral infection",
        "etiological agent",
        "drug resistance",
        "human immunodeficiency virus",
        "human cytomegalovirus",
        "reverse transcriptase",
        "new drug applications",
        "dihydroxyphenyl",
        "antiviral agent",
        "hemorrhagic fever",
        "varicella-zoster virus",
        "HIV-1",
        "acquired immunodeficiency syndrome",
        "glutamine",
        "hepatitis B virus",
        "Food and Drug Administration",
        "nucleoside",
        "respiratory syncytial virus",
        "nucleoside reverse transcriptase inhibitors",
        "Sindbis virus",
        "cytomegalovirus infection",
        "hepatitis b",
        "yellow fever",
        "hepatitis C virus",
        "GABA",
        "nucleoside inhibitor binding site"
    ],
    "keyword_relevance": {
        "human immunodeficiency virus": 0.17475728155339806,
        "reverse transcriptase": 0.11003236245954692,
        "HIV-1": 0.07119741100323625,
        "nucleoside reverse transcriptase inhibitors": 0.061488673139158574,
        "Nucleoside reverse transcriptase inhibitors": 0.05177993527508091,
        "thiadiazole derivative": 0.04854368932038835,
        "nucleoside": 0.04854368932038835,
        "NNRTI": 0.045307443365695796,
        "viral infection": 0.038834951456310676,
        "acquired immunodeficiency syndrome": 0.032362459546925564,
        "Food and Drug Administration": 0.032362459546925564,
        "synthesis": 0.025889967637540454,
        "antiviral drug": 0.022653721682847898,
        "antiviral agent": 0.022653721682847898,
        "2-amino-1,3,4-thiadiazole": 0.019417475728155338,
        "herpes simplex virus": 0.019417475728155338,
        "glutamine": 0.019417475728155338,
        "central nervous system": 0.012944983818770227,
        "respiratory syncytial virus": 0.012944983818770227,
        "hepatitis C virus": 0.012944983818770227,
        "thiadiazole moiety": 0.009708737864077669,
        "drug resistance": 0.009708737864077669,
        "human cytomegalovirus": 0.009708737864077669,
        "hepatitis B virus": 0.009708737864077669,
        "cytomegalovirus infection": 0.009708737864077669,
        "etiological agent": 0.006472491909385114,
        "new drug applications": 0.006472491909385114,
        "dihydroxyphenyl": 0.006472491909385114,
        "hemorrhagic fever": 0.006472491909385114,
        "varicella-zoster virus": 0.006472491909385114,
        "Sindbis virus": 0.006472491909385114,
        "yellow fever": 0.006472491909385114,
        "GABA": 0.006472491909385114,
        "nucleoside inhibitor binding site": 0.006472491909385114,
        "mechanism of action": 0.003236245954692557,
        "natural product": 0.003236245954692557,
        "inhibitory concentration": 0.003236245954692557,
        "hepatitis b": 0.0
    },
    "species": [
        "Sindbis virus"
    ],
    "summary": [
        "<h2 style=\"display: inline\">Introduction:</h2> Viruses are the smallest among all self-replicating organisms and yet they are the etiological agents of many difficult to treat diseases in human populations [1].",
        "There are broad types of human infections caused by viruses, such as respiratory infections, digestive infections, central nervous system infections, skin or mucosal infections, hepatic infections, blood infections and hemorrhagic fever.",
        "Some viruses are etiological agents in the development of human tumors, cervical cancer and hepatic cancer [3].",
        "Efforts to develop safe and effective vaccines against viruses that cause chronic infections, such as human immunodeficiency virus or hepatitis C virus did not give the expected results [1,4,5]",
        "<h2 style=\"display: inline\">Conclusion:</h2> TThhee researrchh focusedd on 1,3,4-thiaddiiaazzoollee ddeerriivvaattiivveess iinnddiiccaatteess aa bbrrooaadd speeccttrruumm of phaarrmTmhaaeccoollrooeggsieiccaaarllcahaccttifivovicittuiieesssedaassssoooncciiaat1tee,d3d,4ww-tihitthihagdgoioaoozddolpephhyydsseiicrcioovccahhteievmmeisiccaalilnaadnnidcdaptpehhsaarrmamaabccorookkaiindneettisicpc pepcrrtoorpupemerrttiieeossf.",
        "Tphhiasrmaarrtaticcicolelleopgrpiecrseaeslneatnscttasivliaitteirleiastteuarrsaestourecrvieaiterewedvoiwef w2it-haomgf ion2oo-da-1mp,3ihn,4yo-st-ih1c,io3ac,d4hi-aetzhmoiailcedadilaezaronivldeatpidvheearsrivtmhaaatitcvohekasvinetehbtaiectenphreaovpaeleurbateiteesnd.",
        "ETfovhraislaunaatrtietvidicrlael fapocrrteisveiantyntstaigvaairilanitlsetrasaetucvtreievraitrlyevviireaawlgsatoirnafsin2t -sa.",
        "MsIneivnaeodr-da1l,i3ti,o4vn-tihrtoaialtdhieaszt2ro-aaliemnsdin.eor-iIv1n,a3t,i4v-aetdhsdiatihdtiaioatnzhoalevtoemobietehetney, 2ea-vnaatmilvuiianrtaoel-da1c,3ti,4vfo-itrhyiiasdaanilastziovodilreapl emnodaiceetntiyvt ,oitnyatnhteiavgniaraaitnul sretacotfisvtehivteyesruaiblsstaivtlusiroeanltds,easptnerdnaidsntesrnu.",
        "TctuIonrne\u2013atahcdteidviinttiyaotsnutruedtioeosf hatthhveee s2su-habomswtiinntuote-h1ne,t3sm,,4oa-tnshtdieaffisdtircauizecontulterseu\u2013mbasocttiieitvtuyiet,yntasstnuftodivriiearsnalthiavavicreatilsvhaitcoytwivniistythaienlsmoeaocdshteceplfeafniscsdi.eeBnntatsseuodbnsotnitthuteheenntlsiattefuorraretaunroetfivditarhtaael, asthuctebivs2ti-itatyumeiinnntose-,a1ac,3hn,d4c-ltsahtsrisau.dcBtiuaazrsoee\u2013ldeacsotcinavffittohyledstlmiutedaryiaebtsuehrcaeovdnesasitdhae,orwtehdne at2hp-eaomsmsiionbsolte-1ep,f3hfi,a4cri-emthnaitacsdoupiabhzsootirlteugesrncoatusffpfooltrdhaamtnctaiavynirbbaeel cainoctcniosvriidptyeorrieandteedaacpinhotsocslitabhslese.sptBrhauascretmduraeocnofptkhhnoeorlewitgenrraocotuumprepthodauatntacda,sntthobee2ni-hnaacmonricnpeooa-rn1a,tt3iev,d4i-rtaihnlitaaocdttiihavezitoyslteraunscdctaucffrooenltdorfibmkunatyoeswbtneo ccthoomensspiedoaeurrcnehddasantdopodesensvhibeallnoecppemhaeannrmttivoaifcronalpewhaocmtrieveigdtyricoiaunnpedsthacsaotannctraianbltubetreensiantciovoerthpteoortsaheteaerdtcrheinatatmondethndet eosvtfrevuliocrptaumlrienenfoetfctokifonnonswe.wn mcoemdpicoinuensdasstaoneanlthearnncaetivaenttiovitrhael tarcetaitvmiteynat nodf vcioranltrinibfuectetisontos.",
        "The search and development of new mFuenddiicning:esThaissarenseaaltrechrnraetcieviveetdontoheexttreerantaml feunntdoinfgv.iral infections",
        "Tphhiasrmaarrtaticcicolelleopgrpiecrseaeslneatnscttasivliaitteirleiastteuarrsaestourecrvieaiterewedvoiwef w2it-haomgf ion2oo-da-1mp,3ihn,4yo-st-ih1c,io3ac,d4hi-aetzhmoiailcedadilaezaronivldeatpidvheearsrivtmhaaatitcvohekasvinetehbtaiectenphreaovpaeleurbateiteesnd. eTfovhraislaunaatrtietvidicrlael fapocrrteisveiantyntstaigvaairilanitlsetrasaetucvtreievraitrlyevviireaawlgsatoirnafsin2t -sa. msIneivnaeodr-da1l,i3ti,o4vn-tihrtoaialtdhieaszt2ro-aaliemnsdin.eor-iIv1n,a3t,i4v-aetdhsdiatihdtiaioatnzhoalevtoemobietehetney, 2ea-vnaatmilvuiianrtaoel-da1c,3ti,4vfo-itrhyiiasdaanilastziovodilreapl emnodaiceetntiyvt ,oitnyatnhteiavgniaraaitnul sretacotfisvtehivteyesruaiblsstaivtlusiroeanltds,easptnerdnaidsntesrnu. tctuIonrne\u2013atahcdteidviinttiyaotsnutruedtioeosf hatthhveee s2su-habomswtiinntuote-h1ne,t3sm,,4oa-tnshtdieaffisdtircauizecontulterseu\u2013mbasocttiieitvtuyiet,yntasstnuftodivriiearsnalthiavavicreatilsvhaitcoytwivniistythaienlsmoeaocdshteceplfeafniscsdi.eeBnntatsseuodbnsotnitthuteheenntlsiattefuorraretaunroetfivditarhtaael, asthuctebivs2ti-itatyumeiinnntose-,a1ac,3hn,d4c-ltsahtsrisau.dcBtiuaazrsoee\u2013ldeacsotcinavffittohyledstlmiutedaryiaebtsuehrcaeovdnesasitdhae,orwtehdne at2hp-eaomsmsiionbsolte-1ep,f3hfi,a4cri-emthnaitacsdoupiabhzsootirlteugesrncoatusffpfooltrdhaamtnctaiavynirbbaeel cainoctcniosvriidptyeorrieandteedaacpinhotsocslitabhslese.sptBrhauascretmduraeocnofptkhhnoeorlewitgenrraocotuumprepthodauatntacda,sntthobee2ni-hnaacmonricnpeooa-rn1a,tt3iev,d4i-rtaihnlitaaocdttiihavezitoyslteraunscdctaucffrooenltdorfibmkunatyoeswbtneo ccthoomensspiedoaeurrcnehddasantdopodesensvhibeallnoecppemhaeannrmttivoaifcronalpewhaocmtrieveigdtyricoiaunnpedsthacsaotannctraianbltubetreensiantciovoerthpteoortsaheteaerdtcrheinatatmondethndet eosvtfrevuliocrptaumlrienenfoetfctokifonnonswe.wn mcoemdpicoinuensdasstaoneanlthearnncaetivaenttiovitrhael tarcetaitvmiteynat nodf vcioranltrinibfuectetisontos. the search and development of new mFuenddiicning:esThaissarenseaaltrechrnraetcieviveetdontoheexttreerantaml feunntdoinfgv.iral infections"
    ],
    "structured_summary": {
        "Introduction": [
            "Viruses are the smallest among all self-replicating organisms and yet they are the etiological agents of many difficult to treat diseases in human populations [1].",
            "There are broad types of human infections caused by viruses, such as respiratory infections, digestive infections, central nervous system infections, skin or mucosal infections, hepatic infections, blood infections and hemorrhagic fever.",
            "Some viruses are etiological agents in the development of human tumors, cervical cancer and hepatic cancer [3].",
            "Efforts to develop safe and effective vaccines against viruses that cause chronic infections, such as human immunodeficiency virus or hepatitis C virus did not give the expected results [1,4,5]"
        ],
        "Conclusion": [
            "TThhee researrchh focusedd on 1,3,4-thiaddiiaazzoollee ddeerriivvaattiivveess iinnddiiccaatteess aa bbrrooaadd speeccttrruumm of phaarrmTmhaaeccoollrooeggsieiccaaarllcahaccttifivovicittuiieesssedaassssoooncciiaat1tee,d3d,4ww-tihitthihagdgoioaoozddolpephhyydsseiicrcioovccahhteievmmeisiccaalilnaadnnidcdaptpehhsaarrmamaabccorookkaiindneettisicpc pepcrrtoorpupemerrttiieeossf.",
            "Tphhiasrmaarrtaticcicolelleopgrpiecrseaeslneatnscttasivliaitteirleiastteuarrsaestourecrvieaiterewedvoiwef w2it-haomgf ion2oo-da-1mp,3ihn,4yo-st-ih1c,io3ac,d4hi-aetzhmoiailcedadilaezaronivldeatpidvheearsrivtmhaaatitcvohekasvinetehbtaiectenphreaovpaeleurbateiteesnd.",
            "ETfovhraislaunaatrtietvidicrlael fapocrrteisveiantyntstaigvaairilanitlsetrasaetucvtreievraitrlyevviireaawlgsatoirnafsin2t -sa.",
            "MsIneivnaeodr-da1l,i3ti,o4vn-tihrtoaialtdhieaszt2ro-aaliemnsdin.eor-iIv1n,a3t,i4v-aetdhsdiatihdtiaioatnzhoalevtoemobietehetney, 2ea-vnaatmilvuiianrtaoel-da1c,3ti,4vfo-itrhyiiasdaanilastziovodilreapl emnodaiceetntiyvt ,oitnyatnhteiavgniaraaitnul sretacotfisvtehivteyesruaiblsstaivtlusiroeanltds,easptnerdnaidsntesrnu.",
            "TctuIonrne\u2013atahcdteidviinttiyaotsnutruedtioeosf hatthhveee s2su-habomswtiinntuote-h1ne,t3sm,,4oa-tnshtdieaffisdtircauizecontulterseu\u2013mbasocttiieitvtuyiet,yntasstnuftodivriiearsnalthiavavicreatilsvhaitcoytwivniistythaienlsmoeaocdshteceplfeafniscsdi.eeBnntatsseuodbnsotnitthuteheenntlsiattefuorraretaunroetfivditarhtaael, asthuctebivs2ti-itatyumeiinnntose-,a1ac,3hn,d4c-ltsahtsrisau.dcBtiuaazrsoee\u2013ldeacsotcinavffittohyledstlmiutedaryiaebtsuehrcaeovdnesasitdhae,orwtehdne at2hp-eaomsmsiionbsolte-1ep,f3hfi,a4cri-emthnaitacsdoupiabhzsootirlteugesrncoatusffpfooltrdhaamtnctaiavynirbbaeel cainoctcniosvriidptyeorrieandteedaacpinhotsocslitabhslese.sptBrhauascretmduraeocnofptkhhnoeorlewitgenrraocotuumprepthodauatntacda,sntthobee2ni-hnaacmonricnpeooa-rn1a,tt3iev,d4i-rtaihnlitaaocdttiihavezitoyslteraunscdctaucffrooenltdorfibmkunatyoeswbtneo ccthoomensspiedoaeurrcnehddasantdopodesensvhibeallnoecppemhaeannrmttivoaifcronalpewhaocmtrieveigdtyricoiaunnpedsthacsaotannctraianbltubetreensiantciovoerthpteoortsaheteaerdtcrheinatatmondethndet eosvtfrevuliocrptaumlrienenfoetfctokifonnonswe.wn mcoemdpicoinuensdasstaoneanlthearnncaetivaenttiovitrhael tarcetaitvmiteynat nodf vcioranltrinibfuectetisontos.",
            "The search and development of new mFuenddiicning:esThaissarenseaaltrechrnraetcieviveetdontoheexttreerantaml feunntdoinfgv.iral infections",
            "Tphhiasrmaarrtaticcicolelleopgrpiecrseaeslneatnscttasivliaitteirleiastteuarrsaestourecrvieaiterewedvoiwef w2it-haomgf ion2oo-da-1mp,3ihn,4yo-st-ih1c,io3ac,d4hi-aetzhmoiailcedadilaezaronivldeatpidvheearsrivtmhaaatitcvohekasvinetehbtaiectenphreaovpaeleurbateiteesnd. eTfovhraislaunaatrtietvidicrlael fapocrrteisveiantyntstaigvaairilanitlsetrasaetucvtreievraitrlyevviireaawlgsatoirnafsin2t -sa. msIneivnaeodr-da1l,i3ti,o4vn-tihrtoaialtdhieaszt2ro-aaliemnsdin.eor-iIv1n,a3t,i4v-aetdhsdiatihdtiaioatnzhoalevtoemobietehetney, 2ea-vnaatmilvuiianrtaoel-da1c,3ti,4vfo-itrhyiiasdaanilastziovodilreapl emnodaiceetntiyvt ,oitnyatnhteiavgniaraaitnul sretacotfisvtehivteyesruaiblsstaivtlusiroeanltds,easptnerdnaidsntesrnu. tctuIonrne\u2013atahcdteidviinttiyaotsnutruedtioeosf hatthhveee s2su-habomswtiinntuote-h1ne,t3sm,,4oa-tnshtdieaffisdtircauizecontulterseu\u2013mbasocttiieitvtuyiet,yntasstnuftodivriiearsnalthiavavicreatilsvhaitcoytwivniistythaienlsmoeaocdshteceplfeafniscsdi.eeBnntatsseuodbnsotnitthuteheenntlsiattefuorraretaunroetfivditarhtaael, asthuctebivs2ti-itatyumeiinnntose-,a1ac,3hn,d4c-ltsahtsrisau.dcBtiuaazrsoee\u2013ldeacsotcinavffittohyledstlmiutedaryiaebtsuehrcaeovdnesasitdhae,orwtehdne at2hp-eaomsmsiionbsolte-1ep,f3hfi,a4cri-emthnaitacsdoupiabhzsootirlteugesrncoatusffpfooltrdhaamtnctaiavynirbbaeel cainoctcniosvriidptyeorrieandteedaacpinhotsocslitabhslese.sptBrhauascretmduraeocnofptkhhnoeorlewitgenrraocotuumprepthodauatntacda,sntthobee2ni-hnaacmonricnpeooa-rn1a,tt3iev,d4i-rtaihnlitaaocdttiihavezitoyslteraunscdctaucffrooenltdorfibmkunatyoeswbtneo ccthoomensspiedoaeurrcnehddasantdopodesensvhibeallnoecppemhaeannrmttivoaifcronalpewhaocmtrieveigdtyricoiaunnpedsthacsaotannctraianbltubetreensiantciovoerthpteoortsaheteaerdtcrheinatatmondethndet eosvtfrevuliocrptaumlrienenfoetfctokifonnonswe.wn mcoemdpicoinuensdasstaoneanlthearnncaetivaenttiovitrhael tarcetaitvmiteynat nodf vcioranltrinibfuectetisontos. the search and development of new mFuenddiicning:esThaissarenseaaltrechrnraetcieviveetdontoheexttreerantaml feunntdoinfgv.iral infections"
        ]
    },
    "reference_links": [
        {
            "id": "1",
            "alt_id": "Beale_2011_a",
            "entry": "1. Beale, J.M., Jr. Antiviral agents. In Wilson and Gisvold\u2019s Textbook of Organic Medicinal and Pharmaceutical Chemistry, 12th ed.; Beale, J.M., Jr., Block, J.H., Eds.; Lippincott Williams and Wilkins: Baltimore, MD, USA, 2011; pp. 330\u2013336.",
            "scholar_url": "https://scholar.google.co.uk/scholar?q=Beale%2C%20Jr%2C%20J.M.%20Antiviral%20agents.%20In%20Wilson%20and%20Gisvold%E2%80%99s%20Textbook%20of%20Organic%20Medicinal%20and%20Pharmaceutical%20Chemistry%202011"
        },
        {
            "id": "2",
            "alt_id": "Rohwer_2013_a",
            "entry": "2. Rohwer, F.; Barrot, K. Viral information. Biol. Philos. 2013, 28, 283\u2013297. [CrossRef] 3. Woster, P.M. Antiviral agents and protease inhibitors. In Foye\u2019s Principles of Medicinal Chemistry, 7th ed.; Lemke, T.L., Williams, D.A., Roche, V.F., Zito, S.W., Eds.; Lippincott Williams and Wilkins, Wolters Kluwer: Baltimore, MD, USA, 2013; pp. 1274\u20131302.",
            "scholar_url": "https://scholar.google.co.uk/scholar?q=Rohwer%2C%20F.%20Barrot%2C%20K.%20Viral%20information%202013",
            "oa_query": "https://sandbox-api.scholarcy.com/oa_version?query=Rohwer%2C%20F.%20Barrot%2C%20K.%20Viral%20information%202013",
            "scite": "https://sandbox-api.scholarcy.com/scite_url?query=Rohwer%2C%20F.%20Barrot%2C%20K.%20Viral%20information%202013"
        },
        {
            "id": "4",
            "alt_id": "Berzofsky_et+al_2004_a",
            "entry": "4. Berzofsky, J.A.; Ahlers, J.D.; Janik, J.; Morris, J.; Oh, S.K.; Terabe, M.; Belyakov, I.M. Progress on new vaccine strategies against chronic viral infections. J. Clin. Invest. 2004, 114, 450\u2013462. [CrossRef] [PubMed] 5. World Health Organization. Human papillomavirus vaccines: WHO position paper, May 2017, Weekly epidemiological record. Available online: http://www.who.int/wer (accessed on 11 January 2020).",
            "url": "http://www.who.int/wer"
        },
        {
            "id": "6",
            "alt_id": "El-Essawy_et+al_2008_a",
            "entry": "6. El-Essawy, F.A.; El-Sayed, W.A.; El-Kafrawy, S.A.; Morshedy, A.S.; Abdel-Rahman, A.H. Anti-Hepatitis B virus activity of new 1,2,4-triazol-2-yl- and1,3,4-oxadiazol-2-yl-2-pyridinone derivatives. Z. Naturforsch. 2008, 63c, 667\u2013674. [CrossRef] [PubMed] 7. Tonelli, M.; Cichero, E. Fight against H1N1 Influenza A virus: recent insights towards the development of druggable compounds. Curr. Med. Chem. 2016, 23, 1802\u20131817. [CrossRef] [PubMed] 8.",
            "scholar_url": "https://scholar.google.co.uk/scholar?q=El-Essawy%2C%20F.A.%20El-Sayed%2C%20W.A.%20El-Kafrawy%2C%20S.A.%20Morshedy%2C%20A.S.%20Anti-Hepatitis%20B%20virus%20activity%20of%20new%201%2C2%2C4-triazol-2-yl-%20and1%2C3%2C4-oxadiazol-2-yl-2-pyridinone%20derivatives%202008",
            "oa_query": "https://sandbox-api.scholarcy.com/oa_version?query=El-Essawy%2C%20F.A.%20El-Sayed%2C%20W.A.%20El-Kafrawy%2C%20S.A.%20Morshedy%2C%20A.S.%20Anti-Hepatitis%20B%20virus%20activity%20of%20new%201%2C2%2C4-triazol-2-yl-%20and1%2C3%2C4-oxadiazol-2-yl-2-pyridinone%20derivatives%202008",
            "scite": "https://sandbox-api.scholarcy.com/scite_url?query=El-Essawy%2C%20F.A.%20El-Sayed%2C%20W.A.%20El-Kafrawy%2C%20S.A.%20Morshedy%2C%20A.S.%20Anti-Hepatitis%20B%20virus%20activity%20of%20new%201%2C2%2C4-triazol-2-yl-%20and1%2C3%2C4-oxadiazol-2-yl-2-pyridinone%20derivatives%202008"
        },
        {
            "id": "Diaba_et+al_2015_a",
            "alt_id": "5",
            "entry": "Diaba, F.; Montiel, J.A.; Serban, G.; Bonjoch, J. Synthesis of normorphans through an efficient intramolecular carbamoylation of ketones. Org. Lett. 2015, 17, 3860\u20133863. [CrossRef] 9.",
            "scholar_url": "https://scholar.google.co.uk/scholar?q=Diaba%2C%20F.%20Montiel%2C%20J.A.%20Serban%2C%20G.%20Bonjoch%2C%20J.%20Synthesis%20of%20normorphans%20through%20an%20efficient%20intramolecular%20carbamoylation%20of%20ketones%202015",
            "oa_query": "https://sandbox-api.scholarcy.com/oa_version?query=Diaba%2C%20F.%20Montiel%2C%20J.A.%20Serban%2C%20G.%20Bonjoch%2C%20J.%20Synthesis%20of%20normorphans%20through%20an%20efficient%20intramolecular%20carbamoylation%20of%20ketones%202015",
            "scite": "https://sandbox-api.scholarcy.com/scite_url?query=Diaba%2C%20F.%20Montiel%2C%20J.A.%20Serban%2C%20G.%20Bonjoch%2C%20J.%20Synthesis%20of%20normorphans%20through%20an%20efficient%20intramolecular%20carbamoylation%20of%20ketones%202015"
        },
        {
            "id": "Serban_et+al_2011_a",
            "alt_id": "6",
            "entry": "Serban, G.; Abe, H.; Takeuchi, Y. Synthetic studies of substituted pyridine aldehydes as intermediates for the synthesis of toddaquinoline, its derivatives and other natural products. Heterocycles 2011, 83, 1989\u20132000. [CrossRef] 10.",
            "scholar_url": "https://scholar.google.co.uk/scholar?q=Serban%2C%20G.%20Abe%2C%20H.%20Takeuchi%2C%20Y.%20Synthetic%20studies%20of%20substituted%20pyridine%20aldehydes%20as%20intermediates%20for%20the%20synthesis%20of%20toddaquinoline%2C%20its%20derivatives%20and%20other%20natural%20products%202011",
            "oa_query": "https://sandbox-api.scholarcy.com/oa_version?query=Serban%2C%20G.%20Abe%2C%20H.%20Takeuchi%2C%20Y.%20Synthetic%20studies%20of%20substituted%20pyridine%20aldehydes%20as%20intermediates%20for%20the%20synthesis%20of%20toddaquinoline%2C%20its%20derivatives%20and%20other%20natural%20products%202011",
            "scite": "https://sandbox-api.scholarcy.com/scite_url?query=Serban%2C%20G.%20Abe%2C%20H.%20Takeuchi%2C%20Y.%20Synthetic%20studies%20of%20substituted%20pyridine%20aldehydes%20as%20intermediates%20for%20the%20synthesis%20of%20toddaquinoline%2C%20its%20derivatives%20and%20other%20natural%20products%202011"
        },
        {
            "id": "Serban_et+al_2008_a",
            "alt_id": "7",
            "entry": "Serban, G.; Abe, H.; Takeuchi, Y.; Harayama, T. A new approach to the benzopyridoxepine core by metal mediated intramolecular biaryl ether formation. Heterocycles 2008, 75, 2949\u20132958. [CrossRef] 11.",
            "scholar_url": "https://scholar.google.co.uk/scholar?q=Serban%2C%20G.%20Abe%2C%20H.%20Takeuchi%2C%20Y.%20Harayama%2C%20T.%20A%20new%20approach%20to%20the%20benzopyridoxepine%20core%20by%20metal%20mediated%20intramolecular%20biaryl%20ether%20formation%202008",
            "oa_query": "https://sandbox-api.scholarcy.com/oa_version?query=Serban%2C%20G.%20Abe%2C%20H.%20Takeuchi%2C%20Y.%20Harayama%2C%20T.%20A%20new%20approach%20to%20the%20benzopyridoxepine%20core%20by%20metal%20mediated%20intramolecular%20biaryl%20ether%20formation%202008",
            "scite": "https://sandbox-api.scholarcy.com/scite_url?query=Serban%2C%20G.%20Abe%2C%20H.%20Takeuchi%2C%20Y.%20Harayama%2C%20T.%20A%20new%20approach%20to%20the%20benzopyridoxepine%20core%20by%20metal%20mediated%20intramolecular%20biaryl%20ether%20formation%202008"
        },
        {
            "id": "Serban_et+al_2007_a",
            "alt_id": "8",
            "entry": "Serban, G.; Shigeta, Y.; Nishioka, H.; Abe, H.; Takeuchi, Y.; Harayama, T. Studies toward the synthesis of toddaquinoline by intramolecular cyclization. Heterocycles 2007, 71, 1623\u20131630. [CrossRef] 12.",
            "scholar_url": "https://scholar.google.co.uk/scholar?q=Serban%2C%20G.%20Shigeta%2C%20Y.%20Nishioka%2C%20H.%20Abe%2C%20H.%20Studies%20toward%20the%20synthesis%20of%20toddaquinoline%20by%20intramolecular%20cyclization%202007",
            "oa_query": "https://sandbox-api.scholarcy.com/oa_version?query=Serban%2C%20G.%20Shigeta%2C%20Y.%20Nishioka%2C%20H.%20Abe%2C%20H.%20Studies%20toward%20the%20synthesis%20of%20toddaquinoline%20by%20intramolecular%20cyclization%202007",
            "scite": "https://sandbox-api.scholarcy.com/scite_url?query=Serban%2C%20G.%20Shigeta%2C%20Y.%20Nishioka%2C%20H.%20Abe%2C%20H.%20Studies%20toward%20the%20synthesis%20of%20toddaquinoline%20by%20intramolecular%20cyclization%202007"
        },
        {
            "id": "Gupta_2015_a",
            "alt_id": "9",
            "entry": "Gupta, R. Biological significance of nitrogen containing heterocyclic compounds\u2014a mini review. IJCA 2015, 8, 18\u201323.",
            "scholar_url": "https://scholar.google.co.uk/scholar?q=Gupta%2C%20R.%20Biological%20significance%20of%20nitrogen%20containing%20heterocyclic%20compounds%E2%80%94a%20mini%20review%202015",
            "oa_query": "https://sandbox-api.scholarcy.com/oa_version?query=Gupta%2C%20R.%20Biological%20significance%20of%20nitrogen%20containing%20heterocyclic%20compounds%E2%80%94a%20mini%20review%202015",
            "scite": "https://sandbox-api.scholarcy.com/scite_url?query=Gupta%2C%20R.%20Biological%20significance%20of%20nitrogen%20containing%20heterocyclic%20compounds%E2%80%94a%20mini%20review%202015"
        },
        {
            "id": "13",
            "alt_id": "Joule_2016_a",
            "entry": "13. Joule, J.A. Natural products containing nitrogen heterocycles\u2014some highlights 1990\u20132015. In Advances in Heterocyclic Chemistry: Heterocyclic Chemistry in the 21st Century\u2014A Tribute to Alan Katritzky, 1st ed.; Scriven, E.F.V., Ramsden, C.A., Eds.; Academic Press Elsevier: Cambridge, UK, 2016; Volume 119, pp. 81\u2013106.",
            "scholar_url": "https://scholar.google.co.uk/scholar?q=Joule%20JA%20Natural%20products%20containing%20nitrogen%20heterocyclessome%20highlights%2019902015%20In%20Advances%20in%20Heterocyclic%20Chemistry%20Heterocyclic%20Chemistry%20in%20the%2021st%20CenturyA%20Tribute%20to%20Alan%20Katritzky%201st%20ed%20Scriven%20EFV%20Ramsden%20CA%20Eds%20Academic%20Press%20Elsevier%20Cambridge%20UK%202016%20Volume%20119%20pp%2081106"
        },
        {
            "id": "14",
            "alt_id": "Takashima_et+al_2019_a",
            "entry": "14. Takashima, K.; Hayakawa, D.; Gouda, H.; Toyooka, N. Formal syntheses of (-)-Lepadiformines A, C and (-)-Fasicularin. J. Org. Chem. 2019, 84, 5222\u20135229. [CrossRef] 15. Vitaku, E.; Smith, D.T.; Njardarson, J.T. Analysis of the structural diversity, substitution patterns, and frequency of nitrogen heterocycles among U.S. FDA approved pharmaceuticals. J. Med. Chem. 2014, 57, 10257\u201310274. [CrossRef] [PubMed] 16.",
            "scholar_url": "https://scholar.google.co.uk/scholar?q=Takashima%2C%20K.%20Hayakawa%2C%20D.%20Gouda%2C%20H.%20Toyooka%2C%20N.%20Formal%20syntheses%20of%20%28-%29-Lepadiformines%202019",
            "oa_query": "https://sandbox-api.scholarcy.com/oa_version?query=Takashima%2C%20K.%20Hayakawa%2C%20D.%20Gouda%2C%20H.%20Toyooka%2C%20N.%20Formal%20syntheses%20of%20%28-%29-Lepadiformines%202019",
            "scite": "https://sandbox-api.scholarcy.com/scite_url?query=Takashima%2C%20K.%20Hayakawa%2C%20D.%20Gouda%2C%20H.%20Toyooka%2C%20N.%20Formal%20syntheses%20of%20%28-%29-Lepadiformines%202019"
        },
        {
            "id": "Shukla_et+al_2017_a",
            "alt_id": "12",
            "entry": "Shukla, P.K.; Verma, A.; Mishra, P. Significance of nitrogen heterocyclic nuclei in the search of pharmacological active compounds. In New Perspective in Agricultural and Human Health; Shukla, R.P., Mishra, R.S., Tripathi, A.D., Yadav, A.K., Tiwari, M., Mishra, R.R., Eds.; Bharti Publication: New Delhi, India, 2017; pp. 100\u2013126.",
            "scholar_url": "https://scholar.google.co.uk/scholar?q=Shukla%2C%20P.K.%20Verma%2C%20A.%20Mishra%2C%20P.%20Significance%20of%20nitrogen%20heterocyclic%20nuclei%20in%20the%20search%20of%20pharmacological%20active%20compounds.%20In%20New%20Perspective%20in%20Agricultural%20and%20Human%20Health%202017"
        },
        {
            "id": "17",
            "alt_id": "Rajput_2017_a",
            "entry": "17. Rajput, A.P.; Kankhare, A.R. Synthetic utility of azaheterocycles: A short review. Int. J. Pharm. Sci. Invent. 2017, 6, 19\u201325.",
            "scholar_url": "https://scholar.google.co.uk/scholar?q=Rajput%2C%20A.P.%20Kankhare%2C%20A.R.%20Synthetic%20utility%20of%20azaheterocycles%3A%20A%20short%20review%202017",
            "oa_query": "https://sandbox-api.scholarcy.com/oa_version?query=Rajput%2C%20A.P.%20Kankhare%2C%20A.R.%20Synthetic%20utility%20of%20azaheterocycles%3A%20A%20short%20review%202017",
            "scite": "https://sandbox-api.scholarcy.com/scite_url?query=Rajput%2C%20A.P.%20Kankhare%2C%20A.R.%20Synthetic%20utility%20of%20azaheterocycles%3A%20A%20short%20review%202017"
        },
        {
            "id": "18",
            "alt_id": "de_Clercq_2016_a",
            "entry": "18. De Clercq, E.; Li, G. Approved antiviral drugs over the past 50 years. Clin. Microbiol. Rev. 2016, 29, 695\u2013747. [CrossRef] [PubMed] 19. Razonable, R.R. Antiviral drugs for viruses other than human immunodeficiency virus. Mayo Clin. Proc. 2011, 86, 1009\u20131026. [CrossRef] [PubMed] 20.",
            "scholar_url": "https://scholar.google.co.uk/scholar?q=De%20Clercq%2C%20E.%20Li%2C%20G.%20Approved%20antiviral%20drugs%20over%20the%20past%2050%20years%202016",
            "oa_query": "https://sandbox-api.scholarcy.com/oa_version?query=De%20Clercq%2C%20E.%20Li%2C%20G.%20Approved%20antiviral%20drugs%20over%20the%20past%2050%20years%202016",
            "scite": "https://sandbox-api.scholarcy.com/scite_url?query=De%20Clercq%2C%20E.%20Li%2C%20G.%20Approved%20antiviral%20drugs%20over%20the%20past%2050%20years%202016"
        },
        {
            "id": "Serban_et+al_2018_a",
            "alt_id": "15",
            "entry": "Serban, G.; Stanasel, O.; Serban, E.; Bota, S. 2-Amino-1,3,4-thiadiazole as a potential scaffold for promising antimicrobial agents. Drug Des. Devel. Ther. 2018, 12, 1545\u20131566. [CrossRef] 21.",
            "scholar_url": "https://scholar.google.co.uk/scholar?q=Serban%2C%20G.%20Stanasel%2C%20O.%20Serban%2C%20E.%20Bota%2C%20S.%202-Amino-1%2C3%2C4-thiadiazole%20as%20a%20potential%20scaffold%20for%20promising%20antimicrobial%20agents.%20Drug%20Des%202018",
            "oa_query": "https://sandbox-api.scholarcy.com/oa_version?query=Serban%2C%20G.%20Stanasel%2C%20O.%20Serban%2C%20E.%20Bota%2C%20S.%202-Amino-1%2C3%2C4-thiadiazole%20as%20a%20potential%20scaffold%20for%20promising%20antimicrobial%20agents.%20Drug%20Des%202018",
            "scite": "https://sandbox-api.scholarcy.com/scite_url?query=Serban%2C%20G.%20Stanasel%2C%20O.%20Serban%2C%20E.%20Bota%2C%20S.%202-Amino-1%2C3%2C4-thiadiazole%20as%20a%20potential%20scaffold%20for%20promising%20antimicrobial%20agents.%20Drug%20Des%202018"
        },
        {
            "id": "Schenone_et+al_2006_a",
            "alt_id": "16",
            "entry": "Schenone, S.; Brullo, C.; Bruno, O.; Bondavalli, F.; Ranise, A.; Filippelli, W.; Rinaldi, B.; Capuano, A.; Falcone, G. New 1,3,4-thiadiazole derivatives endowed with analgesic and anti-inflammatory activities. Bioorg Med Chem. 2006, 14, 1698\u20131705. [CrossRef]",
            "scholar_url": "https://scholar.google.co.uk/scholar?q=Schenone%2C%20S.%20Brullo%2C%20C.%20Bruno%2C%20O.%20Bondavalli%2C%20F.%20New%201%2C3%2C4-thiadiazole%20derivatives%20endowed%20with%20analgesic%20and%20anti-inflammatory%20activities%202006",
            "oa_query": "https://sandbox-api.scholarcy.com/oa_version?query=Schenone%2C%20S.%20Brullo%2C%20C.%20Bruno%2C%20O.%20Bondavalli%2C%20F.%20New%201%2C3%2C4-thiadiazole%20derivatives%20endowed%20with%20analgesic%20and%20anti-inflammatory%20activities%202006",
            "scite": "https://sandbox-api.scholarcy.com/scite_url?query=Schenone%2C%20S.%20Brullo%2C%20C.%20Bruno%2C%20O.%20Bondavalli%2C%20F.%20New%201%2C3%2C4-thiadiazole%20derivatives%20endowed%20with%20analgesic%20and%20anti-inflammatory%20activities%202006"
        },
        {
            "id": "22",
            "alt_id": "Labanauskas_et+al_2001_a",
            "entry": "22. Labanauskas, L.; Kalcas, V.; Udrenaite, E.; Gaidelis, P.; Brukstus, A.; Dauksas, A. Synthesis of 3-(3,4-dimethoxyphenyl)-1H-1,2,4-triazole-5-thiol and 2-amino-5-(3,4-dimethoxyphenyl)-1,3,4-thiadiazole derivatives exhibiting anti-inflammatory activity. Pharmazie 2001, 56, 617\u2013619.",
            "scholar_url": "https://scholar.google.co.uk/scholar?q=Labanauskas%2C%20L.%20Kalcas%2C%20V.%20Udrenaite%2C%20E.%20Gaidelis%2C%20P.%20Synthesis%20of%203-%283%2C4-dimethoxyphenyl%29-1H-1%2C2%2C4-triazole-5-thiol%20and%202-amino-5-%283%2C4-dimethoxyphenyl%29-1%2C3%2C4-thiadiazole%20derivatives%20exhibiting%20anti-inflammatory%20activity%202001",
            "oa_query": "https://sandbox-api.scholarcy.com/oa_version?query=Labanauskas%2C%20L.%20Kalcas%2C%20V.%20Udrenaite%2C%20E.%20Gaidelis%2C%20P.%20Synthesis%20of%203-%283%2C4-dimethoxyphenyl%29-1H-1%2C2%2C4-triazole-5-thiol%20and%202-amino-5-%283%2C4-dimethoxyphenyl%29-1%2C3%2C4-thiadiazole%20derivatives%20exhibiting%20anti-inflammatory%20activity%202001",
            "scite": "https://sandbox-api.scholarcy.com/scite_url?query=Labanauskas%2C%20L.%20Kalcas%2C%20V.%20Udrenaite%2C%20E.%20Gaidelis%2C%20P.%20Synthesis%20of%203-%283%2C4-dimethoxyphenyl%29-1H-1%2C2%2C4-triazole-5-thiol%20and%202-amino-5-%283%2C4-dimethoxyphenyl%29-1%2C3%2C4-thiadiazole%20derivatives%20exhibiting%20anti-inflammatory%20activity%202001"
        },
        {
            "id": "23",
            "alt_id": "Clerici_et+al_2001_a",
            "entry": "23. Clerici, F.; Pocar, D.; Guido, M.; Loche, A.; Perlini, V.; Brufani, M. Synthesis of 2-amino-5-sulfanyl1,3,4-thiadiazole derivatives and evaluation of their antidepressant and anxiolytic activity. J Med Chem. 2001, 44, 931\u2013936. [CrossRef]",
            "scholar_url": "https://scholar.google.co.uk/scholar?q=Clerici%2C%20F.%20Pocar%2C%20D.%20Guido%2C%20M.%20Loche%2C%20A.%20Synthesis%20of%202-amino-5-sulfanyl1%2C3%2C4-thiadiazole%20derivatives%20and%20evaluation%20of%20their%20antidepressant%20and%20anxiolytic%20activity%202001",
            "oa_query": "https://sandbox-api.scholarcy.com/oa_version?query=Clerici%2C%20F.%20Pocar%2C%20D.%20Guido%2C%20M.%20Loche%2C%20A.%20Synthesis%20of%202-amino-5-sulfanyl1%2C3%2C4-thiadiazole%20derivatives%20and%20evaluation%20of%20their%20antidepressant%20and%20anxiolytic%20activity%202001",
            "scite": "https://sandbox-api.scholarcy.com/scite_url?query=Clerici%2C%20F.%20Pocar%2C%20D.%20Guido%2C%20M.%20Loche%2C%20A.%20Synthesis%20of%202-amino-5-sulfanyl1%2C3%2C4-thiadiazole%20derivatives%20and%20evaluation%20of%20their%20antidepressant%20and%20anxiolytic%20activity%202001"
        },
        {
            "id": "24",
            "alt_id": "Basso_et+al_2019_a",
            "entry": "24. Basso, A.; Liu, M.; Dai, C.; Gray, K.; Nale, L.; Tevar, S.; Lee, S.; Liang, L.; Ponery, A.; Yaremko, B.; et al. SCH 2047069, a novel oral kinesin spindle protein inhibitor, shows single-agent antitumor activity and enhances the efficacy of chemotherapeutics. Mol. Cancer Ther. 2019, 9, 2993\u20133002. [CrossRef]",
            "scholar_url": "https://scholar.google.co.uk/scholar?q=Basso%2C%20A.%20Liu%2C%20M.%20Dai%2C%20C.%20Gray%2C%20K.%20SCH%202047069%2C%20a%20novel%20oral%20kinesin%20spindle%20protein%20inhibitor%2C%20shows%20single-agent%20antitumor%20activity%20and%20enhances%20the%20efficacy%20of%20chemotherapeutics%202019",
            "oa_query": "https://sandbox-api.scholarcy.com/oa_version?query=Basso%2C%20A.%20Liu%2C%20M.%20Dai%2C%20C.%20Gray%2C%20K.%20SCH%202047069%2C%20a%20novel%20oral%20kinesin%20spindle%20protein%20inhibitor%2C%20shows%20single-agent%20antitumor%20activity%20and%20enhances%20the%20efficacy%20of%20chemotherapeutics%202019",
            "scite": "https://sandbox-api.scholarcy.com/scite_url?query=Basso%2C%20A.%20Liu%2C%20M.%20Dai%2C%20C.%20Gray%2C%20K.%20SCH%202047069%2C%20a%20novel%20oral%20kinesin%20spindle%20protein%20inhibitor%2C%20shows%20single-agent%20antitumor%20activity%20and%20enhances%20the%20efficacy%20of%20chemotherapeutics%202019"
        },
        {
            "id": "25",
            "alt_id": "Dawood_2017_a",
            "entry": "25. Dawood, K.M.; Farghaly, T.A. Thiadiazole inhibitors: A patent review. Expert Opin. Ther. Pat. 2017, 27, 477\u2013505. [CrossRef]",
            "scholar_url": "https://scholar.google.co.uk/scholar?q=Dawood%2C%20K.M.%20Farghaly%2C%20T.A.%20Thiadiazole%20inhibitors%3A%20A%20patent%20review.%20Expert%20Opin%202017",
            "oa_query": "https://sandbox-api.scholarcy.com/oa_version?query=Dawood%2C%20K.M.%20Farghaly%2C%20T.A.%20Thiadiazole%20inhibitors%3A%20A%20patent%20review.%20Expert%20Opin%202017",
            "scite": "https://sandbox-api.scholarcy.com/scite_url?query=Dawood%2C%20K.M.%20Farghaly%2C%20T.A.%20Thiadiazole%20inhibitors%3A%20A%20patent%20review.%20Expert%20Opin%202017"
        },
        {
            "id": "26",
            "alt_id": "Haider_et+al_2015_a",
            "entry": "26. Haider, S.; Alam, M.S.; Hamid, H. 1,3,4-Thiadiazoles: a potent multi targeted pharmacological scaffold. Eur. J. Med. Chem. 2015, 92, 156\u2013177. [CrossRef] [PubMed]",
            "scholar_url": "https://scholar.google.co.uk/scholar?q=Haider%2C%20S.%20Alam%2C%20M.S.%20Hamid%2C%20H.%201%2C3%2C4-Thiadiazoles%3A%20a%20potent%20multi%20targeted%20pharmacological%20scaffold%202015",
            "oa_query": "https://sandbox-api.scholarcy.com/oa_version?query=Haider%2C%20S.%20Alam%2C%20M.S.%20Hamid%2C%20H.%201%2C3%2C4-Thiadiazoles%3A%20a%20potent%20multi%20targeted%20pharmacological%20scaffold%202015",
            "scite": "https://sandbox-api.scholarcy.com/scite_url?query=Haider%2C%20S.%20Alam%2C%20M.S.%20Hamid%2C%20H.%201%2C3%2C4-Thiadiazoles%3A%20a%20potent%20multi%20targeted%20pharmacological%20scaffold%202015"
        },
        {
            "id": "27",
            "alt_id": "Serban_2019_a",
            "entry": "27. Serban, G. Future prospects in the treatment of parasitic diseases: 2-amino-1,3,4-thiadiazoles in leishmaniasis. Molecules 2019, 24, 1557. [CrossRef] [PubMed]",
            "scholar_url": "https://scholar.google.co.uk/scholar?q=Serban%2C%20G.%20Future%20prospects%20in%20the%20treatment%20of%20parasitic%20diseases%3A%202-amino-1%2C3%2C4-thiadiazoles%20in%20leishmaniasis%202019",
            "oa_query": "https://sandbox-api.scholarcy.com/oa_version?query=Serban%2C%20G.%20Future%20prospects%20in%20the%20treatment%20of%20parasitic%20diseases%3A%202-amino-1%2C3%2C4-thiadiazoles%20in%20leishmaniasis%202019",
            "scite": "https://sandbox-api.scholarcy.com/scite_url?query=Serban%2C%20G.%20Future%20prospects%20in%20the%20treatment%20of%20parasitic%20diseases%3A%202-amino-1%2C3%2C4-thiadiazoles%20in%20leishmaniasis%202019"
        },
        {
            "id": "28",
            "alt_id": "Li_et+al_2013_a",
            "entry": "28. Li, Y.; Geng, J.; Liu, Y.; Yu, S.; Zhao, G. Thiadiazole\u2014A promising structure in Medicinal Chemistry. ChemMedChem 2013, 8, 27\u201341. [CrossRef] [PubMed]",
            "scholar_url": "https://scholar.google.co.uk/scholar?q=Li%2C%20Y.%20Geng%2C%20J.%20Liu%2C%20Y.%20Yu%2C%20S.%20Thiadiazole%E2%80%94A%20promising%20structure%20in%20Medicinal%20Chemistry%202013",
            "oa_query": "https://sandbox-api.scholarcy.com/oa_version?query=Li%2C%20Y.%20Geng%2C%20J.%20Liu%2C%20Y.%20Yu%2C%20S.%20Thiadiazole%E2%80%94A%20promising%20structure%20in%20Medicinal%20Chemistry%202013",
            "scite": "https://sandbox-api.scholarcy.com/scite_url?query=Li%2C%20Y.%20Geng%2C%20J.%20Liu%2C%20Y.%20Yu%2C%20S.%20Thiadiazole%E2%80%94A%20promising%20structure%20in%20Medicinal%20Chemistry%202013"
        },
        {
            "id": "29",
            "alt_id": "Senff-Ribeiro_et+al_2004_a",
            "entry": "29. Senff-Ribeiro, A.; Echevarria, A.; Silva, E.F.; Franco, C.R.C.; Veiga, S.S.; Oliveira, M.B.M. Cytotoxic effect of a new 1,3,4-thiadiazolium mesoionic compound (MI-D) on cell lines of human mellanoma. Br. J. Cancer 2004, 91, 297\u2013304. [CrossRef] [PubMed]",
            "scholar_url": "https://scholar.google.co.uk/scholar?q=Senff-Ribeiro%2C%20A.%20Echevarria%2C%20A.%20Silva%2C%20E.F.%20Franco%2C%20C.R.C.%20Cytotoxic%20effect%20of%20a%20new%201%2C3%2C4-thiadiazolium%20mesoionic%20compound%20%28MI-D%29%20on%20cell%20lines%20of%20human%20mellanoma%202004",
            "oa_query": "https://sandbox-api.scholarcy.com/oa_version?query=Senff-Ribeiro%2C%20A.%20Echevarria%2C%20A.%20Silva%2C%20E.F.%20Franco%2C%20C.R.C.%20Cytotoxic%20effect%20of%20a%20new%201%2C3%2C4-thiadiazolium%20mesoionic%20compound%20%28MI-D%29%20on%20cell%20lines%20of%20human%20mellanoma%202004",
            "scite": "https://sandbox-api.scholarcy.com/scite_url?query=Senff-Ribeiro%2C%20A.%20Echevarria%2C%20A.%20Silva%2C%20E.F.%20Franco%2C%20C.R.C.%20Cytotoxic%20effect%20of%20a%20new%201%2C3%2C4-thiadiazolium%20mesoionic%20compound%20%28MI-D%29%20on%20cell%20lines%20of%20human%20mellanoma%202004"
        },
        {
            "id": "30",
            "alt_id": "Wermuth_2011_a",
            "entry": "30. Wermuth, C.G. Are pyridazines privileged structures? Med.Chem.Commun. 2011, 2, 935\u2013941. [CrossRef] 31. Biziere, K.; Worms, P.; Kan, J.P.; Mandel, P.; Garattini, S.; Roncucci, R. Minaprine, a new drug with antidepressant properties. Drugs Exp. Clin. Res. 1985, 11, 831\u2013840. [PubMed] 32.",
            "scholar_url": "https://scholar.google.co.uk/scholar?q=Wermuth%2C%20C.G.%20Are%20pyridazines%20privileged%20structures%3F%202011",
            "oa_query": "https://sandbox-api.scholarcy.com/oa_version?query=Wermuth%2C%20C.G.%20Are%20pyridazines%20privileged%20structures%3F%202011",
            "scite": "https://sandbox-api.scholarcy.com/scite_url?query=Wermuth%2C%20C.G.%20Are%20pyridazines%20privileged%20structures%3F%202011"
        },
        {
            "id": "Ueno_et+al_1997_a",
            "alt_id": "26",
            "entry": "Ueno, S.; Bracamontes, J.; Zorumski, C.; Weiss, D.S.; Steinbach, J.H. Bicuculline and gabazine are allosteric inhibitors of channel opening of the GABA A receptor. J. Neurosci. 1997, 17, 625\u2013634. [CrossRef] [PubMed] 33.",
            "scholar_url": "https://scholar.google.co.uk/scholar?q=Ueno%2C%20S.%20Bracamontes%2C%20J.%20Zorumski%2C%20C.%20Weiss%2C%20D.S.%20Bicuculline%20and%20gabazine%20are%20allosteric%20inhibitors%20of%20channel%20opening%20of%20the%20GABA%20A%20receptor%201997",
            "oa_query": "https://sandbox-api.scholarcy.com/oa_version?query=Ueno%2C%20S.%20Bracamontes%2C%20J.%20Zorumski%2C%20C.%20Weiss%2C%20D.S.%20Bicuculline%20and%20gabazine%20are%20allosteric%20inhibitors%20of%20channel%20opening%20of%20the%20GABA%20A%20receptor%201997",
            "scite": "https://sandbox-api.scholarcy.com/scite_url?query=Ueno%2C%20S.%20Bracamontes%2C%20J.%20Zorumski%2C%20C.%20Weiss%2C%20D.S.%20Bicuculline%20and%20gabazine%20are%20allosteric%20inhibitors%20of%20channel%20opening%20of%20the%20GABA%20A%20receptor%201997"
        },
        {
            "id": "Holla_et+al_2002_a",
            "alt_id": "27",
            "entry": "Holla, B.S.; Poorjary, K.N.; Rao, B.S.; Shivananda, M.K. New bis-aminomercaptotriazoles and bis-triazolothiadiazoles as possible anticancer agents. Eur. J. Med. Chem. 2002, 37, 511\u2013517. [CrossRef] 34.",
            "scholar_url": "https://scholar.google.co.uk/scholar?q=Holla%2C%20B.S.%20Poorjary%2C%20K.N.%20Rao%2C%20B.S.%20Shivananda%2C%20M.K.%20New%20bis-aminomercaptotriazoles%20and%20bis-triazolothiadiazoles%20as%20possible%20anticancer%20agents%202002",
            "oa_query": "https://sandbox-api.scholarcy.com/oa_version?query=Holla%2C%20B.S.%20Poorjary%2C%20K.N.%20Rao%2C%20B.S.%20Shivananda%2C%20M.K.%20New%20bis-aminomercaptotriazoles%20and%20bis-triazolothiadiazoles%20as%20possible%20anticancer%20agents%202002",
            "scite": "https://sandbox-api.scholarcy.com/scite_url?query=Holla%2C%20B.S.%20Poorjary%2C%20K.N.%20Rao%2C%20B.S.%20Shivananda%2C%20M.K.%20New%20bis-aminomercaptotriazoles%20and%20bis-triazolothiadiazoles%20as%20possible%20anticancer%20agents%202002"
        },
        {
            "id": "Yousif_et+al_2013_a",
            "alt_id": "28",
            "entry": "Yousif, E.; Majeed, A.; Al-Sammarrae, K.; Salih, N.; Salimon, J.; Abdullah, B. Metal complexes of Schiff base: preparation, characterization and antibacterial activity. Arabian J. Chem. 2013, 5. [CrossRef] 35.",
            "scholar_url": "https://scholar.google.co.uk/scholar?q=Yousif%2C%20E.%20Majeed%2C%20A.%20Al-Sammarrae%2C%20K.%20Salih%2C%20N.%20Metal%20complexes%20of%20Schiff%20base%3A%20preparation%2C%20characterization%20and%20antibacterial%20activity%202013",
            "oa_query": "https://sandbox-api.scholarcy.com/oa_version?query=Yousif%2C%20E.%20Majeed%2C%20A.%20Al-Sammarrae%2C%20K.%20Salih%2C%20N.%20Metal%20complexes%20of%20Schiff%20base%3A%20preparation%2C%20characterization%20and%20antibacterial%20activity%202013",
            "scite": "https://sandbox-api.scholarcy.com/scite_url?query=Yousif%2C%20E.%20Majeed%2C%20A.%20Al-Sammarrae%2C%20K.%20Salih%2C%20N.%20Metal%20complexes%20of%20Schiff%20base%3A%20preparation%2C%20characterization%20and%20antibacterial%20activity%202013"
        },
        {
            "id": "Juszczak_et+al_2008_a",
            "alt_id": "29",
            "entry": "Juszczak, M.; Matysiak, J.; Brzana, W.; Niewiadomy, A.; Rzeski, W. Evaluation of antiproliferative activity of 2-(monohalogenophenylamino)-5-(2,4-dihydroxyphenyl)-1,3,4-thiadiazoles. Arzneim. Forsch. Drug Res. 2008, 58, 353\u2013357. [CrossRef] 36.",
            "scholar_url": "https://scholar.google.co.uk/scholar?q=Juszczak%2C%20M.%20Matysiak%2C%20J.%20Brzana%2C%20W.%20Niewiadomy%2C%20A.%20Evaluation%20of%20antiproliferative%20activity%20of%202-%28monohalogenophenylamino%29-5-%282%2C4-dihydroxyphenyl%29-1%2C3%2C4-thiadiazoles.%20Arzneim.%20Forsch%202008",
            "oa_query": "https://sandbox-api.scholarcy.com/oa_version?query=Juszczak%2C%20M.%20Matysiak%2C%20J.%20Brzana%2C%20W.%20Niewiadomy%2C%20A.%20Evaluation%20of%20antiproliferative%20activity%20of%202-%28monohalogenophenylamino%29-5-%282%2C4-dihydroxyphenyl%29-1%2C3%2C4-thiadiazoles.%20Arzneim.%20Forsch%202008",
            "scite": "https://sandbox-api.scholarcy.com/scite_url?query=Juszczak%2C%20M.%20Matysiak%2C%20J.%20Brzana%2C%20W.%20Niewiadomy%2C%20A.%20Evaluation%20of%20antiproliferative%20activity%20of%202-%28monohalogenophenylamino%29-5-%282%2C4-dihydroxyphenyl%29-1%2C3%2C4-thiadiazoles.%20Arzneim.%20Forsch%202008"
        },
        {
            "id": "Matysiak_2006_a",
            "alt_id": "30",
            "entry": "Matysiak, J. Evaluation of antiproliferative effect in vitro of some 2-amino-5-(2,4-dihydroxyphenyl)-1,3,4thiadiazole derivatives. Chem. Pharm. Bull. 2006, 54, 988\u2013991. [CrossRef] [PubMed] 37.",
            "scholar_url": "https://scholar.google.co.uk/scholar?q=Matysiak%2C%20J.%20Evaluation%20of%20antiproliferative%20effect%20in%20vitro%20of%20some%202-amino-5-%282%2C4-dihydroxyphenyl%29-1%2C3%2C4thiadiazole%20derivatives%202006",
            "oa_query": "https://sandbox-api.scholarcy.com/oa_version?query=Matysiak%2C%20J.%20Evaluation%20of%20antiproliferative%20effect%20in%20vitro%20of%20some%202-amino-5-%282%2C4-dihydroxyphenyl%29-1%2C3%2C4thiadiazole%20derivatives%202006",
            "scite": "https://sandbox-api.scholarcy.com/scite_url?query=Matysiak%2C%20J.%20Evaluation%20of%20antiproliferative%20effect%20in%20vitro%20of%20some%202-amino-5-%282%2C4-dihydroxyphenyl%29-1%2C3%2C4thiadiazole%20derivatives%202006"
        },
        {
            "id": "Yoosefian_et+al_2015_a",
            "alt_id": "31",
            "entry": "Yoosefian, M.; Chermahini, Z.J.; Raissi, H.; Mola, A.; Sadeghi, M. A theoretical study on the structure of 2-amino-1,3,4-thiadiazole and its 5-substituted derivatives in the gas phase, water, THF and DMSO solutions. J. Mol. Liq. 2015, 203, 137\u2013142. [CrossRef] 38.",
            "scholar_url": "https://scholar.google.co.uk/scholar?q=Yoosefian%2C%20M.%20Chermahini%2C%20Z.J.%20Raissi%2C%20H.%20Mola%2C%20A.%20A%20theoretical%20study%20on%20the%20structure%20of%202-amino-1%2C3%2C4-thiadiazole%20and%20its%205-substituted%20derivatives%20in%20the%20gas%20phase%2C%20water%2C%20THF%20and%20DMSO%20solutions%202015",
            "oa_query": "https://sandbox-api.scholarcy.com/oa_version?query=Yoosefian%2C%20M.%20Chermahini%2C%20Z.J.%20Raissi%2C%20H.%20Mola%2C%20A.%20A%20theoretical%20study%20on%20the%20structure%20of%202-amino-1%2C3%2C4-thiadiazole%20and%20its%205-substituted%20derivatives%20in%20the%20gas%20phase%2C%20water%2C%20THF%20and%20DMSO%20solutions%202015",
            "scite": "https://sandbox-api.scholarcy.com/scite_url?query=Yoosefian%2C%20M.%20Chermahini%2C%20Z.J.%20Raissi%2C%20H.%20Mola%2C%20A.%20A%20theoretical%20study%20on%20the%20structure%20of%202-amino-1%2C3%2C4-thiadiazole%20and%20its%205-substituted%20derivatives%20in%20the%20gas%20phase%2C%20water%2C%20THF%20and%20DMSO%20solutions%202015"
        },
        {
            "id": "Serban_0000_a",
            "alt_id": "32",
            "entry": "Serban, G. 2-Amino-1,3,4-thiadiazoles as prospective agents in trypanosomiasis and other parasitoses. Acta Pharm. 2020, 70, 259\u2013290. [CrossRef] [PubMed] 39.",
            "scholar_url": "https://scholar.google.co.uk/scholar?q=Serban%2C%20G.%202-Amino-1%2C3%2C4-thiadiazoles%20as%20prospective%20agents%20in%20trypanosomiasis%20and%20other%20parasitoses",
            "oa_query": "https://sandbox-api.scholarcy.com/oa_version?query=Serban%2C%20G.%202-Amino-1%2C3%2C4-thiadiazoles%20as%20prospective%20agents%20in%20trypanosomiasis%20and%20other%20parasitoses",
            "scite": "https://sandbox-api.scholarcy.com/scite_url?query=Serban%2C%20G.%202-Amino-1%2C3%2C4-thiadiazoles%20as%20prospective%20agents%20in%20trypanosomiasis%20and%20other%20parasitoses"
        },
        {
            "id": "Serban_2015_a",
            "alt_id": "33",
            "entry": "Serban, G. 5-Arylamino-1,3,4-thiadiazol-2-yl acetic acid esters as intermediates for the synthesis of new bisheterocyclic compounds. Farmacia 2015, 63, 146\u2013149.",
            "scholar_url": "https://scholar.google.co.uk/scholar?q=Serban%2C%20G.%205-Arylamino-1%2C3%2C4-thiadiazol-2-yl%20acetic%20acid%20esters%20as%20intermediates%20for%20the%20synthesis%20of%20new%20bisheterocyclic%20compounds%202015",
            "oa_query": "https://sandbox-api.scholarcy.com/oa_version?query=Serban%2C%20G.%205-Arylamino-1%2C3%2C4-thiadiazol-2-yl%20acetic%20acid%20esters%20as%20intermediates%20for%20the%20synthesis%20of%20new%20bisheterocyclic%20compounds%202015",
            "scite": "https://sandbox-api.scholarcy.com/scite_url?query=Serban%2C%20G.%205-Arylamino-1%2C3%2C4-thiadiazol-2-yl%20acetic%20acid%20esters%20as%20intermediates%20for%20the%20synthesis%20of%20new%20bisheterocyclic%20compounds%202015"
        },
        {
            "id": "40",
            "alt_id": "Serban_et+al_2005_a",
            "entry": "40. Serban, G.; Coman, M.; Curea, E. Synthesis of some heterocyclic nitro\u2013coumarins by Knoevenagel condensation. Farmacia 2005, 53, 78\u201384.",
            "scholar_url": "https://scholar.google.co.uk/scholar?q=Serban%2C%20G.%20Coman%2C%20M.%20Curea%2C%20E.%20Synthesis%20of%20some%20heterocyclic%20nitro%E2%80%93coumarins%20by%20Knoevenagel%20condensation%202005",
            "oa_query": "https://sandbox-api.scholarcy.com/oa_version?query=Serban%2C%20G.%20Coman%2C%20M.%20Curea%2C%20E.%20Synthesis%20of%20some%20heterocyclic%20nitro%E2%80%93coumarins%20by%20Knoevenagel%20condensation%202005",
            "scite": "https://sandbox-api.scholarcy.com/scite_url?query=Serban%2C%20G.%20Coman%2C%20M.%20Curea%2C%20E.%20Synthesis%20of%20some%20heterocyclic%20nitro%E2%80%93coumarins%20by%20Knoevenagel%20condensation%202005"
        },
        {
            "id": "41",
            "alt_id": "Serban_et+al_2005_b",
            "entry": "41. Serban, G.; Matinca, D.; Bradea, O.; Gherman, L.; Coman, M.; Curea, E. The study of the biological activity of some heterocyclic coumarins. Farmacia 2005, 53, 91\u201399.",
            "scholar_url": "https://scholar.google.co.uk/scholar?q=Serban%2C%20G.%20Matinca%2C%20D.%20Bradea%2C%20O.%20Gherman%2C%20L.%20The%20study%20of%20the%20biological%20activity%20of%20some%20heterocyclic%20coumarins%202005",
            "oa_query": "https://sandbox-api.scholarcy.com/oa_version?query=Serban%2C%20G.%20Matinca%2C%20D.%20Bradea%2C%20O.%20Gherman%2C%20L.%20The%20study%20of%20the%20biological%20activity%20of%20some%20heterocyclic%20coumarins%202005",
            "scite": "https://sandbox-api.scholarcy.com/scite_url?query=Serban%2C%20G.%20Matinca%2C%20D.%20Bradea%2C%20O.%20Gherman%2C%20L.%20The%20study%20of%20the%20biological%20activity%20of%20some%20heterocyclic%20coumarins%202005"
        },
        {
            "id": "42",
            "alt_id": "Serban_et+al_2002_a",
            "entry": "42. Serban, G.; Suciu, A.; Coman, M.; Curea, E. Synthesis and physical-chemical study of some 3-(5-arylamino-1,3,4-thiadiazol-2-yl)cou\u2013marins. Farmacia 2002, 50, 50\u201354.",
            "scholar_url": "https://scholar.google.co.uk/scholar?q=Serban%2C%20G.%20Suciu%2C%20A.%20Coman%2C%20M.%20Curea%2C%20E.%20Synthesis%20and%20physical-chemical%20study%20of%20some%203-%285-arylamino-1%2C3%2C4-thiadiazol-2-yl%29cou%E2%80%93marins%202002",
            "oa_query": "https://sandbox-api.scholarcy.com/oa_version?query=Serban%2C%20G.%20Suciu%2C%20A.%20Coman%2C%20M.%20Curea%2C%20E.%20Synthesis%20and%20physical-chemical%20study%20of%20some%203-%285-arylamino-1%2C3%2C4-thiadiazol-2-yl%29cou%E2%80%93marins%202002",
            "scite": "https://sandbox-api.scholarcy.com/scite_url?query=Serban%2C%20G.%20Suciu%2C%20A.%20Coman%2C%20M.%20Curea%2C%20E.%20Synthesis%20and%20physical-chemical%20study%20of%20some%203-%285-arylamino-1%2C3%2C4-thiadiazol-2-yl%29cou%E2%80%93marins%202002"
        },
        {
            "id": "43",
            "alt_id": "Horvath_et+al_2014_a",
            "entry": "43. Horvath, T.; Serban, G.; Cuc, S. Synthesis of new 2-phenylamino-5-[(\u03b1-acylamino)-p-X-stiryl] -1,3,4-thiadiazole compounds. Farmacia 2014, 62, 422\u2013427.",
            "scholar_url": "https://scholar.google.co.uk/scholar?q=Horvath%2C%20T.%20Serban%2C%20G.%20Cuc%2C%20S.%20Synthesis%20of%20new%202-phenylamino-5-%5B%28%CE%B1-acylamino%29-p-X-stiryl%5D%20-1%2C3%2C4-thiadiazole%20compounds%202014",
            "oa_query": "https://sandbox-api.scholarcy.com/oa_version?query=Horvath%2C%20T.%20Serban%2C%20G.%20Cuc%2C%20S.%20Synthesis%20of%20new%202-phenylamino-5-%5B%28%CE%B1-acylamino%29-p-X-stiryl%5D%20-1%2C3%2C4-thiadiazole%20compounds%202014",
            "scite": "https://sandbox-api.scholarcy.com/scite_url?query=Horvath%2C%20T.%20Serban%2C%20G.%20Cuc%2C%20S.%20Synthesis%20of%20new%202-phenylamino-5-%5B%28%CE%B1-acylamino%29-p-X-stiryl%5D%20-1%2C3%2C4-thiadiazole%20compounds%202014"
        },
        {
            "id": "44",
            "alt_id": "Serban_et+al_2001_a",
            "entry": "44. Serban, G.; Coman, M.; Curea, E.; Proinov, L. Synthesis and description of some heterocyclic coumarins. Farmacia 2001, 49, 45\u201352.",
            "scholar_url": "https://scholar.google.co.uk/scholar?q=Serban%2C%20G.%20Coman%2C%20M.%20Curea%2C%20E.%20Proinov%2C%20L.%20Synthesis%20and%20description%20of%20some%20heterocyclic%20coumarins%202001",
            "oa_query": "https://sandbox-api.scholarcy.com/oa_version?query=Serban%2C%20G.%20Coman%2C%20M.%20Curea%2C%20E.%20Proinov%2C%20L.%20Synthesis%20and%20description%20of%20some%20heterocyclic%20coumarins%202001",
            "scite": "https://sandbox-api.scholarcy.com/scite_url?query=Serban%2C%20G.%20Coman%2C%20M.%20Curea%2C%20E.%20Proinov%2C%20L.%20Synthesis%20and%20description%20of%20some%20heterocyclic%20coumarins%202001"
        },
        {
            "id": "45",
            "alt_id": "45._2016_a",
            "entry": "45. Global AIDS Update 2016. Joint United Nations Programme on HIV/AIDS, Geneva, Switzerland. Available online: https://www.unaids.org/sites/default/files/media_asset/global-AIDS-update-2016en.pdf (accessed on 17 July 2018).",
            "url": "https://www.unaids.org/sites/default/files/media_asset/global-AIDS-update-2016en.pdf"
        },
        {
            "id": "46",
            "alt_id": "Sharma_et+al_2013_a",
            "entry": "46. Sharma, P.C.; Sinhmar, A.; Sharma, A.; Rajak, H.; Pathak, D.P. Medicinal significance of benzothiazole scaffold: An insight view. J. Enzyme Inhib. Med. Chem. 2013, 28, 240\u2013266. [CrossRef]",
            "scholar_url": "https://scholar.google.co.uk/scholar?q=Sharma%2C%20P.C.%20Sinhmar%2C%20A.%20Sharma%2C%20A.%20Rajak%2C%20H.%20Medicinal%20significance%20of%20benzothiazole%20scaffold%3A%20An%20insight%20view%202013",
            "oa_query": "https://sandbox-api.scholarcy.com/oa_version?query=Sharma%2C%20P.C.%20Sinhmar%2C%20A.%20Sharma%2C%20A.%20Rajak%2C%20H.%20Medicinal%20significance%20of%20benzothiazole%20scaffold%3A%20An%20insight%20view%202013",
            "scite": "https://sandbox-api.scholarcy.com/scite_url?query=Sharma%2C%20P.C.%20Sinhmar%2C%20A.%20Sharma%2C%20A.%20Rajak%2C%20H.%20Medicinal%20significance%20of%20benzothiazole%20scaffold%3A%20An%20insight%20view%202013"
        },
        {
            "id": "47",
            "alt_id": "Xiaohe_et+al_2010_a",
            "entry": "47. Xiaohe, Z.; Yu, Q.; Hong, Y.; Xiuqing, S.; Rugang, Z. Synthesis, biological evaluation and molecular modeling studies of N-aryl-2-arylthioacetamides as non-nucleoside HIV-1 reverse transcriptase inhibitors. Chem. Biol. Drug Des. 2010, 76, 330\u2013339. [CrossRef] [PubMed]",
            "scholar_url": "https://scholar.google.co.uk/scholar?q=Xiaohe%2C%20Z.%20Yu%2C%20Q.%20Hong%2C%20Y.%20Xiuqing%2C%20S.%20Synthesis%2C%20biological%20evaluation%20and%20molecular%20modeling%20studies%20of%20N-aryl-2-arylthioacetamides%20as%20non-nucleoside%20HIV-1%20reverse%20transcriptase%20inhibitors%202010",
            "oa_query": "https://sandbox-api.scholarcy.com/oa_version?query=Xiaohe%2C%20Z.%20Yu%2C%20Q.%20Hong%2C%20Y.%20Xiuqing%2C%20S.%20Synthesis%2C%20biological%20evaluation%20and%20molecular%20modeling%20studies%20of%20N-aryl-2-arylthioacetamides%20as%20non-nucleoside%20HIV-1%20reverse%20transcriptase%20inhibitors%202010",
            "scite": "https://sandbox-api.scholarcy.com/scite_url?query=Xiaohe%2C%20Z.%20Yu%2C%20Q.%20Hong%2C%20Y.%20Xiuqing%2C%20S.%20Synthesis%2C%20biological%20evaluation%20and%20molecular%20modeling%20studies%20of%20N-aryl-2-arylthioacetamides%20as%20non-nucleoside%20HIV-1%20reverse%20transcriptase%20inhibitors%202010"
        },
        {
            "id": "48",
            "alt_id": "Harms_2007_a",
            "entry": "48. Harms, A. Non-nucleoside reverse transcriptase inhibitors. In The art of drug synthesis; Johnson, D.S., Li, J.J., Eds.; Wiley Interscience, John Wiley and Sons, Inc., Hoboken: New Jersey, NJ, USA, 2007; p. 84.",
            "scholar_url": "https://scholar.google.co.uk/scholar?q=Harms%2C%20A.%20Non-nucleoside%20reverse%20transcriptase%20inhibitors.%20In%20The%20art%20of%20drug%20synthesis%202007"
        },
        {
            "id": "49",
            "alt_id": "Tatar_et+al_2015_a",
            "entry": "49. Tatar, E.; Kucukguzel, S.G.; Karakus, S.; De Clercq, E.; Andrei, G.; Snoeck, R.; Pannecouque, C.; OktemOkullu, S.; Unubol, N.; Kocagoz, T.; et al. Synthesis and biological evaluation of some new 1,3,4-thiadiazole and 1,2,4-triazole derivatives from L-methionine as antituberculosis and antiviral agents. Marmara Pharm. J. 2015, 19, 88\u2013102. [CrossRef]",
            "scholar_url": "https://scholar.google.co.uk/scholar?q=Tatar%2C%20E.%20Kucukguzel%2C%20S.G.%20Karakus%2C%20S.%20De%20Clercq%2C%20E.%20Synthesis%20and%20biological%20evaluation%20of%20some%20new%201%2C3%2C4-thiadiazole%20and%201%2C2%2C4-triazole%20derivatives%20from%20L-methionine%20as%20antituberculosis%20and%20antiviral%20agents%202015",
            "oa_query": "https://sandbox-api.scholarcy.com/oa_version?query=Tatar%2C%20E.%20Kucukguzel%2C%20S.G.%20Karakus%2C%20S.%20De%20Clercq%2C%20E.%20Synthesis%20and%20biological%20evaluation%20of%20some%20new%201%2C3%2C4-thiadiazole%20and%201%2C2%2C4-triazole%20derivatives%20from%20L-methionine%20as%20antituberculosis%20and%20antiviral%20agents%202015",
            "scite": "https://sandbox-api.scholarcy.com/scite_url?query=Tatar%2C%20E.%20Kucukguzel%2C%20S.G.%20Karakus%2C%20S.%20De%20Clercq%2C%20E.%20Synthesis%20and%20biological%20evaluation%20of%20some%20new%201%2C3%2C4-thiadiazole%20and%201%2C2%2C4-triazole%20derivatives%20from%20L-methionine%20as%20antituberculosis%20and%20antiviral%20agents%202015"
        },
        {
            "id": "50",
            "alt_id": "Wit_et+al_2008_a",
            "entry": "50. Wit, F.W.N.M.; Lange, J.M.A.; Volberding, P.A. New HIV Drug Development. In Global HIV/AIDS Medicine; Volberding, P.A., Sande, M.A., Greene, W.C., Lange, J.M.A., Eds.; Elsevier: Philadelphia, PA, USA, 2008; pp. 123\u2013134.",
            "scholar_url": "https://scholar.google.co.uk/scholar?q=Wit%2C%20F.W.N.M.%20Lange%2C%20J.M.A.%20Volberding%2C%20P.A.%20New%20HIV%20Drug%20Development.%20In%20Global%20HIV/AIDS%20Medicine%202008"
        },
        {
            "id": "51",
            "alt_id": "Schiller_2009_a",
            "entry": "51. Schiller, D.S.; Youssef-Bessler, M. Etravirine: A second-generation nonnucleoside reverse transcriptase inhibitor (NNRTI) active against NNRTI-resistant strains of HIV. Clin. Ther. 2009, 31, 692\u2013704. [CrossRef] [PubMed]",
            "scholar_url": "https://scholar.google.co.uk/scholar?q=Schiller%2C%20D.S.%20Youssef-Bessler%2C%20M.%20Etravirine%3A%20A%20second-generation%20nonnucleoside%20reverse%20transcriptase%20inhibitor%20%28NNRTI%29%20active%20against%20NNRTI-resistant%20strains%20of%20HIV%202009",
            "oa_query": "https://sandbox-api.scholarcy.com/oa_version?query=Schiller%2C%20D.S.%20Youssef-Bessler%2C%20M.%20Etravirine%3A%20A%20second-generation%20nonnucleoside%20reverse%20transcriptase%20inhibitor%20%28NNRTI%29%20active%20against%20NNRTI-resistant%20strains%20of%20HIV%202009",
            "scite": "https://sandbox-api.scholarcy.com/scite_url?query=Schiller%2C%20D.S.%20Youssef-Bessler%2C%20M.%20Etravirine%3A%20A%20second-generation%20nonnucleoside%20reverse%20transcriptase%20inhibitor%20%28NNRTI%29%20active%20against%20NNRTI-resistant%20strains%20of%20HIV%202009"
        },
        {
            "id": "52",
            "alt_id": "Miller_et+al_2011_a",
            "entry": "52. Miller, C.D.; Crain, J.; Tran, B.; Patel, N. Rilpivirine: A new addition to the anti-HIV-1 armamentarium. Drugs Today 2011, 47, 5\u201315. [CrossRef] [PubMed]",
            "scholar_url": "https://scholar.google.co.uk/scholar?q=Miller%2C%20C.D.%20Crain%2C%20J.%20Tran%2C%20B.%20Patel%2C%20N.%20Rilpivirine%3A%20A%20new%20addition%20to%20the%20anti-HIV-1%20armamentarium%202011",
            "oa_query": "https://sandbox-api.scholarcy.com/oa_version?query=Miller%2C%20C.D.%20Crain%2C%20J.%20Tran%2C%20B.%20Patel%2C%20N.%20Rilpivirine%3A%20A%20new%20addition%20to%20the%20anti-HIV-1%20armamentarium%202011",
            "scite": "https://sandbox-api.scholarcy.com/scite_url?query=Miller%2C%20C.D.%20Crain%2C%20J.%20Tran%2C%20B.%20Patel%2C%20N.%20Rilpivirine%3A%20A%20new%20addition%20to%20the%20anti-HIV-1%20armamentarium%202011"
        },
        {
            "id": "53",
            "alt_id": "53._0000_b",
            "entry": "53. Doravirine combination pill looks good for initial HIV treatment. Available online: https://www.aidsmap.com/news/jul-2017/doravirine-combination-pill-looks-good-initial-hiv-treatment;http://www.aidsmap.com/Doravirine-combination-pill-looks-good-for-initial-HIV-treatment/pagee3160520 (accessed on 5 June 2018).",
            "url": "https://www.aidsmap.com/news/jul-2017/doravirine-combination-pill-looks-good-initial-hiv-treatment;http://www.aidsmap.com/Doravirine-combination-pill-looks-good-for-initial-HIV-treatment/pagee3160520"
        },
        {
            "id": "54",
            "alt_id": "Gatell_et+al_2016_a",
            "entry": "54. Gatell, J.M.; Raffi, F.; Plettenberg, A.; Smith, D.; Portilla, J.; Hoffmann, C.; Arasteh, K.; Thompson, M.; Xu, X.; Teppler, H. Doravirine 100 mg QD vs Efavirenz + TDF/FTC in ART-Naive HIV+ Patients: Week 48 Results. In Proceedings of the Conference on Retroviruses and Opportunistic Infections, Boston, MA, USA, 22\u201325 February 2016. abstract number 470.",
            "scholar_url": "https://scholar.google.co.uk/scholar?q=Gatell%2C%20J.M.%20Raffi%2C%20F.%20Plettenberg%2C%20A.%20Smith%2C%20D.%20Doravirine%20100%20mg%20QD%20vs%20Efavirenz%20%2B%20TDF/FTC%20in%20ART-Naive%20HIV%2B%20Patients%3A%20Week%2048%20Results%202016-02-22",
            "oa_query": "https://sandbox-api.scholarcy.com/oa_version?query=Gatell%2C%20J.M.%20Raffi%2C%20F.%20Plettenberg%2C%20A.%20Smith%2C%20D.%20Doravirine%20100%20mg%20QD%20vs%20Efavirenz%20%2B%20TDF/FTC%20in%20ART-Naive%20HIV%2B%20Patients%3A%20Week%2048%20Results%202016-02-22",
            "scite": "https://sandbox-api.scholarcy.com/scite_url?query=Gatell%2C%20J.M.%20Raffi%2C%20F.%20Plettenberg%2C%20A.%20Smith%2C%20D.%20Doravirine%20100%20mg%20QD%20vs%20Efavirenz%20%2B%20TDF/FTC%20in%20ART-Naive%20HIV%2B%20Patients%3A%20Week%2048%20Results%202016-02-22"
        },
        {
            "id": "55",
            "alt_id": "55._0000_c",
            "entry": "55. FDA Accepts New Drug Applications for Merck\u2019s Doravirine, the Company\u2019s Investigational Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI), for Treatment of HIV-1 Infection. Available online: http://investors.merck.com/news/press-release-details/2018/FDA-Accepts-New-Drug-Applications-forMercks-Doravirine-the-Companys-Investigational-Non-Nucleoside-Reverse-Transcriptase-InhibitorNNRTI-for-Treatment-of-HIV-1-Infection/default.aspx (accessed on 5 June 2018).",
            "url": "http://investors.merck.com/news/press-release-details/2018/FDA-Accepts-New-Drug-Applications-forMercks-Doravirine-the-Companys-Investigational-Non-Nucleoside-Reverse-Transcriptase-InhibitorNNRTI-for-Treatment-of-HIV-1-Infection/default.aspx"
        },
        {
            "id": "56",
            "alt_id": "56._0000_d",
            "entry": "56. FDA approves Merck\u2019s Pifeltro (doravirine). Available online: https://www.drugs.com/newdrugs/fdaapproves-merck-s-pifeltro-doravirine-hiv-1-appropriate-patients-4815.html (accessed on 6 November 2019). 20 September 2019. Available online: https://investors.merck.com/news/press-release-details/2019/Mercks-PIFELTROdoravirine-and-DELSTRIGO-doravirinelamivudinetenofovir-disoproxil-fumarate-Receive-US-FDAApproval-for-Use-in-Appropriate-Adults-Living-with-HIV-1-Who-Are-Virologically-Suppressed/default.aspx (accessed on 6 November 2019).",
            "url": "https://www.drugs.com/newdrugs/fdaapproves-merck-s-pifeltro-doravirine-hiv-1-appropriate-patients-4815.html"
        },
        {
            "id": "58",
            "alt_id": "Margolis_et+al_2014_a",
            "entry": "58. Margolis, D.A.; Eron, J.J.; DeJesus, E.; White, S.; Wannamaker, P.; Stancil, B.; Johnson, M. Unexpected finding of delayed-onset seizures in HIV-positive, treatment-experienced subjects in the Phase IIb evaluation of fosdevirine (GSK2248761). Antivir. Ther. 2014, 19, 69\u201378. [CrossRef]",
            "scholar_url": "https://scholar.google.co.uk/scholar?q=Margolis%2C%20D.A.%20Eron%2C%20J.J.%20DeJesus%2C%20E.%20White%2C%20S.%20Unexpected%20finding%20of%20delayed-onset%20seizures%20in%20HIV-positive%2C%20treatment-experienced%20subjects%20in%20the%20Phase%20IIb%20evaluation%20of%20fosdevirine%20%28GSK2248761%29.%20Antivir%202014"
        },
        {
            "id": "59",
            "alt_id": "Vernazza_et+al_2013_a",
            "entry": "59. Vernazza, P.; Wang, C.; Pozniak, A.; Weil, E.; Pulik, P.; Cooper, D.A.; Kaplan, R.; Lazzarin, A.; Valdez, H.; Goodrich, J.; et al. Efficacy and safety of lersivirine (UK-453,061) versus efavirenz in antiretroviral treatment-naive HIV-1 infected patients: week 48 primary analysis results from an ongoing, multicenter, randomized, double-blind, Phase IIb trial. J. Acquir. Immune Defic. Syndr. 2013, 62, 171\u2013179. [CrossRef]",
            "scholar_url": "https://scholar.google.co.uk/scholar?q=Vernazza%2C%20P.%20Wang%2C%20C.%20Pozniak%2C%20A.%20Weil%2C%20E.%20Efficacy%20and%20safety%20of%20lersivirine%20%28UK-453%2C061%29%20versus%20efavirenz%20in%20antiretroviral%20treatment-naive%20HIV-1%20infected%20patients%3A%20week%2048%20primary%20analysis%20results%20from%20an%20ongoing%2C%20multicenter%2C%20randomized%2C%20double-blind%2C%20Phase%20IIb%20trial%202013",
            "oa_query": "https://sandbox-api.scholarcy.com/oa_version?query=Vernazza%2C%20P.%20Wang%2C%20C.%20Pozniak%2C%20A.%20Weil%2C%20E.%20Efficacy%20and%20safety%20of%20lersivirine%20%28UK-453%2C061%29%20versus%20efavirenz%20in%20antiretroviral%20treatment-naive%20HIV-1%20infected%20patients%3A%20week%2048%20primary%20analysis%20results%20from%20an%20ongoing%2C%20multicenter%2C%20randomized%2C%20double-blind%2C%20Phase%20IIb%20trial%202013",
            "scite": "https://sandbox-api.scholarcy.com/scite_url?query=Vernazza%2C%20P.%20Wang%2C%20C.%20Pozniak%2C%20A.%20Weil%2C%20E.%20Efficacy%20and%20safety%20of%20lersivirine%20%28UK-453%2C061%29%20versus%20efavirenz%20in%20antiretroviral%20treatment-naive%20HIV-1%20infected%20patients%3A%20week%2048%20primary%20analysis%20results%20from%20an%20ongoing%2C%20multicenter%2C%20randomized%2C%20double-blind%2C%20Phase%20IIb%20trial%202013"
        },
        {
            "id": "60",
            "alt_id": "Platten_2013_a",
            "entry": "60. Platten, M.; Fatkenheuer, G. Lersavirine\u2014a new drug for HIV infection therapy. Expert. Opin. Investig. Drugs 2013, 22, 1687\u20131694. [CrossRef]",
            "scholar_url": "https://scholar.google.co.uk/scholar?q=Platten%2C%20M.%20Fatkenheuer%2C%20G.%20Lersavirine%E2%80%94a%20new%20drug%20for%20HIV%20infection%20therapy%202013",
            "oa_query": "https://sandbox-api.scholarcy.com/oa_version?query=Platten%2C%20M.%20Fatkenheuer%2C%20G.%20Lersavirine%E2%80%94a%20new%20drug%20for%20HIV%20infection%20therapy%202013",
            "scite": "https://sandbox-api.scholarcy.com/scite_url?query=Platten%2C%20M.%20Fatkenheuer%2C%20G.%20Lersavirine%E2%80%94a%20new%20drug%20for%20HIV%20infection%20therapy%202013"
        },
        {
            "id": "61",
            "alt_id": "Sacks_et+al_2017_a",
            "entry": "61. Sacks, D.; Ledwaba, J.; Morris, L.; Hunt, G.M. Rapid detection of common HIV-1 drug resistance mutations by use of high-resolution melting analysis and unlabeled probes. J. Clin. Microbiol. 2017, 55, 122\u2013133. [CrossRef]",
            "scholar_url": "https://scholar.google.co.uk/scholar?q=Sacks%2C%20D.%20Ledwaba%2C%20J.%20Morris%2C%20L.%20Hunt%2C%20G.M.%20Rapid%20detection%20of%20common%20HIV-1%20drug%20resistance%20mutations%20by%20use%20of%20high-resolution%20melting%20analysis%20and%20unlabeled%20probes%202017",
            "oa_query": "https://sandbox-api.scholarcy.com/oa_version?query=Sacks%2C%20D.%20Ledwaba%2C%20J.%20Morris%2C%20L.%20Hunt%2C%20G.M.%20Rapid%20detection%20of%20common%20HIV-1%20drug%20resistance%20mutations%20by%20use%20of%20high-resolution%20melting%20analysis%20and%20unlabeled%20probes%202017",
            "scite": "https://sandbox-api.scholarcy.com/scite_url?query=Sacks%2C%20D.%20Ledwaba%2C%20J.%20Morris%2C%20L.%20Hunt%2C%20G.M.%20Rapid%20detection%20of%20common%20HIV-1%20drug%20resistance%20mutations%20by%20use%20of%20high-resolution%20melting%20analysis%20and%20unlabeled%20probes%202017"
        },
        {
            "id": "62",
            "alt_id": "Yahi_et+al_1999_a",
            "entry": "62. Yahi, N.; Tamalet, C.; Tourres, C.; Tivoli, N.; Ariasi, F.; Volot, F.; Gastaut, J.A.; Gallais, H.; Moreau, J.; Fantini, J. Mutation patterns of the reverse transcriptase and protease genes in Human Immunodeficiency Virus type 1-infected patients undergoing combination therapy: survey of 787 sequences. J. Clin. Microbiol. 1999, 37, 4099\u20134106. [CrossRef]",
            "scholar_url": "https://scholar.google.co.uk/scholar?q=Yahi%2C%20N.%20Tamalet%2C%20C.%20Tourres%2C%20C.%20Tivoli%2C%20N.%20Mutation%20patterns%20of%20the%20reverse%20transcriptase%20and%20protease%20genes%20in%20Human%20Immunodeficiency%20Virus%20type%201-infected%20patients%20undergoing%20combination%20therapy%3A%20survey%20of%20787%20sequences%201999",
            "oa_query": "https://sandbox-api.scholarcy.com/oa_version?query=Yahi%2C%20N.%20Tamalet%2C%20C.%20Tourres%2C%20C.%20Tivoli%2C%20N.%20Mutation%20patterns%20of%20the%20reverse%20transcriptase%20and%20protease%20genes%20in%20Human%20Immunodeficiency%20Virus%20type%201-infected%20patients%20undergoing%20combination%20therapy%3A%20survey%20of%20787%20sequences%201999",
            "scite": "https://sandbox-api.scholarcy.com/scite_url?query=Yahi%2C%20N.%20Tamalet%2C%20C.%20Tourres%2C%20C.%20Tivoli%2C%20N.%20Mutation%20patterns%20of%20the%20reverse%20transcriptase%20and%20protease%20genes%20in%20Human%20Immunodeficiency%20Virus%20type%201-infected%20patients%20undergoing%20combination%20therapy%3A%20survey%20of%20787%20sequences%201999"
        },
        {
            "id": "63",
            "alt_id": "Hu_et+al_2014_a",
            "entry": "63. Hu, Y.; Li, C.Y.; Wang, X.M.; Yang, Y.H.; Zhu, H.L. 1,3,4-Thiadiazole: synthesis, reactions and applications in medicinal, agricultural, and materials chemistry. Chem. Rev. 2014, 114, 5572\u20135610. [CrossRef]",
            "scholar_url": "https://scholar.google.co.uk/scholar?q=Hu%2C%20Y.%20Li%2C%20C.Y.%20Wang%2C%20X.M.%20Yang%2C%20Y.H.%201%2C3%2C4-Thiadiazole%3A%20synthesis%2C%20reactions%20and%20applications%20in%20medicinal%2C%20agricultural%2C%20and%20materials%20chemistry%202014",
            "oa_query": "https://sandbox-api.scholarcy.com/oa_version?query=Hu%2C%20Y.%20Li%2C%20C.Y.%20Wang%2C%20X.M.%20Yang%2C%20Y.H.%201%2C3%2C4-Thiadiazole%3A%20synthesis%2C%20reactions%20and%20applications%20in%20medicinal%2C%20agricultural%2C%20and%20materials%20chemistry%202014",
            "scite": "https://sandbox-api.scholarcy.com/scite_url?query=Hu%2C%20Y.%20Li%2C%20C.Y.%20Wang%2C%20X.M.%20Yang%2C%20Y.H.%201%2C3%2C4-Thiadiazole%3A%20synthesis%2C%20reactions%20and%20applications%20in%20medicinal%2C%20agricultural%2C%20and%20materials%20chemistry%202014"
        },
        {
            "id": "64",
            "alt_id": "Szulczyk_et+al_2017_a",
            "entry": "64. Szulczyk, D.; Tomaszewski, P.; Jozwiak, M.; Koziol, A.E.; Lis, T.; Collu, D.; Iuliano, F.; Struga, M. Synthesis and biological activities of ethyl 2-(2-pyridylacetate) derivatives containing thiourea, 1,2,4-triazole, thiadiazole and oxadiazole moieties. Molecules 2017, 22, 409. [CrossRef] [PubMed]",
            "scholar_url": "https://scholar.google.co.uk/scholar?q=Szulczyk%2C%20D.%20Tomaszewski%2C%20P.%20Jozwiak%2C%20M.%20Koziol%2C%20A.E.%20Synthesis%20and%20biological%20activities%20of%20ethyl%202-%282-pyridylacetate%29%20derivatives%20containing%20thiourea%2C%201%2C2%2C4-triazole%2C%20thiadiazole%20and%20oxadiazole%20moieties%202017",
            "oa_query": "https://sandbox-api.scholarcy.com/oa_version?query=Szulczyk%2C%20D.%20Tomaszewski%2C%20P.%20Jozwiak%2C%20M.%20Koziol%2C%20A.E.%20Synthesis%20and%20biological%20activities%20of%20ethyl%202-%282-pyridylacetate%29%20derivatives%20containing%20thiourea%2C%201%2C2%2C4-triazole%2C%20thiadiazole%20and%20oxadiazole%20moieties%202017",
            "scite": "https://sandbox-api.scholarcy.com/scite_url?query=Szulczyk%2C%20D.%20Tomaszewski%2C%20P.%20Jozwiak%2C%20M.%20Koziol%2C%20A.E.%20Synthesis%20and%20biological%20activities%20of%20ethyl%202-%282-pyridylacetate%29%20derivatives%20containing%20thiourea%2C%201%2C2%2C4-triazole%2C%20thiadiazole%20and%20oxadiazole%20moieties%202017"
        },
        {
            "id": "65",
            "alt_id": "Akhtar_et+al_2007_a",
            "entry": "65. Akhtar, T.; Hameed, S.; Al-Masoudi, N.A.; Khan, K.M. Synthesis and anti-HIV activity of new chiral 1,2,4-triazoles and 1,3,4-thiadiazoles. Heteroatom Chem. 2007, 18, 316\u2013322. [CrossRef]",
            "scholar_url": "https://scholar.google.co.uk/scholar?q=Akhtar%2C%20T.%20Hameed%2C%20S.%20Al-Masoudi%2C%20N.A.%20Khan%2C%20K.M.%20Synthesis%20and%20anti-HIV%20activity%20of%20new%20chiral%201%2C2%2C4-triazoles%20and%201%2C3%2C4-thiadiazoles%202007",
            "oa_query": "https://sandbox-api.scholarcy.com/oa_version?query=Akhtar%2C%20T.%20Hameed%2C%20S.%20Al-Masoudi%2C%20N.A.%20Khan%2C%20K.M.%20Synthesis%20and%20anti-HIV%20activity%20of%20new%20chiral%201%2C2%2C4-triazoles%20and%201%2C3%2C4-thiadiazoles%202007",
            "scite": "https://sandbox-api.scholarcy.com/scite_url?query=Akhtar%2C%20T.%20Hameed%2C%20S.%20Al-Masoudi%2C%20N.A.%20Khan%2C%20K.M.%20Synthesis%20and%20anti-HIV%20activity%20of%20new%20chiral%201%2C2%2C4-triazoles%20and%201%2C3%2C4-thiadiazoles%202007"
        },
        {
            "id": "66",
            "alt_id": "Hamad_et+al_2010_a",
            "entry": "66. Hamad, N.S.; Al-Haidery, N.H.; Al-Masoudi, I.A.; Sabri, M.; Sabri, L.; Al-Masoudi, N.A. Amino acid derivatives, part 4: synthesis and anti-HIV activity of new naphthalene derivatives. Arch. Pharm. Chem. Life Sci. 2010, 343, 397\u2013403. [CrossRef] [PubMed]",
            "scholar_url": "https://scholar.google.co.uk/scholar?q=Hamad%2C%20N.S.%20Al-Haidery%2C%20N.H.%20Al-Masoudi%2C%20I.A.%20Sabri%2C%20M.%20Amino%20acid%20derivatives%2C%20part%204%3A%20synthesis%20and%20anti-HIV%20activity%20of%20new%20naphthalene%20derivatives%202010",
            "oa_query": "https://sandbox-api.scholarcy.com/oa_version?query=Hamad%2C%20N.S.%20Al-Haidery%2C%20N.H.%20Al-Masoudi%2C%20I.A.%20Sabri%2C%20M.%20Amino%20acid%20derivatives%2C%20part%204%3A%20synthesis%20and%20anti-HIV%20activity%20of%20new%20naphthalene%20derivatives%202010",
            "scite": "https://sandbox-api.scholarcy.com/scite_url?query=Hamad%2C%20N.S.%20Al-Haidery%2C%20N.H.%20Al-Masoudi%2C%20I.A.%20Sabri%2C%20M.%20Amino%20acid%20derivatives%2C%20part%204%3A%20synthesis%20and%20anti-HIV%20activity%20of%20new%20naphthalene%20derivatives%202010"
        },
        {
            "id": "67",
            "alt_id": "Wang_et+al_2006_a",
            "entry": "67. Wang, Z.; Wu, B.; Kuhen, K.L.; Bursulaya, B.; Nguyen, T.N.; Nguyen, D.G.; He, Y. Synthesis and biological evaluations of sulfanyltriazoles as novel HIV-1 non-nucleoside reverse transcriptase inhibitors. Bioorg. Med. Chem. Lett. 2006, 16, 4174\u20134177. [CrossRef] [PubMed]",
            "scholar_url": "https://scholar.google.co.uk/scholar?q=Wang%2C%20Z.%20Wu%2C%20B.%20Kuhen%2C%20K.L.%20Bursulaya%2C%20B.%20Synthesis%20and%20biological%20evaluations%20of%20sulfanyltriazoles%20as%20novel%20HIV-1%20non-nucleoside%20reverse%20transcriptase%20inhibitors%202006",
            "oa_query": "https://sandbox-api.scholarcy.com/oa_version?query=Wang%2C%20Z.%20Wu%2C%20B.%20Kuhen%2C%20K.L.%20Bursulaya%2C%20B.%20Synthesis%20and%20biological%20evaluations%20of%20sulfanyltriazoles%20as%20novel%20HIV-1%20non-nucleoside%20reverse%20transcriptase%20inhibitors%202006",
            "scite": "https://sandbox-api.scholarcy.com/scite_url?query=Wang%2C%20Z.%20Wu%2C%20B.%20Kuhen%2C%20K.L.%20Bursulaya%2C%20B.%20Synthesis%20and%20biological%20evaluations%20of%20sulfanyltriazoles%20as%20novel%20HIV-1%20non-nucleoside%20reverse%20transcriptase%20inhibitors%202006"
        },
        {
            "id": "68",
            "alt_id": "Muraglia_et+al_2006_a",
            "entry": "68. Muraglia, E.; Kinzel, O.D.; Laufer, R.; Miller, M.D.; Moyer, G.; Munshi, V.; Orvieto, F.; Palumbi, M.C.; Pescatore, G.; Rowley, M.; et al. Tetrazole thioacetanilides: potent non-nucleoside inhibitors of WT HIV reverse transcriptase and its K103N mutant. Bioorg. Med. Chem. Lett. 2006, 16, 2748\u20132752. [CrossRef] [PubMed]",
            "scholar_url": "https://scholar.google.co.uk/scholar?q=Muraglia%2C%20E.%20Kinzel%2C%20O.D.%20Laufer%2C%20R.%20Miller%2C%20M.D.%20Tetrazole%20thioacetanilides%3A%20potent%20non-nucleoside%20inhibitors%20of%20WT%20HIV%20reverse%20transcriptase%20and%20its%20K103N%20mutant%202006",
            "oa_query": "https://sandbox-api.scholarcy.com/oa_version?query=Muraglia%2C%20E.%20Kinzel%2C%20O.D.%20Laufer%2C%20R.%20Miller%2C%20M.D.%20Tetrazole%20thioacetanilides%3A%20potent%20non-nucleoside%20inhibitors%20of%20WT%20HIV%20reverse%20transcriptase%20and%20its%20K103N%20mutant%202006",
            "scite": "https://sandbox-api.scholarcy.com/scite_url?query=Muraglia%2C%20E.%20Kinzel%2C%20O.D.%20Laufer%2C%20R.%20Miller%2C%20M.D.%20Tetrazole%20thioacetanilides%3A%20potent%20non-nucleoside%20inhibitors%20of%20WT%20HIV%20reverse%20transcriptase%20and%20its%20K103N%20mutant%202006"
        },
        {
            "id": "69",
            "alt_id": "Zhan_et+al_2008_a",
            "entry": "69. Zhan, P.; Liu, X.; Cao, Y.; Wang, Y.; Pannecouque, C.; De Clercq, E. 1,2,3-Thiadiazole thioacetanilides as a novel class of potent HIV-1 non-nucleoside reverse transcriptase inhibitors. Bioorg. Med. Chem. Lett. 2008, 18, 5368\u20135371. [CrossRef] [PubMed]",
            "scholar_url": "https://scholar.google.co.uk/scholar?q=Zhan%2C%20P.%20Liu%2C%20X.%20Cao%2C%20Y.%20Wang%2C%20Y.%201%2C2%2C3-Thiadiazole%20thioacetanilides%20as%20a%20novel%20class%20of%20potent%20HIV-1%20non-nucleoside%20reverse%20transcriptase%20inhibitors%202008",
            "oa_query": "https://sandbox-api.scholarcy.com/oa_version?query=Zhan%2C%20P.%20Liu%2C%20X.%20Cao%2C%20Y.%20Wang%2C%20Y.%201%2C2%2C3-Thiadiazole%20thioacetanilides%20as%20a%20novel%20class%20of%20potent%20HIV-1%20non-nucleoside%20reverse%20transcriptase%20inhibitors%202008",
            "scite": "https://sandbox-api.scholarcy.com/scite_url?query=Zhan%2C%20P.%20Liu%2C%20X.%20Cao%2C%20Y.%20Wang%2C%20Y.%201%2C2%2C3-Thiadiazole%20thioacetanilides%20as%20a%20novel%20class%20of%20potent%20HIV-1%20non-nucleoside%20reverse%20transcriptase%20inhibitors%202008"
        },
        {
            "id": "70",
            "alt_id": "Zhang_et+al_2007_a",
            "entry": "70. Zhang, Z.; Xu, W.; Koh, Y.H.; Shim, J.H.; Girardet, J.L.; Yeh, L.T.; Hamatake, R.K.; Hong, Z. A novel non-nucleoside analogue that inhibits human immunodeficiency virus type 1 isolates resistant to current non-nucleoside reverse transcriptase inhibitors. Antimicrob. Agents Chemother. 2007, 51, 429\u2013437. [CrossRef]",
            "scholar_url": "https://scholar.google.co.uk/scholar?q=Zhang%2C%20Z.%20Xu%2C%20W.%20Koh%2C%20Y.H.%20Shim%2C%20J.H.%20A%20novel%20non-nucleoside%20analogue%20that%20inhibits%20human%20immunodeficiency%20virus%20type%201%20isolates%20resistant%20to%20current%20non-nucleoside%20reverse%20transcriptase%20inhibitors%202007",
            "oa_query": "https://sandbox-api.scholarcy.com/oa_version?query=Zhang%2C%20Z.%20Xu%2C%20W.%20Koh%2C%20Y.H.%20Shim%2C%20J.H.%20A%20novel%20non-nucleoside%20analogue%20that%20inhibits%20human%20immunodeficiency%20virus%20type%201%20isolates%20resistant%20to%20current%20non-nucleoside%20reverse%20transcriptase%20inhibitors%202007",
            "scite": "https://sandbox-api.scholarcy.com/scite_url?query=Zhang%2C%20Z.%20Xu%2C%20W.%20Koh%2C%20Y.H.%20Shim%2C%20J.H.%20A%20novel%20non-nucleoside%20analogue%20that%20inhibits%20human%20immunodeficiency%20virus%20type%201%20isolates%20resistant%20to%20current%20non-nucleoside%20reverse%20transcriptase%20inhibitors%202007"
        },
        {
            "id": "71",
            "alt_id": "Huang_et+al_2011_a",
            "entry": "71. Huang, Y.; Zhao, L.; Jia, B.; Wu, L.; Li, Y.; Curthoys, N.; Zheng, J.C. Glutaminase dysregulation in HIV-1-infected human microglia mediates neurotoxicity: relevant to HIV-1 associated neurocognitive disorders. J. Neurosci. 2011, 31, 15195\u201315204. [CrossRef]",
            "scholar_url": "https://scholar.google.co.uk/scholar?q=Huang%2C%20Y.%20Zhao%2C%20L.%20Jia%2C%20B.%20Wu%2C%20L.%20Glutaminase%20dysregulation%20in%20HIV-1-infected%20human%20microglia%20mediates%20neurotoxicity%3A%20relevant%20to%20HIV-1%20associated%20neurocognitive%20disorders%202011",
            "oa_query": "https://sandbox-api.scholarcy.com/oa_version?query=Huang%2C%20Y.%20Zhao%2C%20L.%20Jia%2C%20B.%20Wu%2C%20L.%20Glutaminase%20dysregulation%20in%20HIV-1-infected%20human%20microglia%20mediates%20neurotoxicity%3A%20relevant%20to%20HIV-1%20associated%20neurocognitive%20disorders%202011",
            "scite": "https://sandbox-api.scholarcy.com/scite_url?query=Huang%2C%20Y.%20Zhao%2C%20L.%20Jia%2C%20B.%20Wu%2C%20L.%20Glutaminase%20dysregulation%20in%20HIV-1-infected%20human%20microglia%20mediates%20neurotoxicity%3A%20relevant%20to%20HIV-1%20associated%20neurocognitive%20disorders%202011"
        },
        {
            "id": "72",
            "alt_id": "Zhao_et+al_2004_a",
            "entry": "72. Zhao, J.; Lopez, A.L.; Erichsen, D.; Herek, S.; Cotter, R.L.; Curthoys, N.P.; Zheng, J. Mitochondrial glutaminase enhances extracellular glutamate production in HIV-1-infected macrophages: Linkage to HIV-1 associated dementia. J. Neurochem. 2004, 88, 169\u2013180. [CrossRef]",
            "scholar_url": "https://scholar.google.co.uk/scholar?q=Zhao%2C%20J.%20Lopez%2C%20A.L.%20Erichsen%2C%20D.%20Herek%2C%20S.%20Mitochondrial%20glutaminase%20enhances%20extracellular%20glutamate%20production%20in%20HIV-1-infected%20macrophages%3A%20Linkage%20to%20HIV-1%20associated%20dementia%202004",
            "oa_query": "https://sandbox-api.scholarcy.com/oa_version?query=Zhao%2C%20J.%20Lopez%2C%20A.L.%20Erichsen%2C%20D.%20Herek%2C%20S.%20Mitochondrial%20glutaminase%20enhances%20extracellular%20glutamate%20production%20in%20HIV-1-infected%20macrophages%3A%20Linkage%20to%20HIV-1%20associated%20dementia%202004",
            "scite": "https://sandbox-api.scholarcy.com/scite_url?query=Zhao%2C%20J.%20Lopez%2C%20A.L.%20Erichsen%2C%20D.%20Herek%2C%20S.%20Mitochondrial%20glutaminase%20enhances%20extracellular%20glutamate%20production%20in%20HIV-1-infected%20macrophages%3A%20Linkage%20to%20HIV-1%20associated%20dementia%202004"
        },
        {
            "id": "73",
            "alt_id": "Stumvoll_et+al_1999_a",
            "entry": "73. Stumvoll, M.; Perriello, G.; Meyer, C.; Gerich, J. Role of glutamine in human carbohydrate metabolism in kidney and other tissues. Kidney Int. 1999, 55, 778\u2013792. [CrossRef]",
            "scholar_url": "https://scholar.google.co.uk/scholar?q=Stumvoll%2C%20M.%20Perriello%2C%20G.%20Meyer%2C%20C.%20Gerich%2C%20J.%20Role%20of%20glutamine%20in%20human%20carbohydrate%20metabolism%20in%20kidney%20and%20other%20tissues.%20Kidney%20Int%201999"
        },
        {
            "id": "74",
            "alt_id": "Smith_1990_a",
            "entry": "74. Smith, R.J. Glutamine metabolism and its physiological importance. J. Parenter. Enteral. Nutr. 1990, 14, 40S\u201344S. [CrossRef] [PubMed]",
            "scholar_url": "https://scholar.google.co.uk/scholar?q=Smith%2C%20R.J.%20Glutamine%20metabolism%20and%20its%20physiological%20importance%201990",
            "oa_query": "https://sandbox-api.scholarcy.com/oa_version?query=Smith%2C%20R.J.%20Glutamine%20metabolism%20and%20its%20physiological%20importance%201990",
            "scite": "https://sandbox-api.scholarcy.com/scite_url?query=Smith%2C%20R.J.%20Glutamine%20metabolism%20and%20its%20physiological%20importance%201990"
        },
        {
            "id": "75",
            "alt_id": "Bromley_et+al_2015_a",
            "entry": "75. Bromley, S.D.; Bennett, M.K.; Gross, M.I.; Li, J.; Chen, L.; Goyal, B.; Laidig, G.; Stanton, T.F.; Sjogren, E.B. Treatment of viral infections with inhibitors of glutaminase. PCT Int. Appl. PCT/US2014/061746; WO 2015/061432 A1. 2015.",
            "scholar_url": "https://scholar.google.co.uk/scholar?q=Bromley%2C%20S.D.%20Bennett%2C%20M.K.%20Gross%2C%20M.I.%20Li%2C%20J.%20Treatment%20of%20viral%20infections%20with%20inhibitors%20of%20glutaminase%202015",
            "oa_query": "https://sandbox-api.scholarcy.com/oa_version?query=Bromley%2C%20S.D.%20Bennett%2C%20M.K.%20Gross%2C%20M.I.%20Li%2C%20J.%20Treatment%20of%20viral%20infections%20with%20inhibitors%20of%20glutaminase%202015",
            "scite": "https://sandbox-api.scholarcy.com/scite_url?query=Bromley%2C%20S.D.%20Bennett%2C%20M.K.%20Gross%2C%20M.I.%20Li%2C%20J.%20Treatment%20of%20viral%20infections%20with%20inhibitors%20of%20glutaminase%202015"
        },
        {
            "id": "76",
            "alt_id": "Newsholme_et+al_2003_a",
            "entry": "76. Newsholme, P.; Lima, M.M.R.; Procopio, J.; Pithon-Curi, T.C.; Doi, S.Q.; Bazotte, R.B.; Curi, R. Glutamine and glutamate as vital metabolites. Braz. J. Med. Biol. Res. 2003, 36, 153\u2013162. [CrossRef] [PubMed]",
            "scholar_url": "https://scholar.google.co.uk/scholar?q=Newsholme%2C%20P.%20Lima%2C%20M.M.R.%20Procopio%2C%20J.%20Pithon-Curi%2C%20T.C.%20Glutamine%20and%20glutamate%20as%20vital%20metabolites%202003",
            "oa_query": "https://sandbox-api.scholarcy.com/oa_version?query=Newsholme%2C%20P.%20Lima%2C%20M.M.R.%20Procopio%2C%20J.%20Pithon-Curi%2C%20T.C.%20Glutamine%20and%20glutamate%20as%20vital%20metabolites%202003",
            "scite": "https://sandbox-api.scholarcy.com/scite_url?query=Newsholme%2C%20P.%20Lima%2C%20M.M.R.%20Procopio%2C%20J.%20Pithon-Curi%2C%20T.C.%20Glutamine%20and%20glutamate%20as%20vital%20metabolites%202003"
        },
        {
            "id": "77",
            "alt_id": "Behar_2001_a",
            "entry": "77. Behar, K.L.; Rothman, D.L. In vivo NMR studies of glutamate-GABA-glutamine cycling in rodent and human cortex: the central role of glutamine. J. Nutr. 2001, 131, 2498\u20132504. [CrossRef] [PubMed]",
            "scholar_url": "https://scholar.google.co.uk/scholar?q=Behar%2C%20K.L.%20Rothman%2C%20D.L.%20In%20vivo%20NMR%20studies%20of%20glutamate-GABA-glutamine%20cycling%20in%20rodent%20and%20human%20cortex%3A%20the%20central%20role%20of%20glutamine%202001",
            "oa_query": "https://sandbox-api.scholarcy.com/oa_version?query=Behar%2C%20K.L.%20Rothman%2C%20D.L.%20In%20vivo%20NMR%20studies%20of%20glutamate-GABA-glutamine%20cycling%20in%20rodent%20and%20human%20cortex%3A%20the%20central%20role%20of%20glutamine%202001",
            "scite": "https://sandbox-api.scholarcy.com/scite_url?query=Behar%2C%20K.L.%20Rothman%2C%20D.L.%20In%20vivo%20NMR%20studies%20of%20glutamate-GABA-glutamine%20cycling%20in%20rodent%20and%20human%20cortex%3A%20the%20central%20role%20of%20glutamine%202001"
        },
        {
            "id": "78",
            "alt_id": "Erdmann_et+al_2007_a",
            "entry": "78. Erdmann, N.; Zhao, J.; Lopez, A.L.; Herek, S.; Curthoys, N.; Hexum, T.D.; Tsukamoto, T.; Ferraris, D.; Zheng, J. Glutamate production by HIV-1 infected human macrophage is blocked by the inhibition of glutaminase. J. Neurochem. 2007, 102, 539\u2013549. [CrossRef]",
            "scholar_url": "https://scholar.google.co.uk/scholar?q=Erdmann%2C%20N.%20Zhao%2C%20J.%20Lopez%2C%20A.L.%20Herek%2C%20S.%20Glutamate%20production%20by%20HIV-1%20infected%20human%20macrophage%20is%20blocked%20by%20the%20inhibition%20of%20glutaminase%202007",
            "oa_query": "https://sandbox-api.scholarcy.com/oa_version?query=Erdmann%2C%20N.%20Zhao%2C%20J.%20Lopez%2C%20A.L.%20Herek%2C%20S.%20Glutamate%20production%20by%20HIV-1%20infected%20human%20macrophage%20is%20blocked%20by%20the%20inhibition%20of%20glutaminase%202007",
            "scite": "https://sandbox-api.scholarcy.com/scite_url?query=Erdmann%2C%20N.%20Zhao%2C%20J.%20Lopez%2C%20A.L.%20Herek%2C%20S.%20Glutamate%20production%20by%20HIV-1%20infected%20human%20macrophage%20is%20blocked%20by%20the%20inhibition%20of%20glutaminase%202007"
        },
        {
            "id": "79",
            "alt_id": "Babayo_et+al_2014_a",
            "entry": "79. Babayo, A.; Thairu, Y.; Nasir, I.A.; Baba, M.M. Serological evidence and sociodemographic risk factors of recent cytomegalovirus infection in pregnant women attending a tertiary hospital in Maiduguri, Nigeria. J. Med. Microbiol. Infec. Dis. 2014, 2, 49\u201355.",
            "scholar_url": "https://scholar.google.co.uk/scholar?q=Babayo%2C%20A.%20Thairu%2C%20Y.%20Nasir%2C%20I.A.%20Baba%2C%20M.M.%20Serological%20evidence%20and%20sociodemographic%20risk%20factors%20of%20recent%20cytomegalovirus%20infection%20in%20pregnant%20women%20attending%20a%20tertiary%20hospital%20in%20Maiduguri%2C%20Nigeria%202014",
            "oa_query": "https://sandbox-api.scholarcy.com/oa_version?query=Babayo%2C%20A.%20Thairu%2C%20Y.%20Nasir%2C%20I.A.%20Baba%2C%20M.M.%20Serological%20evidence%20and%20sociodemographic%20risk%20factors%20of%20recent%20cytomegalovirus%20infection%20in%20pregnant%20women%20attending%20a%20tertiary%20hospital%20in%20Maiduguri%2C%20Nigeria%202014",
            "scite": "https://sandbox-api.scholarcy.com/scite_url?query=Babayo%2C%20A.%20Thairu%2C%20Y.%20Nasir%2C%20I.A.%20Baba%2C%20M.M.%20Serological%20evidence%20and%20sociodemographic%20risk%20factors%20of%20recent%20cytomegalovirus%20infection%20in%20pregnant%20women%20attending%20a%20tertiary%20hospital%20in%20Maiduguri%2C%20Nigeria%202014"
        },
        {
            "id": "80",
            "alt_id": "Forbes_1989_a",
            "entry": "80. Forbes, B.A. Acquisition of cytomegalovirus infection: An update. Clin. Microbiol. Rev. 1989, 2, 204\u2013216. [CrossRef]",
            "scholar_url": "https://scholar.google.co.uk/scholar?q=Forbes%2C%20B.A.%20Acquisition%20of%20cytomegalovirus%20infection%3A%20An%20update%201989",
            "oa_query": "https://sandbox-api.scholarcy.com/oa_version?query=Forbes%2C%20B.A.%20Acquisition%20of%20cytomegalovirus%20infection%3A%20An%20update%201989",
            "scite": "https://sandbox-api.scholarcy.com/scite_url?query=Forbes%2C%20B.A.%20Acquisition%20of%20cytomegalovirus%20infection%3A%20An%20update%201989"
        },
        {
            "id": "81",
            "alt_id": "Spruance_2003_a",
            "entry": "81. Spruance, S.L. Viral infections. In The Merck Manual of Medical Information: Second Home Edition; Beers, M.H., Ed.; Merck Research Laboratories, Merck and Co., Inc.: Whitehouse Station, NJ, USA, 2003; p. 1164.",
            "scholar_url": "https://scholar.google.co.uk/scholar?q=Spruance%2C%20S.L.%20Viral%20infections.%20In%20The%20Merck%20Manual%20of%20Medical%20Information%3A%20Second%20Home%20Edition%202003"
        },
        {
            "id": "82",
            "alt_id": "82._0000_e",
            "entry": "82. Centers for Disease Control and Prevention. Cytomegalovirus (CMV) and Congenital CMV Infection. Available online: https://www.cdc.gov/cmv/overview.html (accessed on 11 July 2018).",
            "url": "https://www.cdc.gov/cmv/overview.html"
        },
        {
            "id": "83",
            "alt_id": "Tan_2014_a",
            "entry": "83. Tan, B.H. Cytomegalovirus treatment. Curr. Treat. Options Infect. Dis. 2014, 6, 256\u2013270. [CrossRef] 84. McGavin, J.K.; Goa, K.L. Ganciclovir: An update of its use in the prevention of cytomegalovirus infection and disease in transplant recipients. Drugs 2001, 61, 1153\u20131183. [CrossRef] 85.",
            "scholar_url": "https://scholar.google.co.uk/scholar?q=Tan%2C%20B.H.%20Cytomegalovirus%20treatment.%20Curr%202014",
            "oa_query": "https://sandbox-api.scholarcy.com/oa_version?query=Tan%2C%20B.H.%20Cytomegalovirus%20treatment.%20Curr%202014",
            "scite": "https://sandbox-api.scholarcy.com/scite_url?query=Tan%2C%20B.H.%20Cytomegalovirus%20treatment.%20Curr%202014"
        },
        {
            "id": "A_2013_a",
            "alt_id": "77",
            "entry": "A case of severe ganciclovir-induced encephalopathy. Case Rep. Neurol. 2013, 5, 183\u2013186. [CrossRef] 86.",
            "scholar_url": "https://scholar.google.co.uk/scholar?q=A%20case%20of%20severe%20ganciclovirinduced%20encephalopathy%20Case%20Rep%20Neurol%202013%205%20183186%20CrossRef%2086",
            "oa_query": "https://sandbox-api.scholarcy.com/oa_version?query=A%20case%20of%20severe%20ganciclovirinduced%20encephalopathy%20Case%20Rep%20Neurol%202013%205%20183186%20CrossRef%2086",
            "scite": "https://sandbox-api.scholarcy.com/scite_url?query=A%20case%20of%20severe%20ganciclovirinduced%20encephalopathy%20Case%20Rep%20Neurol%202013%205%20183186%20CrossRef%2086"
        },
        {
            "id": "Organization_2018_a",
            "alt_id": "78",
            "entry": "6,150,385, 2000.",
            "scholar_url": "https://scholar.google.co.uk/scholar?q=Organization%2C%20World%20Health%20Battle%20against%20Respiratory%202018-06"
        },
        {
            "id": "87",
            "alt_id": "Organization_0000_a",
            "entry": "87. World Health Organization. Battle against Respiratory Viruses (BRaVe) initiative. Available online: http://www.who.int/influenza/patient_care/clinical/brave/en/ (accessed on 14 June 2018).",
            "url": "http://www.who.int/influenza/patient_care/clinical/brave/en/"
        },
        {
            "id": "88",
            "alt_id": "Bellos_et+al_2010_a",
            "entry": "88. World Health Organization. Research needs for the battle against respiratory viruses (BRAve). Background document 2013. Available online: http://www.who.int/influenza/patient_care/clinical/BRaVe_Research_ Agenda_2013.pdf (accessed on 14 June 2018).",
            "url": "http://www.who.int/influenza/patient_care/clinical/BRaVe_Research_Agenda_2013.pdf",
            "oa_query": "https://sandbox-api.scholarcy.com/oa_version?query=Bellos%2C%20A.%20Mulholland%2C%20K.%20O%E2%80%99Brien%2C%20K.L.%20Qazi%2C%20S.A.%20The%20burden%20of%20acute%20respiratory%20infections%20in%20crisis-affected%20populations%3A%20A%20systematic%20review%202010",
            "scite": "https://sandbox-api.scholarcy.com/scite_url?query=Bellos%2C%20A.%20Mulholland%2C%20K.%20O%E2%80%99Brien%2C%20K.L.%20Qazi%2C%20S.A.%20The%20burden%20of%20acute%20respiratory%20infections%20in%20crisis-affected%20populations%3A%20A%20systematic%20review%202010"
        },
        {
            "id": "89",
            "alt_id": "Da_et+al_2015_a",
            "entry": "89. Bellos, A.; Mulholland, K.; O\u2019Brien, K.L.; Qazi, S.A.; Gayer, M.; Checchil, F. The burden of acute respiratory infections in crisis-affected populations: A systematic review. Confl. Health 2010, 4, 1\u201312. [CrossRef] 90. Straliotto, S.M.; Siqueira, M.M.; Muller, R.L.; Fischer, G.B.; Cunha, M.L.T.; Nestor, S.M. Viral etiology of acute respiratory infections among children in Porto Alegre, RS, Brazil. Rev. Soc. Bras. Med. Tro. 2002, 35, 283\u2013291. [CrossRef] [PubMed] 91.",
            "scholar_url": "https://scholar.google.co.uk/scholar?q=Da%20Silva%2C%20R.C.%20da%20Silva%20Mendes%2C%20G.%20Rojas%2C%20M.A.%20Amorim%2C%20A.R.%20Frequency%20of%20viral%20etiology%20in%20symptomatic%20adult%20upper%20respiratory%20tract%20infections%202015",
            "oa_query": "https://sandbox-api.scholarcy.com/oa_version?query=Da%20Silva%2C%20R.C.%20da%20Silva%20Mendes%2C%20G.%20Rojas%2C%20M.A.%20Amorim%2C%20A.R.%20Frequency%20of%20viral%20etiology%20in%20symptomatic%20adult%20upper%20respiratory%20tract%20infections%202015",
            "scite": "https://sandbox-api.scholarcy.com/scite_url?query=Da%20Silva%2C%20R.C.%20da%20Silva%20Mendes%2C%20G.%20Rojas%2C%20M.A.%20Amorim%2C%20A.R.%20Frequency%20of%20viral%20etiology%20in%20symptomatic%20adult%20upper%20respiratory%20tract%20infections%202015"
        },
        {
            "id": "Fendrick_et+al_2003_a",
            "alt_id": "82",
            "entry": "Da Silva, R.C.; da Silva Mendes, G.; Rojas, M.A.; Amorim, A.R.; Couceiro, J.N.; Lupi, O.; Elabras, J.; Pires, G.; Valle, S.; Santos, N. Frequency of viral etiology in symptomatic adult upper respiratory tract infections. Braz. J. Infect. Dis. 2015, 19, 30\u201335. [CrossRef] [PubMed] 92.",
            "scholar_url": "https://scholar.google.co.uk/scholar?q=Fendrick%2C%20A.M.%20Monto%2C%20A.S.%20Nightengale%2C%20B.%20Sarnes%2C%20M.%20The%20economic%20burden%20of%20non-influenza-related%20viral%20respiratory%20tract%20infections%20in%20the%20United%20States%202003",
            "oa_query": "https://sandbox-api.scholarcy.com/oa_version?query=Fendrick%2C%20A.M.%20Monto%2C%20A.S.%20Nightengale%2C%20B.%20Sarnes%2C%20M.%20The%20economic%20burden%20of%20non-influenza-related%20viral%20respiratory%20tract%20infections%20in%20the%20United%20States%202003",
            "scite": "https://sandbox-api.scholarcy.com/scite_url?query=Fendrick%2C%20A.M.%20Monto%2C%20A.S.%20Nightengale%2C%20B.%20Sarnes%2C%20M.%20The%20economic%20burden%20of%20non-influenza-related%20viral%20respiratory%20tract%20infections%20in%20the%20United%20States%202003"
        },
        {
            "id": "Johnson_2007_a",
            "alt_id": "83",
            "entry": "Fendrick, A.M.; Monto, A.S.; Nightengale, B.; Sarnes, M. The economic burden of non-influenza-related viral respiratory tract infections in the United States. Arch. Intern. Med. 2003, 163, 487\u2013494. [CrossRef] [PubMed] 93.",
            "scholar_url": "https://scholar.google.co.uk/scholar?q=Johnson%2C%20D.S.%20Li%2C%20J.J.%20Neuraminidase%20inhibitors%20for%20influenza%3A%20oseltamivir%20phosphate%20%28Tamiflu%29%20and%20zanamivir%20%28Relenza%29.%20In%20The%20art%20of%20drug%20synthesis%202007"
        },
        {
            "id": "Al-Muharrmi_2010_a",
            "alt_id": "84",
            "entry": "Johnson, D.S.; Li, J.J. Neuraminidase inhibitors for influenza: oseltamivir phosphate (Tamiflu) and zanamivir (Relenza). In The art of drug synthesis; Johnson, D.S., Li, J.J., Eds.; Wiley Interscience, John Wiley and Sons, Inc., Hoboken: New Jersey, NJ, USA, 2007; pp. 95\u201396.",
            "scholar_url": "https://scholar.google.co.uk/scholar?q=Johnson%20DS%20Li%20JJ%20Neuraminidase%20inhibitors%20for%20influenza%20oseltamivir%20phosphate%20Tamiflu%20and%20zanamivir%20Relenza%20In%20The%20art%20of%20drug%20synthesis%20Johnson%20DS%20Li%20JJ%20Eds%20Wiley%20Interscience%20John%20Wiley%20and%20Sons%20Inc%20Hoboken%20New%20Jersey%20NJ%20USA%202007%20pp%209596",
            "oa_query": "https://sandbox-api.scholarcy.com/oa_version?query=Johnson%20DS%20Li%20JJ%20Neuraminidase%20inhibitors%20for%20influenza%20oseltamivir%20phosphate%20Tamiflu%20and%20zanamivir%20Relenza%20In%20The%20art%20of%20drug%20synthesis%20Johnson%20DS%20Li%20JJ%20Eds%20Wiley%20Interscience%20John%20Wiley%20and%20Sons%20Inc%20Hoboken%20New%20Jersey%20NJ%20USA%202007%20pp%209596",
            "scite": "https://sandbox-api.scholarcy.com/scite_url?query=Johnson%20DS%20Li%20JJ%20Neuraminidase%20inhibitors%20for%20influenza%20oseltamivir%20phosphate%20Tamiflu%20and%20zanamivir%20Relenza%20In%20The%20art%20of%20drug%20synthesis%20Johnson%20DS%20Li%20JJ%20Eds%20Wiley%20Interscience%20John%20Wiley%20and%20Sons%20Inc%20Hoboken%20New%20Jersey%20NJ%20USA%202007%20pp%209596"
        },
        {
            "id": "94",
            "alt_id": "Tonelli_et+al_2017_a",
            "entry": "94. Al-Muharrmi, Z. Understanding the Influenza A H1N1 2009 pandemic. SQU Med. J. 2010, 10, 187\u2013195.",
            "scholar_url": "https://scholar.google.co.uk/scholar?q=Tonelli%2C%20M.%20Naesens%2C%20L.%20Gazzarrini%2C%20S.%20Santucci%2C%20M.%20Host%20dihydrofolate%20reductase%20%28DHFR%29-directed%20cycloguanil%20analogues%20endowed%20with%20activity%20against%20influenza%20virus%20and%20respiratory%20syncytial%20virus%202017",
            "oa_query": "https://sandbox-api.scholarcy.com/oa_version?query=Tonelli%2C%20M.%20Naesens%2C%20L.%20Gazzarrini%2C%20S.%20Santucci%2C%20M.%20Host%20dihydrofolate%20reductase%20%28DHFR%29-directed%20cycloguanil%20analogues%20endowed%20with%20activity%20against%20influenza%20virus%20and%20respiratory%20syncytial%20virus%202017",
            "scite": "https://sandbox-api.scholarcy.com/scite_url?query=Tonelli%2C%20M.%20Naesens%2C%20L.%20Gazzarrini%2C%20S.%20Santucci%2C%20M.%20Host%20dihydrofolate%20reductase%20%28DHFR%29-directed%20cycloguanil%20analogues%20endowed%20with%20activity%20against%20influenza%20virus%20and%20respiratory%20syncytial%20virus%202017"
        },
        {
            "id": "95",
            "alt_id": "Organization_2019_a",
            "entry": "95. Tonelli, M.; Naesens, L.; Gazzarrini, S.; Santucci, M.; Cichero, E.; Tasso, B.; Moroni, A.; Costi, M.P.; Loddo, R. Host dihydrofolate reductase (DHFR)-directed cycloguanil analogues endowed with activity against influenza virus and respiratory syncytial virus. Eur. J. Med. Chem. 2017, 135, 467\u2013478. [CrossRef] 96. Francesconi, V.; Giovannini, L.; Santucci, M.; Cichero, E.; Costi, M.P.; Naesens, L.; Giordanetto, F.; Tonelli, M. Synthesis, biological evaluation and molecular modeling of novel azaspiro dihydrotriazines as influenza virus inhibitors targeting the host factor dihydrofolate reductase (DHFR). Eur. J. Med. Chem. 2018, 155, 229\u2013243. [CrossRef] 97. World Health Organization. Fact sheets on sustainable development goals: health target, Viral hepatitis, World Health Organization 2017, Copenhagen, Denmark, www.euro.who.int/sdgs. Available online: http://www.euro.who.int/__data/assets/pdf_file/0003/348222/Fact-sheet-SDG-viral-hepatitis-FINALen.pdf?ua=1 (accessed on 23 January 2020).",
            "url": "http://www.euro.who.int/sdgs"
        },
        {
            "id": "98",
            "alt_id": "F_0000_a",
            "entry": "98. World Health Organization. Hepatitis B in the WHO European Region, Fact sheet \u2013 July 2019, World Health Organization 2019. Available online: http://www.euro.who.int/__data/assets/pdf_file/0007/377251/ Fact-Sheet-Hepatitis-B_2019-ENG.pdf?ua=1 (accessed on 23 January 2020).",
            "url": "http://www.euro.who.int/__data/assets/pdf_file/0007/377251/Fact-Sheet-Hepatitis-B_2019-ENG.pdf?ua=1"
        },
        {
            "id": "99",
            "alt_id": "Kurkela_et+al_2008_a",
            "entry": "99. FDA. Hepatitis B and C treatments. Available online: https://www.fda.gov/patients/hepatitis-b-c/hepatitis-band-c-treatments (accessed on 23 January 2020).",
            "url": "https://www.fda.gov/patients/hepatitis-b-c/hepatitis-band-c-treatments",
            "oa_query": "https://sandbox-api.scholarcy.com/oa_version?query=Kurkela%2C%20S.%20Ratti%2C%20O.%20Huhtamo%2C%20E.%20Uzcategui%2C%20N.%20Sindbis%20virus%20infection%20in%20resident%20birds%2C%20migratory%20birds%2C%20and%20humans%2C%20Finland%202008",
            "scite": "https://sandbox-api.scholarcy.com/scite_url?query=Kurkela%2C%20S.%20Ratti%2C%20O.%20Huhtamo%2C%20E.%20Uzcategui%2C%20N.%20Sindbis%20virus%20infection%20in%20resident%20birds%2C%20migratory%20birds%2C%20and%20humans%2C%20Finland%202008"
        },
        {
            "id": "100",
            "alt_id": "Kucukguzel_et+al_2007_a",
            "entry": "100. Kurkela, S.; Ratti, O.; Huhtamo, E.; Uzcategui, N.; Nuorti, J.P.; Laakkonen, J.; Manni, T.; Helle, P.; Vaheri, A.; Vapalahti, O. Sindbis virus infection in resident birds, migratory birds, and humans, Finland. Emerg. Infect. Dis. 2008, 14, 41\u201347. [CrossRef]",
            "scholar_url": "https://scholar.google.co.uk/scholar?q=Kucukguzel%2C%20S.G.%20Kucukguzel%2C%20I.%20Tatar%2C%20E.%20Rollas%2C%20S.%20Synthesis%20of%20some%20novel%20heterocyclic%20compounds%20derived%20from%20diflunisal%20hydrazide%20as%20potential%20anti-infective%20and%20anti-inflammatory%20agents%202007",
            "oa_query": "https://sandbox-api.scholarcy.com/oa_version?query=Kucukguzel%2C%20S.G.%20Kucukguzel%2C%20I.%20Tatar%2C%20E.%20Rollas%2C%20S.%20Synthesis%20of%20some%20novel%20heterocyclic%20compounds%20derived%20from%20diflunisal%20hydrazide%20as%20potential%20anti-infective%20and%20anti-inflammatory%20agents%202007",
            "scite": "https://sandbox-api.scholarcy.com/scite_url?query=Kucukguzel%2C%20S.G.%20Kucukguzel%2C%20I.%20Tatar%2C%20E.%20Rollas%2C%20S.%20Synthesis%20of%20some%20novel%20heterocyclic%20compounds%20derived%20from%20diflunisal%20hydrazide%20as%20potential%20anti-infective%20and%20anti-inflammatory%20agents%202007"
        },
        {
            "id": "101",
            "alt_id": "Bonina_et+al_1982_a",
            "entry": "101. Kucukguzel, S.G.; Kucukguzel, I.; Tatar, E.; Rollas, S.; Sahin, F.; Gulluce, M.; De Clercq, E.; Kabasakal, L. Synthesis of some novel heterocyclic compounds derived from diflunisal hydrazide as potential anti-infective and anti-inflammatory agents. Eur. J. Med. Chem. 2007, 42, 893\u2013901. [CrossRef]",
            "scholar_url": "https://scholar.google.co.uk/scholar?q=Bonina%2C%20L.%20Orzalesi%2C%20G.%20Merendino%2C%20R.%20Arena%2C%20A.%20Structure-activity%20relationships%20of%20new%20antiviral%20compounds%201982",
            "oa_query": "https://sandbox-api.scholarcy.com/oa_version?query=Bonina%2C%20L.%20Orzalesi%2C%20G.%20Merendino%2C%20R.%20Arena%2C%20A.%20Structure-activity%20relationships%20of%20new%20antiviral%20compounds%201982",
            "scite": "https://sandbox-api.scholarcy.com/scite_url?query=Bonina%2C%20L.%20Orzalesi%2C%20G.%20Merendino%2C%20R.%20Arena%2C%20A.%20Structure-activity%20relationships%20of%20new%20antiviral%20compounds%201982"
        },
        {
            "id": "102",
            "alt_id": "Streissle_et+al_1985_a",
            "entry": "102. Bonina, L.; Orzalesi, G.; Merendino, R.; Arena, A.; Mastroeni, P. Structure-activity relationships of new antiviral compounds. Antimicrob. Agents Chemother. 1982, 22, 1067\u20131069. [CrossRef]",
            "scholar_url": "https://scholar.google.co.uk/scholar?q=Streissle%2C%20G.%20Paesseus%2C%20A.%20Oediger%2C%20H.%20New%20antiviral%20compounds%201985",
            "oa_query": "https://sandbox-api.scholarcy.com/oa_version?query=Streissle%2C%20G.%20Paesseus%2C%20A.%20Oediger%2C%20H.%20New%20antiviral%20compounds%201985",
            "scite": "https://sandbox-api.scholarcy.com/scite_url?query=Streissle%2C%20G.%20Paesseus%2C%20A.%20Oediger%2C%20H.%20New%20antiviral%20compounds%201985"
        },
        {
            "id": "103",
            "alt_id": "Cui_et+al_2010_a",
            "entry": "103. Streissle, G.; Paesseus, A.; Oediger, H. New antiviral compounds. In Advances in Virus Research; Maramorosch, K., Murphy, F.A., Shatkin, A.J., Eds.; Academic Press., Elsevier: London, UK, 1985; Volume 30, p. 115.",
            "scholar_url": "https://scholar.google.co.uk/scholar?q=Cui%2C%20T.%20Chum%2C%20M.P.%20Lam%2C%20Y.%20Gao%2C%20Y.%20Compounds%20for%20use%20as%20anti-viral%20agents%202010",
            "oa_query": "https://sandbox-api.scholarcy.com/oa_version?query=Cui%2C%20T.%20Chum%2C%20M.P.%20Lam%2C%20Y.%20Gao%2C%20Y.%20Compounds%20for%20use%20as%20anti-viral%20agents%202010",
            "scite": "https://sandbox-api.scholarcy.com/scite_url?query=Cui%2C%20T.%20Chum%2C%20M.P.%20Lam%2C%20Y.%20Gao%2C%20Y.%20Compounds%20for%20use%20as%20anti-viral%20agents%202010"
        },
        {
            "id": "104",
            "alt_id": "Yadav_2001_a",
            "entry": "104. Cui, T.; Chum, M.P.; Lam, Y.; Gao, Y. Compounds for use as anti-viral agents. Singapore Pat. Appl. SG 162629 A1 20100729. 2010.",
            "scholar_url": "https://scholar.google.co.uk/scholar?q=Yadav%2C%20L.D.S.%20Singh%2C%20S.%20Synthesis%20of%20antiviral%20acyclic%20C-nucleosides%20incorporating%20thiazolo-1%2C3%2C4-oxa%28thia%29diazole%20or%20thiazolo-1%2C2%2C4-triazole%20structure%20as%20a%20nucleobase%202001",
            "oa_query": "https://sandbox-api.scholarcy.com/oa_version?query=Yadav%2C%20L.D.S.%20Singh%2C%20S.%20Synthesis%20of%20antiviral%20acyclic%20C-nucleosides%20incorporating%20thiazolo-1%2C3%2C4-oxa%28thia%29diazole%20or%20thiazolo-1%2C2%2C4-triazole%20structure%20as%20a%20nucleobase%202001",
            "scite": "https://sandbox-api.scholarcy.com/scite_url?query=Yadav%2C%20L.D.S.%20Singh%2C%20S.%20Synthesis%20of%20antiviral%20acyclic%20C-nucleosides%20incorporating%20thiazolo-1%2C3%2C4-oxa%28thia%29diazole%20or%20thiazolo-1%2C2%2C4-triazole%20structure%20as%20a%20nucleobase%202001"
        }
    ],
    "facts": [
        "Viral infections have resulted in millions of victims",
        "approximately 90 drugs approved for the treatment of human viral infections",
        "As resistance toward available antiviral drugs has become a global threat to health",
        "This review provides an overview of the various synthetic compounds containing the",
        "2-amino-1,3,4-thiadiazole moiety that has been evaluated for antiviral activity against several viral strains",
        "There are broad types of human infections caused by viruses",
        "most cost-effective strategy for preventing viral infections is through vaccination",
        "smallpox and hepatitis B were developed during the 20th century",
        "its derivatives are known for their antitumor",
        "2-Amino-1,3,4-thiadiazole derivatives are currently being synthesized in many laboratories"
    ],
    "claims": [
        "This review provides an overview of the various synthetic compounds containing the 2-amino-1,3,4-thiadiazole moiety that has been evaluated for antiviral activity against several viral strains and could be considered possible prototypes for the development of new antiviral drugs",
        "The amine derivatives of 1,3,4-thiadiazole are also studied. 2-Amino-1,3,4-thiadiazole moiety and its derivatives are known for their antitumor, antitrypanosomal and uricogenic properties [20,25,27,35\u201338]. 2-Amino-1,3,4-thiadiazole derivatives are currently being synthesized in many laboratories, and in previous papers, we described several 2-amino-1,3,4-thiadiazoles that exhibit antibacterial, antifungal, antitubercular [20,39\u201344], and antiparasitic activities [27,38]",
        "The purpose of this paper is to present some small molecules possessing the 2-amino-1,3,4-thiadiazole moiety that have shown antiviral activity"
    ],
    "findings": [],
    "processes": [],
    "key_statements": [
        "There are broad types of human infections caused by viruses, such as respiratory infections, digestive infections, central nervous system infections, skin or mucosal infections, hepatic infections, blood infections and hemorrhagic fever",
        "The main method and most cost-effective strategy for preventing viral infections is through vaccination, which is meant to prevent outbreaks by increasing immunity [4]",
        "Vaccines for the prevention of several common acute viral infections, such as polio, rubella, measles, mumps, Influenza, yellow fever, encephalitis, rabies, smallpox and hepatitis B were developed during the 20th century and are available on a large scale [1,4]",
        "The amine derivatives of 1,3,4-thiadiazole are studied. 2-Amino-1,3,4-thiadiazole moiety and its derivatives are known for their antitumor, antitrypanosomal and uricogenic properties [20,25,27,35\u201338]. 2-Amino-1,3,4-thiadiazole derivatives are currently being synthesized in many laboratories, and in previous papers, we described several 2-amino-1,3,4-thiadiazoles that exhibit antibacterial, antifungal, antitubercular [20,39\u201344], and antiparasitic activities [27,38]",
        "The purpose of this paper is to present some small molecules possessing the 2-amino-1,3,4-thiadiazole moiety that have shown antiviral activity"
    ],
    "top_statements": [
        "Viruses are the smallest among all self-replicating organisms and yet they are the etiological agents of many difficult to treat diseases in human populations [1]",
        "There are broad types of human infections caused by viruses, such as respiratory infections, digestive infections, central nervous system infections, skin or mucosal infections, hepatic infections, blood infections and hemorrhagic fever",
        "The main method and most cost-effective strategy for preventing viral infections is through vaccination, which is meant to prevent outbreaks by increasing immunity [4]",
        "Vaccines for the prevention of several common acute viral infections, such as polio, rubella, measles, mumps, Influenza, yellow fever, encephalitis, rabies, smallpox and hepatitis B were developed during the 20th century and are available on a large scale [1,4]",
        "The amine derivatives of 1,3,4-thiadiazole are studied. 2-Amino-1,3,4-thiadiazole moiety and its derivatives are known for their antitumor, antitrypanosomal and uricogenic properties [20,25,27,35\u201338]. 2-Amino-1,3,4-thiadiazole derivatives are currently being synthesized in many laboratories, and in previous papers, we described several 2-amino-1,3,4-thiadiazoles that exhibit antibacterial, antifungal, antitubercular [20,39\u201344], and antiparasitic activities [27,38]",
        "The purpose of this paper is to present some small molecules possessing the 2-amino-1,3,4-thiadiazole moiety that have shown antiviral activity"
    ],
    "headline": "The amine derivatives of 1,3,4-thiadiazole are studied. 2-Amino-1,3,4-thiadiazole moiety and its derivatives are known for their antitumor, antitrypanosomal and uricogenic properties. 2-Amino-1,3,4-thiadiazole derivatives are currently being synthesized in many laboratories, and in previous papers, we described several 2-amino-1,3,4-thiadiazoles that exhibit antibacterial, antifungal, antitubercular, and antiparasitic activities",
    "contexts": [],
    "abbreviations": {
        "HIV": "human immunodeficiency virus",
        "HBV": "hepatitis B virus",
        "HCV": "hepatitis C virus",
        "HSV": "herpes simplex virus",
        "HCMV": "human cytomegalovirus",
        "VZV": "varicella-zoster virus",
        "RSV": "respiratory syncytial virus",
        "AIDS": "acquired immunodeficiency syndrome",
        "RT": "reverse transcriptase",
        "NRTIs": "Nucleoside reverse transcriptase inhibitors",
        "NNRTIs": "nucleoside reverse transcriptase inhibitors",
        "NNBS": "nucleoside inhibitor binding site",
        "FDA": "Food and Drug Administration",
        "NDAs": "new drug applications",
        "CNS": "central nervous system"
    }
}
